{"PMC7319936": [["Beneficial adaptations by the microbes ::: IntroductionMicroorganisms boom all the way through natural world, and microbes have adjusted to endure under a wide range of punitive or unaccommodating conditions, ensuing in adaptation by the microorganisms to specific niches (Edge et al., 2020; Handelsman et al., 1998).", [["punitive or unaccommodating conditions", "PROBLEM", 169, 207]]], ["These adaptations by the microbes lead to evolution of meritorious phenotypes, which could be further exploited for prospective biotechnological applications (Grossart et al., 2020; Hamner et al., 2019).", [["meritorious phenotypes", "PROBLEM", 55, 77], ["meritorious phenotypes", "OBSERVATION", 55, 77]]], ["For example, following the success of Taq DNA polymerase from Thermus aquaticus, a thermophile, and similar trends followed isolate important enzymes like pfu from Pyrococcus furiosus (Singh et al., 2019).", [["Taq", "GENE_OR_GENE_PRODUCT", 38, 41], ["DNA", "CELLULAR_COMPONENT", 42, 45], ["Thermus aquaticus", "ORGANISM", 62, 79], ["Pyrococcus furiosus", "ORGANISM", 164, 183], ["Taq DNA polymerase", "PROTEIN", 38, 56], ["enzymes", "PROTEIN", 142, 149], ["Thermus aquaticus", "SPECIES", 62, 79], ["Pyrococcus furiosus", "SPECIES", 164, 183], ["Thermus aquaticus", "SPECIES", 62, 79], ["Pyrococcus furiosus", "SPECIES", 164, 183], ["Taq DNA polymerase", "PROBLEM", 38, 56], ["a thermophile", "TREATMENT", 81, 94]]], ["Two lipases belonging patatin-like phospholipase family from hot springs and a naphthalene catabolic gene from oil contaminated sites were isolated through metagenome approach (Awasthi et al., 2020; Yooseph et al., 2013).", [["sites", "ANATOMY", 128, 133], ["naphthalene", "CHEMICAL", 79, 90], ["naphthalene", "CHEMICAL", 79, 90], ["patatin-like phospholipase", "GENE_OR_GENE_PRODUCT", 22, 48], ["naphthalene", "SIMPLE_CHEMICAL", 79, 90], ["oil", "ORGANISM_SUBSTANCE", 111, 114], ["patatin-like phospholipase family", "PROTEIN", 22, 55], ["naphthalene catabolic gene", "DNA", 79, 105], ["Two lipases belonging patatin", "PROBLEM", 0, 29], ["a naphthalene catabolic gene", "TREATMENT", 77, 105]]], ["Moreover, current estimations show that 99% of the microbes existing in many natural environments are not readily culturable and therefore not available for basic or biotechnology research (Boifot et al., 2020).", [["current estimations", "TEST", 10, 29]]], ["This assessment suggested that an alternate microbial biotechnological technique could provide an insight into these particularly modified exclusive microbes, their potentially useful gens or genome outlines (Kirubakaran et al., 2019).Metagenomics \u2013 an alternative tool ::: IntroductionMetagenomics, a powerful technique involves isolation of genomic DNA directly from the environment, without the need for prior culturing of organisms under laboratory conditions (Singh et al., 2019; Wang et al., 2013; Wang et al., 2000).", [["DNA", "CELLULAR_COMPONENT", 351, 354], ["genomic DNA", "DNA", 343, 354], ["This assessment", "TEST", 0, 15], ["an alternate microbial biotechnological technique", "TREATMENT", 31, 80], ["a powerful technique", "TREATMENT", 300, 320], ["genomic DNA", "PROBLEM", 343, 354], ["prior culturing", "TEST", 407, 422]]], ["Analysis of the total metagenomic DNA by sequencing can reveal information about numerous features of the sample, which enables us to thoroughly understand the microbiome in any given environment i.e. air, water and soil (Meneghine et al., 2017; Behzad et al., 2015; Gastauer et al., 2019).", [["sample", "ANATOMY", 106, 112], ["DNA", "CELLULAR_COMPONENT", 34, 37], ["metagenomic DNA", "DNA", 22, 37], ["the total metagenomic DNA", "TEST", 12, 37]]], ["Metagenomics involve pyrosequencing technology, as one of the alternatives to the usual di-deoxynucleotide-sanger method for metagenomic DNA sequencing that provides reliable data about the important genes involved in the decontamination of environmental pollutant residues (Ibekwe et al., 2013).", [["DNA", "CELLULAR_COMPONENT", 137, 140], ["the usual di-deoxynucleotide-sanger method", "TREATMENT", 78, 120], ["metagenomic DNA sequencing", "TREATMENT", 125, 151]]], ["Although functional metagenomics, a powerful technique for the discovery of novel functional genes from unculturable microorganism which involves screening of the subsequent phenotypes by the artificially transforming metagenomic DNA in a suitable host to uncover a desired activity/product (Lim et al., 2014; Otto et al., 2020).", [["DNA", "CELLULAR_COMPONENT", 230, 233], ["metagenomic DNA", "DNA", 218, 233], ["a powerful technique", "TREATMENT", 34, 54], ["novel functional genes", "PROBLEM", 76, 98], ["unculturable microorganism", "PROBLEM", 104, 130], ["the subsequent phenotypes", "PROBLEM", 159, 184]]], ["The existence of so many novel gene families from these rich microbial diversity and uncultured populations pose a challenge for the understanding and exploration of the environmental microorganisms (Gilbert and Dupont, 2011; Schallmey et al., 2011).", [["a challenge", "TREATMENT", 113, 124]]], ["Based on literature evidences, the microbial population will undoubtedly undergo a further symbiotic shift or conjugation (vertical or horizontal) which will lead to recombination and evolution of novel strains with greater significance (Tilwari et al., 2013; Kirubakaran et al., 2017).", [["a further symbiotic shift", "PROBLEM", 81, 106], ["novel strains", "PROBLEM", 197, 210]]], ["Under these circumstances, metagenomics disciplines such as meta-transcriptomics, meta-proteomics, metabolomics and functional enzyme discovery can be successfully employed to extract the systematic information of the samples (Cheema et al., 2012; Hess et al., 2011).", [["samples", "ANATOMY", 218, 225], ["metagenomics disciplines", "PROBLEM", 27, 51], ["meta-transcriptomics", "TEST", 60, 80], ["meta-proteomics", "TEST", 82, 97], ["metabolomics", "TEST", 99, 111], ["functional enzyme discovery", "PROBLEM", 116, 143]]], ["Recently, metagenomics has been nurtured by the recreation of natural environmental settings combined with focused screening for novel discovery of industrial enzymes and drugs (Sarsaiya et al., 2019; Yao et al., 2011).", [["focused screening", "TEST", 107, 124], ["industrial enzymes", "TREATMENT", 148, 166]]], ["Hence, it is crucial that both natural environmental science and effective screening to be pursued as part of the innovative field of metagenomics (Shakoor et al., 2019).Metagenomic approach towards air ::: Metagenomic approach towards microbial biotechnologyMicroorganisms are far and wide in the air and is estimated that the concentrations approximately range between 104 and 106 microbes/m3.", [["effective screening", "TEST", 65, 84], ["Metagenomic approach", "TREATMENT", 207, 227], ["microbial biotechnologyMicroorganisms", "TEST", 236, 273], ["the concentrations", "TEST", 324, 342], ["wide", "OBSERVATION_MODIFIER", 286, 290], ["air", "OBSERVATION", 298, 301], ["concentrations", "OBSERVATION_MODIFIER", 328, 342]]], ["Previous studies suggested that microbes in atmospheric air are metabolically active, for example, in biogeochemical cycles they play prominent roles and act as a catalyst in natural processes such as nucleation of ice and cloud formation (Conrad et al., 2016; Nelkner et al., 2019).", [["Previous studies", "TEST", 0, 16], ["microbes in atmospheric air", "PROBLEM", 32, 59], ["microbes", "OBSERVATION_MODIFIER", 32, 40], ["atmospheric air", "OBSERVATION", 44, 59], ["metabolically", "OBSERVATION_MODIFIER", 64, 77], ["active", "OBSERVATION_MODIFIER", 78, 84], ["biogeochemical cycles", "OBSERVATION", 102, 123], ["prominent", "OBSERVATION_MODIFIER", 134, 143]]], ["It is worth noting that the increased cloud formation may possibly be implicated for earth global warming and climate changes; despite these crucial contributions, there are fewer reports on the probable impact of atmospheric microorganisms upon the environment (Gilbert and Dupont, 2011).", [["the increased cloud formation", "PROBLEM", 24, 53], ["earth global warming", "TREATMENT", 85, 105], ["atmospheric microorganisms", "PROBLEM", 214, 240], ["increased", "OBSERVATION_MODIFIER", 28, 37], ["cloud formation", "OBSERVATION", 38, 53], ["may possibly be", "UNCERTAINTY", 54, 69], ["atmospheric microorganisms", "OBSERVATION", 214, 240]]], ["Metagenomics has provided the information about atmospheric microbial diversity and their crucial metabolic impact on climate changes by molecular analysis of microbial genome through culture-independent studies (Schloss and Handelsman, 2003; Lorenz et al., 2002).", [["microbial genome", "DNA", 159, 175], ["atmospheric microbial diversity", "PROBLEM", 48, 79], ["molecular analysis", "TEST", 137, 155], ["microbial genome", "PROBLEM", 159, 175], ["culture", "TEST", 184, 191], ["microbial genome", "OBSERVATION", 159, 175]]], ["For metagenomic analysis, the air samples are collected using dry filter air sampler which are usually operated at a flowrate of 450 L/min and the samples are collected into the sterile sampling buffer for a required amount of time (varies between 2 and 12 h) depending on the environment.", [["air samples", "ANATOMY", 30, 41], ["samples", "ANATOMY", 147, 154], ["air samples", "CANCER", 30, 41], ["metagenomic analysis", "TEST", 4, 24], ["the air samples", "TEST", 26, 41], ["dry filter air sampler", "TREATMENT", 62, 84], ["the samples", "TEST", 143, 154], ["the sterile sampling buffer", "TREATMENT", 174, 201], ["filter air", "OBSERVATION", 66, 76]]], ["The sampling buffers are stored at 4 \u00b0C until further use and maintained under aseptic condition throughout the procedure.", [["The sampling buffers", "TREATMENT", 0, 20], ["aseptic condition", "TREATMENT", 79, 96], ["the procedure", "TREATMENT", 108, 121], ["aseptic condition", "OBSERVATION", 79, 96]]], ["The samples were further fractionated through different filters of size 3.0 \u03bcm to 0.1 \u03bcm to remove any unwanted biological substances other than the desired metagenomic DNA.", [["samples", "ANATOMY", 4, 11], ["DNA", "CELLULAR_COMPONENT", 169, 172], ["metagenomic DNA", "DNA", 157, 172], ["The samples", "TEST", 0, 11], ["different filters of size", "TREATMENT", 46, 71], ["any unwanted biological substances", "PROBLEM", 99, 133], ["the desired metagenomic DNA", "PROBLEM", 145, 172], ["size", "OBSERVATION_MODIFIER", 67, 71], ["metagenomic DNA", "OBSERVATION", 157, 172]]], ["BSL-II hoods and reagents sterilized with UV light are used to extract DNA with the available commercial kits.", [["BSL-II", "CHEMICAL", 0, 6], ["DNA", "CELLULAR_COMPONENT", 71, 74], ["UV light", "TREATMENT", 42, 50]]], ["Interestingly, few reports suggest that, due to the low density of microbes in the air, the DNA isolation must be coupled with an amplification of DNA fragments step to facilitate adequate recovery of the DNA (Fig. 1A) (King et al., 2016; Behzad et al., 2015; Yooseph et al., 2013; Ung et al., 2020).Metagenomic approach towards water ::: Metagenomic approach towards microbial biotechnologyMicrobes are found abundantly in both fresh and marine water bodies and play a prominent role in maintaining ecosystem and water quality.", [["DNA", "CELLULAR_COMPONENT", 92, 95], ["DNA", "CELLULAR_COMPONENT", 147, 150], ["DNA", "CELLULAR_COMPONENT", 205, 208], ["the low density of microbes in the air", "PROBLEM", 48, 86], ["the DNA isolation", "TREATMENT", 88, 105], ["an amplification of DNA fragments step", "TREATMENT", 127, 165], ["the DNA", "PROBLEM", 201, 208], ["Metagenomic approach", "TREATMENT", 339, 359], ["low density", "OBSERVATION_MODIFIER", 52, 63], ["microbes", "OBSERVATION", 67, 75], ["air", "ANATOMY", 83, 86], ["both fresh", "OBSERVATION_MODIFIER", 424, 434], ["marine", "OBSERVATION_MODIFIER", 439, 445], ["water bodies", "OBSERVATION", 446, 458], ["prominent", "OBSERVATION_MODIFIER", 470, 479], ["ecosystem", "OBSERVATION", 500, 509]]], ["Importantly, they play a crucial role in maintaining biogeochemical cycles and dissolved chemical constitution in water ecosystems (Shakoor et al., 2019; Sabale et al., 2019).", [["biogeochemical cycles", "TREATMENT", 53, 74], ["biogeochemical cycles", "OBSERVATION", 53, 74]]], ["The usability of water bodies is mainly determined by the dissolved oxygen, electrical conductivity, oxidation reduction potential, hydrogen ion concentrations, dissolved solids and turbidity (Mendes et al., 2014; Pan et al., 2014; Mason et al., 2014).", [["oxygen", "CHEMICAL", 68, 74], ["hydrogen", "CHEMICAL", 132, 140], ["oxygen", "CHEMICAL", 68, 74], ["hydrogen", "CHEMICAL", 132, 140], ["oxygen", "SIMPLE_CHEMICAL", 68, 74], ["hydrogen", "SIMPLE_CHEMICAL", 132, 140], ["the dissolved oxygen", "TREATMENT", 54, 74], ["electrical conductivity", "TREATMENT", 76, 99], ["oxidation reduction", "TREATMENT", 101, 120], ["hydrogen ion concentrations", "TREATMENT", 132, 159], ["water bodies", "OBSERVATION", 17, 29], ["dissolved oxygen", "OBSERVATION", 58, 74], ["electrical conductivity", "OBSERVATION", 76, 99]]], ["The chemical composition such as nitrate, ammonia, nitrite, phosphorus and dissolved reactive phosphorus are determined by the titre values of precipitation.", [["nitrate", "CHEMICAL", 33, 40], ["ammonia", "CHEMICAL", 42, 49], ["nitrite", "CHEMICAL", 51, 58], ["phosphorus", "CHEMICAL", 60, 70], ["phosphorus", "CHEMICAL", 94, 104], ["nitrate", "CHEMICAL", 33, 40], ["ammonia", "CHEMICAL", 42, 49], ["nitrite", "CHEMICAL", 51, 58], ["phosphorus", "CHEMICAL", 60, 70], ["phosphorus", "CHEMICAL", 94, 104], ["nitrate", "SIMPLE_CHEMICAL", 33, 40], ["ammonia", "SIMPLE_CHEMICAL", 42, 49], ["nitrite", "SIMPLE_CHEMICAL", 51, 58], ["phosphorus", "SIMPLE_CHEMICAL", 60, 70], ["dissolved reactive phosphorus", "SIMPLE_CHEMICAL", 75, 104], ["nitrate", "TREATMENT", 33, 40], ["ammonia", "TEST", 42, 49], ["nitrite", "TREATMENT", 51, 58], ["phosphorus", "TREATMENT", 60, 70], ["dissolved reactive phosphorus", "TEST", 75, 104], ["reactive phosphorus", "OBSERVATION", 85, 104]]], ["The irrigation water with heavy metal pollution, concentrated nutrients, toxins or pathogens can adversely impact the agricultural lands and the food production (Maurice et al., 2013; Gaytan et al., 2020).", [["The irrigation water", "TREATMENT", 0, 20], ["heavy metal pollution", "TREATMENT", 26, 47], ["toxins", "PROBLEM", 73, 79], ["pathogens", "PROBLEM", 83, 92], ["irrigation", "OBSERVATION", 4, 14]]], ["Therefore, it is essential to monitor the microbial population which directly or indirectly influences the water quality.", [["the microbial population", "PROBLEM", 38, 62]]], ["Metagenomic tools have been in use to assess the microbial population and diversity of water ecosystems.", [["Metagenomic tools", "TEST", 0, 17]]], ["Indeed, it has been used to determine the issues related to anthropogenic impacts on surface waters involving microbial community structure and the resulting re-structural biomes (Lefterova et al., 2015; Boulange et al., 2016; Nakagawa and Fujita, 2018; Samarkos et al., 2018).", [["surface waters", "ANATOMY", 85, 99], ["community", "ANATOMY", 120, 129]]], ["Microbes also aid with the deprivation and decontamination of toxic pollutants from industrial wastewater, an exogenous or microbial enzyme can be supplied to enhance the system to improve remediation process (Hess et al., 2011; Schloss and Handelsman, 2003; Cheema et al., 2012).", [["the deprivation", "TREATMENT", 23, 38], ["decontamination", "TREATMENT", 43, 58], ["toxic pollutants", "PROBLEM", 62, 78], ["industrial wastewater", "TREATMENT", 84, 105], ["an exogenous or microbial enzyme", "PROBLEM", 107, 139], ["toxic", "OBSERVATION_MODIFIER", 62, 67]]], ["Also, to determine the beneficial and pathogenic microbes, metagenomics can be employed as an efficient tool.", [["the beneficial and pathogenic microbes", "PROBLEM", 19, 57]]], ["Through this approach, we can improve the water quality which serves as an important measure to address the issues related to public health (Meneghine et al., 2017; Ahern et al., 2007).", [["this approach", "TREATMENT", 8, 21]]], ["For analysis of metagenome, the water samples are collected, usually in triplicates in sterile containers.", [["samples", "ANATOMY", 38, 45], ["metagenome", "PROBLEM", 16, 26], ["the water samples", "TREATMENT", 28, 45]]], ["The water samples, under sterile conditions, are concentrated using vacuum concentrator and subjected to a series of filtration with membrane filters, for example, 6 \u03bcm to 0.1 \u03bcm sized filters.", [["samples", "ANATOMY", 10, 17], ["membrane", "ANATOMY", 133, 141], ["The water samples", "TREATMENT", 0, 17], ["vacuum concentrator", "TREATMENT", 68, 87], ["filtration with membrane filters", "TREATMENT", 117, 149], ["0.1 \u03bcm sized filters", "TREATMENT", 172, 192], ["membrane filters", "OBSERVATION", 133, 149], ["sized", "OBSERVATION_MODIFIER", 179, 184], ["filters", "OBSERVATION", 185, 192]]], ["The meta-DNA can be isolated from those filter membranes using appropriate kit methods based on the manufacturer's protocol (Fig. 1B) (Calderon et al., 2017; Bharagava et al., 2019; Kori et al., 2019; Hamner et al., 2019).Metagenomic approach towards soil ::: Metagenomic approach towards microbial biotechnologyThe soil microbial population possibly has the highest level of microbial diversity of any environment.", [["filter membranes", "ANATOMY", 40, 56], ["DNA", "CELLULAR_COMPONENT", 9, 12], ["meta-DNA", "DNA", 4, 12], ["The meta-DNA", "TREATMENT", 0, 12], ["those filter membranes", "TREATMENT", 34, 56], ["appropriate kit methods", "TREATMENT", 63, 86], ["the manufacturer's protocol", "TREATMENT", 96, 123], ["Metagenomic approach", "TREATMENT", 260, 280], ["The soil microbial population", "PROBLEM", 312, 341], ["soil", "OBSERVATION_MODIFIER", 316, 320], ["microbial", "OBSERVATION_MODIFIER", 321, 330], ["population", "OBSERVATION", 331, 341], ["highest", "OBSERVATION_MODIFIER", 359, 366], ["microbial diversity", "OBSERVATION", 376, 395]]], ["Each gram of soil has been reported to be occupied by approximately 10 billion microorganisms and thousands of different microbial species (Putra et al., 2019; Gastauer et al., 2019).", [["different microbial species", "PROBLEM", 111, 138], ["microbial species", "OBSERVATION", 121, 138]]], ["Soil microbial community has been widely exploited for pharmaceutical and agricultural benefits and bioremediation of xenobiotics.", [["community", "ANATOMY", 15, 24], ["bioremediation of xenobiotics", "TREATMENT", 100, 129]]], ["Recently developed functional metagenomic tools provide relatively quick and extensive information of the metagenome samples, for example, meta-DNA sequencing provides complete sequence information of the DNA extracted at a moderate cost (Yadav et al., 2019; Ibekwe et al., 2013).", [["samples", "ANATOMY", 117, 124], ["DNA", "CELLULAR_COMPONENT", 144, 147], ["DNA", "CELLULAR_COMPONENT", 205, 208], ["functional metagenomic tools", "PROBLEM", 19, 47], ["the DNA", "PROBLEM", 201, 208], ["moderate", "OBSERVATION_MODIFIER", 224, 232]]], ["A lot of altered biomass remains such as edible vegetables, drainage, and animal dung are used for fertilizer.", [["vegetables", "ANATOMY", 48, 58], ["vegetables", "ORGANISM_SUBDIVISION", 48, 58], ["altered biomass", "PROBLEM", 9, 24], ["drainage", "TREATMENT", 60, 68], ["animal dung", "TREATMENT", 74, 85], ["fertilizer", "TREATMENT", 99, 109], ["altered", "OBSERVATION_MODIFIER", 9, 16], ["biomass", "OBSERVATION", 17, 24], ["edible vegetables", "OBSERVATION", 41, 58], ["drainage", "OBSERVATION", 60, 68]]], ["Studies have shown that organic matter with its enriched nutrients increased the bacterial diversity of the soil independent of the changes in climate conditions (Biver and Vandenbol, 2013; Biver et al., 2013; Calderon et al., 2017).", [["Studies", "TEST", 0, 7], ["organic matter", "PROBLEM", 24, 38], ["organic matter", "OBSERVATION", 24, 38], ["enriched", "OBSERVATION_MODIFIER", 48, 56], ["nutrients", "OBSERVATION_MODIFIER", 57, 66], ["increased", "OBSERVATION_MODIFIER", 67, 76], ["bacterial diversity", "OBSERVATION", 81, 100], ["soil independent", "OBSERVATION_MODIFIER", 108, 124]]], ["Furthermore, the use of chemical-based nitrogen fertilizers, phosphorus fertilizers and animal manure-based compost can also enhance the bacterial diversity.", [["nitrogen fertilizers", "CHEMICAL", 39, 59], ["phosphorus", "CHEMICAL", 61, 71], ["nitrogen", "CHEMICAL", 39, 47], ["phosphorus", "CHEMICAL", 61, 71], ["phosphorus", "SIMPLE_CHEMICAL", 61, 71], ["chemical-based nitrogen fertilizers", "TREATMENT", 24, 59], ["phosphorus fertilizers", "TREATMENT", 61, 83], ["animal manure-based compost", "TREATMENT", 88, 115], ["the bacterial diversity", "PROBLEM", 133, 156], ["bacterial diversity", "OBSERVATION", 137, 156]]], ["Based on these studies, it is evident that the supplement of manure can influence the microbial diversity which in turn can improve the fertility of the soil.", [["these studies", "TEST", 9, 22], ["manure", "TREATMENT", 61, 67], ["the microbial diversity", "PROBLEM", 82, 105]]], ["Metagenomic tools can be efficiently employed to determine the microbial diversity under different supplement conditions to attain highest level of nutrition enrichment (Chu et al., 2008; Ellila et al., 2019).", [["Metagenomic tools", "PROBLEM", 0, 17], ["different supplement conditions", "TREATMENT", 89, 120]]], ["In addition, Metagenomic approaches are widely used to discover the composition of microbial community and their bioremediation potential in a contaminated environment which will be discussed in biotechnological application section.", [["community", "ANATOMY", 93, 102], ["Metagenomic approaches", "TREATMENT", 13, 35], ["biotechnological application section", "TREATMENT", 195, 231]]], ["For soil metagenome analysis, the samples can be collected from different layers of soil based on the need and objective, and the soil samples must be transferred under ice cold conditions to preserve the samples (Deininger et al., 1998; Knapik et al., 2019).", [["samples", "ANATOMY", 34, 41], ["samples", "ANATOMY", 135, 142], ["soil metagenome analysis", "TEST", 4, 28], ["the samples", "TEST", 30, 41], ["the soil samples", "TEST", 126, 142]]], ["The sterile soil samples must be homogenized before extraction of DNA using appropriate technique (Fig. 1C).Metagenomic approach towards soil ::: Metagenomic approach towards microbial biotechnologyA general workflow of metagenomics, post DNA isolation is presented in Fig. 2.", [["soil samples", "ANATOMY", 12, 24], ["DNA", "CELLULAR_COMPONENT", 66, 69], ["DNA", "CELLULAR_COMPONENT", 239, 242], ["The sterile soil samples", "TREATMENT", 0, 24], ["extraction of DNA", "TREATMENT", 52, 69], ["appropriate technique (Fig", "TREATMENT", 76, 102], ["DNA isolation", "TREATMENT", 239, 252]]], ["Taken together, the metagenomic DNA collected from various environments viz. aerosols, soil and water samples from different sites represent the microbial communities and provide the essential information on their beneficial traits (Nelkner et al., 2019; Ngara and Zhang, 2018).Ecological application ::: Applications of metagenomicsEnvironmental microbes govern the biosphere and majority of them have not been studied completely (Yadav et al., 2019; Gastauer et al., 2019).", [["samples", "ANATOMY", 102, 109], ["communities", "ANATOMY", 155, 166], ["DNA", "CELLULAR_COMPONENT", 32, 35], ["metagenomic DNA", "DNA", 20, 35], ["the metagenomic DNA", "PROBLEM", 16, 35], ["aerosols", "TREATMENT", 77, 85], ["soil and water samples", "TREATMENT", 87, 109]]], ["Microbial consortia permit the scientists to carry out studies on natural communication and co-habitation (Hirsch et al., 2010; National Research Council, 2007).", [["Microbial consortia", "PROBLEM", 0, 19]]], ["Mutualism, parasitism, competition, predation neutralism, amensalism and commensalism play a major role in the stability and dynamics of microfloral communities; consequently, co-culturing enables the detection of complex interaction networks, as well dependent or independent signalling molecules (Delmont et al., 2011; Kori et al., 2019; Broderick et al., 2010).Ecological application ::: Applications of metagenomicsSince the invention of microscope, we are able to study only less than 1% of microbes and the rest are not easily accessible for the research because, the standard culturing practice is not helpful to study them (Schloss and Handelsman, 2003; Stanley and Sadowsky, 2015).", [["microfloral communities", "ANATOMY", 137, 160], ["Mutualism", "DISEASE", 0, 9], ["predation neutralism", "DISEASE", 36, 56], ["amensalism", "DISEASE", 58, 68], ["commensalism", "DISEASE", 73, 85], ["complex interaction networks", "PROTEIN", 214, 242], ["signalling molecules", "PROTEIN", 277, 297], ["parasitism", "PROBLEM", 11, 21], ["amensalism", "TREATMENT", 58, 68], ["metagenomics", "TREATMENT", 407, 419], ["microscope", "TEST", 442, 452], ["parasitism", "OBSERVATION", 11, 21]]], ["In fact, most powerful genomics analysis is applied to the whole community of microbes, bypassing the need to isolate and culture individual bacterial population portion in array to classify the microorganisms in the community (Steele and Streit, 2005; Alvarenga et al., 2017; Palackal et al., 2007).", [["culture individual bacterial population portion", "PROBLEM", 122, 169]]], ["The track of microbial community is important in a habitation as the microorganisms maintain or modify the environment and it is also responsible for survival of surrounding organisms (Garland and Mills, 1991; Joergensen and Wichern, 2008; Docherty et al., 2015).", [["community", "ANATOMY", 23, 32], ["surrounding organisms", "PROBLEM", 162, 183], ["microbial", "OBSERVATION_MODIFIER", 13, 22], ["community", "OBSERVATION_MODIFIER", 23, 32]]], ["Our present trend of knowledge about the media dependent techniques is unable to achieve the complete portion of microbial diversity and functioning of microorganisms residing even in a single environment (Bharagava et al., 2019).", [["the media dependent techniques", "TREATMENT", 37, 67], ["microorganisms", "PROBLEM", 152, 166]]], ["Thus, the novel methodology holds the potential to overcome the difficulties to capture the complete profile of microbial diversity (Chodak et al., 2013; Leckie, 2005; Liu et al., 1997; Sklarz et al., 2009).", [["the difficulties", "PROBLEM", 60, 76]]], ["While in silico tools considered the biomolecules, microorganisms, and their interaction, as one whole component, metagenomics provide novel directions to experiments and advances in functional tools, such as meta-transcriptomics, meta-proteomics, and metabolomics (Ngara and Zhang, 2018; Calderon et al., 2017; Tilwari et al., 2013; Miura et al., 2017).", [["the biomolecules", "PROBLEM", 33, 49], ["microorganisms", "PROBLEM", 51, 65]]], ["Therefore, metagenomic approach will be an important tool to understand the complex association and how these inter-relationships appear to benefit all other organisms in the environment.Agricultural benefits ::: Applications of metagenomicsThe field of metagenomics in agriculture helps to discover the habitat and metabolic potential of soil microbiomes, plant growth promoting microorganisms and new genes for better agro-products (Pii et al., 2016; Lavecchia et al., 2015; Gupta et al., 2018; Nelkner et al., 2019).", [["metagenomic approach", "TREATMENT", 11, 31], ["metagenomics", "TREATMENT", 229, 241], ["soil microbiomes", "PROBLEM", 339, 355], ["plant growth promoting microorganisms", "PROBLEM", 357, 394]]], ["Complex pattern of interactions including commensalism, mutualism, parasitism etc., occur among the microorganisms in the soil that lead to complex genome rearrangement (Carbonetto et al., 2014).", [["commensalism", "PROBLEM", 42, 54], ["mutualism", "PROBLEM", 56, 65], ["parasitism", "PROBLEM", 67, 77], ["the microorganisms", "PROBLEM", 96, 114], ["parasitism", "OBSERVATION", 67, 77]]], ["The profusion of gene cluster assigned for transcription results in excess nucleotide transport and metabolism, protein modification, membrane and wall biogenesis and intracellular trafficking and secretion in microbiome of cultivated fertilized soils compared to uncultivated soils (Mendes et al., 2014; Johanna et al., 2019).", [["membrane", "ANATOMY", 134, 142], ["wall", "ANATOMY", 147, 151], ["intracellular", "ANATOMY", 167, 180], ["nucleotide", "CHEMICAL", 75, 85], ["nucleotide", "CHEMICAL", 75, 85], ["nucleotide", "SIMPLE_CHEMICAL", 75, 85], ["membrane", "CELLULAR_COMPONENT", 134, 142], ["wall", "CELLULAR_COMPONENT", 147, 151], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 167, 180], ["excess nucleotide transport", "PROBLEM", 68, 95], ["protein modification", "TREATMENT", 112, 132], ["wall biogenesis", "PROBLEM", 147, 162], ["intracellular trafficking", "PROBLEM", 167, 192], ["cultivated fertilized soils", "PROBLEM", 224, 251], ["wall biogenesis", "OBSERVATION", 147, 162], ["intracellular trafficking", "OBSERVATION", 167, 192]]], ["Indeed, a shotgun metagenomics approach revealed that the taxonomic and functional diversities of microbial communities in the rhizosphere of soybean plants are based on the metabolic resemblances of the bacteria.", [["communities", "ANATOMY", 108, 119], ["soybean plants", "ORGANISM", 142, 156], ["soybean", "SPECIES", 142, 149], ["soybean", "SPECIES", 142, 149], ["a shotgun metagenomics approach", "TEST", 8, 39], ["soybean plants", "TREATMENT", 142, 156], ["the bacteria", "PROBLEM", 200, 212], ["functional", "OBSERVATION_MODIFIER", 72, 82], ["diversities", "OBSERVATION_MODIFIER", 83, 94], ["microbial", "OBSERVATION_MODIFIER", 98, 107], ["communities", "OBSERVATION_MODIFIER", 108, 119], ["soybean plants", "OBSERVATION", 142, 156], ["bacteria", "OBSERVATION", 204, 212]]], ["The study also stated that the blending of the microbiome community in the rhizosphere is a niche-based process (Pan et al., 2014; Mendes et al., 2014; Rastogi et al., 2013).", [["The study", "TEST", 0, 9]]], ["The shift in taxonomic composition and functional redundancy of microbial communities in rhizosphere properly explains the changes associated with the fertilization and agricultural management.", [["communities", "ANATOMY", 74, 85], ["The shift", "PROBLEM", 0, 9], ["taxonomic composition", "PROBLEM", 13, 34], ["the changes", "PROBLEM", 119, 130], ["the fertilization", "TREATMENT", 147, 164], ["agricultural management", "TREATMENT", 169, 192], ["shift", "OBSERVATION_MODIFIER", 4, 9], ["taxonomic composition", "OBSERVATION", 13, 34], ["functional redundancy", "OBSERVATION", 39, 60], ["microbial", "OBSERVATION_MODIFIER", 64, 73], ["communities", "OBSERVATION_MODIFIER", 74, 85]]], ["Understanding of the soil and rhizosphere microbiome through soil metagenomics can be used as a guiding line to innovate new agricultural norms for sustainable environment (Bevivino et al., 2014; Souza et al., 2015).Hydrocarbon degradation ::: Applications of metagenomicsLarge quantities of contaminants, mainly aromatic and aliphatic hydrocarbons having complex chemical structures released into the environment by industrial activities and accidental spills prevail in the environment for a longer time, resulting in contamination of the ecosystem (Meneghine et al., 2017).", [["Hydrocarbon", "CHEMICAL", 216, 227], ["aliphatic hydrocarbons", "CHEMICAL", 326, 348], ["Hydrocarbon", "CHEMICAL", 216, 227], ["aromatic and aliphatic hydrocarbons", "CHEMICAL", 313, 348], ["Hydrocarbon", "SIMPLE_CHEMICAL", 216, 227], ["aliphatic hydrocarbons", "SIMPLE_CHEMICAL", 326, 348], ["the soil and rhizosphere microbiome", "TREATMENT", 17, 52], ["soil metagenomics", "TREATMENT", 61, 78], ["a guiding line", "TREATMENT", 94, 108], ["Hydrocarbon degradation", "PROBLEM", 216, 239], ["metagenomics", "TREATMENT", 260, 272], ["Large quantities of contaminants", "PROBLEM", 272, 304], ["mainly aromatic and aliphatic hydrocarbons", "PROBLEM", 306, 348], ["quantities", "OBSERVATION_MODIFIER", 278, 288], ["contaminants", "OBSERVATION", 292, 304], ["aromatic", "OBSERVATION_MODIFIER", 313, 321], ["aliphatic hydrocarbons", "OBSERVATION", 326, 348], ["chemical structures", "OBSERVATION", 364, 383]]], ["The enzymes produced by the microorganisms can mediate the degradation and detoxification of hydrocarbons.", [["hydrocarbons", "CHEMICAL", 93, 105], ["hydrocarbons", "SIMPLE_CHEMICAL", 93, 105], ["enzymes", "PROTEIN", 4, 11], ["The enzymes", "TEST", 0, 11], ["the microorganisms", "PROBLEM", 24, 42], ["the degradation", "PROBLEM", 55, 70]]], ["The biodegradation by aerobic population has been documented by two pathways, involving either by intradiol or estradiol pathway for removal of aromatic rings of di or trihydroxylated intermediate compounds.", [["intradiol", "CHEMICAL", 98, 107], ["estradiol", "CHEMICAL", 111, 120], ["intradiol", "CHEMICAL", 98, 107], ["estradiol", "CHEMICAL", 111, 120], ["intradiol", "SIMPLE_CHEMICAL", 98, 107], ["estradiol", "SIMPLE_CHEMICAL", 111, 120], ["di or trihydroxylated intermediate compounds", "SIMPLE_CHEMICAL", 162, 206], ["estradiol pathway", "TREATMENT", 111, 128], ["removal", "TREATMENT", 133, 140], ["aromatic rings of di", "PROBLEM", 144, 164], ["trihydroxylated intermediate compounds", "PROBLEM", 168, 206], ["aromatic rings", "OBSERVATION", 144, 158], ["intermediate compounds", "OBSERVATION", 184, 206]]], ["The anaerobic class of microbial population degrading hydrocarbons in oil fields converts them into bitumen by targeting low molecular weight components (Thomas et al., 2012).", [["hydrocarbons", "CHEMICAL", 54, 66], ["hydrocarbons", "CHEMICAL", 54, 66], ["hydrocarbons", "SIMPLE_CHEMICAL", 54, 66], ["oil", "ORGANISM_SUBSTANCE", 70, 73], ["bitumen", "SIMPLE_CHEMICAL", 100, 107], ["anaerobic class", "OBSERVATION_MODIFIER", 4, 19], ["microbial", "OBSERVATION_MODIFIER", 23, 32], ["population", "OBSERVATION_MODIFIER", 33, 43], ["hydrocarbons", "OBSERVATION_MODIFIER", 54, 66], ["bitumen", "OBSERVATION_MODIFIER", 100, 107], ["low molecular", "OBSERVATION_MODIFIER", 121, 134]]], ["However, anaerobic bacteria able to degrade hydrocarbons found in deep petroleum reservoirs have not been isolated and cultured so far.", [["hydrocarbons", "CHEMICAL", 44, 56], ["hydrocarbons", "CHEMICAL", 44, 56], ["hydrocarbons", "SIMPLE_CHEMICAL", 44, 56], ["anaerobic bacteria", "PROBLEM", 9, 27], ["deep petroleum reservoirs", "TREATMENT", 66, 91], ["deep", "ANATOMY_MODIFIER", 66, 70], ["petroleum reservoirs", "OBSERVATION", 71, 91]]], ["There are numerous wild type bacteria and few genetically modified bacteria like \u201csuper bug\u201d are employed in hydrocarbon bioremediation (Gong et al., 2013).Hydrocarbon degradation ::: Applications of metagenomicsTo combat this scenario, metagenomic approach is an excellent avenue for finding new microbial strains and genes, gene clusters that are capable of degrading hydrocarbon contaminants (Pham et al., 2009; Youssef et al., 2009).", [["Hydrocarbon", "CHEMICAL", 156, 167], ["hydrocarbon", "CHEMICAL", 109, 120], ["Hydrocarbon", "CHEMICAL", 156, 167], ["hydrocarbon", "CHEMICAL", 370, 381], ["hydrocarbon", "SIMPLE_CHEMICAL", 109, 120], ["Hydrocarbon", "SIMPLE_CHEMICAL", 156, 167], ["numerous wild type bacteria", "PROBLEM", 10, 37], ["few genetically modified bacteria", "PROBLEM", 42, 75], ["metagenomics", "TREATMENT", 200, 212], ["metagenomic approach", "TREATMENT", 237, 257], ["new microbial strains and genes, gene clusters", "PROBLEM", 293, 339], ["numerous", "OBSERVATION_MODIFIER", 10, 18], ["wild type", "OBSERVATION_MODIFIER", 19, 28], ["bacteria", "OBSERVATION_MODIFIER", 29, 37], ["few", "OBSERVATION_MODIFIER", 42, 45], ["genetically", "OBSERVATION_MODIFIER", 46, 57], ["modified", "OBSERVATION_MODIFIER", 58, 66], ["bacteria", "OBSERVATION", 67, 75]]], ["The screening method for metagenomic clones are customized using atomized oil assay, oil coated agar plate overlay approach (P\u0142ociniczak et al., 2011; Karanth et al., 1999).", [["clones", "ANATOMY", 37, 43], ["clones", "CELL", 37, 43], ["oil", "ORGANISM_SUBSTANCE", 85, 88], ["The screening method", "TEST", 0, 20], ["metagenomic clones", "TREATMENT", 25, 43], ["atomized oil assay", "TREATMENT", 65, 83], ["oil coated agar plate overlay approach", "TREATMENT", 85, 123]]], ["Interestingly, in a study that constructed a metagenomic library from samples collected in an oil reservoir, comprised genes belonging to different pathways including metabolic pathways involved in the biodegradation of aromatic compounds with novel gene arrangements (Burch et al., 2010; Morikawa et al., 1992).", [["samples", "ANATOMY", 70, 77], ["oil", "ORGANISM_SUBSTANCE", 94, 97], ["a study", "TEST", 18, 25], ["an oil reservoir", "TREATMENT", 91, 107], ["oil reservoir", "OBSERVATION", 94, 107], ["metabolic pathways", "OBSERVATION", 167, 185], ["aromatic compounds", "OBSERVATION", 220, 238]]], ["Metagenomic approach is considered advantageous since it applies a special community of microorganisms by providing access to the taxonomic as well as functional gene composition (Mason et al., 2014; Garcia et al., 2014; Langelier et al., 2018).Xenobiotic degradation ::: Applications of metagenomicsXenobiotics are often persistent over long time in the environment resulting from human activities and released in large amounts into common sites.", [["Xenobiotic", "SIMPLE_CHEMICAL", 245, 255], ["human", "ORGANISM", 382, 387], ["human", "SPECIES", 382, 387], ["human", "SPECIES", 382, 387], ["Metagenomic approach", "TREATMENT", 0, 20], ["metagenomicsXenobiotics", "TREATMENT", 288, 311]]], ["Soil Microorganisms in their living environment can adapt to the presence of xenobiotics in several different ways: (i) toxic xenobiotic can result in the random mutation, (ii) mutations can also enhance the microbial ability to degrade a xenobiotic, (iii) can acquire novel genes encoding catabolic enzymes through horizontal transfer.", [["catabolic enzymes", "PROTEIN", 290, 307], ["Soil Microorganisms", "PROBLEM", 0, 19], ["xenobiotics", "TREATMENT", 77, 88], ["the random mutation", "PROBLEM", 151, 170], ["encoding catabolic enzymes", "TEST", 281, 307], ["horizontal transfer", "TREATMENT", 316, 335], ["Microorganisms", "OBSERVATION", 5, 19]]], ["It has been reported that, some microbial species can degrade large range of xenobiotics, especially poly-aromatic, halogenated and polyester molecules (Lisa Ufarte et al., 2015; Yashir et al., 2014; Jeffries et al., 2018; Ferrer et al., 2005).", [["poly-aromatic", "CHEMICAL", 101, 114], ["poly-aromatic, halogenated and polyester", "CHEMICAL", 101, 141], ["poly-aromatic", "SIMPLE_CHEMICAL", 101, 114], ["halogenated", "SIMPLE_CHEMICAL", 116, 127], ["polyester molecules", "SIMPLE_CHEMICAL", 132, 151], ["some microbial species", "PROBLEM", 27, 49], ["large", "OBSERVATION_MODIFIER", 62, 67]]], ["Elucidating the causal mechanisms for xenobiotic resistance and metabolism in microbes will reveal the host microbial communications, novel enzymes and provide an insight for the unexplained toxicity (Maurice et al., 2013; Itzel Gaytan et al., 2020).Xenobiotic degradation ::: Applications of metagenomicsThe gut microbiome is another important component of xenobiotic metabolism, the response of gut microbial population to the xenobiotics (drugs) can ultimately be used in analytical tests predicting drug therapeutic interventions (Knapik et al., 2019; Kirubakaran et al., 2018).", [["gut microbiome", "ANATOMY", 309, 323], ["gut", "ANATOMY", 397, 400], ["toxicity", "DISEASE", 191, 199], ["Xenobiotic", "SIMPLE_CHEMICAL", 250, 260], ["gut", "ORGANISM_SUBDIVISION", 309, 312], ["gut", "ORGANISM_SUBDIVISION", 397, 400], ["novel enzymes", "PROTEIN", 134, 147], ["xenobiotic resistance", "PROBLEM", 38, 59], ["metabolism in microbes", "PROBLEM", 64, 86], ["novel enzymes", "TEST", 134, 147], ["the unexplained toxicity", "PROBLEM", 175, 199], ["metagenomics", "TREATMENT", 293, 305], ["xenobiotic metabolism", "PROBLEM", 358, 379], ["the xenobiotics (drugs", "TREATMENT", 425, 447], ["analytical tests", "TEST", 475, 491], ["drug therapeutic interventions", "TREATMENT", 503, 533], ["xenobiotic metabolism", "OBSERVATION", 358, 379]]], ["Since the gut microbiome and their xenobiotic activity plays crucial role in host therapy, it is valuable to understand personalized microbiome through mNGS approach.", [["gut microbiome", "ANATOMY", 10, 24], ["gut", "ORGANISM_SUBDIVISION", 10, 13], ["host therapy", "TREATMENT", 77, 89]]], ["Indeed, the understanding of gut microbiome and host interactions through mNGS and metabolomics leads to development of novel drugs, biomarkers and therapeutic strategies (Spanogiannopoulos et al., 2016).", [["gut microbiome", "ANATOMY", 29, 43], ["gut", "ORGANISM_SUBDIVISION", 29, 32], ["novel drugs", "TREATMENT", 120, 131], ["biomarkers", "TEST", 133, 143], ["therapeutic strategies", "TREATMENT", 148, 170]]], ["Taken together, understanding the xenobiotic activity of in vivo and environmental microbiome through the metagenomic approach will benefit clinical and industrial research respectively.Industrial components ::: Applications of metagenomicsThe impact of metagenomics in industrial components is increasingly recognized in the agrochemical, pharmaceutical and several other industries.", [["the metagenomic approach", "TREATMENT", 102, 126], ["metagenomics", "TREATMENT", 228, 240], ["metagenomics in industrial components", "PROBLEM", 254, 291], ["metagenomics", "OBSERVATION", 254, 266], ["industrial components", "OBSERVATION", 270, 291]]], ["Metagenomics revolves around two categories: (i) production of secondary metabolites as bioactive products by microbial biocatalysts and (ii) synthesis and development of enzyme system from novel genes or gene clusters (Wong, 2010; Bashir et al., 2014; Lisa Ufrate et al., 2015).", [["secondary metabolites", "PROBLEM", 63, 84], ["bioactive products", "TREATMENT", 88, 106], ["microbial biocatalysts", "TREATMENT", 110, 132], ["enzyme system", "PROBLEM", 171, 184]]], ["Industries are keen in uncultivated microorganisms to explore the knowledge that has been identified through large-scale environmental genomics for several reasons including efficiency, economical, more suitable biocatalyst, novelty, maximum diversity and elusive metabolites (Lorenz and Eck, 2005).", [["large", "OBSERVATION_MODIFIER", 109, 114]]], ["Metagenomics promises to provide new molecules with diverse functions, the biocatalyst operating system with high efficiency, the detergent additives, bioactive compounds, fuels (alcohol, biodiesel), chemical intermediates for chemical and drug synthesis (Curtis et al., 2002; Ward, 2002; Schloss and Handelsman, 2004).", [["alcohol", "CHEMICAL", 179, 186], ["alcohol", "CHEMICAL", 179, 186], ["alcohol", "SIMPLE_CHEMICAL", 179, 186], ["biodiesel", "SIMPLE_CHEMICAL", 188, 197], ["Metagenomics promises", "TREATMENT", 0, 21], ["the biocatalyst operating system", "TREATMENT", 71, 103], ["high efficiency", "PROBLEM", 109, 124], ["the detergent additives", "TREATMENT", 126, 149], ["high efficiency", "OBSERVATION_MODIFIER", 109, 124]]], ["Various other industrially important enzymes produced through metagenomics are cellulases, lipases, xylanases, amylases, proteases etc., (Nazir, 2016; Lorenz et al., 2002; Coughlan et al., 2015; Kang et al., 2011) (refer Table 1).", [["lipases", "GENE_OR_GENE_PRODUCT", 91, 98], ["xylanases", "GENE_OR_GENE_PRODUCT", 100, 109], ["amylases", "GENE_OR_GENE_PRODUCT", 111, 119], ["enzymes", "PROTEIN", 37, 44], ["cellulases", "PROTEIN", 79, 89], ["lipases", "PROTEIN", 91, 98], ["xylanases", "PROTEIN", 100, 109], ["amylases", "PROTEIN", 111, 119], ["proteases", "PROTEIN", 121, 130], ["cellulases", "TEST", 79, 89], ["lipases", "TEST", 91, 98], ["xylanases", "TEST", 100, 109], ["amylases", "TEST", 111, 119]]], ["There are many examples in the literature where metagenomics has facilitated the process of degradation of toxic industrial pollutants and other components (Leigh et al., 2007).", [["toxic industrial pollutants", "PROBLEM", 107, 134], ["toxic", "OBSERVATION_MODIFIER", 107, 112], ["industrial pollutants", "OBSERVATION", 113, 134]]], ["For example, polychlorinated biphenyls, a synthetic aromatic compound, a component of adhesives and plastic materials widely used in the electronics industry and an organophosphorus insecticide, chlorpyrifos (3,5,6-trichloro-2-pyridinol (TCP)) which is widely used for crop protection have been degraded using the enzymes derived from metagenomic approach (Mukhopadhyaya et al., 2010; Uhlik et al., 2013).Clinical approach ::: Applications of metagenomicsMetagenomic approaches have been applied in various niches, ranging from the complex macroenvironment to human microbiome (Lavezzo et al., 2016; Samarkos et al., 2018).", [["polychlorinated biphenyls", "CHEMICAL", 13, 38], ["chlorpyrifos", "CHEMICAL", 195, 207], ["3,5,6-trichloro-2-pyridinol", "CHEMICAL", 209, 236], ["TCP", "CHEMICAL", 238, 241], ["polychlorinated biphenyls", "CHEMICAL", 13, 38], ["organophosphorus", "CHEMICAL", 165, 181], ["chlorpyrifos", "CHEMICAL", 195, 207], ["3,5,6-trichloro-2-pyridinol", "CHEMICAL", 209, 236], ["TCP", "CHEMICAL", 238, 241], ["polychlorinated biphenyls", "SIMPLE_CHEMICAL", 13, 38], ["chlorpyrifos", "SIMPLE_CHEMICAL", 195, 207], ["3,5,6-trichloro-2-pyridinol", "SIMPLE_CHEMICAL", 209, 236], ["TCP", "SIMPLE_CHEMICAL", 238, 241], ["human", "ORGANISM", 560, 565], ["enzymes", "PROTEIN", 314, 321], ["human", "SPECIES", 560, 565], ["human", "SPECIES", 560, 565], ["polychlorinated biphenyls", "PROBLEM", 13, 38], ["a synthetic aromatic compound", "PROBLEM", 40, 69], ["adhesives and plastic materials", "TREATMENT", 86, 117], ["an organophosphorus insecticide", "TREATMENT", 162, 193], ["chlorpyrifos", "TREATMENT", 195, 207], ["trichloro", "TREATMENT", 215, 224], ["pyridinol (TCP)", "TREATMENT", 227, 242], ["crop protection", "TREATMENT", 269, 284], ["the enzymes", "TEST", 310, 321], ["metagenomicsMetagenomic approaches", "TREATMENT", 443, 477], ["component", "OBSERVATION_MODIFIER", 73, 82], ["adhesives", "OBSERVATION_MODIFIER", 86, 95], ["plastic materials", "OBSERVATION", 100, 117]]], ["Metagenomic studies became increasingly accessible in the clinical settings with the advent of Next Generation Sequencing (NGS).", [["Metagenomic studies", "TEST", 0, 19]]], ["NGS can be used with two different approaches: targeted metagenomics, focusing on a specific target region or shotgun metagenomics, non-specifically amplifying all the sequences in a sample (Nakagawa and Fujita, 2018; Chiu and Miller, 2019).", [["target region", "DNA", 93, 106], ["NGS", "TREATMENT", 0, 3], ["targeted metagenomics", "PROBLEM", 47, 68]]], ["The clinical approach of metagenomic next-generation sequencing (mNGS) can help us to evaluate the comprehensive whole microbial community (Viruses, Bacteria, Fungi and Parasites) and their genetic material (DNA and RNA) in the host organisms (Chiu and Miller, 2019).", [["community", "ANATOMY", 129, 138], ["DNA", "CELLULAR_COMPONENT", 208, 211], ["metagenomic next-generation sequencing", "TREATMENT", 25, 63], ["Bacteria", "PROBLEM", 149, 157], ["Fungi", "PROBLEM", 159, 164], ["Parasites", "PROBLEM", 169, 178], ["their genetic material (DNA and RNA", "PROBLEM", 184, 219]]], ["The emerging mNGS approach changes the whole perspectives of diagnosis and treatment of infectious diseases.", [["infectious diseases", "DISEASE", 88, 107], ["infectious diseases", "PROBLEM", 88, 107], ["infectious", "OBSERVATION", 88, 98]]], ["Indeed, the technique is effectively used to study the antimicrobial resistance, clinical microbiome, human host response and also if applicable, in oncological sciences to extract the viral genome information (Human Microbiome Project Consortium, 2012; Rastogi and Sani, 2011).", [["human", "ORGANISM", 102, 107], ["Human", "ORGANISM", 211, 216], ["viral genome", "DNA", 185, 197], ["human", "SPECIES", 102, 107], ["Human", "SPECIES", 211, 216], ["human", "SPECIES", 102, 107], ["antimicrobial resistance", "OBSERVATION", 55, 79]]], ["For example, alterations of the microbiome, known as dysbiosis, had shown to be related to obesity, diabetes mellitus and inflammatory bowel disease and manipulation of the microbiome might be a route to treat these conditions, which can be achieved by mNGS method (Chiu and Miller, 2019; Boulange et al., 2018; Palmer et al., 2006).", [["bowel", "ANATOMY", 135, 140], ["dysbiosis", "DISEASE", 53, 62], ["obesity", "DISEASE", 91, 98], ["diabetes mellitus", "DISEASE", 100, 117], ["inflammatory bowel disease", "DISEASE", 122, 148], ["bowel", "ORGAN", 135, 140], ["dysbiosis", "PROBLEM", 53, 62], ["obesity", "PROBLEM", 91, 98], ["diabetes mellitus", "PROBLEM", 100, 117], ["inflammatory bowel disease", "PROBLEM", 122, 148], ["obesity", "OBSERVATION", 91, 98], ["inflammatory", "OBSERVATION_MODIFIER", 122, 134], ["bowel", "ANATOMY", 135, 140], ["disease", "OBSERVATION", 141, 148]]], ["Moreover, in oncology, whole-genome or directed NGS approaches identify the mutated genes and can be used simultaneously to uncover viruses associated with cancer (that is, herpes, papilloma and polyoma) and its host interactions through metabolomics study (Lefterova et al., 2015; Rota, 2003; Sotiriou and Pusztai, 2009; Samarkos et al., 2018).", [["cancer", "ANATOMY", 156, 162], ["papilloma", "ANATOMY", 181, 190], ["polyoma", "ANATOMY", 195, 202], ["cancer", "DISEASE", 156, 162], ["herpes, papilloma and polyoma", "DISEASE", 173, 202], ["cancer", "CANCER", 156, 162], ["herpes", "ORGANISM", 173, 179], ["papilloma", "CANCER", 181, 190], ["polyoma", "ORGANISM", 195, 202], ["mutated genes", "DNA", 76, 89], ["directed NGS approaches", "TREATMENT", 39, 62], ["cancer", "PROBLEM", 156, 162], ["herpes", "PROBLEM", 173, 179], ["papilloma and polyoma)", "PROBLEM", 181, 203], ["metabolomics study", "TEST", 238, 256], ["cancer", "OBSERVATION", 156, 162]]], ["Some early successes using this technology include, the discovery of the SARS coronavirus genes, profiling of mutations in cancer and in-depth microbiome analysis of different sites in the human body (Chiu and Miller, 2019).ConclusionMetagenomics an amalgam of genomics, structural biology, microbial biotechnology and genetic engineering investigates the illimitable environmental benefits of uncultured microbes.", [["cancer", "ANATOMY", 123, 129], ["body", "ANATOMY", 195, 199], ["SARS coronavirus", "DISEASE", 73, 89], ["cancer", "DISEASE", 123, 129], ["SARS coronavirus", "ORGANISM", 73, 89], ["cancer", "CANCER", 123, 129], ["human", "ORGANISM", 189, 194], ["body", "ORGANISM_SUBDIVISION", 195, 199], ["SARS coronavirus genes", "DNA", 73, 95], ["human", "SPECIES", 189, 194], ["SARS coronavirus", "SPECIES", 73, 89], ["human", "SPECIES", 189, 194], ["this technology", "TREATMENT", 27, 42], ["the SARS coronavirus genes", "PROBLEM", 69, 95], ["mutations in cancer", "PROBLEM", 110, 129], ["cancer", "OBSERVATION", 123, 129], ["human", "ANATOMY", 189, 194], ["body", "ANATOMY_MODIFIER", 195, 199], ["amalgam", "OBSERVATION", 250, 257]]], ["The discovery of bioactive substances using metagenomics has given the bioremediation, enzyme industries, and clinical diagnosis new directions.", [["bioactive substances", "TREATMENT", 17, 37], ["metagenomics", "TREATMENT", 44, 56], ["the bioremediation", "TREATMENT", 67, 85], ["bioactive substances", "OBSERVATION", 17, 37]]], ["Further advancement in metagenomics can enable humans to create a sustainable world, balancing ecosystems, improve agricultural production, and their productive bioremediation systems.", [["humans", "ORGANISM", 47, 53], ["humans", "SPECIES", 47, 53], ["humans", "SPECIES", 47, 53], ["productive", "OBSERVATION_MODIFIER", 150, 160]]], ["Clinical metagenome is a promising approach to effective diagnosis and personalized treatment.", [["personalized treatment", "TREATMENT", 71, 93]]], ["Metagenomics will be used successfully in environmental and clinical monitoring.", [["clinical monitoring", "TEST", 60, 79]]], ["Furthermore, clinical metagenomics and metatranscriptomics with metaresistomics enable to estimate pathogens pharmaceutical resistance and develop successful therapeutic strategies.Author contribution statementRangasamy Kirubakaran -Writing and Editing; KN Arul Jothi - Writing and conceptualization; Sundaravadivel Revathi - Writing and literature search; Nowsheen Shameem - Data collection and reviewing; Javid A. Parray Draft preparation and Final Editing.Uncited reference", [["clinical metagenomics", "TEST", 13, 34], ["metatranscriptomics", "TREATMENT", 39, 58], ["metaresistomics", "TREATMENT", 64, 79], ["successful therapeutic strategies", "TREATMENT", 147, 180], ["Rangasamy Kirubakaran", "TREATMENT", 210, 231], ["Javid A. Parray Draft preparation", "TREATMENT", 407, 440]]]], "456c269e26d84f144f14086bc555a5b0b325324e": [["Background InformationSignificance of Research Question/Purpose:Background InformationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing COVID19.", [["acute respiratory syndrome coronavirus", "DISEASE", 93, 131], ["viral infection", "DISEASE", 169, 184], ["Background InformationSevere acute respiratory syndrome coronavirus 2", "ORGANISM", 64, 133], ["SARS-CoV-2", "ORGANISM", 135, 145], ["COVID19", "GENE_OR_GENE_PRODUCT", 193, 200], ["InformationSevere acute respiratory syndrome coronavirus", "SPECIES", 75, 131], ["SARS-CoV-2", "SPECIES", 135, 145], ["acute respiratory syndrome coronavirus", "PROBLEM", 93, 131], ["SARS-CoV", "TEST", 135, 143], ["a rapidly emerging viral infection", "PROBLEM", 150, 184], ["acute", "OBSERVATION_MODIFIER", 93, 98], ["respiratory syndrome", "OBSERVATION", 99, 119], ["viral infection", "OBSERVATION", 169, 184]]], ["The current strategy uses a public health model of identifying infected cases, isolation, and quarantine to stop transmission.", [["isolation", "TREATMENT", 79, 88], ["infected", "OBSERVATION", 63, 71]]], ["Once exposed, observation is standard-of-care.Background InformationNo effective therapy currently exists for treatment.", [["Background InformationNo effective therapy", "TREATMENT", 46, 88], ["treatment", "TREATMENT", 110, 119]]], ["The lack of effective therapy diminishes persons presenting post-exposure for self-quarantine.", [["persons", "ORGANISM", 41, 48], ["persons", "SPECIES", 41, 48], ["effective therapy", "TREATMENT", 12, 29], ["effective", "OBSERVATION_MODIFIER", 12, 21], ["therapy", "OBSERVATION", 22, 29]]], ["Having an effective postexposure prophylaxis, even if only partially effective, may additionally create synergy for the public health strategy of case identification and isolation -if a safe prophylaxis is available.Background InformationPeople who develop COVID-19 disease generally develop signs and symptoms, including mild respiratory symptoms and fever, after an average of 5-6 days after exposure (i.e. mean incubation period).", [["respiratory", "ANATOMY", 327, 338], ["respiratory symptoms", "DISEASE", 327, 347], ["fever", "DISEASE", 352, 357], ["an effective postexposure prophylaxis", "TREATMENT", 7, 44], ["isolation", "TREATMENT", 170, 179], ["a safe prophylaxis", "TREATMENT", 184, 202], ["COVID-19 disease", "PROBLEM", 257, 273], ["signs and symptoms", "PROBLEM", 292, 310], ["mild respiratory symptoms", "PROBLEM", 322, 347], ["fever", "PROBLEM", 352, 357], ["effective", "OBSERVATION_MODIFIER", 10, 19], ["postexposure prophylaxis", "OBSERVATION", 20, 44], ["mild", "OBSERVATION_MODIFIER", 322, 326], ["fever", "OBSERVATION", 352, 357]]], ["The range of the incubation period is between 1 to 14 days.", [["range", "OBSERVATION_MODIFIER", 4, 9]]], ["[1] Most people infected with the COVID-19 virus have mild disease and recover.", [["people", "ORGANISM", 9, 15], ["COVID-19 virus", "ORGANISM", 34, 48], ["people", "SPECIES", 9, 15], ["COVID-19 virus", "SPECIES", 34, 48], ["the COVID", "TEST", 30, 39], ["mild disease", "PROBLEM", 54, 66], ["mild", "OBSERVATION_MODIFIER", 54, 58], ["disease", "OBSERVATION", 59, 66]]], ["Approximately 80% of laboratory-confirmed patients have had mild to moderate disease, which includes non-pneumonia and pneumonia cases, 14% have severe disease, and 6% are critically ill with respiratory failure, shock, and/or multiple organ dysfunction [1] .Preliminary Data:Chloroquine has in vitro activity in cell lines against SARS-CoV and SARS-CoV2.", [["respiratory", "ANATOMY", 192, 203], ["organ", "ANATOMY", 236, 241], ["cell lines", "ANATOMY", 313, 323], ["non-pneumonia", "DISEASE", 101, 114], ["pneumonia", "DISEASE", 119, 128], ["critically ill", "DISEASE", 172, 186], ["respiratory failure", "DISEASE", 192, 211], ["shock", "DISEASE", 213, 218], ["organ dysfunction", "DISEASE", 236, 253], ["Chloroquine", "CHEMICAL", 276, 287], ["SARS", "DISEASE", 345, 349], ["Chloroquine", "CHEMICAL", 276, 287], ["patients", "ORGANISM", 42, 50], ["organ", "ORGAN", 236, 241], ["Chloroquine", "SIMPLE_CHEMICAL", 276, 287], ["cell lines", "CELL", 313, 323], ["SARS-CoV", "ORGANISM", 332, 340], ["SARS-CoV2", "ORGANISM", 345, 354], ["cell lines", "CELL_LINE", 313, 323], ["patients", "SPECIES", 42, 50], ["SARS-CoV", "SPECIES", 332, 340], ["SARS-CoV2", "SPECIES", 345, 354], ["mild to moderate disease", "PROBLEM", 60, 84], ["non-pneumonia", "PROBLEM", 101, 114], ["pneumonia cases", "PROBLEM", 119, 134], ["severe disease", "PROBLEM", 145, 159], ["respiratory failure", "PROBLEM", 192, 211], ["shock", "PROBLEM", 213, 218], ["multiple organ dysfunction", "PROBLEM", 227, 253], ["Chloroquine", "TREATMENT", 276, 287], ["SARS", "PROBLEM", 332, 336], ["SARS", "PROBLEM", 345, 349], ["mild", "OBSERVATION_MODIFIER", 60, 64], ["moderate", "OBSERVATION_MODIFIER", 68, 76], ["disease", "OBSERVATION", 77, 84], ["pneumonia", "OBSERVATION", 119, 128], ["severe", "OBSERVATION_MODIFIER", 145, 151], ["disease", "OBSERVATION", 152, 159], ["respiratory failure", "OBSERVATION", 192, 211], ["shock", "OBSERVATION", 213, 218], ["multiple", "OBSERVATION_MODIFIER", 227, 235], ["organ", "ANATOMY", 236, 241], ["dysfunction", "OBSERVATION", 242, 253], ["cell lines", "OBSERVATION", 313, 323]]], ["In a Vero E6 cell line, the half-maximal effective concentration (EC50) activity of chloroquine was 1.13 \u03bcM against SARS-CoV2 [2] .", [["Vero E6 cell line", "ANATOMY", 5, 22], ["chloroquine", "CHEMICAL", 84, 95], ["SARS", "DISEASE", 116, 120], ["chloroquine", "CHEMICAL", 84, 95], ["Vero E6 cell line", "CELL", 5, 22], ["chloroquine", "SIMPLE_CHEMICAL", 84, 95], ["Vero E6 cell line", "CELL_LINE", 5, 22], ["Vero E6", "SPECIES", 5, 12], ["a Vero E6 cell line", "TREATMENT", 3, 22], ["chloroquine", "TREATMENT", 84, 95], ["E6 cell line", "OBSERVATION", 10, 22]]], ["Hydroxychloroquine is functionally equivalent as chloroquine.Preliminary Data:Another compound under treatment trials, remdesivir (Gilead) had an EC50 of 0.77 \u03bcM [2] .", [["Hydroxychloroquine", "CHEMICAL", 0, 18], ["chloroquine", "CHEMICAL", 49, 60], ["remdesivir", "CHEMICAL", 119, 129], ["Gilead", "CHEMICAL", 131, 137], ["Hydroxychloroquine", "CHEMICAL", 0, 18], ["chloroquine", "CHEMICAL", 49, 60], ["remdesivir", "CHEMICAL", 119, 129], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 0, 18], ["chloroquine", "SIMPLE_CHEMICAL", 49, 60], ["remdesivir", "SIMPLE_CHEMICAL", 119, 129], ["Hydroxychloroquine", "TREATMENT", 0, 18], ["chloroquine", "TREATMENT", 49, 60], ["treatment trials", "TREATMENT", 101, 117], ["an EC50", "TEST", 143, 150]]], ["Remdesivir (Gilead) is not FDA-approved and in limited quantities.", [["Remdesivir", "CHEMICAL", 0, 10], ["Gilead", "CHEMICAL", 12, 18], ["Remdesivir", "CHEMICAL", 0, 10], ["Remdesivir", "SIMPLE_CHEMICAL", 0, 10], ["Remdesivir (Gilead)", "TREATMENT", 0, 19]]], ["Hydroxychloroquine is FDA-approved and globally is inexpensive.", [["Hydroxychloroquine", "CHEMICAL", 0, 18], ["Hydroxychloroquine", "CHEMICAL", 0, 18], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 0, 18], ["Hydroxychloroquine", "TREATMENT", 0, 18]]], ["Chloroquine is no longer broadly available in the USA.Preliminary Data:Existing Literature:Preliminary Data:Several drugs, such as ribavirin, interferon, lopinavir-ritonavir, corticosteroids, have been used in patients with SARS or MERS, although the efficacy is poorly understood as a gold standard randomized clinical trial has not been conducted.", [["Chloroquine", "CHEMICAL", 0, 11], ["ribavirin", "CHEMICAL", 131, 140], ["interferon", "CHEMICAL", 142, 152], ["lopinavir-ritonavir", "CHEMICAL", 154, 173], ["corticosteroids", "CHEMICAL", 175, 190], ["SARS", "DISEASE", 224, 228], ["MERS", "DISEASE", 232, 236], ["Chloroquine", "CHEMICAL", 0, 11], ["ribavirin", "CHEMICAL", 131, 140], ["lopinavir", "CHEMICAL", 154, 163], ["ritonavir", "CHEMICAL", 164, 173], ["corticosteroids", "CHEMICAL", 175, 190], ["Chloroquine", "SIMPLE_CHEMICAL", 0, 11], ["ribavirin", "SIMPLE_CHEMICAL", 131, 140], ["interferon", "SIMPLE_CHEMICAL", 142, 152], ["lopinavir-ritonavir", "SIMPLE_CHEMICAL", 154, 173], ["corticosteroids", "SIMPLE_CHEMICAL", 175, 190], ["patients", "ORGANISM", 210, 218], ["interferon", "PROTEIN", 142, 152], ["patients", "SPECIES", 210, 218], ["Chloroquine", "TREATMENT", 0, 11], ["Several drugs", "TREATMENT", 108, 121], ["ribavirin", "TREATMENT", 131, 140], ["interferon", "TREATMENT", 142, 152], ["lopinavir", "TREATMENT", 154, 163], ["ritonavir", "TREATMENT", 164, 173], ["corticosteroids", "TREATMENT", 175, 190], ["SARS", "PROBLEM", 224, 228], ["a gold standard randomized clinical trial", "TREATMENT", 284, 325], ["no longer", "UNCERTAINTY", 15, 24]]], ["3 CDC investigators reported that post-infection chloroquine treatment was effective in vitro at preventing the spread of SARS-CoV infection in an in vitro cell-based system [3] .", [["cell", "ANATOMY", 156, 160], ["chloroquine", "CHEMICAL", 49, 60], ["SARS-CoV infection", "DISEASE", 122, 140], ["chloroquine", "CHEMICAL", 49, 60], ["chloroquine", "SIMPLE_CHEMICAL", 49, 60], ["SARS-CoV", "ORGANISM", 122, 130], ["cell", "CELL", 156, 160], ["SARS-CoV", "SPECIES", 122, 130], ["post-infection chloroquine treatment", "TREATMENT", 34, 70], ["SARS", "PROBLEM", 122, 126], ["CoV infection", "PROBLEM", 127, 140], ["CoV", "OBSERVATION_MODIFIER", 127, 130], ["infection", "OBSERVATION", 131, 140]]], ["Vincent et al reported:Preliminary Data:\"In order to investigate the antiviral properties of chloroquine on SARS-CoV after the initiation of infection, Vero E6 cells were infected with the virus and fresh medium supplemented with various concentrations of chloroquine was added immediately after virus adsorption.", [["Vero E6 cells", "ANATOMY", 152, 165], ["chloroquine", "CHEMICAL", 93, 104], ["SARS", "DISEASE", 108, 112], ["infection", "DISEASE", 141, 150], ["chloroquine", "CHEMICAL", 256, 267], ["chloroquine", "CHEMICAL", 93, 104], ["chloroquine", "CHEMICAL", 256, 267], ["chloroquine", "SIMPLE_CHEMICAL", 93, 104], ["SARS-CoV", "ORGANISM", 108, 116], ["Vero E6 cells", "CELL", 152, 165], ["chloroquine", "SIMPLE_CHEMICAL", 256, 267], ["Vero E6 cells", "CELL_LINE", 152, 165], ["SARS-CoV", "SPECIES", 108, 116], ["Vero E6", "SPECIES", 152, 159], ["the antiviral properties", "TREATMENT", 65, 89], ["chloroquine", "TREATMENT", 93, 104], ["SARS", "TREATMENT", 108, 112], ["infection", "PROBLEM", 141, 150], ["Vero E6 cells", "TREATMENT", 152, 165], ["the virus and fresh medium", "TREATMENT", 185, 211], ["chloroquine", "TREATMENT", 256, 267], ["virus adsorption", "TREATMENT", 296, 312], ["infection", "OBSERVATION", 141, 150]]], ["Infected cells were incubated for an additional 16-18 h, after which the presence of virus antigens was analyzed by indirect immunofluorescence analysis.", [["cells", "ANATOMY", 9, 14], ["cells", "CELL", 9, 14], ["virus antigens", "PROTEIN", 85, 99], ["Infected cells", "PROBLEM", 0, 14], ["virus antigens", "PROBLEM", 85, 99], ["indirect immunofluorescence analysis", "TEST", 116, 152], ["virus", "OBSERVATION", 85, 90]]], ["When chloroquine was added after the initiation of infection, there was a dramatic dose-dependent decrease in the number of virus antigen-positive cells ( Fig. 2A) .", [["cells", "ANATOMY", 147, 152], ["chloroquine", "CHEMICAL", 5, 16], ["infection", "DISEASE", 51, 60], ["chloroquine", "CHEMICAL", 5, 16], ["chloroquine", "SIMPLE_CHEMICAL", 5, 16], ["virus antigen-positive cells", "CELL_TYPE", 124, 152], ["chloroquine", "TREATMENT", 5, 16], ["infection", "PROBLEM", 51, 60], ["dependent decrease", "PROBLEM", 88, 106], ["virus antigen", "TEST", 124, 137], ["infection", "OBSERVATION", 51, 60], ["dramatic", "OBSERVATION_MODIFIER", 74, 82], ["dependent", "OBSERVATION_MODIFIER", 88, 97], ["decrease", "OBSERVATION_MODIFIER", 98, 106], ["positive cells", "OBSERVATION", 138, 152]]], ["As little as 0.1-1 \u03bcM chloroquine reduced the infection by 50% and up to 90-94% inhibition was observed with 33-100 \u03bcM concentrations (Fig. 2B) .", [["chloroquine", "CHEMICAL", 22, 33], ["infection", "DISEASE", 46, 55], ["chloroquine", "CHEMICAL", 22, 33], ["chloroquine", "SIMPLE_CHEMICAL", 22, 33], ["chloroquine", "TREATMENT", 22, 33], ["the infection", "PROBLEM", 42, 55], ["infection", "OBSERVATION", 46, 55]]], ["At concentrations of chloroquine in excess of 1 \u03bcM, only a small number of individual cells were initially infected, and the spread of the infection to adjacent cells was all but eliminated.", [["cells", "ANATOMY", 86, 91], ["cells", "ANATOMY", 161, 166], ["chloroquine", "CHEMICAL", 21, 32], ["infection", "DISEASE", 139, 148], ["chloroquine", "CHEMICAL", 21, 32], ["chloroquine", "SIMPLE_CHEMICAL", 21, 32], ["cells", "CELL", 86, 91], ["cells", "CELL", 161, 166], ["adjacent cells", "CELL_TYPE", 152, 166], ["chloroquine", "TREATMENT", 21, 32], ["individual cells", "PROBLEM", 75, 91], ["the infection to adjacent cells", "PROBLEM", 135, 166], ["small", "OBSERVATION_MODIFIER", 59, 64], ["infected", "OBSERVATION", 107, 115], ["spread", "OBSERVATION_MODIFIER", 125, 131], ["infection", "OBSERVATION", 139, 148]]], ["A half-maximal inhibitory effect (EC50) was estimated to occur at 4.4 \u00b1 1.0 \u03bcM chloroquine (Fig. 2C) .", [["chloroquine", "CHEMICAL", 79, 90], ["chloroquine", "CHEMICAL", 79, 90], ["chloroquine", "SIMPLE_CHEMICAL", 79, 90], ["EC50", "TEST", 34, 38], ["chloroquine (Fig", "TREATMENT", 79, 95]]], ["These data clearly show that the addition of chloroquine can effectively reduce the establishment of infection and spread of SARS-CoV if the drug is added immediately following virus adsorption.\" [3] 4 Vincent et al also reported: \"Since we observed antiviral effects by chloroquine immediately after virus adsorption, we further extended the analysis by adding chloroquine 3 and 5 h after virus adsorption and examined for the presence of virus antigens after 20 h.", [["chloroquine", "CHEMICAL", 45, 56], ["infection", "DISEASE", 101, 110], ["SARS", "DISEASE", 125, 129], ["chloroquine", "CHEMICAL", 271, 282], ["chloroquine", "CHEMICAL", 362, 373], ["chloroquine", "CHEMICAL", 45, 56], ["chloroquine", "CHEMICAL", 271, 282], ["chloroquine", "CHEMICAL", 362, 373], ["chloroquine", "SIMPLE_CHEMICAL", 45, 56], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 125, 133], ["chloroquine", "SIMPLE_CHEMICAL", 271, 282], ["chloroquine", "SIMPLE_CHEMICAL", 362, 373], ["virus antigens", "PROTEIN", 440, 454], ["SARS-CoV", "SPECIES", 125, 133], ["chloroquine", "TREATMENT", 45, 56], ["infection", "PROBLEM", 101, 110], ["SARS", "PROBLEM", 125, 129], ["antiviral effects", "TREATMENT", 250, 267], ["chloroquine", "TREATMENT", 271, 282], ["virus adsorption", "TREATMENT", 301, 317], ["the analysis", "TEST", 339, 351], ["chloroquine", "TREATMENT", 362, 373], ["virus adsorption", "TREATMENT", 390, 406], ["virus antigens", "PROBLEM", 440, 454], ["infection", "OBSERVATION", 101, 110]]], ["We found that chloroquine was still significantly effective even when added 5 h after infection (Fig. 3) ; however, to obtain equivalent antiviral effect, a higher concentration of chloroquine was required if the drug was added 3 or 5 h after adsorption.\" [3] Further experiments demonstrated that chloroquine impaired the terminal glycosylation of angiotensin-converting enzyme-2 (ACE2) receptor, which is the binding site for the envelope spike glycoprotein of SARS-CoV and SAR-CoV2 [3] .Preliminary Data:Conversely, chloroquine did not have activity against Middle East respiratory syndrome coronavirus (MERS-CoV), which may be related to MERS binding to CD26 receptor protein [4] .Preliminary Data:In a March 9, 2020 publication, hydroxychloroquine was found to have greater activity than chloroquine [5.", [["chloroquine", "CHEMICAL", 14, 25], ["infection", "DISEASE", 86, 95], ["chloroquine", "CHEMICAL", 181, 192], ["chloroquine", "CHEMICAL", 298, 309], ["angiotensin", "CHEMICAL", 349, 360], ["chloroquine", "CHEMICAL", 519, 530], ["Middle East respiratory syndrome coronavirus", "DISEASE", 561, 605], ["hydroxychloroquine", "CHEMICAL", 734, 752], ["chloroquine", "CHEMICAL", 793, 804], ["chloroquine", "CHEMICAL", 14, 25], ["chloroquine", "CHEMICAL", 181, 192], ["chloroquine", "CHEMICAL", 298, 309], ["chloroquine", "CHEMICAL", 519, 530], ["hydroxychloroquine", "CHEMICAL", 734, 752], ["chloroquine", "CHEMICAL", 793, 804], ["chloroquine", "SIMPLE_CHEMICAL", 14, 25], ["chloroquine", "SIMPLE_CHEMICAL", 181, 192], ["chloroquine", "SIMPLE_CHEMICAL", 298, 309], ["angiotensin-converting enzyme-2", "GENE_OR_GENE_PRODUCT", 349, 380], ["ACE2", "GENE_OR_GENE_PRODUCT", 382, 386], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 463, 471], ["SAR-CoV2", "GENE_OR_GENE_PRODUCT", 476, 484], ["chloroquine", "SIMPLE_CHEMICAL", 519, 530], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 561, 605], ["MERS-CoV", "ORGANISM", 607, 615], ["CD26 receptor", "GENE_OR_GENE_PRODUCT", 658, 671], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 734, 752], ["chloroquine", "SIMPLE_CHEMICAL", 793, 804], ["angiotensin-converting enzyme-2 (ACE2) receptor", "PROTEIN", 349, 396], ["envelope spike glycoprotein", "PROTEIN", 432, 459], ["SAR", "PROTEIN", 476, 479], ["MERS", "PROTEIN", 642, 646], ["CD26 receptor protein", "PROTEIN", 658, 679], ["SARS-CoV", "SPECIES", 463, 471], ["Middle East respiratory syndrome coronavirus", "SPECIES", 561, 605], ["MERS-CoV", "SPECIES", 607, 615], ["chloroquine", "TREATMENT", 14, 25], ["infection", "PROBLEM", 86, 95], ["a higher concentration of chloroquine", "TREATMENT", 155, 192], ["Further experiments", "TEST", 260, 279], ["chloroquine", "TREATMENT", 298, 309], ["angiotensin", "TREATMENT", 349, 360], ["converting enzyme-2 (ACE2) receptor", "TREATMENT", 361, 396], ["the binding site", "PROBLEM", 407, 423], ["SARS", "PROBLEM", 463, 467], ["chloroquine", "TREATMENT", 519, 530], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 561, 605], ["MERS binding", "PROBLEM", 642, 654], ["hydroxychloroquine", "TREATMENT", 734, 752], ["chloroquine", "TREATMENT", 793, 804], ["respiratory syndrome", "OBSERVATION", 573, 593]]], ["The SARS-CoV-2 EC 50 values for hydroxychloroquine were 6.14 \u03bcM at 24 hours and 0.72 \u03bcM at 48 hours, [5] .", [["SARS", "DISEASE", 4, 8], ["hydroxychloroquine", "CHEMICAL", 32, 50], ["hydroxychloroquine", "CHEMICAL", 32, 50], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 32, 50], ["The SARS", "TEST", 0, 8], ["CoV", "TEST", 9, 12], ["hydroxychloroquine", "TREATMENT", 32, 50]]], ["Conversely, chloroquine EC50 values were >100 \u03bcM at 24 hours and 18.01 \u03bcM at 48 hours [5] .", [["chloroquine", "CHEMICAL", 12, 23], ["chloroquine", "CHEMICAL", 12, 23], ["chloroquine", "SIMPLE_CHEMICAL", 12, 23], ["chloroquine EC50 values", "TEST", 12, 35]]], ["This inhibition assay was performed with Vero cells using an infectious dose of 100 plaque forming units.RationaleCurrent standard of care is observation and quarantine after exposure to COVID19.RationaleAs of March 6, 2020, the CDC estimates that the transmission of SARS-CoV2 after a U.S. household close contract is 10.5% (95%CI, 2.9 to 31.4%) [6] .", [["Vero cells", "ANATOMY", 41, 51], ["plaque", "ANATOMY", 84, 90], ["COVID19", "CHEMICAL", 187, 194], ["SARS", "DISEASE", 268, 272], ["COVID19", "CHEMICAL", 187, 194], ["Vero cells", "CELL", 41, 51], ["SARS-CoV2", "ORGANISM", 268, 277], ["Vero cells", "CELL_LINE", 41, 51], ["COVID19", "PROTEIN", 187, 194], ["This inhibition assay", "TEST", 0, 21], ["Vero cells", "TREATMENT", 41, 51], ["an infectious dose of 100 plaque forming units", "TREATMENT", 58, 104], ["COVID19", "TREATMENT", 187, 194], ["SARS", "PROBLEM", 268, 272], ["CI", "TEST", 329, 331]]], ["Among all close contacts, the SARS-CoV2 transmission rate is estimated at 0.45% (95%CI, 0.12 to 1.6%) by the CDC.", [["SARS", "DISEASE", 30, 34], ["the SARS", "TEST", 26, 34], ["CI", "TEST", 84, 86]]], ["Conversely, in a setting with community transmission, the secondary attack rate in China was 35% (95%CI, 27-44%) based on 48 transmissions among 137 persons in 9 index patients.RationaleChloroquine or Hydroxychloroquine may have antiviral effects against SARS-COV2 which may prevent COVID19 disease or early preemptive therapy may ameliorate disease severity.", [["Chloroquine", "CHEMICAL", 186, 197], ["Hydroxychloroquine", "CHEMICAL", 201, 219], ["SARS", "DISEASE", 255, 259], ["Chloroquine", "CHEMICAL", 186, 197], ["Hydroxychloroquine", "CHEMICAL", 201, 219], ["persons", "ORGANISM", 149, 156], ["patients", "ORGANISM", 168, 176], ["Chloroquine", "SIMPLE_CHEMICAL", 186, 197], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 201, 219], ["SARS-COV2", "ORGANISM", 255, 264], ["COVID19", "GENE_OR_GENE_PRODUCT", 283, 290], ["persons", "SPECIES", 149, 156], ["patients", "SPECIES", 168, 176], ["the secondary attack rate", "TEST", 54, 79], ["CI", "TEST", 101, 103], ["RationaleChloroquine", "TREATMENT", 177, 197], ["Hydroxychloroquine", "TREATMENT", 201, 219], ["antiviral effects", "TREATMENT", 229, 246], ["SARS", "PROBLEM", 255, 259], ["COV2", "TREATMENT", 260, 264], ["COVID19 disease", "PROBLEM", 283, 298], ["early preemptive therapy", "TREATMENT", 302, 326], ["disease severity", "PROBLEM", 342, 358]]], ["This trial will use a modification of standard malaria dosing of hydroxychloroquine to provide postexposure prophylaxis / preemptive therapy.RationaleStandard malaria treatment dosing is:Rationale\u2022 800mg once, then 400mg in 6-8 hours, then 400mg daily x 2 days (3 days in total).", [["malaria", "DISEASE", 47, 54], ["hydroxychloroquine", "CHEMICAL", 65, 83], ["malaria", "DISEASE", 159, 166], ["hydroxychloroquine", "CHEMICAL", 65, 83], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 65, 83], ["a modification of standard malaria dosing", "TREATMENT", 20, 61], ["hydroxychloroquine", "TREATMENT", 65, 83], ["postexposure prophylaxis", "TREATMENT", 95, 119], ["preemptive therapy", "TREATMENT", 122, 140], ["RationaleStandard malaria treatment dosing", "TREATMENT", 141, 183], ["Rationale\u2022", "TREATMENT", 187, 197]]], ["We propose to dose for SARS-CoV-2 post-exposure prophylaxis at:Rationale\u2022 800mg once, then 600mg in 6-8 hours, then 600mg daily x 4 days (5 days in total).", [["SARS", "DISEASE", 23, 27], ["SARS-CoV", "SPECIES", 23, 31], ["SARS", "PROBLEM", 23, 27], ["CoV", "TEST", 28, 31], ["exposure prophylaxis", "TREATMENT", 39, 59], ["Rationale\u2022", "TREATMENT", 63, 73]]], ["A delayed start to prophylaxis will be occurring --based on the intrinsic delay from the exposure to case notification to trial enrollment, and to receipt of the first medication dose.", [["prophylaxis", "TREATMENT", 19, 30], ["the first medication dose", "TREATMENT", 158, 183]]], ["Thereby, higher doses may be necessary as seen in the CDC study [3] .", [["the CDC study", "TEST", 50, 63]]], ["Thus a malaria loading dose sequence will be used, but with higher daily doses thereafter to target reaching the above the EC50.RationaleAs the incubation period is 2-14 days with a mean incubation period of 5-6 days, we seek to deliver post-exposure prophylaxis by the morning of day 4 at the latest. (<=3 days is an inclusion criteria).", [["malaria", "DISEASE", 7, 14], ["a malaria loading dose sequence", "TREATMENT", 5, 36], ["post-exposure prophylaxis", "TREATMENT", 237, 262]]], ["We recognize this may turn \"post-exposure prophylaxis\" into more of a \"preemptive therapy\" for some subjects who rapidly develop disease after trial randomization.", [["a \"preemptive therapy", "TREATMENT", 68, 89], ["disease", "PROBLEM", 129, 136], ["trial randomization", "TREATMENT", 143, 162]]], ["If hydroxychloroquine does not prevent disease for some, preemptive therapy may ameliorate the COVID19 disease severity.", [["hydroxychloroquine", "CHEMICAL", 3, 21], ["hydroxychloroquine", "CHEMICAL", 3, 21], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 3, 21], ["COVID19", "GENE_OR_GENE_PRODUCT", 95, 102], ["hydroxychloroquine", "TREATMENT", 3, 21], ["disease", "PROBLEM", 39, 46], ["preemptive therapy", "TREATMENT", 57, 75], ["the COVID19 disease severity", "PROBLEM", 91, 119]]], ["Attenuated disease may in turn be associated with reduced rates of transmission.Potential RisksShort-term use of hydroxychloroquine is well-tolerated with a safe track record since 1955.", [["hydroxychloroquine", "CHEMICAL", 113, 131], ["hydroxychloroquine", "CHEMICAL", 113, 131], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 113, 131], ["Attenuated disease", "PROBLEM", 0, 18], ["reduced rates of transmission", "PROBLEM", 50, 79], ["hydroxychloroquine", "TREATMENT", 113, 131], ["disease", "OBSERVATION", 11, 18], ["reduced", "OBSERVATION_MODIFIER", 50, 57], ["rates", "OBSERVATION_MODIFIER", 58, 63]]], ["The most common reported side effects include:Potential Risks\u2022 headache, dizziness, ringing in your ears; \u2022 nausea, vomiting, stomach pain; \u2022 loss of appetite, weight loss; \u2022 mood changes, feeling nervous or irritable; \u2022 skin rash or itching; or. \u2022 hair loss.Potential RisksGI side effects are minimized when taken with a meal or with milk.", [["ears", "ANATOMY", 100, 104], ["stomach", "ANATOMY", 126, 133], ["nervous", "ANATOMY", 197, 204], ["skin", "ANATOMY", 221, 225], ["hair", "ANATOMY", 249, 253], ["milk", "ANATOMY", 335, 339], ["headache", "DISEASE", 63, 71], ["dizziness", "DISEASE", 73, 82], ["nausea", "DISEASE", 108, 114], ["vomiting", "DISEASE", 116, 124], ["stomach pain", "DISEASE", 126, 138], ["loss of appetite", "DISEASE", 142, 158], ["weight loss", "DISEASE", 160, 171], ["skin rash", "DISEASE", 221, 230], ["itching", "DISEASE", 234, 241], ["hair loss", "DISEASE", 249, 258], ["ears", "ORGAN", 100, 104], ["stomach", "ORGANISM_SUBDIVISION", 126, 133], ["skin", "ORGAN", 221, 225], ["hair", "MULTI-TISSUE_STRUCTURE", 249, 253], ["milk", "ORGANISM_SUBSTANCE", 335, 339], ["headache", "PROBLEM", 63, 71], ["dizziness", "PROBLEM", 73, 82], ["ringing in your ears", "PROBLEM", 84, 104], ["\u2022", "PROBLEM", 106, 107], ["nausea", "PROBLEM", 108, 114], ["vomiting", "PROBLEM", 116, 124], ["stomach pain", "PROBLEM", 126, 138], ["loss of appetite", "PROBLEM", 142, 158], ["weight loss", "PROBLEM", 160, 171], ["mood changes", "PROBLEM", 175, 187], ["feeling nervous", "PROBLEM", 189, 204], ["irritable", "PROBLEM", 208, 217], ["skin rash", "PROBLEM", 221, 230], ["itching", "PROBLEM", 234, 241], ["hair loss", "PROBLEM", 249, 258], ["Potential RisksGI side effects", "PROBLEM", 259, 289], ["ears", "ANATOMY", 100, 104], ["stomach", "ANATOMY", 126, 133], ["skin", "ANATOMY", 221, 225], ["rash", "OBSERVATION", 226, 230], ["hair loss", "OBSERVATION", 249, 258]]], ["Antacid medications should be spaced apart by at least 4 hours.Potential Risks\u2022 Potential adverse effects by system, as listed on the FDA package insert:Potential Risks\u25cb Eye: \"Chloroquine retinopathy\" is a rate side-effect of chronic use after multiple years of use.", [["Chloroquine", "CHEMICAL", 176, 187], ["retinopathy", "DISEASE", 188, 199], ["Chloroquine", "CHEMICAL", 176, 187], ["Chloroquine", "SIMPLE_CHEMICAL", 176, 187], ["Antacid medications", "TREATMENT", 0, 19], ["Potential adverse effects", "PROBLEM", 80, 105], ["Chloroquine retinopathy", "PROBLEM", 176, 199], ["Eye", "ANATOMY", 170, 173], ["chronic", "OBSERVATION_MODIFIER", 226, 233]]], ["This has not occurred with <1 year of continuous use.Study ObjectivesTo determine if post-exposure prophylaxis with hydroxychloroquine is effective at prevention of COVID19 disease or ameliorating disease severity.", [["hydroxychloroquine", "CHEMICAL", 116, 134], ["COVID19", "CHEMICAL", 165, 172], ["hydroxychloroquine", "CHEMICAL", 116, 134], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 116, 134], ["Study Objectives", "TEST", 53, 69], ["post-exposure prophylaxis", "TREATMENT", 85, 110], ["hydroxychloroquine", "TREATMENT", 116, 134], ["COVID19 disease", "PROBLEM", 165, 180], ["ameliorating disease severity", "PROBLEM", 184, 213], ["ameliorating", "OBSERVATION_MODIFIER", 184, 196], ["disease", "OBSERVATION", 197, 204]]], ["As necessary, COVID19 disease will be verified from public health records, medical records, or death certificates.STUDY DESIGNThere are two strata: 1) asymptomatic exposures; 2) symptomatic COVID-19 disease Follow up will occur up to 90 days for those with symptomatic COVID-19 disease.4.4Individually identifiable health information: Name, date of birth, and phone number will be collected so as to prescribe study medication.", [["death", "DISEASE", 95, 100], ["COVID19", "GENE_OR_GENE_PRODUCT", 14, 21], ["COVID19 disease", "PROBLEM", 14, 29], ["asymptomatic exposures", "PROBLEM", 151, 173], ["symptomatic COVID-19 disease", "PROBLEM", 178, 206], ["symptomatic COVID-19 disease", "PROBLEM", 257, 285], ["study medication", "TREATMENT", 410, 426]]], ["If participants are hospitalized, the hospitalization date will be collected.Substudies (if applicable)N/ASTUDY ENROLLMENT AND WITHDRAWALParticipants will undergo screening via internet-based google forms.", [["participants", "SPECIES", 3, 15], ["screening", "TEST", 163, 172]]], ["The screening and inclusion criteria will be based on self-report.", [["The screening", "TEST", 0, 13]]], ["Mean Incubation period is ~5.2 days, thus we wish to limit enrollment to those with a higher risk of progression and deliver study medicine in a time period to intervene to COVID-19 PEP RCT Version 1.0 17 March 2020 prevent disease or ameliorate disease (i.e. start of study medicine by <=4 days after exposure).", [["COVID", "TEST", 173, 178], ["PEP RCT Version", "TREATMENT", 182, 197], ["disease", "PROBLEM", 224, 231], ["ameliorate disease", "PROBLEM", 235, 253], ["study medicine", "TREATMENT", 269, 283]]], ["The current (as of March 17, 2020) delays in testing makes this window particularly tight, and it may need to be relaxed in the future via protocol amendment.Subject Inclusion CriteriaIn clinical practice of tropical medicine, chloroquine or hydroxychloroquine are prescribed without any baseline laboratory testing or monitoring.Subject Inclusion CriteriaChronic use of hydroxychloroquine for >1 year can cause retinopathy or cardiomyopathy, thus persons with baseline conditions will be excluded.", [["chloroquine", "CHEMICAL", 227, 238], ["hydroxychloroquine", "CHEMICAL", 242, 260], ["hydroxychloroquine", "CHEMICAL", 371, 389], ["retinopathy", "DISEASE", 412, 423], ["cardiomyopathy", "DISEASE", 427, 441], ["chloroquine", "CHEMICAL", 227, 238], ["hydroxychloroquine", "CHEMICAL", 242, 260], ["hydroxychloroquine", "CHEMICAL", 371, 389], ["chloroquine", "SIMPLE_CHEMICAL", 227, 238], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 242, 260], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 371, 389], ["persons", "ORGANISM", 448, 455], ["persons", "SPECIES", 448, 455], ["delays in testing", "TEST", 35, 52], ["tropical medicine", "TREATMENT", 208, 225], ["chloroquine", "TREATMENT", 227, 238], ["hydroxychloroquine", "TREATMENT", 242, 260], ["laboratory testing", "TEST", 297, 315], ["monitoring", "TEST", 319, 329], ["hydroxychloroquine", "TREATMENT", 371, 389], ["retinopathy", "PROBLEM", 412, 423], ["cardiomyopathy", "PROBLEM", 427, 441], ["baseline conditions", "PROBLEM", 461, 480], ["retinopathy", "OBSERVATION", 412, 423], ["cardiomyopathy", "OBSERVATION", 427, 441]]], ["Study medicine is excreted via the kidney with dose reduction recommended in CrCl <30 cc/min (Stage 4 Kidney Disease).", [["kidney", "ANATOMY", 35, 41], ["Kidney", "ANATOMY", 102, 108], ["Kidney Disease", "DISEASE", 102, 116], ["kidney", "ORGAN", 35, 41], ["CrCl", "SIMPLE_CHEMICAL", 77, 81], ["Kidney", "ORGAN", 102, 108], ["Study medicine", "TREATMENT", 0, 14], ["dose reduction", "TREATMENT", 47, 61], ["CrCl", "TEST", 77, 81], ["Stage 4 Kidney Disease", "PROBLEM", 94, 116], ["kidney", "ANATOMY", 35, 41], ["Kidney", "ANATOMY", 102, 108], ["Disease", "OBSERVATION", 109, 116]]], ["G-6-PD deficiency is listed as a caution on the FDA label.", [["G-6-PD", "CHEMICAL", 0, 6], ["G-6", "GENE_OR_GENE_PRODUCT", 0, 3], ["G", "TEST", 0, 1], ["PD deficiency", "PROBLEM", 4, 17]]], ["G-6-PD testing is not routinely performed in clinical care prior to giving hydroxychloroquine prescriptions (unlike with primaquine).", [["G-6-PD", "CHEMICAL", 0, 6], ["hydroxychloroquine", "CHEMICAL", 75, 93], ["primaquine", "CHEMICAL", 121, 131], ["hydroxychloroquine", "CHEMICAL", 75, 93], ["primaquine", "CHEMICAL", 121, 131], ["G-6", "GENE_OR_GENE_PRODUCT", 0, 3], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 75, 93], ["primaquine", "SIMPLE_CHEMICAL", 121, 131], ["G", "TEST", 0, 1], ["PD testing", "TEST", 4, 14], ["hydroxychloroquine prescriptions", "TREATMENT", 75, 107], ["primaquine", "TREATMENT", 121, 131]]], ["Medication exclusions are for possible drug-drug interactions, particularly with cardiac arrhythmia medicines with a caution on the FDApackage insert.Randomization ProceduresParticipants will be randomized via permuted block randomization.", [["cardiac", "ANATOMY", 81, 88], ["cardiac arrhythmia", "DISEASE", 81, 99], ["cardiac", "ORGAN", 81, 88], ["FDApackage insert", "DNA", 132, 149], ["Medication exclusions", "TREATMENT", 0, 21], ["cardiac arrhythmia medicines", "TREATMENT", 81, 109], ["the FDApackage insert", "TREATMENT", 128, 149], ["Randomization ProceduresParticipants", "TREATMENT", 150, 186], ["permuted block randomization", "TREATMENT", 210, 238]]], ["Randomization will be recorded on an electronic log by the pharmacy.", [["Randomization", "TREATMENT", 0, 13]]], ["Study investigators and subjects will be blinded.", [["Study investigators", "TEST", 0, 19]]], ["Randomization will be stratified by symptom/disease status at time of entry.Masking ProceduresParticipants will be provided masked study medicine, shipped by courier (e.g. FedEx).", [["Randomization", "TREATMENT", 0, 13]]], ["The intervention vs. placebo will not be identical; however, participants and outcome assessors will be masked to their assignment.Reasons for WithdrawalParticipants may withdraw at any time point at their discretion.Handling of WithdrawalsWithdraws will be counted as failures for the secondary endpoint of completion of study medication.Termination of StudyThis study may be prematurely terminated if there is sufficient reasonable cause, including but not limited to:Termination of Study\u2022 Unexpected, significant, or unacceptable risk to subjects \u2022 Interim analyses by the DSMB.Termination of Study\u2022 Insufficient compliance with protocol requirements \u2022 Data are not sufficiently complete and/or not evaluable \u2022 Regulatory authorities decide that study should be terminated If the study is prematurely terminated for harm, current subjects will complete follow up, and no further subjects will be enrolled.", [["participants", "SPECIES", 61, 73], ["The intervention", "TREATMENT", 0, 16], ["placebo", "TREATMENT", 21, 28], ["WithdrawalParticipants", "TREATMENT", 143, 165], ["study medication", "TREATMENT", 322, 338], ["Study", "TEST", 354, 359], ["This study", "TEST", 359, 369], ["Study", "TEST", 485, 490], ["Interim analyses", "TEST", 552, 568], ["Study", "TEST", 596, 601], ["protocol requirements", "TREATMENT", 632, 653], ["the study", "TEST", 779, 788], ["significant", "OBSERVATION_MODIFIER", 504, 515]]], ["If the study is terminated due to benefit, then the study will immediately convert into an open-label prospective cohort to collect further observational data on the safety and efficacy of the intervention, up to the IRB approved recruitment limit.", [["the study", "TEST", 3, 12], ["the study", "TEST", 48, 57], ["observational data", "TEST", 140, 158], ["the intervention", "TREATMENT", 189, 205], ["recruitment limit", "OBSERVATION", 230, 247]]], ["FDA-approved formulation of hydroxychloroquine will be purchased.Formulation, Packaging, and LabelingThe study medicines will be packaged by the MHealth Investigational Drug Services.", [["hydroxychloroquine", "CHEMICAL", 28, 46], ["hydroxychloroquine", "CHEMICAL", 28, 46], ["FDA", "SIMPLE_CHEMICAL", 0, 3], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 28, 46], ["hydroxychloroquine", "TREATMENT", 28, 46], ["Packaging", "TREATMENT", 78, 87], ["The study medicines", "TREATMENT", 101, 120]]], ["Dispensed medications will be delivered by courier (e.g. Fedex) to study participants.Drug Description:Hydroxychloroquine sulfatePharmacokinetics:\u2022 Absorption: Rapid and almost completely \u2022 Distribution: Widely distributed into body tissues \u2022 Metabolism: Partially hepatic to main metabolyte of desethylchloroquine \u2022 Excretion: Urine (>=50% as unchanged drug); acidification of urine increases elimination \u2022 C max = 1.2 nmol/mL = 1.2 \u00b5mol/L = 1.2 \u00b5M at 400mg single dose.", [["body tissues", "ANATOMY", 228, 240], ["hepatic", "ANATOMY", 265, 272], ["urine", "ANATOMY", 378, 383], ["Hydroxychloroquine", "CHEMICAL", 103, 121], ["desethylchloroquine", "CHEMICAL", 295, 314], ["Hydroxychloroquine", "CHEMICAL", 103, 121], ["desethylchloroquine", "CHEMICAL", 295, 314], ["Urine", "CHEMICAL", 328, 333], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 103, 121], ["body tissues", "TISSUE", 228, 240], ["hepatic", "ORGAN", 265, 272], ["desethylchloroquine", "SIMPLE_CHEMICAL", 295, 314], ["Urine", "ORGANISM_SUBSTANCE", 328, 333], ["urine", "ORGANISM_SUBSTANCE", 378, 383], ["participants", "SPECIES", 73, 85], ["Dispensed medications", "TREATMENT", 0, 21], ["Hydroxychloroquine sulfatePharmacokinetics", "TREATMENT", 103, 145], ["Urine", "TEST", 328, 333], ["acidification of urine increases elimination", "PROBLEM", 361, 405], ["C max", "TEST", 408, 413], ["body tissues", "ANATOMY", 228, 240], ["hepatic", "ANATOMY", 265, 272]]], ["[5, 7] \u2022 T max = 2.4 hours \u2022 T1/2 = 172 + 39 hours = 7.1 +1.6 days \u2022 AUC last = 75.4 + 47 nmol/h/mL \u2022 This C max is in the therapeutic window for SARS-COV2 activity.Pharmacokinetics:\u2022 Steady state doses for 400mg dose is 974 \u00b5g/L = 2.24 \u00b5M [8] , thus a 600mg dose should generate approximately 3.4 \u00b5M , which is above the EC50 of viral inhibition of 1.3 \u00b5M (EC50 = 50% inhibition; however, the more inhibition the better, likely).", [["T max", "TEST", 9, 14], ["T1", "TEST", 29, 31], ["AUC", "TEST", 69, 72], ["This C max", "TEST", 102, 112], ["SARS", "PROBLEM", 146, 150], ["viral inhibition", "TEST", 330, 346], ["EC50", "TEST", 358, 362]]], ["The EC50 has been reported as 0.72 \u00b5M [5] , although this is not a precise measurement, and should be view with a range of error present (but not reported).", [["The EC50", "TEST", 0, 8]]], ["The EC50 is the point of 50% maximal inhibition, so more drug would be better (balanced against toxicity and drug supply).", [["toxicity", "DISEASE", 96, 104]]], ["The percentage of persons achieving a 24 hour level above the EC50 is as follows (Figure) .", [["persons", "ORGANISM", 18, 25], ["persons", "SPECIES", 18, 25], ["percentage", "OBSERVATION_MODIFIER", 4, 14]]], ["The medicine will then be provided to research volunteers via FedEx / courier delivery in the United States.Modification of Investigational Product for a ParticipantWith mild side effects, participants will be instructed to split the 3 tablet daily dosing into multiple times per day.Modification of Investigational Product for a ParticipantIn the event of substantial side effects, participants may discontinue the study medication.Modification of Investigational Product for a ParticipantIn the event of the development of acute kidney injury with creatinine clearance <30 mL/min, the dose should be reduced by one-third.Accountability Procedures for the Investigational Product:Accountability will be via self-report at the day 5 virtual visit.Assessment of Subject ComplianceAdherence will be via self-report at day 5 virtual visit.Concomitant Medications/TreatmentsParticipants may receive other concomitant medications or therapies, and will be asked to report these in regards to other therapies received in the event of hospitalization.Screening\u2022 Baseline screening for eligibility \u2022 Informed consent by self-administered \u2022 This will be performed via a web-based form.", [["kidney", "ANATOMY", 531, 537], ["acute kidney injury", "DISEASE", 525, 544], ["creatinine", "CHEMICAL", 550, 560], ["creatinine", "CHEMICAL", 550, 560], ["volunteers", "ORGANISM", 47, 57], ["kidney", "ORGAN", 531, 537], ["creatinine", "SIMPLE_CHEMICAL", 550, 560], ["participants", "SPECIES", 189, 201], ["participants", "SPECIES", 383, 395], ["Participants", "SPECIES", 870, 882], ["FedEx / courier delivery", "TREATMENT", 62, 86], ["Investigational Product", "TREATMENT", 124, 147], ["a ParticipantWith mild side effects", "PROBLEM", 152, 187], ["Investigational Product", "TREATMENT", 300, 323], ["substantial side effects", "PROBLEM", 357, 381], ["the study medication", "TREATMENT", 412, 432], ["Investigational Product", "TREATMENT", 449, 472], ["acute kidney injury", "PROBLEM", 525, 544], ["creatinine clearance", "PROBLEM", 550, 570], ["Medications/Treatments", "TREATMENT", 848, 870], ["other concomitant medications", "TREATMENT", 895, 924], ["therapies", "TREATMENT", 928, 937], ["other therapies", "TREATMENT", 987, 1002], ["substantial", "OBSERVATION_MODIFIER", 357, 368], ["side effects", "OBSERVATION_MODIFIER", 369, 381], ["acute", "OBSERVATION_MODIFIER", 525, 530], ["kidney", "ANATOMY", 531, 537], ["injury", "OBSERVATION", 538, 544]]], ["Eligibility criteria will be by self-report.Randomization (Day 0)\u2022 Participants will be randomized by a computer-generated algorithm using a permuted block randomization sequence. \u2022 Randomization will be stratified by symptomatic vs. asymptomatic status at baseline.Randomization (Day 0)\u2022 Investigational pharmacy will dispense the masked study medicine \u2022 Study personnel will then FedEx study medicine to the participant \u2022 Participant will be sent an email to expect medication to arrive by 10:30amEarly Termination VisitIf participants develop new / worsening symptoms of coronavirus, they will be directed to their healthcare provider and/or local public health authority.", [["coronavirus", "DISEASE", 574, 585], ["coronavirus", "ORGANISM", 574, 585], ["Participants", "SPECIES", 67, 79], ["participant", "SPECIES", 410, 421], ["participants", "SPECIES", 525, 537], ["a permuted block randomization sequence", "TREATMENT", 139, 178], ["Randomization", "TREATMENT", 182, 195], ["asymptomatic status", "PROBLEM", 234, 253], ["new / worsening symptoms", "PROBLEM", 546, 570], ["coronavirus", "PROBLEM", 574, 585]]], ["Follow up of hospitalized patients up to 90 days for their final outcome.Unscheduled VisitSubjects will be provided a central email contact: faq.covid19@gmail.com as a contact point for questions or concerns.", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34]]], ["This email will forward to an on-call study physician who will call the participant to resolve their concerns.Unscheduled VisitAdditionally, email communications will contain a URL for a sick visit web-form that participants can note their current development of symptoms of medication side effects.", [["participants", "SPECIES", 212, 224], ["symptoms", "PROBLEM", 263, 271], ["medication side effects", "PROBLEM", 275, 298]]], ["This will be the same follow up eCRF sent on Day 1, 5, and 14.", [["eCRF", "CANCER", 32, 36]]], ["This can be completed multiple times.Clinical EvaluationsClinical evaluations will be by self reportLaboratory EvaluationsThere are no laboratory evaluations in the protocol.Laboratory EvaluationsClinical outcomes are by self-report.Laboratory EvaluationsSARS-COV2 positivity is by self-report.Laboratory EvaluationsInformed consent will request permission to contact local public health authorities or their medical provider in the event of lost to follow up or COVID19 disease.Laboratory EvaluationsThere is no incentive to be dishonest, and we believe healthcare workers in particular will take their responsibilities seriously.", [["COV2", "DNA", 260, 264], ["Clinical Evaluations", "TEST", 37, 57], ["Clinical evaluations", "TEST", 57, 77], ["self reportLaboratory Evaluations", "TEST", 89, 122], ["laboratory evaluations", "TEST", 135, 157], ["the protocol", "TEST", 161, 173], ["Laboratory Evaluations", "TEST", 174, 196], ["Laboratory EvaluationsSARS", "TEST", 233, 259], ["COVID19 disease", "PROBLEM", 463, 478], ["Laboratory Evaluations", "TEST", 479, 501], ["no", "UNCERTAINTY", 510, 512]]], ["ASSESSMENT OF SAFETYSpecification of Safety ParametersHydroxychloroquine has a track record of safety since its FDA-approval in 1955.", [["Hydroxychloroquine", "CHEMICAL", 54, 72], ["Hydroxychloroquine", "CHEMICAL", 54, 72], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 54, 72], ["Hydroxychloroquine", "TREATMENT", 54, 72]]], ["As an already, FDA-approved medicine, this trial is designed as a pragmatic trial in the setting of a public health emergency.Adverse EventsHydroxychloroquine has an excellent safety track record, being first FDA-approved in 1955.", [["Hydroxychloroquine", "CHEMICAL", 140, 158], ["Hydroxychloroquine", "CHEMICAL", 140, 158], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 140, 158], ["a pragmatic trial", "TREATMENT", 64, 81], ["Adverse Events", "PROBLEM", 126, 140], ["Hydroxychloroquine", "TREATMENT", 140, 158]]], ["Adverse events will not be captured, unless they result in hospitalization.", [["Adverse events", "PROBLEM", 0, 14]]], ["See Serious Adverse Events below.Adverse EventsExpected adverse events would include normal events within the general population as well COVID19-related disease events which may include need for hospitalization, pneumonia, respiratory failure, sepsis, and death.Reactogenicity (for Vaccine Studies and Some Therapeutic Trials)Not applicableSerious Adverse EventsHospitalization or death are protocol-defined endpoints.Procedures to be Followed in the Event of Abnormal Laboratory Test Values or Abnormal Clinical FindingsNot applicableSerious Adverse EventsAn AE or suspected adverse reaction is considered a serious adverse event (SAE) if it results in any of the following outcomes:Serious Adverse Events\u2022 a life-threatening adverse event (as below) , \u2022 hospitalization \u2022 a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or \u2022 a congenital anomaly/birth defect.Serious Adverse Events\u2022 Important medical events that may not result in death, be life-threatening, or require hospitalizations may be considered serious when, based upon appropriate medical judgment they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.", [["respiratory", "ANATOMY", 223, 234], ["pneumonia", "DISEASE", 212, 221], ["respiratory failure", "DISEASE", 223, 242], ["sepsis", "DISEASE", 244, 250], ["death", "DISEASE", 256, 261], ["death", "DISEASE", 381, 386], ["congenital anomaly", "DISEASE", 895, 913], ["birth defect", "DISEASE", 914, 926], ["death", "DISEASE", 999, 1004], ["COVID19", "GENE_OR_GENE_PRODUCT", 137, 144], ["patient", "ORGANISM", 1151, 1158], ["patient", "SPECIES", 1151, 1158], ["Adverse Events", "PROBLEM", 33, 47], ["Expected adverse events", "PROBLEM", 47, 70], ["normal events", "PROBLEM", 85, 98], ["related disease events", "PROBLEM", 145, 167], ["hospitalization", "TREATMENT", 195, 210], ["pneumonia", "PROBLEM", 212, 221], ["respiratory failure", "PROBLEM", 223, 242], ["sepsis", "PROBLEM", 244, 250], ["death", "PROBLEM", 256, 261], ["Reactogenicity", "TEST", 262, 276], ["Vaccine Studies", "TEST", 282, 297], ["Some Therapeutic Trials", "TREATMENT", 302, 325], ["Abnormal Laboratory Test Values", "PROBLEM", 460, 491], ["suspected adverse reaction", "PROBLEM", 566, 592], ["Serious Adverse Events", "PROBLEM", 684, 706], ["significant incapacity", "PROBLEM", 790, 812], ["a congenital anomaly", "PROBLEM", 893, 913], ["birth defect", "PROBLEM", 914, 926], ["Serious Adverse Events", "PROBLEM", 927, 949], ["death", "PROBLEM", 999, 1004], ["surgical intervention", "TREATMENT", 1197, 1218], ["pneumonia", "OBSERVATION", 212, 221], ["respiratory failure", "OBSERVATION", 223, 242], ["sepsis", "OBSERVATION", 244, 250], ["persistent", "OBSERVATION_MODIFIER", 776, 786], ["significant", "OBSERVATION_MODIFIER", 790, 801], ["incapacity", "OBSERVATION", 802, 812], ["substantial", "OBSERVATION_MODIFIER", 816, 827], ["disruption", "OBSERVATION", 828, 838], ["congenital", "OBSERVATION_MODIFIER", 895, 905], ["anomaly", "OBSERVATION", 906, 913], ["birth defect", "OBSERVATION", 914, 926]]], ["Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse.Serious Adverse EventsLife-threatening adverse event.", [["blood", "ANATOMY", 125, 130], ["allergic bronchospasm", "DISEASE", 40, 61], ["blood dyscrasias", "DISEASE", 125, 141], ["convulsions", "DISEASE", 145, 156], ["drug dependency", "DISEASE", 228, 243], ["drug abuse", "DISEASE", 247, 257], ["blood", "ORGANISM_SUBSTANCE", 125, 130], ["such medical events", "PROBLEM", 12, 31], ["allergic bronchospasm", "PROBLEM", 40, 61], ["intensive treatment", "TREATMENT", 72, 91], ["blood dyscrasias", "PROBLEM", 125, 141], ["convulsions", "PROBLEM", 145, 156], ["drug dependency", "PROBLEM", 228, 243], ["threatening adverse event", "PROBLEM", 285, 310], ["allergic", "OBSERVATION_MODIFIER", 40, 48], ["bronchospasm", "OBSERVATION", 49, 61]]], ["An AE is considered \"life-threatening\" if, in the view of either the site principal investigator or sponsor, its occurrence places the patient or subject at immediate risk of death.", [["death", "DISEASE", 175, 180], ["patient", "ORGANISM", 135, 142], ["patient", "SPECIES", 135, 142], ["death", "PROBLEM", 175, 180]]], ["It does not include an AE that, had it occurred in a more severe form, might have caused death.", [["death", "DISEASE", 89, 94], ["death", "PROBLEM", 89, 94]]], ["For life threatening AEs, subjects would be recommended /expected to be hospitalized.Serious Adverse EventsBased on the known safety track record of hydroxychloroquine, this pragmatic protocol will focus on death, life-threatening AEs, and hospitalizations.", [["hydroxychloroquine", "CHEMICAL", 149, 167], ["death", "DISEASE", 207, 212], ["hydroxychloroquine", "CHEMICAL", 149, 167], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 149, 167], ["Serious Adverse EventsBased", "PROBLEM", 85, 112], ["hydroxychloroquine", "TREATMENT", 149, 167], ["this pragmatic protocol", "TREATMENT", 169, 192], ["death", "PROBLEM", 207, 212]]], ["Incapacity / permanent disability is a possibility with COVID19, but this is not associated with hydroxychloroquine.", [["permanent disability", "DISEASE", 13, 33], ["hydroxychloroquine", "CHEMICAL", 97, 115], ["hydroxychloroquine", "CHEMICAL", 97, 115], ["COVID19", "GENE_OR_GENE_PRODUCT", 56, 63], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 97, 115], ["Incapacity / permanent disability", "PROBLEM", 0, 33], ["COVID19", "TREATMENT", 56, 63], ["hydroxychloroquine", "TREATMENT", 97, 115], ["permanent disability", "OBSERVATION", 13, 33]]], ["In the event of incapacity, the subject would be expected to be hospitalized.Serious Adverse EventsHydroxychloroquine and chloroquine are not known to cause teratogenic events and are viewed as safe in pregnancy, especially with short term use.", [["Hydroxychloroquine", "CHEMICAL", 99, 117], ["chloroquine", "CHEMICAL", 122, 133], ["Hydroxychloroquine", "CHEMICAL", 99, 117], ["chloroquine", "CHEMICAL", 122, 133], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 99, 117], ["chloroquine", "SIMPLE_CHEMICAL", 122, 133], ["incapacity", "PROBLEM", 16, 26], ["Serious Adverse Events", "PROBLEM", 77, 99], ["Hydroxychloroquine", "TREATMENT", 99, 117], ["chloroquine", "TREATMENT", 122, 133], ["teratogenic events", "PROBLEM", 157, 175], ["incapacity", "OBSERVATION", 16, 26]]], ["With this trial's sample size, this will not further delineate this risk.", [["this trial's sample size", "TREATMENT", 5, 29]]], ["COVID19 disease may indeed be teratogenic.", [["COVID19", "CHEMICAL", 0, 7], ["COVID19", "GENE_OR_GENE_PRODUCT", 0, 7], ["COVID19 disease", "PROBLEM", 0, 15], ["teratogenic", "PROBLEM", 30, 41], ["disease", "OBSERVATION", 8, 15], ["may indeed be", "UNCERTAINTY", 16, 29], ["teratogenic", "OBSERVATION_MODIFIER", 30, 41]]], ["For women who are pregnant, we will ask to follow them through the end of their pregnancy.Serious Adverse EventsThus the hospitalization or death secondary endpoint will capture relevant SAEs.Regulatory ReportingAs hydroxychloroquine is an FDA-approved medicine being used at standard dosing, reporting to regulatory authorities will occur in summary format after each DSMB reports and at a frequency of at least annually.Regulatory ReportingSerious unexpected suspected adverse reactions (SUSARs) which are not expected with COVID19 nor listed in the FDA package insert will be reported to the IRB.", [["death", "DISEASE", 140, 145], ["hydroxychloroquine", "CHEMICAL", 215, 233], ["hydroxychloroquine", "CHEMICAL", 215, 233], ["COVID19", "CHEMICAL", 526, 533], ["women", "ORGANISM", 4, 9], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 215, 233], ["women", "SPECIES", 4, 9], ["Serious Adverse Events", "PROBLEM", 90, 112], ["death", "PROBLEM", 140, 145], ["hydroxychloroquine", "TREATMENT", 215, 233], ["an FDA", "TREATMENT", 237, 243], ["adverse reactions", "PROBLEM", 471, 488], ["COVID19", "TREATMENT", 526, 533]]], ["Those SUSARS which are deemed by an independent medical monitor to be related to the study medicine will be reported to the FDA and IRB.Reporting of PregnancyChloroquine and hydroxychloroquine are not known to be teratogenic.", [["Chloroquine", "CHEMICAL", 158, 169], ["hydroxychloroquine", "CHEMICAL", 174, 192], ["Chloroquine", "CHEMICAL", 158, 169], ["hydroxychloroquine", "CHEMICAL", 174, 192], ["Chloroquine", "SIMPLE_CHEMICAL", 158, 169], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 174, 192], ["PregnancyChloroquine", "TREATMENT", 149, 169], ["hydroxychloroquine", "TREATMENT", 174, 192]]], ["Chloroquine and hydroxychloroquine can accumulate in neonatal eyes.", [["eyes", "ANATOMY", 62, 66], ["Chloroquine", "CHEMICAL", 0, 11], ["hydroxychloroquine", "CHEMICAL", 16, 34], ["Chloroquine", "CHEMICAL", 0, 11], ["hydroxychloroquine", "CHEMICAL", 16, 34], ["Chloroquine", "SIMPLE_CHEMICAL", 0, 11], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 16, 34], ["eyes", "ORGAN", 62, 66], ["Chloroquine", "TREATMENT", 0, 11], ["hydroxychloroquine", "TREATMENT", 16, 34], ["neonatal eyes", "ANATOMY", 53, 66]]], ["Conversely, the risk of severe COVID19 infection is unknown, but likely is a heightened risk in pregnant women.", [["COVID19 infection", "DISEASE", 31, 48], ["COVID19", "GENE_OR_GENE_PRODUCT", 31, 38], ["women", "ORGANISM", 105, 110], ["women", "SPECIES", 105, 110], ["severe COVID19 infection", "PROBLEM", 24, 48], ["severe", "OBSERVATION_MODIFIER", 24, 30], ["infection", "OBSERVATION", 39, 48]]], ["The CDC states, \"We do not have information on adverse pregnancy outcomes in pregnant women with COVID-19.", [["women", "ORGANISM", 86, 91], ["women", "SPECIES", 86, 91], ["adverse pregnancy outcomes", "PROBLEM", 47, 73], ["COVID", "TEST", 97, 102]]], ["Pregnancy loss, including miscarriage and stillbirth, has been observed in cases of infection with other related coronaviruses (SARS-CoV and MERS-CoV) during pregnancy.", [["Pregnancy loss", "DISEASE", 0, 14], ["miscarriage", "DISEASE", 26, 37], ["stillbirth", "DISEASE", 42, 52], ["infection", "DISEASE", 84, 93], ["SARS", "DISEASE", 128, 132], ["coronaviruses", "ORGANISM", 113, 126], ["SARS-CoV", "ORGANISM", 128, 136], ["MERS-CoV", "ORGANISM", 141, 149], ["SARS-CoV", "SPECIES", 128, 136], ["MERS-CoV", "SPECIES", 141, 149], ["Pregnancy loss", "PROBLEM", 0, 14], ["miscarriage", "PROBLEM", 26, 37], ["stillbirth", "PROBLEM", 42, 52], ["infection", "PROBLEM", 84, 93], ["other related coronaviruses", "PROBLEM", 99, 126], ["pregnancy", "PROBLEM", 158, 167], ["infection", "OBSERVATION", 84, 93]]], ["High fevers during the first trimester of pregnancy can increase the risk of certain birth defects.\"Reporting of PregnancyThus, the risk/benefit would favor the enrollment of women who may be or are pregnant, so as to not discriminate against pregnant women.Reporting of PregnancyFor women who are pregnant, we will ask to have follow through the end of their pregnancy to assess outcome of the pregnancy via a brief survey.Type and Duration of Follow-up of Subjects after Adverse EventsParticipants who are hospitalized for COVID19 or SAEs will have up to 90 day follow up conducted to assess their final outcome.", [["fevers", "DISEASE", 5, 11], ["birth defects", "DISEASE", 85, 98], ["women", "ORGANISM", 175, 180], ["women", "ORGANISM", 252, 257], ["women", "ORGANISM", 284, 289], ["Subjects", "ORGANISM", 458, 466], ["women", "SPECIES", 175, 180], ["women", "SPECIES", 252, 257], ["women", "SPECIES", 284, 289], ["High fevers", "PROBLEM", 0, 11], ["certain birth defects", "PROBLEM", 77, 98], ["PregnancyThus", "PROBLEM", 113, 126], ["fevers", "OBSERVATION", 5, 11]]], ["Management will be as per the participant's local healthcare provider.Safety Oversight (DSMB)A data and safety monitoring board (DSMB) will oversee the trial.", [["A data", "TEST", 93, 99]]], ["The PI will be a non-voting observer, providing input as requested.Halting RulesA Lan-DeMets spending function analog of the O'Brien-Fleming boundaries will be provided at each DSMB report for the disease severity outcome, thus dependent on precise DMSB time period, the difference necessary to trigger early stoppage will vary, converging toward >35% relative risk reduction by study conclusion.", [["the disease severity outcome", "PROBLEM", 193, 221]]], ["The provided table assumes four interim analyses with the final analysis with an overall alpha=0.05.", [["the final analysis", "TEST", 54, 72], ["an overall alpha", "TEST", 78, 94]]], ["As the effect size is unknown, the O'Brien-Fleming boundaries are a conservative, yet being truncated at Z-score of 3.1 equating to a P-value of approx 0.001.", [["Z-score", "TEST", 105, 112], ["a P-value", "TEST", 132, 141], ["size", "OBSERVATION_MODIFIER", 14, 18]]], ["At the first DSMB review, the stopping boundary is unlikely to be crossed.", [["unlikely to be", "UNCERTAINTY", 51, 65]]], ["The purpose of this early review will assess the trends for safety/efficacy and allow for the DSMB to determine if more frequent reviews are appropriate.", [["the DSMB", "TEST", 90, 98]]], ["If more interim analyses are desired by the DMSB, the Lan-DeMets spending function will be recalculated using O'Brien-Fleming boundaries and provided with each DSMB report.Interim AnalysisShould a stopping boundary be crossed, we would recommend an analysis to determine whether the findings are consistent across secondary endpoints, such that a clear answer is achieved.", [["Interim Analysis", "TEST", 172, 188], ["an analysis", "TEST", 246, 257]]], ["In the event of early halting due to efficacy, the study will immediately convert to an open label observational cohort of hydroxychloroquine prescribed to all consented participants.Interim AnalysisBased on the public health situation, the DSMB has the prerogative to alter the stopping rules.Sample Size Re-estimation:At time of the second DSMB review, a sample size re-estimation should occur based on the disease transmission rate in the control group.", [["hydroxychloroquine", "CHEMICAL", 123, 141], ["hydroxychloroquine", "CHEMICAL", 123, 141], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 123, 141], ["participants", "SPECIES", 170, 182], ["the study", "TEST", 47, 56], ["hydroxychloroquine", "TREATMENT", 123, 141], ["a sample size re-estimation", "TREATMENT", 355, 382], ["Size", "OBSERVATION_MODIFIER", 301, 305]]], ["The effect size to be powered will remain a 50% relative reduction, and any re-estimation will not account for accumulating data in the intervention arm.", [["a 50% relative reduction", "TREATMENT", 42, 66], ["the intervention arm", "TREATMENT", 132, 152], ["size", "OBSERVATION_MODIFIER", 11, 15]]], ["For example, if the incidence of COVID-19 disease in the control arm is only 5%, then the sample size will increase four-fold to 3000 participants per arm.Futility Analysis:If the conditional power is <20% at the time of the second interim analysis with approximately 50% of participants enrolled, discontinuation should be considered as a possible recommendation by the DSMB.", [["participants", "SPECIES", 134, 146], ["participants", "SPECIES", 275, 287], ["COVID-19 disease in the control arm", "PROBLEM", 33, 68], ["the sample size", "TEST", 86, 101], ["the second interim analysis", "TEST", 221, 248], ["discontinuation", "TREATMENT", 298, 313], ["arm", "ANATOMY", 65, 68], ["size", "OBSERVATION_MODIFIER", 97, 101], ["arm", "ANATOMY", 151, 154]]], ["The sample size re-estimation will be considered here as well as the pace of enrollment.CLINICAL MONITORINGClinical site monitoring is conducted to ensure that the rights and well-being of trial subjects are protected and that the reported trial data are accurate, complete, and verifiable.", [["The sample size re-estimation", "TEST", 0, 29], ["CLINICAL MONITORINGClinical site monitoring", "TEST", 88, 131], ["size", "OBSERVATION_MODIFIER", 11, 15]]], ["Clinical monitoring also ensures that conduct of the trial is in compliance with the currently approved protocol/ amendment(s), ICH, GCP, and with applicable regulatory requirement(s) and Sponsor requirements.", [["ICH", "DISEASE", 128, 131], ["Clinical monitoring", "TEST", 0, 19], ["ICH", "PROBLEM", 128, 131], ["GCP", "PROBLEM", 133, 136]]], ["Clinical monitoring will also verify that any critical study procedures are completed following specific instructions.", [["Clinical monitoring", "TEST", 0, 19], ["any critical study procedures", "TEST", 42, 71]]], ["Monitoring will be the responsibility of the University of Minnesota.Study HypothesesHydroxychloroquine is superior to placebo for preventing progression to COVID19 disease.Study HypothesesHydroxychloroquine is superior to placebo for preventing progression among those with symptomatic mild COVID19 disease preventing hospitalization/death.Sample Size ConsiderationsTwo strata of 1500 subjects each: 1) Asymptomatic exposures; 2) symptomatic COVID-19 diseaseSample Size ConsiderationsThe planned sample size is up to 750 participants per arm, based on the assumptions of:Sample Size Considerations\u2022 Transmission from COVID19 case to close contacts is ~10% with placebo.Sample Size Considerations\u2022 Progression from symptomatic illness to hospitalization is ~10% with placebo (conservative estimate on rate of progression, based on probable enrollment of younger/healthier, more internet savvy population enrolling) \u2022 The primary analysis will be intention to treat.Sample Size Considerations\u2022 Type 1 error is 0.05 (2-sided) and power = 0.90. \u2022 N=621 per arm for 90% Power to detect a 50% relative risk reduction for both disease incidence as well as the ordinal scale of disease severity . \u2022 With up to 20% dropout, N=750 per arm As the transmission frequency increases, the sample size dramatically decreases, need to demonstrate an effect ( Figure Right) .", [["Hydroxychloroquine", "CHEMICAL", 85, 103], ["Hydroxychloroquine", "CHEMICAL", 189, 207], ["COVID19 disease", "DISEASE", 292, 307], ["death", "DISEASE", 335, 340], ["illness", "DISEASE", 727, 734], ["Hydroxychloroquine", "CHEMICAL", 85, 103], ["Hydroxychloroquine", "CHEMICAL", 189, 207], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 85, 103], ["COVID19", "GENE_OR_GENE_PRODUCT", 157, 164], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 189, 207], ["participants", "SPECIES", 522, 534], ["Hydroxychloroquine", "TREATMENT", 85, 103], ["placebo", "TREATMENT", 119, 126], ["COVID19 disease", "PROBLEM", 157, 172], ["Hydroxychloroquine", "TREATMENT", 189, 207], ["placebo", "TREATMENT", 223, 230], ["symptomatic mild COVID19 disease", "PROBLEM", 275, 307], ["death", "PROBLEM", 335, 340], ["Asymptomatic exposures", "PROBLEM", 404, 426], ["symptomatic COVID", "PROBLEM", 431, 448], ["The planned sample size", "TEST", 485, 508], ["placebo", "TREATMENT", 662, 669], ["symptomatic illness", "PROBLEM", 715, 734], ["placebo", "TREATMENT", 767, 774], ["The primary analysis", "TEST", 917, 937], ["a 50% relative risk reduction", "TREATMENT", 1082, 1111], ["both disease incidence", "PROBLEM", 1116, 1138], ["disease severity", "PROBLEM", 1171, 1187], ["Size", "OBSERVATION_MODIFIER", 348, 352], ["size", "OBSERVATION_MODIFIER", 504, 508], ["arm", "ANATOMY", 539, 542], ["Size", "OBSERVATION_MODIFIER", 677, 681], ["Progression", "OBSERVATION_MODIFIER", 698, 709], ["symptomatic", "OBSERVATION_MODIFIER", 715, 726], ["Size", "OBSERVATION_MODIFIER", 972, 976], ["arm", "ANATOMY", 1054, 1057], ["disease", "OBSERVATION", 1121, 1128], ["disease", "OBSERVATION", 1171, 1178], ["arm", "ANATOMY", 1226, 1229], ["size", "OBSERVATION_MODIFIER", 1282, 1286], ["dramatically", "OBSERVATION_MODIFIER", 1287, 1299], ["decreases", "OBSERVATION_MODIFIER", 1300, 1309]]], ["For instance at 20% control prevalence of transmission (orange line), a sample size of n=200 per arm would have 80% power to detect a ~52%reduction to 9.6% transmission in the intervention arm.", [["transmission (orange line", "TREATMENT", 42, 67], ["a sample size", "TEST", 70, 83], ["a ~52%reduction", "TREATMENT", 132, 147], ["the intervention arm", "TREATMENT", 172, 192], ["arm", "ANATOMY", 97, 100], ["arm", "ANATOMY", 189, 192]]], ["Conversely, if transmission frequency is 5%, then there is 80% power to detect an effect size of >67% reduction in transmission (to 1.63%).Planned Interim Analyses (if applicable)Interim analyses will focus on the statistical testing of the primary endpoint with descriptive reporting of the secondary endpoints as well.", [["an effect size", "PROBLEM", 79, 93], ["Interim Analyses", "TEST", 147, 163], ["Interim analyses", "TEST", 179, 195], ["the statistical testing", "TEST", 210, 233], ["size", "OBSERVATION_MODIFIER", 89, 93]]], ["Interim analyses will be conducted after enrollment of approximately: 25%, 50%, 75%, and 100% of participants are enrolled.", [["participants", "ORGANISM", 97, 109], ["participants", "SPECIES", 97, 109], ["Interim analyses", "TEST", 0, 16]]], ["This interval may be modified by the DSMB.Planned Interim Analyses (if applicable)Interim analyses will assess also for: a) Evidence of harm or unintended consequences b) Appropriateness of baseline assumptions, specifically the incidence of disease in the control group; c) Futility, particularly from time of the third DSMB onwards.Final Analysis PlanThose with symptomatic disease at baseline will be separately analyzed.", [["Interim Analyses", "TEST", 50, 66], ["Interim analyses", "TEST", 82, 98], ["disease", "PROBLEM", 242, 249], ["symptomatic disease", "PROBLEM", 364, 383], ["may be", "UNCERTAINTY", 14, 20], ["symptomatic", "OBSERVATION_MODIFIER", 364, 375], ["disease", "OBSERVATION", 376, 383]]], ["Analysis will be stratified by baseline strata of 1) asymptomatic exposure; 2) symptomatic COVID-19 disease.Asymptomatic CohortIncidence of new COVID19 disease will be assessed via Fisher's Exact test, among those who are asymptomatic at baseline.Asymptomatic Cohort\u2022 The primary analysis will use PCR+ confirmed disease.Asymptomatic Cohort\u2022 However, if the absence of sufficient testing supplies continues, outpatients will not be offered SARS-CoV-2 testing unless they are sick enough to be hospitalized.", [["Analysis", "TEST", 0, 8], ["asymptomatic exposure", "PROBLEM", 53, 74], ["symptomatic COVID-19 disease", "PROBLEM", 79, 107], ["new COVID19 disease", "PROBLEM", 140, 159], ["Fisher's Exact test", "TEST", 181, 200], ["The primary analysis", "TEST", 268, 288], ["PCR", "TEST", 298, 301], ["disease", "PROBLEM", 313, 320], ["CoV-2 testing", "TEST", 445, 458], ["new", "OBSERVATION_MODIFIER", 140, 143], ["COVID19 disease", "OBSERVATION", 144, 159], ["disease", "OBSERVATION", 313, 320]]], ["Thus, an alternative a priori planned analysis will define incident COVID19 disease as a composite of SARS-CoV-2 PCR+ confirmed COVID-19 disease OR symptomatic disease (i.e. possible) COVID-19 in those without testing.Symptomatic CohortThe primary endpoint for those who are symptomatic at entry will be assessed on an ordinal scale to estimate a proportional odds model.", [["SARS", "DISEASE", 102, 106], ["COVID19", "GENE_OR_GENE_PRODUCT", 68, 75], ["SARS-CoV", "SPECIES", 102, 110], ["a priori planned analysis", "TEST", 21, 46], ["COVID19 disease", "PROBLEM", 68, 83], ["SARS", "TEST", 102, 106], ["CoV", "TEST", 107, 110], ["PCR", "TEST", 113, 116], ["COVID-19 disease", "PROBLEM", 128, 144], ["symptomatic disease", "PROBLEM", 148, 167], ["COVID", "TEST", 184, 189], ["testing", "TEST", 210, 217], ["symptomatic", "PROBLEM", 275, 286], ["an ordinal scale", "TEST", 316, 332], ["symptomatic", "OBSERVATION_MODIFIER", 148, 159], ["disease", "OBSERVATION", 160, 167]]], ["The primary hypothesis test will be based on whether the commons Odds Ratio for prophylaxis is equal to one.Symptomatic Cohort\u2022 For those with symptomatic illness at baseline, a three score ordinal scale will also be used of: i) illness without hospitalization; ii) hospitalization/post-hospital discharge; iii) Hospitalization with ICU stay/death).", [["illness", "DISEASE", 155, 162], ["illness", "DISEASE", 229, 236], ["death", "DISEASE", 342, 347], ["The primary hypothesis test", "TEST", 0, 27], ["prophylaxis", "TREATMENT", 80, 91], ["symptomatic illness", "PROBLEM", 143, 162], ["a three score ordinal scale", "TREATMENT", 176, 203], ["death", "PROBLEM", 342, 347]]], ["A sensitivity analysis will also be performed at Day 56 to capture delayed hospital outcomes. \u2022 Further descriptive analysis will further report hospitalization, hospitalization with ICU, respiratory failure requiring mechanical ventilation, and/or death; however, these subgroups are expected to be small and will not be formally statistically tested.Symptomatic CohortAnalysis will be by modified, intention to treat limited to participants who receive at least one dose of the study medicine.", [["respiratory", "ANATOMY", 188, 199], ["respiratory failure", "DISEASE", 188, 207], ["death", "DISEASE", 249, 254], ["participants", "SPECIES", 430, 442], ["A sensitivity analysis", "TEST", 0, 22], ["Further descriptive analysis", "TEST", 96, 124], ["respiratory failure", "PROBLEM", 188, 207], ["mechanical ventilation", "TREATMENT", 218, 240], ["death", "PROBLEM", 249, 254], ["Symptomatic CohortAnalysis", "PROBLEM", 352, 378], ["the study medicine", "TREATMENT", 476, 494], ["respiratory", "ANATOMY", 188, 199], ["failure", "OBSERVATION", 200, 207], ["mechanical ventilation", "OBSERVATION", 218, 240], ["small", "OBSERVATION", 300, 305]]], ["Participants who become symptomatic with COVID19 before receiving the study medicine will be censored from the primary analysis on incident disease, but will be separately described.Symptomatic CohortSecondary endpoints will be assessed via Fisher's Exact test for the proportions by study arm.Symptomatic CohortAmong those with symptoms, severity of symptoms (recorded on a 0-10 visual analog scale) will be compared via Mann-Whitney U by study arm at day 5 and 14.Symptomatic CohortDuration of PCR-positivity with the time to PCR negative will be assessed between trial arms by a cumulative incidence function.Symptomatic CohortDuration of hospitalization will be assessed via independent t-test.Symptomatic CohortA priori subgroup analyses will include assessment by:Symptomatic Cohort\u2022 Confirmed SARS-CoV-2 disease or disease exposureSymptomatic Cohort\u2022 Healthcare worker vs. Household contact \u2022 Days from Exposure \u2022 Decile of age \u2022 Sex as a biological variable \u2022 Censored subjects, who became symptomatic before receipt of the first dose of study medicine on D#1, will be separately analyzed and reported.SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTSSource documents will include internet forms self-completed by participants directly entered into a RedCAP database.", [["COVID19", "CHEMICAL", 41, 48], ["SARS-CoV-2 disease", "DISEASE", 800, 818], ["Participants", "SPECIES", 0, 12], ["participants", "SPECIES", 1225, 1237], ["symptomatic", "PROBLEM", 24, 35], ["COVID19", "TREATMENT", 41, 48], ["the study medicine", "TREATMENT", 66, 84], ["incident disease", "PROBLEM", 131, 147], ["Symptomatic CohortSecondary endpoints", "PROBLEM", 182, 219], ["symptoms", "PROBLEM", 329, 337], ["severity of symptoms", "PROBLEM", 339, 359], ["Symptomatic CohortDuration of PCR", "PROBLEM", 466, 499], ["PCR", "TEST", 528, 531], ["independent t-test", "TEST", 679, 697], ["Symptomatic CohortA priori subgroup analyses", "PROBLEM", 698, 742], ["assessment", "TEST", 756, 766], ["SARS", "PROBLEM", 800, 804], ["CoV-2 disease", "PROBLEM", 805, 818], ["disease", "PROBLEM", 822, 829], ["symptomatic", "PROBLEM", 998, 1009], ["study medicine", "TREATMENT", 1046, 1060]]], ["This protocol is based on self-report.SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTSThis internet-based protocol is meant to enable a large number of participants to be recruited, quickly as well as maintain the safety of the research staff.", [["participants", "SPECIES", 156, 168], ["This protocol", "TREATMENT", 0, 13], ["large", "OBSERVATION_MODIFIER", 140, 145]]], ["In person visits, create a public health Participants will be asked to provide consent to obtain medical records from their healthcare provider or public health official, if there is the need to verify outcomes -for SARS-CoV-2 test results or hospitalizations.QUALITY CONTROL AND QUALITY ASSURANCEStudy medications will be FDA-approved following Good Manufacturing Practice.Ethical StandardThis study is to be conducted according to US and international standards of Good Clinical Practice (International Conference on Harmonization guidelines), Declaration of Helsinki, and International Ethical Guidelines for Biomedical Research Involving Human Subjects, applicable U.S. government regulations and institutional research policies and procedures.", [["Human", "ORGANISM", 642, 647], ["person", "SPECIES", 3, 9], ["Human", "SPECIES", 642, 647], ["SARS-CoV", "SPECIES", 216, 224], ["SARS", "PROBLEM", 216, 220], ["CoV-2 test results", "TEST", 221, 239], ["QUALITY ASSURANCEStudy medications", "TREATMENT", 280, 314]]], ["All investigators must have received human subject protection and GCP training prior to human subject involvement.Institutional Review BoardPrior to the initiation of the study, the protocol, all informed consent forms and the participant Information materials will be submitted to and approved by the single IRB of record.", [["human", "ORGANISM", 37, 42], ["human", "ORGANISM", 88, 93], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 88, 93], ["human subject protection", "TREATMENT", 37, 61], ["GCP training", "TREATMENT", 66, 78], ["the study", "TEST", 167, 176]]], ["Likewise, any future amendments to the study protocol will be submitted and approved by the IRB before implementation.", [["the study protocol", "TEST", 35, 53]]], ["This protocol and any amendments will undergo review and approval by the Human Subjects Board at the University of Minnesota under DHHS Assurance FWA00000312.Informed Consent Process\u2022 Written informed consent will be obtained via an English-language, internet-based web form.", [["FWA00000312", "CHEMICAL", 146, 157], ["Human", "ORGANISM", 73, 78], ["Human", "SPECIES", 73, 78], ["This protocol", "TREATMENT", 0, 13]]], ["If potential participants have questions, they may contact faq.covid19@gmail.com to reach a study staff member to answer their questions about research, either via email or a phone call. \u2022 After completion of reading the form, participants will be assessed for comprehension, querying: \u25cb Concept of Randomization to hydroxychloroquine or vitamin placebo \u25cb Whether hydroxychloroquine is known to be effective in preventing diseaseInformed Consent/Assent Process (in Case of a Minor)\u2022 Persons under 18 years of age are not eligible to participate.", [["hydroxychloroquine", "CHEMICAL", 316, 334], ["vitamin", "CHEMICAL", 338, 345], ["hydroxychloroquine", "CHEMICAL", 364, 382], ["hydroxychloroquine", "CHEMICAL", 316, 334], ["vitamin placebo", "CHEMICAL", 338, 353], ["hydroxychloroquine", "CHEMICAL", 364, 382], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 316, 334], ["vitamin", "SIMPLE_CHEMICAL", 338, 345], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 364, 382], ["Persons", "ORGANISM", 483, 490], ["participants", "SPECIES", 13, 25], ["participants", "SPECIES", 227, 239], ["Persons", "SPECIES", 483, 490], ["Randomization", "TREATMENT", 299, 312], ["hydroxychloroquine", "TREATMENT", 316, 334], ["vitamin placebo", "TREATMENT", 338, 353], ["hydroxychloroquine", "TREATMENT", 364, 382], ["disease", "PROBLEM", 422, 429], ["disease", "OBSERVATION", 422, 429]]], ["COVID19 has 0% mortality in children, and rate of progression to symptomatic disease may likely be different.", [["COVID19", "CHEMICAL", 0, 7], ["COVID19", "GENE_OR_GENE_PRODUCT", 0, 7], ["children", "ORGANISM", 28, 36], ["children", "SPECIES", 28, 36], ["symptomatic disease", "PROBLEM", 65, 84], ["symptomatic", "OBSERVATION_MODIFIER", 65, 76], ["disease", "OBSERVATION", 77, 84], ["may likely be", "UNCERTAINTY", 85, 98], ["different", "OBSERVATION_MODIFIER", 99, 108]]], ["Furthermore, pediatric dosing is weight based, making remote administration more complicated.Exclusion of Women, Minorities, and Children\u2022 Persons under 18 years of age are not eligible to participate.", [["Women", "SPECIES", 106, 111], ["Persons", "SPECIES", 139, 146]]], ["COVID19 has 0% mortality in children and young adults. \u2022 Non-English speaking adults are not eligible as the webpage and consents will only be available in English.Subject Confidentiality\u2022 Interaction will be via internet-based RedCAP ECRFs conforming to required U.S. privacy and server security standards. \u2022 Clinical data will be entered into a study specific database by designated staff on a regular basis from completed electronic Case Record Forms (eCRF).", [["COVID19", "CHEMICAL", 0, 7], ["COVID19", "GENE_OR_GENE_PRODUCT", 0, 7], ["children", "ORGANISM", 28, 36], ["adults", "ORGANISM", 78, 84], ["children", "SPECIES", 28, 36]]], ["Access to database will be given to authorized personnel only (members of the immediate study team). eCRF and trial documents will be kept in a secure database. \u2022 Documentation, data and all other information generated will be held in strict confidence.", [["eCRF", "PROBLEM", 101, 105]]], ["No information concerning the study or the data will be released to any unauthorized third party, without prior written approval of the participant except as necessary for monitoring by the IRB or public health authorities \u2022 No participant identifying information will be disclosed in any publication or at any conference activities arising from the study.Future Use of Stored Specimens\u2022 No specimens are to be collected.Data Management ResponsibilitiesInvestigators will maintain a REDCAP database of study records.Data Management ResponsibilitiesSurvey forms will be self-completed by study participants.Data Capture Methods\u2022 Data will be obtained via internet-based REDCAP forms.Types of Data\u2022 Participants will be asked to provide data regarding COVID19 exposure timing and location.", [["specimens", "ANATOMY", 391, 400], ["specimens", "CANCER", 391, 400], ["COVID19", "GENE_OR_GENE_PRODUCT", 750, 757], ["COVID19", "PROTEIN", 750, 757], ["participant", "SPECIES", 228, 239], ["participants", "SPECIES", 593, 605], ["Participants", "SPECIES", 697, 709], ["the study", "TEST", 26, 35], ["the study", "TEST", 346, 355], ["specimens", "PROBLEM", 391, 400], ["COVID19 exposure timing", "TREATMENT", 750, 773], ["specimens", "OBSERVATION", 391, 400]]], ["They will also be asked to provide ongoing symptom reports during the follow-up period.Timing/Reports\u2022 An enrollment progress report will be generated monthly \u25cb Participants Enrolled \u25cb Participants on study \u25cb Participants completed the study \u25cb Lost to Follow Up \u25cb Cumulative COVID19 (pooled, both arms) \u25cb Cumulative Hospitalizations (pooled, both arms) \u2022 A data safety monitoring board (DSMB) will review data after every 100 participants complete 14 days of follow-up. \u2022 De-identified data will be shared with the research team members for analysis.Study Records Retention\u2022 No paper documents will be retained or stored.Study Records Retention\u2022 Digital records will be kept in a secure server setting.Protocol DeviationsProtocol violations will be reported to the IRB of record.STATEMENT OF COMPLIANCEThis protocol will utilize a single institutional review board (IRB) registered with the Office of Human Research Protections (OHRP) and issued a Federal Wide Assurance (FWA).", [["Human", "ORGANISM", 901, 906], ["Participants", "SPECIES", 161, 173], ["Participants", "SPECIES", 185, 197], ["Participants", "SPECIES", 209, 221], ["participants", "SPECIES", 426, 438], ["Human", "SPECIES", 901, 906], ["the study", "TEST", 232, 241], ["Cumulative COVID19 (pooled, both arms)", "TREATMENT", 264, 302], ["analysis", "TEST", 541, 549]]], ["The research will be reviewed and approved by the IRB and will be subject to continuing review [45 CFR 46.103(b)].SIGNATURE PAGEThe signature below constitutes the approval of this protocol and provides the necessary assurances that this trial will be conducted according to all stipulations of the protocol, including all statements regarding confidentiality, and according to local legal and regulatory requirements and applicable US federal regulations and ICH guidelines. xSchematic of Study Design:For participants who develop symptomatic disease, they will be followed for up to 90 days to assess final outcome status in the event of hospitalization.Schematic of Study Design:Stratification is based on symptom status at baseline 1.", [["ICH", "DISEASE", 460, 463], ["participants", "ORGANISM", 507, 519], ["participants", "SPECIES", 507, 519], ["this protocol", "TREATMENT", 176, 189], ["the protocol", "TREATMENT", 295, 307], ["ICH guidelines", "TREATMENT", 460, 474], ["symptomatic disease", "PROBLEM", 532, 551], ["symptom status", "PROBLEM", 709, 723]]], ["1500 symptomatic COVID-19 outpatientsBackground InformationSignificance of Research Question/Purpose:Background InformationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing COVID19.", [["acute respiratory syndrome coronavirus", "DISEASE", 130, 168], ["viral infection", "DISEASE", 206, 221], ["outpatients", "ORGANISM", 26, 37], ["Background InformationSevere acute respiratory syndrome coronavirus 2", "ORGANISM", 101, 170], ["SARS-CoV-2", "ORGANISM", 172, 182], ["COVID19", "GENE_OR_GENE_PRODUCT", 230, 237], ["outpatients", "SPECIES", 26, 37], ["InformationSevere acute respiratory syndrome coronavirus", "SPECIES", 112, 168], ["SARS-CoV-2", "SPECIES", 172, 182], ["acute respiratory syndrome coronavirus", "PROBLEM", 130, 168], ["SARS-CoV", "TEST", 172, 180], ["a rapidly emerging viral infection", "PROBLEM", 187, 221], ["acute", "OBSERVATION_MODIFIER", 130, 135], ["respiratory syndrome", "OBSERVATION", 136, 156], ["viral infection", "OBSERVATION", 206, 221]]], ["The current strategy uses a public health model of identifying infected cases, isolation, and quarantine to stop transmission.", [["isolation", "TREATMENT", 79, 88], ["infected", "OBSERVATION", 63, 71]]], ["Once exposed, observation is standard-of-care.Background InformationNo effective therapy currently exists for treatment.", [["Background InformationNo effective therapy", "TREATMENT", 46, 88], ["treatment", "TREATMENT", 110, 119]]], ["The lack of effective therapy diminishes persons presenting post-exposure for self-quarantine.", [["persons", "ORGANISM", 41, 48], ["persons", "SPECIES", 41, 48], ["effective therapy", "TREATMENT", 12, 29], ["effective", "OBSERVATION_MODIFIER", 12, 21], ["therapy", "OBSERVATION", 22, 29]]], ["Having an effective postexposure prophylaxis, even if only partially effective, may additionally create synergy for the public health strategy of case identification and isolation -if a safe prophylaxis is available.Background InformationPeople who develop COVID-19 disease generally develop signs and symptoms, including mild respiratory symptoms and fever, after an average of 5-6 days after exposure (i.e. mean incubation period).", [["respiratory", "ANATOMY", 327, 338], ["respiratory symptoms", "DISEASE", 327, 347], ["fever", "DISEASE", 352, 357], ["an effective postexposure prophylaxis", "TREATMENT", 7, 44], ["isolation", "TREATMENT", 170, 179], ["a safe prophylaxis", "TREATMENT", 184, 202], ["COVID-19 disease", "PROBLEM", 257, 273], ["signs and symptoms", "PROBLEM", 292, 310], ["mild respiratory symptoms", "PROBLEM", 322, 347], ["fever", "PROBLEM", 352, 357], ["effective", "OBSERVATION_MODIFIER", 10, 19], ["postexposure prophylaxis", "OBSERVATION", 20, 44], ["mild", "OBSERVATION_MODIFIER", 322, 326], ["fever", "OBSERVATION", 352, 357]]], ["The range of the incubation period is between 1 to 14 days.", [["range", "OBSERVATION_MODIFIER", 4, 9]]], ["[1] Most people infected with the COVID-19 virus have mild disease and recover.", [["people", "ORGANISM", 9, 15], ["COVID-19 virus", "ORGANISM", 34, 48], ["people", "SPECIES", 9, 15], ["COVID-19 virus", "SPECIES", 34, 48], ["the COVID", "TEST", 30, 39], ["mild disease", "PROBLEM", 54, 66], ["mild", "OBSERVATION_MODIFIER", 54, 58], ["disease", "OBSERVATION", 59, 66]]], ["Approximately 80% of laboratory-confirmed patients have had mild to moderate disease, which includes non-pneumonia and pneumonia cases, 14% have severe disease, and 6% are critically ill with respiratory failure, shock, and/or multiple organ dysfunction [1] .Preliminary Data:Chloroquine has in vitro activity in cell lines against SARS-CoV and SARS-CoV2.", [["respiratory", "ANATOMY", 192, 203], ["organ", "ANATOMY", 236, 241], ["cell lines", "ANATOMY", 313, 323], ["non-pneumonia", "DISEASE", 101, 114], ["pneumonia", "DISEASE", 119, 128], ["critically ill", "DISEASE", 172, 186], ["respiratory failure", "DISEASE", 192, 211], ["shock", "DISEASE", 213, 218], ["organ dysfunction", "DISEASE", 236, 253], ["Chloroquine", "CHEMICAL", 276, 287], ["SARS", "DISEASE", 345, 349], ["Chloroquine", "CHEMICAL", 276, 287], ["patients", "ORGANISM", 42, 50], ["organ", "ORGAN", 236, 241], ["Chloroquine", "SIMPLE_CHEMICAL", 276, 287], ["cell lines", "CELL", 313, 323], ["SARS-CoV", "ORGANISM", 332, 340], ["SARS-CoV2", "ORGANISM", 345, 354], ["cell lines", "CELL_LINE", 313, 323], ["patients", "SPECIES", 42, 50], ["SARS-CoV", "SPECIES", 332, 340], ["SARS-CoV2", "SPECIES", 345, 354], ["mild to moderate disease", "PROBLEM", 60, 84], ["non-pneumonia", "PROBLEM", 101, 114], ["pneumonia cases", "PROBLEM", 119, 134], ["severe disease", "PROBLEM", 145, 159], ["respiratory failure", "PROBLEM", 192, 211], ["shock", "PROBLEM", 213, 218], ["multiple organ dysfunction", "PROBLEM", 227, 253], ["Chloroquine", "TREATMENT", 276, 287], ["SARS", "PROBLEM", 332, 336], ["SARS", "PROBLEM", 345, 349], ["mild", "OBSERVATION_MODIFIER", 60, 64], ["moderate", "OBSERVATION_MODIFIER", 68, 76], ["disease", "OBSERVATION", 77, 84], ["pneumonia", "OBSERVATION", 119, 128], ["severe", "OBSERVATION_MODIFIER", 145, 151], ["disease", "OBSERVATION", 152, 159], ["respiratory failure", "OBSERVATION", 192, 211], ["shock", "OBSERVATION", 213, 218], ["multiple", "OBSERVATION_MODIFIER", 227, 235], ["organ", "ANATOMY", 236, 241], ["dysfunction", "OBSERVATION", 242, 253], ["cell lines", "OBSERVATION", 313, 323]]], ["In a Vero E6 cell line, the half-maximal effective concentration (EC50) activity of chloroquine was 1.13 \u03bcM against SARS-CoV2 [2] .", [["Vero E6 cell line", "ANATOMY", 5, 22], ["chloroquine", "CHEMICAL", 84, 95], ["SARS", "DISEASE", 116, 120], ["chloroquine", "CHEMICAL", 84, 95], ["Vero E6 cell line", "CELL", 5, 22], ["chloroquine", "SIMPLE_CHEMICAL", 84, 95], ["Vero E6 cell line", "CELL_LINE", 5, 22], ["Vero E6", "SPECIES", 5, 12], ["a Vero E6 cell line", "TREATMENT", 3, 22], ["chloroquine", "TREATMENT", 84, 95], ["E6 cell line", "OBSERVATION", 10, 22]]], ["Hydroxychloroquine is functionally equivalent as chloroquine.Preliminary Data:Another compound under treatment trials, remdesivir (Gilead) had an EC50 of 0.77 \u03bcM [2] .", [["Hydroxychloroquine", "CHEMICAL", 0, 18], ["chloroquine", "CHEMICAL", 49, 60], ["remdesivir", "CHEMICAL", 119, 129], ["Gilead", "CHEMICAL", 131, 137], ["Hydroxychloroquine", "CHEMICAL", 0, 18], ["chloroquine", "CHEMICAL", 49, 60], ["remdesivir", "CHEMICAL", 119, 129], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 0, 18], ["chloroquine", "SIMPLE_CHEMICAL", 49, 60], ["remdesivir", "SIMPLE_CHEMICAL", 119, 129], ["Hydroxychloroquine", "TREATMENT", 0, 18], ["chloroquine", "TREATMENT", 49, 60], ["treatment trials", "TREATMENT", 101, 117], ["an EC50", "TEST", 143, 150]]], ["Remdesivir (Gilead) is not FDA-approved and in limited quantities.", [["Remdesivir", "CHEMICAL", 0, 10], ["Gilead", "CHEMICAL", 12, 18], ["Remdesivir", "CHEMICAL", 0, 10], ["Remdesivir", "SIMPLE_CHEMICAL", 0, 10], ["Remdesivir (Gilead)", "TREATMENT", 0, 19]]], ["Hydroxychloroquine is FDA-approved and globally is inexpensive.", [["Hydroxychloroquine", "CHEMICAL", 0, 18], ["Hydroxychloroquine", "CHEMICAL", 0, 18], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 0, 18], ["Hydroxychloroquine", "TREATMENT", 0, 18]]], ["Chloroquine is no longer broadly available in the USA.Preliminary Data:Existing Literature:Preliminary Data:Several drugs, such as ribavirin, interferon, lopinavir-ritonavir, corticosteroids, have been used in patients with SARS or MERS, although the efficacy is poorly understood as a gold standard randomized clinical trial has not been conducted.", [["Chloroquine", "CHEMICAL", 0, 11], ["ribavirin", "CHEMICAL", 131, 140], ["interferon", "CHEMICAL", 142, 152], ["lopinavir-ritonavir", "CHEMICAL", 154, 173], ["corticosteroids", "CHEMICAL", 175, 190], ["SARS", "DISEASE", 224, 228], ["MERS", "DISEASE", 232, 236], ["Chloroquine", "CHEMICAL", 0, 11], ["ribavirin", "CHEMICAL", 131, 140], ["lopinavir", "CHEMICAL", 154, 163], ["ritonavir", "CHEMICAL", 164, 173], ["corticosteroids", "CHEMICAL", 175, 190], ["Chloroquine", "SIMPLE_CHEMICAL", 0, 11], ["ribavirin", "SIMPLE_CHEMICAL", 131, 140], ["interferon", "SIMPLE_CHEMICAL", 142, 152], ["lopinavir-ritonavir", "SIMPLE_CHEMICAL", 154, 173], ["corticosteroids", "SIMPLE_CHEMICAL", 175, 190], ["patients", "ORGANISM", 210, 218], ["interferon", "PROTEIN", 142, 152], ["patients", "SPECIES", 210, 218], ["Chloroquine", "TREATMENT", 0, 11], ["Several drugs", "TREATMENT", 108, 121], ["ribavirin", "TREATMENT", 131, 140], ["interferon", "TREATMENT", 142, 152], ["lopinavir", "TREATMENT", 154, 163], ["ritonavir", "TREATMENT", 164, 173], ["corticosteroids", "TREATMENT", 175, 190], ["SARS", "PROBLEM", 224, 228], ["a gold standard randomized clinical trial", "TREATMENT", 284, 325], ["no longer", "UNCERTAINTY", 15, 24]]], ["3 CDC investigators reported that post-infection chloroquine treatment was effective in vitro at preventing the spread of SARS-CoV infection in an in vitro cell-based system [3] .", [["cell", "ANATOMY", 156, 160], ["chloroquine", "CHEMICAL", 49, 60], ["SARS-CoV infection", "DISEASE", 122, 140], ["chloroquine", "CHEMICAL", 49, 60], ["chloroquine", "SIMPLE_CHEMICAL", 49, 60], ["SARS-CoV", "ORGANISM", 122, 130], ["cell", "CELL", 156, 160], ["SARS-CoV", "SPECIES", 122, 130], ["post-infection chloroquine treatment", "TREATMENT", 34, 70], ["SARS", "PROBLEM", 122, 126], ["CoV infection", "PROBLEM", 127, 140], ["CoV", "OBSERVATION_MODIFIER", 127, 130], ["infection", "OBSERVATION", 131, 140]]], ["Vincent et al reported:Preliminary Data:\"In order to investigate the antiviral properties of chloroquine on SARS-CoV after the initiation of infection, Vero E6 cells were infected with the virus and fresh medium supplemented with various concentrations of chloroquine was added immediately after virus adsorption.", [["Vero E6 cells", "ANATOMY", 152, 165], ["chloroquine", "CHEMICAL", 93, 104], ["SARS", "DISEASE", 108, 112], ["infection", "DISEASE", 141, 150], ["chloroquine", "CHEMICAL", 256, 267], ["chloroquine", "CHEMICAL", 93, 104], ["chloroquine", "CHEMICAL", 256, 267], ["chloroquine", "SIMPLE_CHEMICAL", 93, 104], ["SARS-CoV", "ORGANISM", 108, 116], ["Vero E6 cells", "CELL", 152, 165], ["chloroquine", "SIMPLE_CHEMICAL", 256, 267], ["Vero E6 cells", "CELL_LINE", 152, 165], ["SARS-CoV", "SPECIES", 108, 116], ["Vero E6", "SPECIES", 152, 159], ["the antiviral properties", "TREATMENT", 65, 89], ["chloroquine", "TREATMENT", 93, 104], ["SARS", "TREATMENT", 108, 112], ["infection", "PROBLEM", 141, 150], ["Vero E6 cells", "TREATMENT", 152, 165], ["the virus and fresh medium", "TREATMENT", 185, 211], ["chloroquine", "TREATMENT", 256, 267], ["virus adsorption", "TREATMENT", 296, 312], ["infection", "OBSERVATION", 141, 150]]], ["Infected cells were incubated for an additional 16-18 h, after which the presence of virus antigens was analyzed by indirect immunofluorescence analysis.", [["cells", "ANATOMY", 9, 14], ["cells", "CELL", 9, 14], ["virus antigens", "PROTEIN", 85, 99], ["Infected cells", "PROBLEM", 0, 14], ["virus antigens", "PROBLEM", 85, 99], ["indirect immunofluorescence analysis", "TEST", 116, 152], ["virus", "OBSERVATION", 85, 90]]], ["When chloroquine was added after the initiation of infection, there was a dramatic dose-dependent decrease in the number of virus antigen-positive cells ( Fig. 2A) .", [["cells", "ANATOMY", 147, 152], ["chloroquine", "CHEMICAL", 5, 16], ["infection", "DISEASE", 51, 60], ["chloroquine", "CHEMICAL", 5, 16], ["chloroquine", "SIMPLE_CHEMICAL", 5, 16], ["virus antigen-positive cells", "CELL_TYPE", 124, 152], ["chloroquine", "TREATMENT", 5, 16], ["infection", "PROBLEM", 51, 60], ["dependent decrease", "PROBLEM", 88, 106], ["virus antigen", "TEST", 124, 137], ["infection", "OBSERVATION", 51, 60], ["dramatic", "OBSERVATION_MODIFIER", 74, 82], ["dependent", "OBSERVATION_MODIFIER", 88, 97], ["decrease", "OBSERVATION_MODIFIER", 98, 106], ["positive cells", "OBSERVATION", 138, 152]]], ["As little as 0.1-1 \u03bcM chloroquine reduced the infection by 50% and up to 90-94% inhibition was observed with 33-100 \u03bcM concentrations (Fig. 2B) .", [["chloroquine", "CHEMICAL", 22, 33], ["infection", "DISEASE", 46, 55], ["chloroquine", "CHEMICAL", 22, 33], ["chloroquine", "SIMPLE_CHEMICAL", 22, 33], ["chloroquine", "TREATMENT", 22, 33], ["the infection", "PROBLEM", 42, 55], ["infection", "OBSERVATION", 46, 55]]], ["At concentrations of chloroquine in excess of 1 \u03bcM, only a small number of individual cells were initially infected, and the spread of the infection to adjacent cells was all but eliminated.", [["cells", "ANATOMY", 86, 91], ["cells", "ANATOMY", 161, 166], ["chloroquine", "CHEMICAL", 21, 32], ["infection", "DISEASE", 139, 148], ["chloroquine", "CHEMICAL", 21, 32], ["chloroquine", "SIMPLE_CHEMICAL", 21, 32], ["cells", "CELL", 86, 91], ["cells", "CELL", 161, 166], ["adjacent cells", "CELL_TYPE", 152, 166], ["chloroquine", "TREATMENT", 21, 32], ["individual cells", "PROBLEM", 75, 91], ["the infection to adjacent cells", "PROBLEM", 135, 166], ["small", "OBSERVATION_MODIFIER", 59, 64], ["infected", "OBSERVATION", 107, 115], ["spread", "OBSERVATION_MODIFIER", 125, 131], ["infection", "OBSERVATION", 139, 148]]], ["A half-maximal inhibitory effect (EC50) was estimated to occur at 4.4 \u00b1 1.0 \u03bcM chloroquine (Fig. 2C) .", [["chloroquine", "CHEMICAL", 79, 90], ["chloroquine", "CHEMICAL", 79, 90], ["chloroquine", "SIMPLE_CHEMICAL", 79, 90], ["EC50", "TEST", 34, 38], ["chloroquine (Fig", "TREATMENT", 79, 95]]], ["These data clearly show that the addition of chloroquine can effectively reduce the establishment of infection and spread of SARS-CoV if the drug is added immediately following virus adsorption.\" [3] Vincent et al also reported: \"Since we observed antiviral effects by chloroquine immediately after virus adsorption, we further extended the analysis by adding chloroquine 3 and 5 h after virus adsorption and examined for the presence of virus antigens after 20 h.", [["chloroquine", "CHEMICAL", 45, 56], ["infection", "DISEASE", 101, 110], ["SARS", "DISEASE", 125, 129], ["chloroquine", "CHEMICAL", 269, 280], ["chloroquine", "CHEMICAL", 360, 371], ["chloroquine", "CHEMICAL", 45, 56], ["chloroquine", "CHEMICAL", 269, 280], ["chloroquine", "CHEMICAL", 360, 371], ["chloroquine", "SIMPLE_CHEMICAL", 45, 56], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 125, 133], ["chloroquine", "SIMPLE_CHEMICAL", 269, 280], ["chloroquine", "SIMPLE_CHEMICAL", 360, 371], ["virus antigens", "PROTEIN", 438, 452], ["SARS-CoV", "SPECIES", 125, 133], ["chloroquine", "TREATMENT", 45, 56], ["infection", "PROBLEM", 101, 110], ["SARS", "PROBLEM", 125, 129], ["antiviral effects", "TREATMENT", 248, 265], ["chloroquine", "TREATMENT", 269, 280], ["virus adsorption", "TREATMENT", 299, 315], ["the analysis", "TEST", 337, 349], ["chloroquine", "TREATMENT", 360, 371], ["virus adsorption", "TREATMENT", 388, 404], ["virus antigens", "PROBLEM", 438, 452], ["infection", "OBSERVATION", 101, 110]]], ["We found that chloroquine was still significantly effective even when added 5 h after infection (Fig. 3) ; however, to obtain equivalent antiviral effect, a higher concentration of chloroquine was required if the drug was added 3 or 5 h after adsorption.\" [3] Further experiments demonstrated that chloroquine impaired the terminal glycosylation of angiotensin-converting enzyme-2 (ACE2) receptor, which is the binding site for the envelope spike glycoprotein of SARS-CoV and SAR-CoV2 [3] .Preliminary Data:Conversely, chloroquine did not have activity against Middle East respiratory syndrome coronavirus (MERS-CoV), which may be related to MERS binding to CD26 receptor protein [4] .Preliminary Data:In a March 9, 2020 publication, hydroxychloroquine was found to have greater activity than chloroquine [5] .", [["chloroquine", "CHEMICAL", 14, 25], ["infection", "DISEASE", 86, 95], ["chloroquine", "CHEMICAL", 181, 192], ["chloroquine", "CHEMICAL", 298, 309], ["angiotensin", "CHEMICAL", 349, 360], ["chloroquine", "CHEMICAL", 519, 530], ["Middle East respiratory syndrome coronavirus", "DISEASE", 561, 605], ["hydroxychloroquine", "CHEMICAL", 734, 752], ["chloroquine", "CHEMICAL", 793, 804], ["chloroquine", "CHEMICAL", 14, 25], ["chloroquine", "CHEMICAL", 181, 192], ["chloroquine", "CHEMICAL", 298, 309], ["chloroquine", "CHEMICAL", 519, 530], ["hydroxychloroquine", "CHEMICAL", 734, 752], ["chloroquine", "CHEMICAL", 793, 804], ["chloroquine", "SIMPLE_CHEMICAL", 14, 25], ["chloroquine", "SIMPLE_CHEMICAL", 181, 192], ["chloroquine", "SIMPLE_CHEMICAL", 298, 309], ["angiotensin-converting enzyme-2", "GENE_OR_GENE_PRODUCT", 349, 380], ["ACE2", "GENE_OR_GENE_PRODUCT", 382, 386], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 463, 471], ["SAR-CoV2", "GENE_OR_GENE_PRODUCT", 476, 484], ["chloroquine", "SIMPLE_CHEMICAL", 519, 530], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 561, 605], ["MERS-CoV", "ORGANISM", 607, 615], ["CD26 receptor", "GENE_OR_GENE_PRODUCT", 658, 671], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 734, 752], ["chloroquine", "SIMPLE_CHEMICAL", 793, 804], ["angiotensin-converting enzyme-2 (ACE2) receptor", "PROTEIN", 349, 396], ["envelope spike glycoprotein", "PROTEIN", 432, 459], ["SAR", "PROTEIN", 476, 479], ["MERS", "PROTEIN", 642, 646], ["CD26 receptor protein", "PROTEIN", 658, 679], ["SARS-CoV", "SPECIES", 463, 471], ["Middle East respiratory syndrome coronavirus", "SPECIES", 561, 605], ["MERS-CoV", "SPECIES", 607, 615], ["chloroquine", "TREATMENT", 14, 25], ["infection", "PROBLEM", 86, 95], ["a higher concentration of chloroquine", "TREATMENT", 155, 192], ["Further experiments", "TEST", 260, 279], ["chloroquine", "TREATMENT", 298, 309], ["angiotensin", "TREATMENT", 349, 360], ["converting enzyme-2 (ACE2) receptor", "TREATMENT", 361, 396], ["the binding site", "PROBLEM", 407, 423], ["SARS", "PROBLEM", 463, 467], ["chloroquine", "TREATMENT", 519, 530], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 561, 605], ["MERS binding", "PROBLEM", 642, 654], ["hydroxychloroquine", "TREATMENT", 734, 752], ["chloroquine", "TREATMENT", 793, 804], ["respiratory syndrome", "OBSERVATION", 573, 593]]], ["The SARS-CoV-2 EC 50 values for hydroxychloroquine were 6.14 \u03bcM at 24 hours and 0.72 \u03bcM at 48 hours, [5] .", [["SARS", "DISEASE", 4, 8], ["hydroxychloroquine", "CHEMICAL", 32, 50], ["hydroxychloroquine", "CHEMICAL", 32, 50], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 32, 50], ["The SARS", "TEST", 0, 8], ["CoV", "TEST", 9, 12], ["hydroxychloroquine", "TREATMENT", 32, 50]]], ["Conversely, chloroquine EC50 values were >100 \u03bcM at 24 hours and 18.01 \u03bcM at 48 hours [5] .", [["chloroquine", "CHEMICAL", 12, 23], ["chloroquine", "CHEMICAL", 12, 23], ["chloroquine", "SIMPLE_CHEMICAL", 12, 23], ["chloroquine EC50 values", "TEST", 12, 35]]], ["This inhibition assay was performed with Vero cells using an infectious dose of 100 plaque forming units.Existing Clinical DataThere is accumulating clinical data on treatment of hospitalized patients with COVID-19 infection with chloroquine or hydroxychloroquine.", [["Vero cells", "ANATOMY", 41, 51], ["plaque", "ANATOMY", 84, 90], ["COVID-19", "CHEMICAL", 206, 214], ["infection", "DISEASE", 215, 224], ["chloroquine", "CHEMICAL", 230, 241], ["hydroxychloroquine", "CHEMICAL", 245, 263], ["chloroquine", "CHEMICAL", 230, 241], ["hydroxychloroquine", "CHEMICAL", 245, 263], ["Vero cells", "CELL", 41, 51], ["patients", "ORGANISM", 192, 200], ["chloroquine", "SIMPLE_CHEMICAL", 230, 241], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 245, 263], ["Vero cells", "CELL_LINE", 41, 51], ["patients", "SPECIES", 192, 200], ["This inhibition assay", "TEST", 0, 21], ["Vero cells", "TREATMENT", 41, 51], ["an infectious dose of 100 plaque forming units", "TREATMENT", 58, 104], ["COVID-19 infection", "PROBLEM", 206, 224], ["chloroquine", "TREATMENT", 230, 241], ["hydroxychloroquine", "TREATMENT", 245, 263], ["infection", "OBSERVATION", 215, 224]]], ["To date, there is no conclusive evidence of clinical benefit of hydroxychloroquine for treatment of hospitalized patients.Existing Clinical DataThere have been no studies of early therapy or preventative therapy.Reference Overall FindingsLimitations Study designNumber of patientsTreatment regimenSeverity of illness (As reported)Location OutcomesHydroxychloroquine (HCQ)Chen J, et al. [7] No statistically significant differences in conversion rate by day 7 (86.7% vs. 93.3%, p>0.05).Hydroxychloroquine (HCQ)No difference in clinical outcomes between groups.Hydroxychloroquine (HCQ)Full article only available in Chinese.Hydroxychloroquine (HCQ)Not peer-reviewed.", [["hydroxychloroquine", "CHEMICAL", 64, 82], ["illness", "DISEASE", 309, 316], ["Hydroxychloroquine", "CHEMICAL", 347, 365], ["HCQ", "CHEMICAL", 367, 370], ["Hydroxychloroquine", "CHEMICAL", 485, 503], ["HCQ", "CHEMICAL", 505, 508], ["Hydroxychloroquine", "CHEMICAL", 559, 577], ["HCQ", "CHEMICAL", 579, 582], ["Hydroxychloroquine", "CHEMICAL", 622, 640], ["HCQ", "CHEMICAL", 642, 645], ["hydroxychloroquine", "CHEMICAL", 64, 82], ["Hydroxychloroquine", "CHEMICAL", 347, 365], ["HCQ", "CHEMICAL", 367, 370], ["Hydroxychloroquine", "CHEMICAL", 485, 503], ["HCQ", "CHEMICAL", 505, 508], ["Hydroxychloroquine", "CHEMICAL", 559, 577], ["HCQ", "CHEMICAL", 579, 582], ["Hydroxychloroquine", "CHEMICAL", 622, 640], ["HCQ", "CHEMICAL", 642, 645], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 64, 82], ["patients", "ORGANISM", 113, 121], ["patients", "ORGANISM", 272, 280], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 485, 503], ["HCQ", "SIMPLE_CHEMICAL", 505, 508], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 559, 577], ["HCQ", "SIMPLE_CHEMICAL", 579, 582], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 622, 640], ["HCQ", "SIMPLE_CHEMICAL", 642, 645], ["patients", "SPECIES", 113, 121], ["patients", "SPECIES", 272, 280], ["hydroxychloroquine", "TREATMENT", 64, 82], ["treatment", "TREATMENT", 87, 96], ["early therapy", "TREATMENT", 174, 187], ["preventative therapy", "TREATMENT", 191, 211], ["illness", "PROBLEM", 309, 316], ["Hydroxychloroquine (HCQ)", "TREATMENT", 347, 371], ["conversion rate", "TEST", 434, 449], ["p", "TEST", 477, 478], ["Hydroxychloroquine (HCQ)", "TREATMENT", 485, 509], ["Hydroxychloroquine (HCQ)", "TREATMENT", 559, 583], ["Hydroxychloroquine (HCQ)", "TREATMENT", 622, 646], ["no conclusive evidence of", "UNCERTAINTY", 18, 43], ["No", "UNCERTAINTY", 390, 392], ["significant", "OBSERVATION_MODIFIER", 407, 418]]], ["Gautret et al. [8] In unadjusted analyses, there were significantly reduced viral titers in the HCQ arm at day 6 (70% compared to 12.5% PCR negative, p<0.001).Hydroxychloroquine (HCQ)All six patients receiving HCQ and azithromycin were SARS-CoV-2 negative on day 6.Hydroxychloroquine (HCQ)Study design.Hydroxychloroquine (HCQ)Small sample size/underpowered.Exclusion of six patients from analysis (no intention to treat analyses).Lack of long-term outcomes.", [["HCQ", "CHEMICAL", 96, 99], ["Hydroxychloroquine", "CHEMICAL", 159, 177], ["HCQ", "CHEMICAL", 179, 182], ["HCQ", "CHEMICAL", 210, 213], ["azithromycin", "CHEMICAL", 218, 230], ["SARS", "DISEASE", 236, 240], ["Hydroxychloroquine", "CHEMICAL", 265, 283], ["HCQ", "CHEMICAL", 285, 288], ["Hydroxychloroquine", "CHEMICAL", 302, 320], ["HCQ", "CHEMICAL", 322, 325], ["HCQ", "CHEMICAL", 96, 99], ["Hydroxychloroquine", "CHEMICAL", 159, 177], ["HCQ", "CHEMICAL", 179, 182], ["HCQ", "CHEMICAL", 210, 213], ["azithromycin", "CHEMICAL", 218, 230], ["Hydroxychloroquine", "CHEMICAL", 265, 283], ["HCQ", "CHEMICAL", 285, 288], ["Hydroxychloroquine", "CHEMICAL", 302, 320], ["HCQ", "CHEMICAL", 322, 325], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 159, 177], ["HCQ", "SIMPLE_CHEMICAL", 179, 182], ["patients", "ORGANISM", 191, 199], ["HCQ", "SIMPLE_CHEMICAL", 210, 213], ["azithromycin", "SIMPLE_CHEMICAL", 218, 230], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 265, 283], ["HCQ", "SIMPLE_CHEMICAL", 285, 288], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 302, 320], ["HCQ", "SIMPLE_CHEMICAL", 322, 325], ["patients", "ORGANISM", 374, 382], ["patients", "SPECIES", 191, 199], ["patients", "SPECIES", 374, 382], ["unadjusted analyses", "TEST", 22, 41], ["significantly reduced viral titers in the HCQ arm", "PROBLEM", 54, 103], ["PCR", "TEST", 136, 139], ["Hydroxychloroquine (HCQ)", "TREATMENT", 159, 183], ["HCQ", "TREATMENT", 210, 213], ["azithromycin", "TREATMENT", 218, 230], ["SARS-CoV", "TEST", 236, 244], ["Hydroxychloroquine (HCQ)", "TREATMENT", 265, 289], ["Hydroxychloroquine (HCQ)", "TREATMENT", 302, 326], ["Small sample size", "TREATMENT", 326, 343], ["analysis", "TEST", 388, 396], ["analyses", "TEST", 420, 428], ["long-term outcomes", "PROBLEM", 438, 456], ["reduced", "OBSERVATION_MODIFIER", 68, 75], ["viral titers", "OBSERVATION", 76, 88], ["HCQ arm", "ANATOMY", 96, 103], ["Small", "OBSERVATION_MODIFIER", 326, 331], ["long-term outcomes", "OBSERVATION_MODIFIER", 438, 456]]], ["Gautret et al. [11] Reduced nasopharyngeal viral titers at day 7 (83% negative) and 8 (93%).Exclusion of six patients from analysis (no intention to treat analyses).Mean length of hospitalization of 5 days.Exclusion of six patients from analysis (no intention to treat analyses).Study design.Exclusion of six patients from analysis (no intention to treat analyses).Small sample size.Exclusion of six patients from analysis (no intention to treat analyses).Short follow-up time.Exclusion of six patients from analysis (no intention to treat analyses).Not peer-reviewed.Chloroquine (CQ)Gao J et al. [12] CQ was stated to be superior to standard of care treatment in preventing exacerbation of pneumonia, reducing days to conversion rate, and shortening time to clinical recovery.RationaleCurrent standard of care is observation and quarantine after exposure to COVID19.RationaleAs of March 6, 2020, the CDC estimates that the transmission of SARS-CoV2 after a U.S. household close contract is 10.5% (95%CI, 2.9 to 31.4%) [13] .", [["nasopharyngeal", "ANATOMY", 28, 42], ["Chloroquine", "CHEMICAL", 568, 579], ["CQ", "CHEMICAL", 581, 583], ["CQ", "CHEMICAL", 602, 604], ["pneumonia", "DISEASE", 691, 700], ["COVID19", "CHEMICAL", 859, 866], ["SARS", "DISEASE", 940, 944], ["Chloroquine", "CHEMICAL", 568, 579], ["CQ", "CHEMICAL", 581, 583], ["COVID19", "CHEMICAL", 859, 866], ["nasopharyngeal", "ORGAN", 28, 42], ["patients", "ORGANISM", 109, 117], ["patients", "ORGANISM", 223, 231], ["patients", "ORGANISM", 309, 317], ["patients", "ORGANISM", 400, 408], ["patients", "ORGANISM", 494, 502], ["Chloroquine", "SIMPLE_CHEMICAL", 568, 579], ["CQ", "SIMPLE_CHEMICAL", 581, 583], ["[12] CQ", "SIMPLE_CHEMICAL", 597, 604], ["SARS-CoV2", "ORGANISM", 940, 949], ["COVID19", "PROTEIN", 859, 866], ["patients", "SPECIES", 109, 117], ["patients", "SPECIES", 223, 231], ["patients", "SPECIES", 309, 317], ["patients", "SPECIES", 400, 408], ["patients", "SPECIES", 494, 502], ["Reduced nasopharyngeal viral titers", "TEST", 20, 55], ["analysis", "TEST", 123, 131], ["analyses", "TEST", 155, 163], ["analysis", "TEST", 237, 245], ["analyses", "TEST", 269, 277], ["analysis", "TEST", 323, 331], ["analyses", "TEST", 355, 363], ["Small sample size", "PROBLEM", 365, 382], ["analysis", "TEST", 414, 422], ["analyses", "TEST", 446, 454], ["analysis", "TEST", 508, 516], ["analyses", "TEST", 540, 548], ["Chloroquine (CQ)Gao J et al.", "TREATMENT", 568, 596], ["care treatment", "TREATMENT", 646, 660], ["pneumonia", "PROBLEM", 691, 700], ["COVID19", "TREATMENT", 859, 866], ["SARS", "PROBLEM", 940, 944], ["CI", "TEST", 1001, 1003], ["nasopharyngeal", "ANATOMY", 28, 42], ["length", "OBSERVATION_MODIFIER", 170, 176], ["sample", "OBSERVATION_MODIFIER", 371, 377], ["size", "OBSERVATION_MODIFIER", 378, 382], ["pneumonia", "OBSERVATION", 691, 700]]], ["Among all close contacts, the SARS-CoV2 transmission rate is estimated at 0.45% (95%CI, 0.12 to 1.6%) by the CDC.", [["SARS", "DISEASE", 30, 34], ["the SARS", "TEST", 26, 34], ["CI", "TEST", 84, 86]]], ["Conversely, in a setting with community transmission, the secondary attack rate in China was 35% (95%CI, 27-44%) based on 48 transmissions among 137 persons in 9 index patients.RationaleChloroquine or Hydroxychloroquine may have antiviral effects against SARS-COV2 which may prevent COVID19 disease or early preemptive therapy may ameliorate disease severity.", [["Chloroquine", "CHEMICAL", 186, 197], ["Hydroxychloroquine", "CHEMICAL", 201, 219], ["SARS", "DISEASE", 255, 259], ["Chloroquine", "CHEMICAL", 186, 197], ["Hydroxychloroquine", "CHEMICAL", 201, 219], ["persons", "ORGANISM", 149, 156], ["patients", "ORGANISM", 168, 176], ["Chloroquine", "SIMPLE_CHEMICAL", 186, 197], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 201, 219], ["SARS-COV2", "ORGANISM", 255, 264], ["COVID19", "GENE_OR_GENE_PRODUCT", 283, 290], ["persons", "SPECIES", 149, 156], ["patients", "SPECIES", 168, 176], ["the secondary attack rate", "TEST", 54, 79], ["CI", "TEST", 101, 103], ["RationaleChloroquine", "TREATMENT", 177, 197], ["Hydroxychloroquine", "TREATMENT", 201, 219], ["antiviral effects", "TREATMENT", 229, 246], ["SARS", "PROBLEM", 255, 259], ["COV2", "TREATMENT", 260, 264], ["COVID19 disease", "PROBLEM", 283, 298], ["early preemptive therapy", "TREATMENT", 302, 326], ["disease severity", "PROBLEM", 342, 358]]], ["This trial will use a modification of standard malaria dosing of hydroxychloroquine to provide postexposure prophylaxis / preemptive therapy.RationaleStandard malaria treatment dosing is:Rationale\u2022 800mg once, then 400mg in 6-8 hours, then 400mg daily x 2 days (3 days in total).", [["malaria", "DISEASE", 47, 54], ["hydroxychloroquine", "CHEMICAL", 65, 83], ["malaria", "DISEASE", 159, 166], ["hydroxychloroquine", "CHEMICAL", 65, 83], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 65, 83], ["a modification of standard malaria dosing", "TREATMENT", 20, 61], ["hydroxychloroquine", "TREATMENT", 65, 83], ["postexposure prophylaxis", "TREATMENT", 95, 119], ["preemptive therapy", "TREATMENT", 122, 140], ["RationaleStandard malaria treatment dosing", "TREATMENT", 141, 183], ["Rationale\u2022", "TREATMENT", 187, 197]]], ["We propose to dose for SARS-CoV-2 post-exposure prophylaxis at:Rationale\u2022 800mg once, then 600mg in 6-8 hours, then 600mg daily x 4 days (5 days in total).", [["SARS", "DISEASE", 23, 27], ["SARS-CoV", "SPECIES", 23, 31], ["SARS", "PROBLEM", 23, 27], ["CoV", "TEST", 28, 31], ["exposure prophylaxis", "TREATMENT", 39, 59], ["Rationale\u2022", "TREATMENT", 63, 73]]], ["A delayed start to prophylaxis will be occurring --based on the intrinsic delay from the exposure to case notification to trial enrollment, and to receipt of the first medication dose.", [["prophylaxis", "TREATMENT", 19, 30], ["the first medication dose", "TREATMENT", 158, 183]]], ["Thereby, higher doses may be necessary as seen in the CDC study [3] .", [["the CDC study", "TEST", 50, 63]]], ["Thus a malaria loading dose sequence will be used, but with higher daily doses thereafter to target reaching the above the EC50.RationaleAs the incubation period is 2-14 days with a mean incubation period of 5-6 days, we seek to deliver post-exposure prophylaxis by the morning of day 4 at the latest. (<=3 days is an inclusion criteria).", [["malaria", "DISEASE", 7, 14], ["a malaria loading dose sequence", "TREATMENT", 5, 36], ["post-exposure prophylaxis", "TREATMENT", 237, 262]]], ["We recognize this may turn \"post-exposure prophylaxis\" into more of a \"preemptive therapy\" for some subjects who rapidly develop disease after trial randomization.", [["a \"preemptive therapy", "TREATMENT", 68, 89], ["disease", "PROBLEM", 129, 136], ["trial randomization", "TREATMENT", 143, 162]]], ["If hydroxychloroquine does not prevent disease for some, preemptive therapy may ameliorate the COVID19 disease severity.", [["hydroxychloroquine", "CHEMICAL", 3, 21], ["hydroxychloroquine", "CHEMICAL", 3, 21], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 3, 21], ["COVID19", "GENE_OR_GENE_PRODUCT", 95, 102], ["hydroxychloroquine", "TREATMENT", 3, 21], ["disease", "PROBLEM", 39, 46], ["preemptive therapy", "TREATMENT", 57, 75], ["the COVID19 disease severity", "PROBLEM", 91, 119]]], ["Attenuated disease may in turn be associated with reduced rates of transmission.Potential RisksShort-term use of hydroxychloroquine is well-tolerated with a safe track record since 1955.", [["hydroxychloroquine", "CHEMICAL", 113, 131], ["hydroxychloroquine", "CHEMICAL", 113, 131], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 113, 131], ["Attenuated disease", "PROBLEM", 0, 18], ["reduced rates of transmission", "PROBLEM", 50, 79], ["hydroxychloroquine", "TREATMENT", 113, 131], ["disease", "OBSERVATION", 11, 18], ["reduced", "OBSERVATION_MODIFIER", 50, 57], ["rates", "OBSERVATION_MODIFIER", 58, 63]]], ["The most common reported side effects include:Potential Risks\u2022 headache, dizziness, ringing in your ears;Potential Risks\u2022 nausea, vomiting, stomach pain;Potential Risks\u2022 loss of appetite, weight loss;Potential Risks\u2022 mood changes, feeling nervous or irritable;Potential Risks\u2022 skin rash or itching; or \u2022 hair loss.Potential RisksGI side effects are minimized when taken with a meal or with milk.", [["stomach", "ANATOMY", 140, 147], ["nervous", "ANATOMY", 239, 246], ["skin", "ANATOMY", 277, 281], ["hair", "ANATOMY", 304, 308], ["milk", "ANATOMY", 390, 394], ["headache", "DISEASE", 63, 71], ["dizziness", "DISEASE", 73, 82], ["nausea", "DISEASE", 122, 128], ["vomiting", "DISEASE", 130, 138], ["stomach pain", "DISEASE", 140, 152], ["loss of appetite", "DISEASE", 170, 186], ["weight loss", "DISEASE", 188, 199], ["rash", "DISEASE", 282, 286], ["itching", "DISEASE", 290, 297], ["hair loss", "DISEASE", 304, 313], ["ears", "ORGAN", 100, 104], ["stomach", "ORGANISM_SUBDIVISION", 140, 147], ["skin", "ORGAN", 277, 281], ["hair", "ORGAN", 304, 308], ["milk", "ORGANISM_SUBSTANCE", 390, 394], ["headache", "PROBLEM", 63, 71], ["dizziness", "PROBLEM", 73, 82], ["ringing in your ears", "PROBLEM", 84, 104], ["nausea", "PROBLEM", 122, 128], ["vomiting", "PROBLEM", 130, 138], ["stomach pain", "PROBLEM", 140, 152], ["loss of appetite", "PROBLEM", 170, 186], ["weight loss", "PROBLEM", 188, 199], ["mood changes", "PROBLEM", 217, 229], ["feeling nervous", "PROBLEM", 231, 246], ["irritable", "PROBLEM", 250, 259], ["skin rash", "PROBLEM", 277, 286], ["itching", "PROBLEM", 290, 297], ["\u2022 hair loss", "PROBLEM", 302, 313], ["Potential RisksGI side effects", "PROBLEM", 314, 344], ["ears", "ANATOMY", 100, 104], ["stomach", "ANATOMY", 140, 147], ["skin", "ANATOMY", 277, 281], ["rash", "OBSERVATION", 282, 286]]], ["Antacid medications should be spaced apart by at least 4 hours.Potential RisksPotential adverse effects by system, as listed on the FDA package insert: \u25cb Eye: \"Chloroquine retinopathy\" is a rare side-effect of chronic use after multiple years of use.", [["Chloroquine", "CHEMICAL", 160, 171], ["retinopathy", "DISEASE", 172, 183], ["Chloroquine", "CHEMICAL", 160, 171], ["Chloroquine", "SIMPLE_CHEMICAL", 160, 171], ["Antacid medications", "TREATMENT", 0, 19], ["Potential RisksPotential adverse effects", "PROBLEM", 63, 103], ["Chloroquine retinopathy", "PROBLEM", 160, 183], ["Eye", "ANATOMY", 154, 157], ["chronic", "OBSERVATION_MODIFIER", 210, 217]]], ["On 24 April 2020, FDA issued a caution:FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problemsClose supervision is strongly recommended \"The FDA is aware of reports of serious heart rhythm problems in patients with COVID-19 treated with hydroxychloroquine or chloroquine, often in combination with azithromycin and other QT prolonging medicines.", [["heart", "ANATOMY", 181, 186], ["heart", "ANATOMY", 284, 289], ["hydroxychloroquine", "CHEMICAL", 67, 85], ["chloroquine", "CHEMICAL", 89, 100], ["heart rhythm problems", "DISEASE", 181, 202], ["heart rhythm problems", "DISEASE", 284, 305], ["COVID-19", "CHEMICAL", 323, 331], ["hydroxychloroquine", "CHEMICAL", 345, 363], ["chloroquine", "CHEMICAL", 367, 378], ["azithromycin", "CHEMICAL", 406, 418], ["hydroxychloroquine", "CHEMICAL", 67, 85], ["chloroquine", "CHEMICAL", 89, 100], ["COVID-19", "CHEMICAL", 105, 113], ["COVID-19", "CHEMICAL", 323, 331], ["hydroxychloroquine", "CHEMICAL", 345, 363], ["chloroquine", "CHEMICAL", 367, 378], ["azithromycin", "CHEMICAL", 406, 418], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 67, 85], ["chloroquine", "SIMPLE_CHEMICAL", 89, 100], ["heart", "ORGAN", 181, 186], ["heart", "ORGAN", 284, 289], ["patients", "ORGANISM", 309, 317], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 345, 363], ["chloroquine", "SIMPLE_CHEMICAL", 367, 378], ["azithromycin", "SIMPLE_CHEMICAL", 406, 418], ["patients", "SPECIES", 309, 317], ["hydroxychloroquine", "TREATMENT", 67, 85], ["chloroquine", "TREATMENT", 89, 100], ["COVID", "TREATMENT", 105, 110], ["heart rhythm problems", "PROBLEM", 181, 202], ["serious heart rhythm problems", "PROBLEM", 276, 305], ["COVID", "TEST", 323, 328], ["hydroxychloroquine", "TREATMENT", 345, 363], ["chloroquine", "TREATMENT", 367, 378], ["azithromycin", "TREATMENT", 406, 418], ["other QT prolonging medicines", "TREATMENT", 423, 452], ["heart", "ANATOMY", 181, 186], ["rhythm", "OBSERVATION", 187, 193]]], ["We are also aware of increased use of these medicines through outpatient prescriptions.", [["these medicines", "TREATMENT", 38, 53], ["outpatient prescriptions", "TREATMENT", 62, 86]]], ["Therefore, we would like to remind health care professionals and patients of the known risks associated with both hydroxychloroquine and chloroquine.", [["hydroxychloroquine", "CHEMICAL", 114, 132], ["chloroquine", "CHEMICAL", 137, 148], ["hydroxychloroquine", "CHEMICAL", 114, 132], ["chloroquine", "CHEMICAL", 137, 148], ["patients", "ORGANISM", 65, 73], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 114, 132], ["chloroquine", "SIMPLE_CHEMICAL", 137, 148], ["patients", "SPECIES", 65, 73], ["hydroxychloroquine", "TREATMENT", 114, 132], ["chloroquine", "TREATMENT", 137, 148]]], ["We will continue to investigate risks associated with the use of hydroxychloroquine and chloroquine for COVID-19 and communicate publicly when we have more information.\"FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems\"Hydroxychloroquine and chloroquine can cause abnormal heart rhythms such as QT interval prolongation and a dangerously rapid heart rate called ventricular tachycardia.", [["heart", "ANATOMY", 311, 316], ["heart", "ANATOMY", 387, 392], ["heart", "ANATOMY", 458, 463], ["ventricular", "ANATOMY", 476, 487], ["hydroxychloroquine", "CHEMICAL", 65, 83], ["chloroquine", "CHEMICAL", 88, 99], ["hydroxychloroquine", "CHEMICAL", 197, 215], ["chloroquine", "CHEMICAL", 219, 230], ["heart rhythm problems", "DISEASE", 311, 332], ["Hydroxychloroquine", "CHEMICAL", 333, 351], ["chloroquine", "CHEMICAL", 356, 367], ["abnormal heart rhythms", "DISEASE", 378, 400], ["ventricular tachycardia", "DISEASE", 476, 499], ["hydroxychloroquine", "CHEMICAL", 65, 83], ["chloroquine", "CHEMICAL", 88, 99], ["COVID-19", "CHEMICAL", 104, 112], ["hydroxychloroquine", "CHEMICAL", 197, 215], ["chloroquine", "CHEMICAL", 219, 230], ["COVID-19", "CHEMICAL", 235, 243], ["Hydroxychloroquine", "CHEMICAL", 333, 351], ["chloroquine", "CHEMICAL", 356, 367], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 65, 83], ["chloroquine", "SIMPLE_CHEMICAL", 88, 99], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 197, 215], ["chloroquine", "SIMPLE_CHEMICAL", 219, 230], ["heart", "ORGAN", 311, 316], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 333, 351], ["chloroquine", "SIMPLE_CHEMICAL", 356, 367], ["heart", "ORGAN", 387, 392], ["heart", "ORGAN", 458, 463], ["ventricular", "ORGAN", 476, 487], ["hydroxychloroquine", "TREATMENT", 65, 83], ["chloroquine", "TREATMENT", 88, 99], ["COVID", "TREATMENT", 104, 109], ["hydroxychloroquine", "TREATMENT", 197, 215], ["chloroquine", "TREATMENT", 219, 230], ["COVID", "TREATMENT", 235, 240], ["heart rhythm problems", "PROBLEM", 311, 332], ["Hydroxychloroquine", "TREATMENT", 333, 351], ["chloroquine", "TREATMENT", 356, 367], ["abnormal heart rhythms", "PROBLEM", 378, 400], ["QT interval prolongation", "PROBLEM", 409, 433], ["a dangerously rapid heart rate", "PROBLEM", 438, 468], ["ventricular tachycardia", "PROBLEM", 476, 499], ["heart", "ANATOMY", 311, 316], ["heart", "ANATOMY", 387, 392], ["ventricular", "ANATOMY", 476, 487], ["tachycardia", "OBSERVATION", 488, 499]]], ["These risks may increase when these medicines are combined with other medicines known to prolong the QT interval, including the antibiotic azithromycin, which is also being used in some COVID-19 patients without FDA approval for this condition.", [["azithromycin", "CHEMICAL", 139, 151], ["azithromycin", "CHEMICAL", 139, 151], ["azithromycin", "SIMPLE_CHEMICAL", 139, 151], ["patients", "ORGANISM", 195, 203], ["patients", "SPECIES", 195, 203], ["these medicines", "TREATMENT", 30, 45], ["other medicines", "TREATMENT", 64, 79], ["the antibiotic azithromycin", "TREATMENT", 124, 151], ["this condition", "PROBLEM", 229, 243], ["increase", "OBSERVATION_MODIFIER", 16, 24]]], ["Patients who also have other health issues such as heart and kidney disease are likely to be at increased risk of these heart problems when receiving these medicines.\"Mitigation of Risk:The inclusion / exclusion criteria exclude cardiac risk factors, chronic kidney disease, and anti-arrhythmia medicines.", [["heart", "ANATOMY", 51, 56], ["kidney", "ANATOMY", 61, 67], ["heart", "ANATOMY", 120, 125], ["cardiac", "ANATOMY", 229, 236], ["kidney", "ANATOMY", 259, 265], ["heart and kidney disease", "DISEASE", 51, 75], ["heart problems", "DISEASE", 120, 134], ["chronic kidney disease", "DISEASE", 251, 273], ["Patients", "ORGANISM", 0, 8], ["heart", "ORGAN", 51, 56], ["kidney", "ORGAN", 61, 67], ["heart", "ORGAN", 120, 125], ["cardiac", "ORGAN", 229, 236], ["kidney", "ORGAN", 259, 265], ["Patients", "SPECIES", 0, 8], ["other health issues", "PROBLEM", 23, 42], ["heart and kidney disease", "PROBLEM", 51, 75], ["these heart problems", "PROBLEM", 114, 134], ["these medicines", "TREATMENT", 150, 165], ["exclusion criteria", "TEST", 202, 220], ["cardiac risk factors", "PROBLEM", 229, 249], ["chronic kidney disease", "PROBLEM", 251, 273], ["anti-arrhythmia medicines", "TREATMENT", 279, 304], ["heart", "ANATOMY", 51, 56], ["kidney", "ANATOMY", 61, 67], ["disease", "OBSERVATION", 68, 75], ["heart", "ANATOMY", 120, 125], ["problems", "OBSERVATION", 126, 134], ["chronic", "OBSERVATION_MODIFIER", 251, 258], ["kidney", "ANATOMY", 259, 265], ["disease", "OBSERVATION", 266, 273]]], ["On 24 April, additional QT prolonging medicines are excluded.Known Potential Benefits\u2022 There are no known benefits in humans for preemptive treatment.Known Potential Benefits\u2022 In vitro antiviral activity against SARS-CoV and SARS-CoV2 viruses.Known Potential Benefits\u2022 Chloroquine and Hydroxychloroquine have a long history of safe, effective use as an antimalarial, both acutely and long-term use.Study ObjectivesTo determine if hydroxychloroquine is effective at prevention of COVID-19 disease or reducing disease severity.Primary Outcome MeasuresAsymptomatic Cohort \u2022 Incidence of COVID-19 disease within 14 days (among those asymptomatic at baseline) Symptomatic CohortPrimary Outcome Measures\u2022 Change in symptom severity score (visual analog scale 0-10) over 14 daysSecondary Outcome Measures\u2022 Incidence of hospitalization or death \u2022 Incidence of confirmed SARS-CoV-2 detection \u2022 Incidence of symptoms compatible with COVID-19 (possible disease) \u2022 Incidence of all-cause study medicine discontinuation or withdrawal \u2022 Incidence of adverse reactions \u2022 Symptom severity on day 5 or 14 via visual analog scale \u2022 Ordinal Scale of COVID-19 Disease Severity at day 14 (among those who are symptomatic at trial entry) Illness without hospitalization Hospitalization (or post-hospital discharge) Hospitalization with ICU stay or Death Assessment of outcome measures will be primarily by self-report.", [["Chloroquine", "CHEMICAL", 269, 280], ["Hydroxychloroquine", "CHEMICAL", 285, 303], ["hydroxychloroquine", "CHEMICAL", 430, 448], ["death", "DISEASE", 831, 836], ["SARS", "DISEASE", 862, 866], ["Chloroquine", "CHEMICAL", 269, 280], ["Hydroxychloroquine", "CHEMICAL", 285, 303], ["hydroxychloroquine", "CHEMICAL", 430, 448], ["humans", "ORGANISM", 118, 124], ["SARS-CoV", "ORGANISM", 212, 220], ["SARS-CoV2 viruses", "ORGANISM", 225, 242], ["Chloroquine", "SIMPLE_CHEMICAL", 269, 280], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 285, 303], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 430, 448], ["humans", "SPECIES", 118, 124], ["humans", "SPECIES", 118, 124], ["SARS-CoV", "SPECIES", 212, 220], ["SARS-CoV2 viruses", "SPECIES", 225, 242], ["additional QT prolonging medicines", "TREATMENT", 13, 47], ["preemptive treatment", "TREATMENT", 129, 149], ["vitro antiviral activity", "TREATMENT", 179, 203], ["SARS", "PROBLEM", 212, 216], ["CoV", "PROBLEM", 217, 220], ["SARS", "PROBLEM", 225, 229], ["CoV2 viruses", "PROBLEM", 230, 242], ["Chloroquine", "TREATMENT", 269, 280], ["Hydroxychloroquine", "TREATMENT", 285, 303], ["an antimalarial", "TREATMENT", 350, 365], ["Study Objectives", "TEST", 398, 414], ["hydroxychloroquine", "TREATMENT", 430, 448], ["COVID-19 disease", "PROBLEM", 479, 495], ["reducing disease severity", "PROBLEM", 499, 524], ["COVID-19 disease", "PROBLEM", 584, 600], ["Change in symptom severity score", "PROBLEM", 699, 731], ["visual analog scale", "TEST", 733, 752], ["death", "PROBLEM", 831, 836], ["SARS", "PROBLEM", 862, 866], ["symptoms", "PROBLEM", 898, 906], ["COVID", "TEST", 923, 928], ["disease", "PROBLEM", 942, 949], ["study medicine", "TREATMENT", 976, 990], ["withdrawal", "PROBLEM", 1010, 1020], ["adverse reactions", "PROBLEM", 1036, 1053], ["Symptom severity", "PROBLEM", 1056, 1072], ["visual analog scale", "TEST", 1092, 1111], ["COVID", "TEST", 1131, 1136], ["no", "UNCERTAINTY", 97, 99], ["reducing", "OBSERVATION_MODIFIER", 499, 507], ["disease", "OBSERVATION", 508, 515]]], ["As necessary, COVID19 disease will be verified from public health records, medical records, or death certificates.", [["death", "DISEASE", 95, 100], ["COVID19", "GENE_OR_GENE_PRODUCT", 14, 21], ["COVID19 disease", "PROBLEM", 14, 29]]], ["The primary endpoints are different for the two cohorts (those who are asymptomatic with known exposure; or those who are symptomatic at trial entry), and analyses will be done separately for the two cohorts.Secondary Outcome MeasuresThe primary analysis will use PCR+ confirmed disease.", [["symptomatic", "PROBLEM", 122, 133], ["Secondary Outcome Measures", "TREATMENT", 208, 234], ["The primary analysis", "TEST", 234, 254], ["PCR", "TEST", 264, 267], ["disease", "PROBLEM", 279, 286], ["disease", "OBSERVATION", 279, 286]]], ["However if the absence of sufficient testing supplies continues then outpatients will not be offered SARS-CoV-2 testing unless they are sick enough to be hospitalized.", [["CoV-2 testing", "TEST", 106, 119]]], ["In that case an alternate a priori planned analysis will define incident COVID19 disease as a composite of SARS-CoV-2 PCR+ confirmed result OR symptomatic disease (i.e. possible) COVID-19 in those without testing.STUDY DESIGNThere are two strata: 1) asymptomatic healthcare workers or household contacts exposed to COVID-19 (n=1500); 2) symptomatic COVID-19 disease (n=1500).", [["SARS", "DISEASE", 107, 111], ["COVID19 disease", "PROBLEM", 73, 88], ["SARS", "PROBLEM", 107, 111], ["CoV-2 PCR", "TEST", 112, 121], ["symptomatic disease", "PROBLEM", 143, 162], ["COVID", "TEST", 179, 184], ["testing", "TEST", 205, 212], ["COVID", "TEST", 315, 320], ["symptomatic COVID-19 disease", "PROBLEM", 337, 365], ["symptomatic", "OBSERVATION_MODIFIER", 143, 154], ["disease", "OBSERVATION", 155, 162]]], ["Follow up will occur up to 90 days for those with symptomatic COVID-19 disease who become hospitalized.DESIGNRandomized, double-blind, placebo-controlled clinical trial, parallel designDESIGN\u2022 Intervention Arm: Hydroxychloroquine 800 mg orally once (4 tablets), followed in 6 to 8 hours by 600 mg (3 tabelts), then 600 mg once a day for 4 consecutive days (5 days in total)DESIGN\u2022 Control Arm: Vitamin Placebo 4 tablets orally once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once a day for 4 consecutive days (5 days in total)Study participant duration\u2022 14 days consisting of internet-based virtual visits \u2022 For participants ill with COVID-19 disease who are hospitalized (an SAE), observational follow up will extend to up to 90 days to assess final outcome status of their SAE. \u2022 Pregnant women have their fetal outcome assessed postpartum to exclude a teratogenic SAE.Study procedures\u2022 All procedures will consist of internet-based questionnaires completed by self-report.Study procedures\u2022 Informed consent is provided to access medical records to verify information, as necessary. \u2022 Optional: blood spot will be collected at approximately day 14.Study procedures\u2022 Optional: daily cardiac monitoring with remote EKG reads of QTc interval.Individually identifiable health information:Name, date of birth, addresses, and phone number will be collected so as to prescribe study medication.", [["fetal", "ANATOMY", 820, 825], ["blood", "ANATOMY", 1109, 1114], ["cardiac", "ANATOMY", 1196, 1203], ["Hydroxychloroquine", "CHEMICAL", 211, 229], ["Vitamin", "CHEMICAL", 394, 401], ["SAE", "DISEASE", 787, 790], ["SAE", "DISEASE", 879, 882], ["Hydroxychloroquine", "CHEMICAL", 211, 229], ["Vitamin Placebo", "CHEMICAL", 394, 409], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 211, 229], ["Vitamin", "SIMPLE_CHEMICAL", 394, 401], ["women", "ORGANISM", 803, 808], ["fetal", "ANATOMICAL_SYSTEM", 820, 825], ["blood", "ORGANISM_SUBSTANCE", 1109, 1114], ["participant", "SPECIES", 544, 555], ["participants", "SPECIES", 624, 636], ["women", "SPECIES", 803, 808], ["symptomatic COVID-19 disease", "PROBLEM", 50, 78], ["placebo", "TREATMENT", 135, 142], ["Hydroxychloroquine", "TREATMENT", 211, 229], ["DESIGN\u2022 Control Arm", "TREATMENT", 373, 392], ["Vitamin Placebo", "TREATMENT", 394, 409], ["a teratogenic SAE", "PROBLEM", 865, 882], ["Study procedures", "TEST", 883, 899], ["All procedures", "TREATMENT", 901, 915], ["Study procedures", "TEST", 987, 1003], ["blood spot", "TEST", 1109, 1119], ["Study procedures", "TEST", 1162, 1178], ["daily cardiac monitoring", "TEST", 1190, 1214], ["remote EKG", "TEST", 1220, 1230], ["QTc interval", "TEST", 1240, 1252], ["study medication", "TREATMENT", 1384, 1400], ["Arm", "ANATOMY", 389, 392]]], ["If participants are hospitalized, the hospitalization date will be collected.Substudies (if applicable)Additional sub-studies will undergo separate IRB approval, and these studies will involve separate informed consent.", [["participants", "SPECIES", 3, 15], ["these studies", "TEST", 166, 179]]], ["Consented participants will be queried as to if they wish to participate in future research.", [["participants", "SPECIES", 10, 22]]], ["1) Serology for Coronavirus Antibodies: New Participants will be offer an optional participation in self-collection of dried blood spots in order to measure serologies for antibodies.", [["blood", "ANATOMY", 125, 130], ["blood", "ORGANISM_SUBSTANCE", 125, 130], ["Coronavirus Antibodies", "PROTEIN", 16, 38], ["antibodies", "PROTEIN", 172, 182], ["Coronavirus", "SPECIES", 16, 27], ["Serology", "TEST", 3, 11], ["Coronavirus Antibodies", "PROBLEM", 16, 38], ["dried blood spots", "PROBLEM", 119, 136], ["serologies", "TEST", 157, 167], ["antibodies", "PROBLEM", 172, 182]]], ["Participants who have already been consented and entered the trial, will be approached for amendment of consent.", [["Participants", "SPECIES", 0, 12]]], ["The purpose of serology testing is twofold: First, to verify infection.", [["infection", "DISEASE", 61, 70], ["serology testing", "TEST", 15, 31], ["infection", "PROBLEM", 61, 70], ["infection", "OBSERVATION", 61, 70]]], ["Second, the prevalence of antibodies will be compared among symptomatic and asymptomatic persons with a scientific question of how many asymptomatic persons seroconvert after a high risk exposure in the absence of symptomatic illness.", [["persons", "ORGANISM", 89, 96], ["persons", "ORGANISM", 149, 156], ["antibodies", "PROTEIN", 26, 36], ["persons", "SPECIES", 89, 96], ["persons", "SPECIES", 149, 156], ["antibodies", "TREATMENT", 26, 36], ["symptomatic illness", "PROBLEM", 214, 233], ["symptomatic", "OBSERVATION_MODIFIER", 214, 225], ["illness", "OBSERVATION", 226, 233]]], ["The exact serology methodology to be conducted will be determined, based on availability and diagnostic performance.", [["The exact serology methodology", "TEST", 0, 30], ["diagnostic performance", "TEST", 93, 115]]], ["Blood spot collection materials (e.g. 18g lancet, filter paper, bandaid, instructions, and return envelope).Substudies (if applicable)2) Cardiac Monitoring with handheld EKG to check cardiac QTc interval once daily for the first 7 days as a safety substudy.", [["Blood", "ANATOMY", 0, 5], ["Cardiac", "ANATOMY", 137, 144], ["cardiac", "ANATOMY", 183, 190], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["cardiac", "ORGAN", 183, 190], ["Blood spot collection materials", "PROBLEM", 0, 31], ["18g lancet, filter paper", "TREATMENT", 38, 62], ["bandaid", "TREATMENT", 64, 71], ["Cardiac Monitoring", "TEST", 137, 155], ["handheld EKG", "TEST", 161, 173], ["cardiac QTc interval", "TREATMENT", 183, 203], ["spot collection", "OBSERVATION", 6, 21]]], ["(Optional)STUDY ENROLLMENT AND WITHDRAWALParticipants will undergo screening via internet-based forms.", [["screening", "TEST", 67, 76]]], ["The screening and inclusion criteria will be based on self-report.Subject Inclusion Criteria\u2022 Exposure to a COVID19 case within <=4 calendar days as either: \u25cb Occupational exposure (healthcare worker, first responder, etc.) \u25cb Household contact OR \u2022 Symptomatic COVID-19 disease \u25cb Confirmed diagnosis with PCR+ SARS-CoV-2 within <=4 days of symptom onset OR \u25cb Individual with compatible symptoms with exposure to known PCR+ SARS-CoV-2 case within 14 days AND compatible symptoms of fever, cough, or shortness of breath (and no available /pending testing for the individual)* \u2022 >= 18 years of age \u2022 Provision of informed consentSubject Exclusion Criteria\u2022 Current Hospitalization \u2022 Contraindication or allergy to hydroxychloroquine \u2022 Retinal eye disease \u2022 Concurrent malignancy requiring chemotherapy \u2022 Known glucose-6 phosphate dehydrogenase (G-6-PD) deficiency \u2022 Known chronic kidney disease, stage 4 or 5 or receiving dialysis \u2022 Known Porphyria \u2022 Weight < 50 kg \u2022 Structural or ischemic heart disease \u2022 Personal or Family history of prolonged QT \u2022 Current use of: hydroxychloroquine, chloroquine, or cardiac medicines of: flecainide, Tambocor; amiodarone, Cordarone, Pacerone; digoxin or Digox, Digitek, Lanoxin; procainamide or Procan, Procanbid, propafenone, Rythmal; or sotalol. \u2022 Current use of QT prolonging medicines of:Subject Exclusion Criteria\u25cb Antimicrobials: levofloxacin, ciprofloxacin, moxifloxacin, azithromycin, clarithromycin, erythromycin, ketoconazole, itraconazole, or mefloquine \u25cb Antidepressants: amitriptyline, citalopram, desipramine, escitalopram, imipramine, doxepin, fluoxetine, wellbutrin, or venlafaxine \u25cb Antipsychotic or mood stabilizers: haloperidol, droperidol, lithium, quetiapine, thioridazine, ziprasidone \u25cb Methadone \u25cb Sumatriptan, zolmitriptan Rationale for inclusion / exclusion criteria: * As of 20 March 2020, testing is limited in many U.S. states and locales due to insufficient supplies.", [["Retinal eye", "ANATOMY", 732, 743], ["kidney", "ANATOMY", 877, 883], ["heart", "ANATOMY", 988, 993], ["cardiac", "ANATOMY", 1101, 1108], ["fever", "DISEASE", 481, 486], ["cough", "DISEASE", 488, 493], ["shortness of breath", "DISEASE", 498, 517], ["allergy", "DISEASE", 700, 707], ["hydroxychloroquine", "CHEMICAL", 711, 729], ["Retinal eye disease", "DISEASE", 732, 751], ["malignancy", "DISEASE", 765, 775], ["glucose-6 phosphate", "CHEMICAL", 807, 826], ["G-6-PD", "CHEMICAL", 842, 848], ["chronic kidney disease", "DISEASE", 869, 891], ["ischemic heart disease", "DISEASE", 979, 1001], ["hydroxychloroquine", "CHEMICAL", 1065, 1083], ["chloroquine", "CHEMICAL", 1085, 1096], ["flecainide", "CHEMICAL", 1123, 1133], ["Tambocor", "CHEMICAL", 1135, 1143], ["amiodarone", "CHEMICAL", 1145, 1155], ["Cordarone", "CHEMICAL", 1157, 1166], ["Pacerone", "CHEMICAL", 1168, 1176], ["digoxin", "CHEMICAL", 1178, 1185], ["Digox", "CHEMICAL", 1189, 1194], ["Lanoxin", "CHEMICAL", 1205, 1212], ["procainamide", "CHEMICAL", 1214, 1226], ["Procan", "CHEMICAL", 1230, 1236], ["Procanbid", "CHEMICAL", 1238, 1247], ["propafenone", "CHEMICAL", 1249, 1260], ["Rythmal", "CHEMICAL", 1262, 1269], ["sotalol", "CHEMICAL", 1274, 1281], ["levofloxacin", "CHEMICAL", 1371, 1383], ["ciprofloxacin", "CHEMICAL", 1385, 1398], ["moxifloxacin", "CHEMICAL", 1400, 1412], ["azithromycin", "CHEMICAL", 1414, 1426], ["clarithromycin", "CHEMICAL", 1428, 1442], ["erythromycin", "CHEMICAL", 1444, 1456], ["ketoconazole", "CHEMICAL", 1458, 1470], ["itraconazole", "CHEMICAL", 1472, 1484], ["mefloquine", "CHEMICAL", 1489, 1499], ["amitriptyline", "CHEMICAL", 1519, 1532], ["citalopram", "CHEMICAL", 1534, 1544], ["desipramine", "CHEMICAL", 1546, 1557], ["escitalopram", "CHEMICAL", 1559, 1571], ["imipramine", "CHEMICAL", 1573, 1583], ["doxepin", "CHEMICAL", 1585, 1592], ["fluoxetine", "CHEMICAL", 1594, 1604], ["wellbutrin", "CHEMICAL", 1606, 1616], ["venlafaxine", "CHEMICAL", 1621, 1632], ["haloperidol", "CHEMICAL", 1670, 1681], ["droperidol", "CHEMICAL", 1683, 1693], ["lithium", "CHEMICAL", 1695, 1702], ["quetiapine", "CHEMICAL", 1704, 1714], ["thioridazine", "CHEMICAL", 1716, 1728], ["ziprasidone", "CHEMICAL", 1730, 1741], ["Methadone", "CHEMICAL", 1744, 1753], ["Sumatriptan", "CHEMICAL", 1756, 1767], ["zolmitriptan", "CHEMICAL", 1769, 1781], ["hydroxychloroquine", "CHEMICAL", 711, 729], ["glucose-6 phosphate", "CHEMICAL", 807, 826], ["hydroxychloroquine", "CHEMICAL", 1065, 1083], ["chloroquine", "CHEMICAL", 1085, 1096], ["flecainide", "CHEMICAL", 1123, 1133], ["Tambocor", "CHEMICAL", 1135, 1143], ["amiodarone", "CHEMICAL", 1145, 1155], ["Cordarone", "CHEMICAL", 1157, 1166], ["Pacerone", "CHEMICAL", 1168, 1176], ["digoxin", "CHEMICAL", 1178, 1185], ["Digox", "CHEMICAL", 1189, 1194], ["Digitek", "CHEMICAL", 1196, 1203], ["Lanoxin", "CHEMICAL", 1205, 1212], ["procainamide", "CHEMICAL", 1214, 1226], ["Procan", "CHEMICAL", 1230, 1236], ["Procanbid", "CHEMICAL", 1238, 1247], ["propafenone", "CHEMICAL", 1249, 1260], ["Rythmal", "CHEMICAL", 1262, 1269], ["sotalol", "CHEMICAL", 1274, 1281], ["levofloxacin", "CHEMICAL", 1371, 1383], ["ciprofloxacin", "CHEMICAL", 1385, 1398], ["moxifloxacin", "CHEMICAL", 1400, 1412], ["azithromycin", "CHEMICAL", 1414, 1426], ["clarithromycin", "CHEMICAL", 1428, 1442], ["erythromycin", "CHEMICAL", 1444, 1456], ["ketoconazole", "CHEMICAL", 1458, 1470], ["itraconazole", "CHEMICAL", 1472, 1484], ["mefloquine", "CHEMICAL", 1489, 1499], ["amitriptyline", "CHEMICAL", 1519, 1532], ["citalopram", "CHEMICAL", 1534, 1544], ["desipramine", "CHEMICAL", 1546, 1557], ["escitalopram", "CHEMICAL", 1559, 1571], ["imipramine", "CHEMICAL", 1573, 1583], ["doxepin", "CHEMICAL", 1585, 1592], ["fluoxetine", "CHEMICAL", 1594, 1604], ["wellbutrin", "CHEMICAL", 1606, 1616], ["venlafaxine", "CHEMICAL", 1621, 1632], ["haloperidol", "CHEMICAL", 1670, 1681], ["droperidol", "CHEMICAL", 1683, 1693], ["lithium", "CHEMICAL", 1695, 1702], ["quetiapine", "CHEMICAL", 1704, 1714], ["thioridazine", "CHEMICAL", 1716, 1728], ["ziprasidone", "CHEMICAL", 1730, 1741], ["Methadone", "CHEMICAL", 1744, 1753], ["Sumatriptan", "CHEMICAL", 1756, 1767], ["zolmitriptan", "CHEMICAL", 1769, 1781], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 711, 729], ["eye", "ORGAN", 740, 743], ["glucose-6 phosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 807, 840], ["G-6-PD", "SIMPLE_CHEMICAL", 842, 848], ["kidney", "ORGAN", 877, 883], ["heart", "ORGAN", 988, 993], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 1065, 1083], ["chloroquine", "SIMPLE_CHEMICAL", 1085, 1096], ["flecainide", "SIMPLE_CHEMICAL", 1123, 1133], ["Tambocor", "SIMPLE_CHEMICAL", 1135, 1143], ["amiodarone", "SIMPLE_CHEMICAL", 1145, 1155], ["Cordarone", "SIMPLE_CHEMICAL", 1157, 1166], ["Pacerone", "SIMPLE_CHEMICAL", 1168, 1176], ["digoxin", "SIMPLE_CHEMICAL", 1178, 1185], ["Digox", "SIMPLE_CHEMICAL", 1189, 1194], ["Digitek", "SIMPLE_CHEMICAL", 1196, 1203], ["Lanoxin", "SIMPLE_CHEMICAL", 1205, 1212], ["procainamide", "SIMPLE_CHEMICAL", 1214, 1226], ["Procan", "SIMPLE_CHEMICAL", 1230, 1236], ["Procanbid", "SIMPLE_CHEMICAL", 1238, 1247], ["propafenone", "SIMPLE_CHEMICAL", 1249, 1260], ["Rythmal", "SIMPLE_CHEMICAL", 1262, 1269], ["sotalol", "SIMPLE_CHEMICAL", 1274, 1281], ["levofloxacin", "SIMPLE_CHEMICAL", 1371, 1383], ["ciprofloxacin", "SIMPLE_CHEMICAL", 1385, 1398], ["moxifloxacin", "SIMPLE_CHEMICAL", 1400, 1412], ["azithromycin", "SIMPLE_CHEMICAL", 1414, 1426], ["clarithromycin", "SIMPLE_CHEMICAL", 1428, 1442], ["erythromycin", "SIMPLE_CHEMICAL", 1444, 1456], ["ketoconazole", "SIMPLE_CHEMICAL", 1458, 1470], ["itraconazole", "SIMPLE_CHEMICAL", 1472, 1484], ["mefloquine", "SIMPLE_CHEMICAL", 1489, 1499], ["amitriptyline", "SIMPLE_CHEMICAL", 1519, 1532], ["citalopram", "SIMPLE_CHEMICAL", 1534, 1544], ["desipramine", "SIMPLE_CHEMICAL", 1546, 1557], ["escitalopram", "SIMPLE_CHEMICAL", 1559, 1571], ["imipramine", "SIMPLE_CHEMICAL", 1573, 1583], ["doxepin", "SIMPLE_CHEMICAL", 1585, 1592], ["fluoxetine", "SIMPLE_CHEMICAL", 1594, 1604], ["wellbutrin", "SIMPLE_CHEMICAL", 1606, 1616], ["venlafaxine", "SIMPLE_CHEMICAL", 1621, 1632], ["haloperidol", "SIMPLE_CHEMICAL", 1670, 1681], ["droperidol", "SIMPLE_CHEMICAL", 1683, 1693], ["lithium", "SIMPLE_CHEMICAL", 1695, 1702], ["quetiapine", "SIMPLE_CHEMICAL", 1704, 1714], ["thioridazine", "SIMPLE_CHEMICAL", 1716, 1728], ["ziprasidone", "SIMPLE_CHEMICAL", 1730, 1741], ["Methadone", "SIMPLE_CHEMICAL", 1744, 1753], ["Sumatriptan", "SIMPLE_CHEMICAL", 1756, 1767], ["zolmitriptan", "SIMPLE_CHEMICAL", 1769, 1781], ["The screening", "TEST", 0, 13], ["a COVID19 case", "TREATMENT", 106, 120], ["Symptomatic COVID-19 disease", "PROBLEM", 249, 277], ["PCR", "TEST", 305, 308], ["SARS", "PROBLEM", 310, 314], ["CoV", "TEST", 315, 318], ["symptom", "PROBLEM", 340, 347], ["compatible symptoms", "PROBLEM", 375, 394], ["known PCR", "PROBLEM", 412, 421], ["SARS", "PROBLEM", 423, 427], ["symptoms", "PROBLEM", 469, 477], ["fever", "PROBLEM", 481, 486], ["cough", "PROBLEM", 488, 493], ["shortness of breath", "PROBLEM", 498, 517], ["allergy", "PROBLEM", 700, 707], ["hydroxychloroquine", "TREATMENT", 711, 729], ["Retinal eye disease", "PROBLEM", 732, 751], ["Concurrent malignancy", "PROBLEM", 754, 775], ["chemotherapy", "TREATMENT", 786, 798], ["glucose", "TEST", 807, 814], ["phosphate dehydrogenase", "TEST", 817, 840], ["G", "TEST", 842, 843], ["PD) deficiency", "PROBLEM", 846, 860], ["Known chronic kidney disease", "PROBLEM", 863, 891], ["stage 4", "PROBLEM", 893, 900], ["dialysis", "TREATMENT", 919, 927], ["Known Porphyria", "PROBLEM", 930, 945], ["Weight", "TEST", 948, 954], ["Structural or ischemic heart disease", "PROBLEM", 965, 1001], ["prolonged QT", "PROBLEM", 1034, 1046], ["hydroxychloroquine", "TREATMENT", 1065, 1083], ["chloroquine", "TREATMENT", 1085, 1096], ["cardiac medicines", "TREATMENT", 1101, 1118], ["flecainide", "TREATMENT", 1123, 1133], ["Tambocor", "TREATMENT", 1135, 1143], ["amiodarone", "TREATMENT", 1145, 1155], ["Cordarone", "TREATMENT", 1157, 1166], ["Pacerone", "TREATMENT", 1168, 1176], ["digoxin", "TREATMENT", 1178, 1185], ["Digox", "TREATMENT", 1189, 1194], ["Digitek", "TREATMENT", 1196, 1203], ["Lanoxin", "TREATMENT", 1205, 1212], ["procainamide", "TREATMENT", 1214, 1226], ["Procan", "TREATMENT", 1230, 1236], ["Procanbid", "TREATMENT", 1238, 1247], ["propafenone", "TREATMENT", 1249, 1260], ["Rythmal", "TREATMENT", 1262, 1269], ["sotalol", "TREATMENT", 1274, 1281], ["QT prolonging medicines", "TREATMENT", 1300, 1323], ["levofloxacin", "TREATMENT", 1371, 1383], ["ciprofloxacin", "TREATMENT", 1385, 1398], ["moxifloxacin", "TREATMENT", 1400, 1412], ["azithromycin", "TREATMENT", 1414, 1426], ["clarithromycin", "TREATMENT", 1428, 1442], ["erythromycin", "TREATMENT", 1444, 1456], ["ketoconazole", "TREATMENT", 1458, 1470], ["itraconazole", "TREATMENT", 1472, 1484], ["mefloquine", "TREATMENT", 1489, 1499], ["Antidepressants", "TREATMENT", 1502, 1517], ["amitriptyline", "TREATMENT", 1519, 1532], ["citalopram", "TREATMENT", 1534, 1544], ["desipramine", "TREATMENT", 1546, 1557], ["escitalopram", "TREATMENT", 1559, 1571], ["imipramine", "TREATMENT", 1573, 1583], ["doxepin", "TREATMENT", 1585, 1592], ["fluoxetine", "TREATMENT", 1594, 1604], ["wellbutrin", "TREATMENT", 1606, 1616], ["venlafaxine", "TREATMENT", 1621, 1632], ["Antipsychotic", "TREATMENT", 1635, 1648], ["mood stabilizers", "TREATMENT", 1652, 1668], ["haloperidol", "TREATMENT", 1670, 1681], ["droperidol", "TREATMENT", 1683, 1693], ["lithium", "TREATMENT", 1695, 1702], ["quetiapine", "TREATMENT", 1704, 1714], ["thioridazine", "TREATMENT", 1716, 1728], ["ziprasidone", "TREATMENT", 1730, 1741], ["Methadone", "TREATMENT", 1744, 1753], ["Sumatriptan", "TREATMENT", 1756, 1767], ["zolmitriptan", "TREATMENT", 1769, 1781], ["eye", "ANATOMY", 740, 743], ["disease", "OBSERVATION", 744, 751], ["malignancy", "OBSERVATION", 765, 775], ["chronic", "OBSERVATION_MODIFIER", 869, 876], ["kidney", "ANATOMY", 877, 883], ["disease", "OBSERVATION", 884, 891], ["ischemic", "OBSERVATION_MODIFIER", 979, 987], ["heart", "ANATOMY", 988, 993], ["disease", "OBSERVATION", 994, 1001]]], ["Thus, outpatient testing may not be available.", [["outpatient testing", "TEST", 6, 24]]], ["A person with known exposure to a confirmed COVID-19 case with subsequent compatible symptoms is eligible for enrollment, if testing is not available.", [["person", "SPECIES", 2, 8], ["subsequent compatible symptoms", "PROBLEM", 63, 93], ["testing", "TEST", 125, 132]]], ["If a symptomatic person tests negative for SARS-CoV-2, they are not eligible for enrollment.Subject Exclusion CriteriaMean Incubation period is ~5.2 days, thus we wish to limit enrollment to those with a higher risk of progression and deliver study medicine in a time period to intervene to prevent disease or ameliorate disease (i.e. start of study medicine by <=4 days after exposure).", [["SARS", "DISEASE", 43, 47], ["person", "SPECIES", 17, 23], ["SARS-CoV", "SPECIES", 43, 51], ["a symptomatic person tests", "TEST", 3, 29], ["SARS", "PROBLEM", 43, 47], ["study medicine", "TREATMENT", 243, 257], ["disease", "PROBLEM", 299, 306], ["ameliorate disease", "PROBLEM", 310, 328], ["study medicine", "TREATMENT", 344, 358]]], ["The current (as of March 17, 2020) delays in testing makes this window particularly tight, and it may need to be relaxed in the future via protocol amendment.Subject Exclusion CriteriaIn clinical practice of tropical medicine, chloroquine or hydroxychloroquine are prescribed without any baseline laboratory testing or monitoring.Subject Exclusion CriteriaChronic use of hydroxychloroquine for >1 year can cause retinopathy or cardiomyopathy, thus persons with baseline conditions will be excluded.", [["chloroquine", "CHEMICAL", 227, 238], ["hydroxychloroquine", "CHEMICAL", 242, 260], ["hydroxychloroquine", "CHEMICAL", 371, 389], ["retinopathy", "DISEASE", 412, 423], ["cardiomyopathy", "DISEASE", 427, 441], ["chloroquine", "CHEMICAL", 227, 238], ["hydroxychloroquine", "CHEMICAL", 242, 260], ["hydroxychloroquine", "CHEMICAL", 371, 389], ["chloroquine", "SIMPLE_CHEMICAL", 227, 238], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 242, 260], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 371, 389], ["persons", "ORGANISM", 448, 455], ["persons", "SPECIES", 448, 455], ["delays in testing", "TEST", 35, 52], ["tropical medicine", "TREATMENT", 208, 225], ["chloroquine", "TREATMENT", 227, 238], ["hydroxychloroquine", "TREATMENT", 242, 260], ["laboratory testing", "TEST", 297, 315], ["monitoring", "TEST", 319, 329], ["hydroxychloroquine", "TREATMENT", 371, 389], ["retinopathy", "PROBLEM", 412, 423], ["cardiomyopathy", "PROBLEM", 427, 441], ["baseline conditions", "PROBLEM", 461, 480], ["retinopathy", "OBSERVATION", 412, 423], ["cardiomyopathy", "OBSERVATION", 427, 441]]], ["Study medicine is excreted via the kidney with dose reduction recommended in CrCl <30 cc/min (Stage 4 Kidney Disease).", [["kidney", "ANATOMY", 35, 41], ["Kidney", "ANATOMY", 102, 108], ["Kidney Disease", "DISEASE", 102, 116], ["kidney", "ORGAN", 35, 41], ["CrCl", "SIMPLE_CHEMICAL", 77, 81], ["Kidney", "ORGAN", 102, 108], ["Study medicine", "TREATMENT", 0, 14], ["dose reduction", "TREATMENT", 47, 61], ["CrCl", "TEST", 77, 81], ["Stage 4 Kidney Disease", "PROBLEM", 94, 116], ["kidney", "ANATOMY", 35, 41], ["Kidney", "ANATOMY", 102, 108], ["Disease", "OBSERVATION", 109, 116]]], ["G-6-PD deficiency is listed as a caution on the FDA label.", [["G-6-PD", "CHEMICAL", 0, 6], ["G-6", "GENE_OR_GENE_PRODUCT", 0, 3], ["G", "TEST", 0, 1], ["PD deficiency", "PROBLEM", 4, 17]]], ["G-6-PD testing is not routinely performed in clinical care prior to giving hydroxychloroquine prescriptions (unlike with primaquine).", [["G-6-PD", "CHEMICAL", 0, 6], ["hydroxychloroquine", "CHEMICAL", 75, 93], ["primaquine", "CHEMICAL", 121, 131], ["hydroxychloroquine", "CHEMICAL", 75, 93], ["primaquine", "CHEMICAL", 121, 131], ["G-6", "GENE_OR_GENE_PRODUCT", 0, 3], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 75, 93], ["primaquine", "SIMPLE_CHEMICAL", 121, 131], ["G", "TEST", 0, 1], ["PD testing", "TEST", 4, 14], ["hydroxychloroquine prescriptions", "TREATMENT", 75, 107], ["primaquine", "TREATMENT", 121, 131]]], ["Medication exclusions are for possible drug-drug interactions, particularly with cardiac arrhythmia medicines with a caution on the FDApackage insert.Subject Exclusion CriteriaOn April 20, 2020, FDA mandated exclusion of structural or ischemic heart disease; or personal or family history of prolonged QT.Subject Exclusion CriteriaOn April 24, 2020, FDA issued a caution for QT prolongation in persons with heart disease, chronic kidney disease, or taking other QT prolonging medicines.Randomization ProceduresParticipants will be randomized via permuted block randomization.", [["cardiac", "ANATOMY", 81, 88], ["heart", "ANATOMY", 244, 249], ["heart", "ANATOMY", 407, 412], ["kidney", "ANATOMY", 430, 436], ["cardiac arrhythmia", "DISEASE", 81, 99], ["ischemic heart disease", "DISEASE", 235, 257], ["QT prolongation", "DISEASE", 375, 390], ["heart disease", "DISEASE", 407, 420], ["chronic kidney disease", "DISEASE", 422, 444], ["cardiac", "ORGAN", 81, 88], ["heart", "ORGAN", 244, 249], ["persons", "ORGANISM", 394, 401], ["heart", "ORGAN", 407, 412], ["kidney", "ORGAN", 430, 436], ["FDApackage insert", "DNA", 132, 149], ["persons", "SPECIES", 394, 401], ["Medication exclusions", "TREATMENT", 0, 21], ["cardiac arrhythmia medicines", "TREATMENT", 81, 109], ["the FDApackage insert", "TREATMENT", 128, 149], ["structural or ischemic heart disease", "PROBLEM", 221, 257], ["prolonged QT", "PROBLEM", 292, 304], ["QT prolongation", "PROBLEM", 375, 390], ["heart disease", "PROBLEM", 407, 420], ["chronic kidney disease", "PROBLEM", 422, 444], ["other QT prolonging medicines", "TREATMENT", 456, 485], ["Randomization ProceduresParticipants", "TREATMENT", 486, 522], ["permuted block randomization", "TREATMENT", 546, 574], ["ischemic", "OBSERVATION_MODIFIER", 235, 243], ["heart", "ANATOMY", 244, 249], ["disease", "OBSERVATION", 250, 257], ["heart", "ANATOMY", 407, 412], ["disease", "OBSERVATION", 413, 420], ["chronic", "OBSERVATION_MODIFIER", 422, 429], ["kidney", "ANATOMY", 430, 436], ["disease", "OBSERVATION", 437, 444]]], ["Randomization will be recorded on an electronic log by the pharmacy.", [["Randomization", "TREATMENT", 0, 13]]], ["Study investigators and subjects will be blinded.", [["Study investigators", "TEST", 0, 19]]], ["There will be separate randomization schedules for the two cohorts (asymptomatic with exposure or symptomatic).", [["separate randomization schedules", "TREATMENT", 14, 46]]], ["Participants will be provided masked study medicine, shipped by courier (e.g. FedEx).", [["Participants", "SPECIES", 0, 12]]], ["The intervention vs. placebo will not be identical; however, participants and outcome assessors will be masked to their assignment.Reasons for WithdrawalParticipants may withdraw at any time point at their discretion.Handling of WithdrawalsWithdraws will be counted as failures for the secondary endpoint of completion of study medication.Handling of WithdrawalsParticipants who discontinue study medication will still be asked to complete the follow up visit schedule.Termination of StudyThis study may be prematurely terminated if there is sufficient reasonable cause, including but not limited to:Termination of Study\u2022 Unexpected, significant, or unacceptable risk to subjects \u2022 Interim analyses by the DSMB.Termination of Study\u2022 Insufficient compliance with protocol requirements \u2022 Data are not sufficiently complete and/or not evaluable \u2022 Regulatory authorities decide that study should be terminated If the study is prematurely terminated for harm, current subjects will complete follow up, and no further subjects will be enrolled.", [["participants", "SPECIES", 61, 73], ["Participants", "SPECIES", 362, 374], ["The intervention", "TREATMENT", 0, 16], ["placebo", "TREATMENT", 21, 28], ["WithdrawalParticipants", "TREATMENT", 143, 165], ["study medication", "TREATMENT", 322, 338], ["study medication", "TREATMENT", 391, 407], ["Study", "TEST", 484, 489], ["This study", "TEST", 489, 499], ["Study", "TEST", 615, 620], ["Interim analyses", "TEST", 682, 698], ["Study", "TEST", 726, 731], ["protocol requirements", "TREATMENT", 762, 783], ["the study", "TEST", 909, 918], ["significant", "OBSERVATION_MODIFIER", 634, 645]]], ["If the study is terminated due to benefit, then the study will immediately convert into an open-label prospective cohort to collect further observational data on the safety and efficacy of the intervention, up to the IRB approved recruitment limit.", [["the study", "TEST", 3, 12], ["the study", "TEST", 48, 57], ["observational data", "TEST", 140, 158], ["the intervention", "TREATMENT", 189, 205], ["recruitment limit", "OBSERVATION", 230, 247]]], ["FDA-approved formulation of hydroxychloroquine will be purchased.Formulation, Packaging, and LabelingThe study medicines will be packaged by the MHealth Investigational Drug Services.", [["hydroxychloroquine", "CHEMICAL", 28, 46], ["hydroxychloroquine", "CHEMICAL", 28, 46], ["FDA", "SIMPLE_CHEMICAL", 0, 3], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 28, 46], ["hydroxychloroquine", "TREATMENT", 28, 46], ["Packaging", "TREATMENT", 78, 87], ["The study medicines", "TREATMENT", 101, 120]]], ["Dispensed medications will be delivered by courier (e.g. Fedex) to study participants.", [["participants", "SPECIES", 73, 85], ["Dispensed medications", "TREATMENT", 0, 21]]], ["The EC50 has been reported as 0.72 \u00b5M [5] , although this is not a precise measurement, and should be view with a range of error present (but not reported).", [["The EC50", "TEST", 0, 8]]], ["The EC50 is the point of 50% maximal inhibition, so more drug would be better (balanced against toxicity and drug supply).", [["toxicity", "DISEASE", 96, 104]]], ["The percentage of persons achieving a 24 hour level above the EC50 is as follows (Figure) .Product Storage and StabilityStore at room up to 30\u00b0 C (86\u00b0 F).", [["persons", "ORGANISM", 18, 25], ["persons", "SPECIES", 18, 25], ["percentage", "OBSERVATION_MODIFIER", 4, 14]]], ["Dispense in a tight, light-resistant container.Dosage, Preparation, and Administration of Investigational ProductDrug/Device Handling:Dosage, Preparation, and Administration of Investigational ProductHydroxychloroquine or placebo will be dispensed by the MHealth Investigational Drug Service (IDS) Pharmacy.", [["Hydroxychloroquine", "CHEMICAL", 200, 218], ["Hydroxychloroquine", "CHEMICAL", 200, 218], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 200, 218], ["light-resistant container", "TREATMENT", 21, 46], ["Investigational ProductDrug/Device", "TREATMENT", 90, 124], ["Investigational ProductHydroxychloroquine", "TREATMENT", 177, 218], ["placebo", "TREATMENT", 222, 229]]], ["The medicine will then be provided to research volunteers via FedEx / courier delivery in the United States.Modification of Investigational Product for a ParticipantWith mild side effects, participants will be instructed to split the 3 tablet daily dosing into multiple times per day.Modification of Investigational Product for a ParticipantIn the event of substantial side effects, participants may discontinue the study medication and stay in the study to complete follow up.Accountability Procedures for the Investigational Product:Accountability will be via self-report at the day 5 virtual visit.Assessment of Subject ComplianceAdherence will be via self-report at day 5 virtual visit.Concomitant Medications/TreatmentsParticipants may receive other concomitant medications or therapies, and will be asked to report these in regards to other therapies received on day 1, day 14, and in the event of hospitalization.Screening\u2022 Baseline screening for eligibility \u2022 Informed consent by self-administered \u2022 This will be performed via a web-based form.", [["volunteers", "ORGANISM", 47, 57], ["participants", "SPECIES", 189, 201], ["participants", "SPECIES", 383, 395], ["Participants", "SPECIES", 724, 736], ["FedEx / courier delivery", "TREATMENT", 62, 86], ["Investigational Product", "TREATMENT", 124, 147], ["a ParticipantWith mild side effects", "PROBLEM", 152, 187], ["Investigational Product", "TREATMENT", 300, 323], ["substantial side effects", "PROBLEM", 357, 381], ["the study medication", "TREATMENT", 412, 432], ["the study", "TEST", 445, 454], ["Medications/Treatments", "TREATMENT", 702, 724], ["other concomitant medications", "TREATMENT", 749, 778], ["therapies", "TREATMENT", 782, 791], ["substantial", "OBSERVATION_MODIFIER", 357, 368], ["side effects", "OBSERVATION_MODIFIER", 369, 381]]], ["Eligibility criteria will be by self-report.Randomization (Day 0)\u2022 Participants will be randomized by a computer-generated algorithm using a permuted block randomization sequence. \u2022 Randomization will be stratified by symptomatic vs. asymptomatic status at baseline.Randomization (Day 0)\u2022 Investigational pharmacy will dispense the masked study medicine \u2022 Study personnel will then FedEx study medicine to the participant \u2022 Participant will be sent an email to expect medication to arrive by 10:30am If participations have a SAE prior to the final study visit (e.g. hospitalization), the final resolution of the event will be followed until resolution or up to 90 days.", [["Participants", "SPECIES", 67, 79], ["participant", "SPECIES", 410, 421], ["a permuted block randomization sequence", "TREATMENT", 139, 178], ["Randomization", "TREATMENT", 182, 195], ["asymptomatic status", "PROBLEM", 234, 253]]], ["The hospitalization eCRF will be sent in 14 days interval to assess clinical outcome / resolution of the hospitalization.", [["The hospitalization eCRF", "TEST", 0, 24]]], ["Pregnancies will be followed through delivery to assess for any teratogenic SAE.Early Termination VisitIf participants develop new / worsening symptoms of coronavirus, they will be directed to their healthcare provider and/or local public health authority for clinical care.", [["SAE", "DISEASE", 76, 79], ["coronavirus", "DISEASE", 155, 166], ["coronavirus", "ORGANISM", 155, 166], ["participants", "SPECIES", 106, 118], ["delivery", "TREATMENT", 37, 45], ["any teratogenic SAE", "PROBLEM", 60, 79], ["new / worsening symptoms", "PROBLEM", 127, 151], ["coronavirus", "PROBLEM", 155, 166]]], ["We will follow up of hospitalized patients for resolution of their SAE for up to 90 days to assess their final outcome.", [["SAE", "DISEASE", 67, 70], ["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42]]], ["Participants will be sent the Hospitalization eCRF 14 days after hospitalization is reported with repeats in 14 day intervals until the participant is discharged from the hospital.Unscheduled / Sick VisitSubjects will be provided a central email contact: faq.covid19@gmail.com as a contact point for questions or concerns.", [["eCRF", "DISEASE", 46, 50], ["Participants", "SPECIES", 0, 12], ["participant", "SPECIES", 136, 147]]], ["This email will forward to an on-call study physician who will call the participant to resolve their concerns.Clinical EvaluationsClinical evaluations are by self-report.Laboratory EvaluationsSARS-COV-2 positivity is by self-report.", [["Clinical Evaluations", "TEST", 110, 130], ["Clinical evaluations", "TEST", 130, 150], ["Laboratory EvaluationsSARS", "TEST", 170, 196], ["COV", "TEST", 197, 200]]], ["Informed consent asks for access to medical records.Laboratory EvaluationsFollow up PCR testing within 14 days is asked on followed questionnaires.", [["Laboratory Evaluations", "TEST", 52, 74], ["PCR testing", "TEST", 84, 95]]], ["Pending test results at 14 days or during hospitalization will be queried for final results with repeat survey sent at day 28.Laboratory EvaluationsInformed consent will request permission to contact local public health authorities or their medical provider in the event of lost to follow up or COVID19 disease.Laboratory EvaluationsThere is no incentive to be dishonest, and we believe healthcare workers in particular will take their responsibilities seriously.Laboratory EvaluationsAn optional dried blood spot collection will be offered at day 14.", [["blood", "ANATOMY", 503, 508], ["blood", "ORGANISM_SUBSTANCE", 503, 508], ["repeat survey", "TEST", 97, 110], ["COVID19 disease", "PROBLEM", 295, 310], ["Laboratory Evaluations", "TEST", 311, 333], ["optional dried blood spot collection", "TREATMENT", 488, 524], ["no", "UNCERTAINTY", 342, 344]]], ["At time of informed consent, participants may opt into this collection.", [["participants", "SPECIES", 29, 41]]], ["The dried blood spots will be used for future serology testing.", [["blood spots", "ANATOMY", 10, 21], ["blood", "ORGANISM_SUBSTANCE", 10, 15], ["The dried blood spots", "PROBLEM", 0, 21], ["future serology testing", "TEST", 39, 62]]], ["Participants who opt into this testing will be mailed: i) instructions; ii) Whatman filter paper for dried blood spot collection; iii) one time use lancet; iv) return envelope.Laboratory EvaluationsParticipants who have entered the trial prior to dried blood spot being offered and are <90 days from study entry will be contact with the option for dried blood spot testing of their antibody serology.", [["blood", "ANATOMY", 107, 112], ["blood", "ANATOMY", 253, 258], ["blood", "ANATOMY", 354, 359], ["blood", "ORGANISM_SUBSTANCE", 107, 112], ["blood", "ORGANISM_SUBSTANCE", 253, 258], ["blood", "ORGANISM_SUBSTANCE", 354, 359], ["Participants", "SPECIES", 0, 12], ["Whatman filter paper", "TREATMENT", 76, 96], ["dried blood spot collection", "PROBLEM", 101, 128], ["dried blood spot", "TREATMENT", 247, 263], ["dried blood spot testing", "TEST", 348, 372], ["their antibody serology", "TEST", 376, 399]]], ["ASSESSMENT OF SAFETYSpecification of Safety ParametersHydroxychloroquine has a track record of safety since its FDA-approval in 1955.", [["Hydroxychloroquine", "CHEMICAL", 54, 72], ["Hydroxychloroquine", "CHEMICAL", 54, 72], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 54, 72], ["Hydroxychloroquine", "TREATMENT", 54, 72]]], ["As an already, FDA-approved medicine, this trial is designed as a pragmatic trial in the setting of a public health emergency.Adverse EventsHydroxychloroquine has an excellent safety track record, being first FDA-approved in 1955.", [["Hydroxychloroquine", "CHEMICAL", 140, 158], ["Hydroxychloroquine", "CHEMICAL", 140, 158], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 140, 158], ["a pragmatic trial", "TREATMENT", 64, 81], ["Adverse Events", "PROBLEM", 126, 140], ["Hydroxychloroquine", "TREATMENT", 140, 158]]], ["Adverse events will not be captured, unless they result in hospitalization.", [["Adverse events", "PROBLEM", 0, 14]]], ["See Serious Adverse Events below.Adverse EventsExpected adverse events would include normal events within the general population as well COVID19-related disease events which may include need for hospitalization, pneumonia, respiratory failure, sepsis, and death.Reactogenicity (for Vaccine Studies and Some Therapeutic Trials)Not applicableSerious Adverse Events (SAEs)Hospitalization or death are protocol-defined endpoints.Serious Adverse Events (SAEs)SAEs (e.g. hospitalizations) will be followed for up to 90 days to assess final outcome.Procedures to be Followed in the Event of Abnormal Laboratory Test Values or Abnormal Clinical FindingsNot applicableSerious Adverse EventsAn AE or suspected adverse reaction is considered a serious adverse event (SAE) if it results in any of the following outcomes: Based on the known safety track record of hydroxychloroquine, this pragmatic protocol will focus on death, life-threatening AEs, and hospitalizations.", [["respiratory", "ANATOMY", 223, 234], ["pneumonia", "DISEASE", 212, 221], ["respiratory failure", "DISEASE", 223, 242], ["sepsis", "DISEASE", 244, 250], ["death", "DISEASE", 256, 261], ["death", "DISEASE", 388, 393], ["hydroxychloroquine", "CHEMICAL", 851, 869], ["death", "DISEASE", 909, 914], ["hydroxychloroquine", "CHEMICAL", 851, 869], ["COVID19", "GENE_OR_GENE_PRODUCT", 137, 144], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 851, 869], ["Adverse Events", "PROBLEM", 33, 47], ["Expected adverse events", "PROBLEM", 47, 70], ["normal events", "PROBLEM", 85, 98], ["related disease events", "PROBLEM", 145, 167], ["hospitalization", "TREATMENT", 195, 210], ["pneumonia", "PROBLEM", 212, 221], ["respiratory failure", "PROBLEM", 223, 242], ["sepsis", "PROBLEM", 244, 250], ["death", "PROBLEM", 256, 261], ["Reactogenicity", "TEST", 262, 276], ["Vaccine Studies", "TEST", 282, 297], ["Some Therapeutic Trials", "TREATMENT", 302, 325], ["applicableSerious Adverse Events", "PROBLEM", 330, 362], ["death", "PROBLEM", 388, 393], ["Serious Adverse Events", "PROBLEM", 425, 447], ["Abnormal Laboratory Test Values", "PROBLEM", 584, 615], ["suspected adverse reaction", "PROBLEM", 690, 716], ["a serious adverse event", "PROBLEM", 731, 754], ["hydroxychloroquine", "TREATMENT", 851, 869], ["this pragmatic protocol", "TREATMENT", 871, 894], ["death", "PROBLEM", 909, 914], ["pneumonia", "OBSERVATION", 212, 221], ["respiratory failure", "OBSERVATION", 223, 242], ["sepsis", "OBSERVATION", 244, 250]]], ["Incapacity / permanent disability is a possibility with COVID19, but this is not associated with hydroxychloroquine.", [["permanent disability", "DISEASE", 13, 33], ["hydroxychloroquine", "CHEMICAL", 97, 115], ["hydroxychloroquine", "CHEMICAL", 97, 115], ["COVID19", "GENE_OR_GENE_PRODUCT", 56, 63], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 97, 115], ["Incapacity / permanent disability", "PROBLEM", 0, 33], ["COVID19", "TREATMENT", 56, 63], ["hydroxychloroquine", "TREATMENT", 97, 115], ["permanent disability", "OBSERVATION", 13, 33]]], ["In the event of incapacity, the subject would be expected to be hospitalized.Serious Adverse EventsHydroxychloroquine and chloroquine are not known to cause teratogenic events and are viewed as safe in pregnancy, especially with short term use.", [["Hydroxychloroquine", "CHEMICAL", 99, 117], ["chloroquine", "CHEMICAL", 122, 133], ["Hydroxychloroquine", "CHEMICAL", 99, 117], ["chloroquine", "CHEMICAL", 122, 133], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 99, 117], ["chloroquine", "SIMPLE_CHEMICAL", 122, 133], ["incapacity", "PROBLEM", 16, 26], ["Serious Adverse Events", "PROBLEM", 77, 99], ["Hydroxychloroquine", "TREATMENT", 99, 117], ["chloroquine", "TREATMENT", 122, 133], ["teratogenic events", "PROBLEM", 157, 175], ["incapacity", "OBSERVATION", 16, 26]]], ["With this trial's sample size, this will not further delineate this risk.", [["this trial's sample size", "TREATMENT", 5, 29]]], ["COVID19 disease may indeed be teratogenic.", [["COVID19", "CHEMICAL", 0, 7], ["COVID19", "GENE_OR_GENE_PRODUCT", 0, 7], ["COVID19 disease", "PROBLEM", 0, 15], ["teratogenic", "PROBLEM", 30, 41], ["disease", "OBSERVATION", 8, 15], ["may indeed be", "UNCERTAINTY", 16, 29], ["teratogenic", "OBSERVATION_MODIFIER", 30, 41]]], ["For women who are pregnant, we will ask to follow them through the end of their pregnancy, and they will be sent a follow up eCRF at 1 month post-partum based on their reported estimated date of delivery as provided at the day 14 study visit.Serious Adverse EventsThus, the hospitalization or death secondary endpoint will capture relevant SAEs.", [["death", "DISEASE", 293, 298], ["women", "ORGANISM", 4, 9], ["women", "SPECIES", 4, 9], ["delivery", "TREATMENT", 195, 203], ["Serious Adverse Events", "PROBLEM", 242, 264], ["death", "PROBLEM", 293, 298]]], ["For those with ongoing hospitalization at the day 14 study visit, participants will be queried in 14 day intervals with the hospital eCRF to assess their final clinical outcome.Regulatory ReportingAs hydroxychloroquine is an FDA-approved medicine being used at standard dosing, reporting to regulatory authorities will occur in summary format after each DSMB reports and at a frequency of at least annually.", [["hydroxychloroquine", "CHEMICAL", 200, 218], ["hydroxychloroquine", "CHEMICAL", 200, 218], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 200, 218], ["participants", "SPECIES", 66, 78], ["hydroxychloroquine", "TREATMENT", 200, 218], ["an FDA", "TREATMENT", 222, 228], ["medicine", "TREATMENT", 238, 246]]], ["Serious unexpected suspected adverse reactions (SUSARs) which are not expected with COVID-19 nor listed in the FDA package insert will be reported to the IRB.", [["COVID-19", "CHEMICAL", 84, 92], ["Serious unexpected suspected adverse reactions", "PROBLEM", 0, 46], ["COVID", "TEST", 84, 89]]], ["Those SUSARS which are deemed by an independent medical monitor to be related to the study medicine will be reported to the FDA and IRB.Reporting of PregnancyChloroquine and hydroxychloroquine are not known to be teratogenic.", [["Chloroquine", "CHEMICAL", 158, 169], ["hydroxychloroquine", "CHEMICAL", 174, 192], ["Chloroquine", "CHEMICAL", 158, 169], ["hydroxychloroquine", "CHEMICAL", 174, 192], ["Chloroquine", "SIMPLE_CHEMICAL", 158, 169], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 174, 192], ["PregnancyChloroquine", "TREATMENT", 149, 169], ["hydroxychloroquine", "TREATMENT", 174, 192]]], ["Chloroquine and hydroxychloroquine can accumulate in neonatal eyes.", [["eyes", "ANATOMY", 62, 66], ["Chloroquine", "CHEMICAL", 0, 11], ["hydroxychloroquine", "CHEMICAL", 16, 34], ["Chloroquine", "CHEMICAL", 0, 11], ["hydroxychloroquine", "CHEMICAL", 16, 34], ["Chloroquine", "SIMPLE_CHEMICAL", 0, 11], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 16, 34], ["eyes", "ORGAN", 62, 66], ["Chloroquine", "TREATMENT", 0, 11], ["hydroxychloroquine", "TREATMENT", 16, 34], ["neonatal eyes", "ANATOMY", 53, 66]]], ["Conversely, the risk of severe COVID-19 infection is unknown, but likely is a heightened risk in pregnant women.", [["COVID", "DISEASE", 31, 36], ["infection", "DISEASE", 40, 49], ["COVID-19", "GENE_OR_GENE_PRODUCT", 31, 39], ["women", "ORGANISM", 106, 111], ["women", "SPECIES", 106, 111], ["severe COVID-19 infection", "PROBLEM", 24, 49], ["severe", "OBSERVATION_MODIFIER", 24, 30], ["infection", "OBSERVATION", 40, 49]]], ["The CDC states, \"We do not have information on adverse pregnancy outcomes in pregnant women with COVID-19.", [["women", "ORGANISM", 86, 91], ["women", "SPECIES", 86, 91], ["adverse pregnancy outcomes", "PROBLEM", 47, 73], ["COVID", "TEST", 97, 102]]], ["Pregnancy loss, including miscarriage and stillbirth, has been observed in cases of infection with other related coronaviruses (SARS-CoV and MERS-CoV) during pregnancy.", [["Pregnancy loss", "DISEASE", 0, 14], ["miscarriage", "DISEASE", 26, 37], ["stillbirth", "DISEASE", 42, 52], ["infection", "DISEASE", 84, 93], ["SARS", "DISEASE", 128, 132], ["coronaviruses", "ORGANISM", 113, 126], ["SARS-CoV", "ORGANISM", 128, 136], ["MERS-CoV", "ORGANISM", 141, 149], ["SARS-CoV", "SPECIES", 128, 136], ["MERS-CoV", "SPECIES", 141, 149], ["Pregnancy loss", "PROBLEM", 0, 14], ["miscarriage", "PROBLEM", 26, 37], ["stillbirth", "PROBLEM", 42, 52], ["infection", "PROBLEM", 84, 93], ["other related coronaviruses", "PROBLEM", 99, 126], ["pregnancy", "PROBLEM", 158, 167], ["infection", "OBSERVATION", 84, 93]]], ["High fevers during the first trimester of pregnancy can increase the risk of certain birth defects.\"", [["fevers", "DISEASE", 5, 11], ["birth defects", "DISEASE", 85, 98], ["High fevers", "PROBLEM", 0, 11], ["certain birth defects", "PROBLEM", 77, 98], ["fevers", "OBSERVATION", 5, 11]]], ["Thus, the risk/benefit would favor the enrollment of women who may be or are pregnant, so as to not discriminate against pregnant women.Reporting of PregnancyFor women who are pregnant, we will ask to have follow through the end of their pregnancy to assess outcome of the pregnancy via a brief survey.Type and Duration of Follow-up of Subjects after Adverse EventsParticipants who are hospitalized for COVID-19 or SAEs will have up to 90 day follow up conducted to assess their final outcome.", [["women", "ORGANISM", 53, 58], ["women", "ORGANISM", 130, 135], ["women", "ORGANISM", 162, 167], ["Subjects", "ORGANISM", 336, 344], ["women", "SPECIES", 53, 58], ["women", "SPECIES", 130, 135], ["women", "SPECIES", 162, 167]]], ["Management will be as per the participant's local healthcare provider.Safety Oversight (DSMB)A data and safety monitoring board (DSMB) will oversee the trial.", [["A data", "TEST", 93, 99]]], ["See the DSMB charter for more details.CLINICAL MONITORINGClinical site monitoring is conducted to ensure that the rights and well-being of trial subjects are protected and that the reported trial data are accurate, complete, and verifiable.", [["CLINICAL MONITORINGClinical site monitoring", "TEST", 38, 81]]], ["Clinical monitoring also ensures that conduct of the trial is in compliance with the currently approved protocol/ amendment(s), ICH, GCP, and with applicable regulatory requirement(s) and Sponsor requirements.", [["ICH", "DISEASE", 128, 131], ["Clinical monitoring", "TEST", 0, 19], ["ICH", "PROBLEM", 128, 131], ["GCP", "PROBLEM", 133, 136]]], ["Clinical monitoring will also verify that any critical study procedures are completed following specific instructions.", [["Clinical monitoring", "TEST", 0, 19], ["any critical study procedures", "TEST", 42, 71]]], ["All data are by self report.Study HypothesesWe hypothesize that hydroxychloroquine is superior to placebo for preventing progression to COVID-19 disease among those who are asymptomatic.Study HypothesesWe hypothesize that hydroxychloroquine is superior to placebo for preventing progression among those with symptomatic mild COVID19 disease preventing hospitalization/death.Sample Size ConsiderationsTwo cohorts of 1500 subjects each: 1) Asymptomatic persons exposed to COVID-19 disease (750 in placebo, 750 in intervention);Sample Size Considerations2) Symptomatic outpatient COVID-19 disease (750 in placebo, 750 in intervention).Sample Size ConsiderationsAssuming 90% power, a two-sided alpha = 0.05 and loss to follow-up up to 20%, for each cohort the planned sample size is 750 participants per arm based on the following assumptions:Sample Size Considerations\u2022 10% transmission rate from COVID-19 cases to close contacts \u2022 For those with symptomatic illness the proportions at day 14 in the placebo group are 90%, 8% and 2%, respectively for illness without hospitalization, hospitalization with ICU stay or death, and hospitalization with an ICU stay or death.Sample Size ConsiderationsThe estimated transmission rates are uncertain.", [["hydroxychloroquine", "CHEMICAL", 64, 82], ["hydroxychloroquine", "CHEMICAL", 222, 240], ["COVID19 disease", "DISEASE", 325, 340], ["death", "DISEASE", 368, 373], ["COVID-19 disease", "DISEASE", 470, 486], ["COVID-19 disease", "DISEASE", 577, 593], ["illness", "DISEASE", 956, 963], ["illness", "DISEASE", 1048, 1055], ["death", "DISEASE", 1114, 1119], ["death", "DISEASE", 1161, 1166], ["hydroxychloroquine", "CHEMICAL", 64, 82], ["hydroxychloroquine", "CHEMICAL", 222, 240], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 64, 82], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 222, 240], ["persons", "ORGANISM", 451, 458], ["persons", "SPECIES", 451, 458], ["participants", "SPECIES", 783, 795], ["hydroxychloroquine", "TREATMENT", 64, 82], ["placebo", "TREATMENT", 98, 105], ["COVID-19 disease", "PROBLEM", 136, 152], ["asymptomatic", "PROBLEM", 173, 185], ["hydroxychloroquine", "TREATMENT", 222, 240], ["placebo", "TREATMENT", 256, 263], ["symptomatic mild COVID19 disease", "PROBLEM", 308, 340], ["death", "PROBLEM", 368, 373], ["Asymptomatic persons", "PROBLEM", 438, 458], ["COVID-19 disease", "PROBLEM", 470, 486], ["placebo", "TREATMENT", 495, 502], ["Symptomatic outpatient COVID-19 disease", "PROBLEM", 554, 593], ["placebo", "TREATMENT", 602, 609], ["Sample", "TEST", 632, 638], ["ConsiderationsAssuming", "TEST", 644, 666], ["a two-sided alpha", "TREATMENT", 678, 695], ["transmission rate", "TEST", 871, 888], ["COVID", "TEST", 894, 899], ["symptomatic illness", "PROBLEM", 944, 963], ["illness", "PROBLEM", 1048, 1055], ["death", "PROBLEM", 1114, 1119], ["death", "PROBLEM", 1161, 1166], ["The estimated transmission rates", "TEST", 1193, 1225], ["Size", "OBSERVATION_MODIFIER", 381, 385], ["Size", "OBSERVATION_MODIFIER", 639, 643], ["Size", "OBSERVATION_MODIFIER", 1174, 1178]]], ["Table 1 below (for the asymptomatic cohort with exposure) shows that we are well powered to detect even a smaller (40%) relative reduction in the incidence of COVID 19 with 80% power for transmission rates of at least 10% with placebo.", [["COVID", "DISEASE", 159, 164], ["relative reduction", "TREATMENT", 120, 138], ["COVID", "TREATMENT", 159, 164], ["transmission rates", "TEST", 187, 205], ["placebo", "TREATMENT", 227, 234], ["smaller", "OBSERVATION_MODIFIER", 106, 113], ["reduction", "OBSERVATION_MODIFIER", 129, 138]]], ["Table 2 (for the symptomatic group) shows that we are well powered to detect a common odds ratio of 0.6-0.75 under the assumption that the control proportions for illness without hospitalization, hospitalization without ICU stay or death and hospitalization with ICU stay or death are 90%, 8% and 2%, respectively.Planned Interim AnalysesA Lan-DeMets spending function analog of the O'Brien-Fleming boundaries will be provided at each DSMB report for the primary outcome for each cohort The O'Brien-Fleming boundaries will be truncated at alpha = 0.001 (|Z| > 3.09).", [["illness", "DISEASE", 163, 170], ["death", "DISEASE", 232, 237], ["death", "DISEASE", 275, 280], ["a common odds ratio", "TEST", 77, 96], ["illness", "PROBLEM", 163, 170], ["death", "PROBLEM", 232, 237], ["death", "TEST", 275, 280], ["alpha", "TEST", 539, 544]]], ["For each cohort, interim analyses are separately planned at 25%, 50% and 75% of trial enrollment.Planned Interim AnalysesAs enrollment may be brisk, the timing of interim analyses may be altered at PI discretion based on that pace of enrollment.", [["interim analyses", "TEST", 17, 33], ["trial enrollment", "TREATMENT", 80, 96], ["interim analyses", "TEST", 163, 179]]], ["It may be possible that the trial is fully enrolled by the time day 14 outcomes are available for the first 25% enrolled.", [["may be possible", "UNCERTAINTY", 3, 18]]], ["In this case, any further analyses would be related as to when to release interim results.Planned Interim AnalysesAt the first DSMB review, the stopping boundary is unlikely to be crossed.", [["any further analyses", "TEST", 14, 34], ["unlikely to be", "UNCERTAINTY", 165, 179]]], ["The purpose of this early review will assess the trends for safety/efficacy and allow for the DSMB to determine the probable timing of further reviews based on the pace of enrollment.Planned Interim AnalysesShould a stopping boundary be crossed, we would recommend an analysis to determine whether the findings are consistent across secondary endpoints, such that a clear answer is achieved.", [["the DSMB", "TEST", 90, 98], ["further reviews", "TEST", 135, 150], ["an analysis", "TEST", 265, 276]]], ["Starting with the 2 nd DSMB review (at approximately 50% enrollment) the DSMB will be given the conditional power for both cohorts under both the study design parameters and the current data.", [["the 2 nd DSMB review", "TREATMENT", 14, 34], ["the study", "TEST", 142, 151], ["the current data", "TEST", 174, 190]]], ["If the conditional power is less than 20% then trial discontinuation may be considered.Planned Interim AnalysesIn the event of early halting due to efficacy of the intervention, the study will immediately convert to an open label observational cohort of hydroxychloroquine prescribed to all consented participants in the relevant cohort.Planned Interim AnalysesIn the event of early halting due to futility of no effect, a protocol modification will be made to alter the intervention.Planned Interim AnalysesBased on the public health situation, the DSMB has the prerogative to alter the stopping rules.Sample Size Re-estimation:At time of ~50% enrollment, a sample size re-estimation should occur based on the disease transmission rate in the control group.", [["hydroxychloroquine", "CHEMICAL", 254, 272], ["hydroxychloroquine", "CHEMICAL", 254, 272], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 254, 272], ["participants", "SPECIES", 301, 313], ["discontinuation", "TREATMENT", 53, 68], ["Interim Analyses", "TEST", 95, 111], ["the intervention", "TREATMENT", 160, 176], ["the study", "TEST", 178, 187], ["hydroxychloroquine", "TREATMENT", 254, 272], ["Interim Analyses", "TEST", 345, 361], ["a protocol modification", "TREATMENT", 421, 444], ["the intervention", "TREATMENT", 467, 483], ["a sample size re-estimation", "TREATMENT", 657, 684], ["Size", "OBSERVATION_MODIFIER", 610, 614]]], ["The new sample size estimation will take into account the updated transmission rate with no treatment and will be powered to detect a 50% relative reduction in outcome.Final Analysis PlanPrimary outcome analyses (intention to treat):Final Analysis PlanAsymptomatic Cohort Primary Analysis:Final Analysis PlanThose with asymptomatic exposure: Incidence of COVID 19 disease by day 14 will be assessed via Fisher's Exact Test.Final Analysis PlanSymptomatic Cohort Primary Analysis:Final Analysis PlanThose with symptomatic disease at study entry: For a summary metric of the change in symptom severity over 14 days, a longitudinal change over time repeated measures mixedregression model will estimate the treatment effect by study arm.", [["sample", "ANATOMY", 8, 14], ["The new sample size estimation", "TEST", 0, 30], ["treatment", "TREATMENT", 92, 101], ["outcome analyses", "TEST", 195, 211], ["COVID 19 disease", "PROBLEM", 355, 371], ["Final Analysis", "TEST", 478, 492], ["symptomatic disease", "PROBLEM", 508, 527], ["the change in symptom severity", "PROBLEM", 568, 598], ["a longitudinal change", "PROBLEM", 613, 634], ["repeated measures mixedregression model", "TREATMENT", 645, 684], ["new", "OBSERVATION_MODIFIER", 4, 7], ["size", "OBSERVATION_MODIFIER", 15, 19], ["reduction", "OBSERVATION_MODIFIER", 147, 156], ["symptomatic", "OBSERVATION_MODIFIER", 508, 519], ["disease", "OBSERVATION", 520, 527]]], ["Subjects without symptoms are coded as a zero severity.", [["Subjects", "ORGANISM", 0, 8], ["symptoms", "PROBLEM", 17, 25], ["a zero severity", "PROBLEM", 39, 54]]], ["Persons hospitalized or dead are coded as 10 severity.Final Analysis PlanParticipants who become symptomatic with COVID19 on Day 1 before receiving the study medicine will be described with the symptomatic cohort.Final Analysis PlanSecondary Analyses:Final Analysis PlanFor the asymptomatic with exposure cohort, the primary analysis (intention to treat) will be repeated for participants who received at least one dose of the study medicine.Final Analysis Plan\u2022 Secondary endpoints will be assessed via Fisher's Exact test and median (with interquartile ranges) as appropriate.Final Analysis Plan\u2022 Those with symptomatic disease at study entry: Proportional odds models will be used to assess the ordinal scale for disease severity at day 14 (illness without hospitalization, hospitalization without ICU stay or death, or hospitalization with ICU stay or death).Final Analysis Plan\u2022 Severity of overall symptoms at Day 0, 1, 5, and 14 is recorded on a 0-10 visual analog scale.", [["illness", "DISEASE", 744, 751], ["death", "DISEASE", 813, 818], ["death", "DISEASE", 856, 861], ["Persons", "ORGANISM", 0, 7], ["Persons", "SPECIES", 0, 7], ["participants", "SPECIES", 376, 388], ["symptomatic", "PROBLEM", 97, 108], ["the study medicine", "TREATMENT", 148, 166], ["the primary analysis", "TEST", 313, 333], ["the study medicine", "TREATMENT", 423, 441], ["symptomatic disease", "PROBLEM", 610, 629], ["Proportional odds models", "PROBLEM", 646, 670], ["the ordinal scale", "TEST", 694, 711], ["disease severity", "PROBLEM", 716, 732], ["death", "PROBLEM", 813, 818], ["overall symptoms", "PROBLEM", 896, 912], ["symptomatic", "OBSERVATION_MODIFIER", 610, 621], ["disease", "OBSERVATION", 622, 629]]], ["Severity of symptoms at Day 5 will be compared first as a categorical analysis (no symptoms vs. symptoms) via Fisher's Exact Chi Square. \u25cb Second among those with symptoms, the 0-10 visual analog scale severity data will be compared via independent two-sample t test.", [["Severity of symptoms", "PROBLEM", 0, 20], ["a categorical analysis", "TEST", 56, 78], ["symptoms", "PROBLEM", 83, 91], ["symptoms", "PROBLEM", 96, 104], ["symptoms", "PROBLEM", 163, 171], ["visual analog scale severity data", "TEST", 182, 215], ["sample t test", "TEST", 253, 266]]], ["If data are non-normally distributed, then data will be compared via Mann-Whitney U by study arm.Final Analysis PlanA priori subgroup analyses will include assessment by:Final Analysis Plan\u2022 Confirmed SARS-CoV-2 disease or disease exposure \u2022 Healthcare worker vs. Household contact \u2022 Days from Exposure \u2022 Decile of age \u2022 Sex as a biological variable \u2022 Censored subjects, who became symptomatic before receipt of the first dose of study medicine on D#1, will be separately analyzed and reported.Handling of withdrawn subjects.If there is a large lost to follow up / study discontinue rate, then the primary endpoint for the asymptomatic cohort would have a secondary analysis to assess incidence as a 3-category analysis of: i) no disease, ii) incident disease, or iii) unknown.Handling of withdrawn subjects.Similarly, the symptomatic cohort would add a fourth category of unknown.Handling of withdrawn subjects.Participants who stop taking the study medicine but who agree to be followed for 14 days will be assessed as intent-to-treat.", [["SARS-CoV-2 disease", "DISEASE", 201, 219], ["Participants", "SPECIES", 912, 924], ["assessment", "TEST", 156, 166], ["Final Analysis", "TEST", 170, 184], ["SARS", "PROBLEM", 201, 205], ["CoV-2 disease", "PROBLEM", 206, 219], ["disease exposure", "PROBLEM", 223, 239], ["symptomatic", "PROBLEM", 382, 393], ["study medicine", "TREATMENT", 430, 444], ["a secondary analysis", "TEST", 654, 674], ["disease", "PROBLEM", 730, 737], ["disease", "PROBLEM", 752, 759], ["the study medicine", "TREATMENT", 941, 959], ["large", "OBSERVATION_MODIFIER", 539, 544], ["symptomatic", "OBSERVATION_MODIFIER", 823, 834]]], ["On Day 14, we will ask for other medications or vitamins that were taken during the study period.Screened PersonsPersons who are screened but not enrolled will be summarized in CONSORT diagrams and other descriptive summaries of their COVID-19 related information -with all data de-identified.SOURCE DOCUMENTS AND ACCESS TO SOURCE DATASource documents will include internet forms self-completed by participants directly entered into a RedCAP database.", [["vitamins", "SIMPLE_CHEMICAL", 48, 56], ["COVID-19", "DNA", 235, 243], ["participants", "SPECIES", 398, 410], ["other medications", "TREATMENT", 27, 44], ["vitamins", "TREATMENT", 48, 56]]], ["This protocol is based on self-report.SOURCE DOCUMENTS AND ACCESS TO SOURCE DATAThis internet-based protocol is meant to enable a large number of participants to be recruited, quickly as well as maintain the safety of the research staff.", [["participants", "SPECIES", 146, 158], ["This protocol", "TREATMENT", 0, 13], ["large", "OBSERVATION_MODIFIER", 130, 135]]], ["In person visits, create a public health Participants will be asked to provide consent to obtain medical records from their healthcare provider or public health official, if there is the need to verify outcomes -for SARS-CoV-2 test results or hospitalizations.QUALITY CONTROL AND QUALITY ASSURANCEStudy medications will be commercially procured U.S. FDA-approved hydroxychloroquine or under ANDA #210959 following Good Manufacturing Practice.Ethical StandardThis study is to be conducted according to US and international standards of Good Clinical Practice (International Conference on Harmonization guidelines), Declaration of Helsinki, and International Ethical Guidelines for Biomedical Research Involving Human Subjects, applicable U.S. government regulations and institutional research policies and procedures.", [["hydroxychloroquine", "CHEMICAL", 363, 381], ["ANDA #210959", "CHEMICAL", 391, 403], ["hydroxychloroquine", "CHEMICAL", 363, 381], ["ANDA #210959", "CHEMICAL", 391, 403], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 363, 381], ["Human", "ORGANISM", 710, 715], ["person", "SPECIES", 3, 9], ["Human", "SPECIES", 710, 715], ["SARS-CoV", "SPECIES", 216, 224], ["SARS", "PROBLEM", 216, 220], ["CoV-2 test results", "TEST", 221, 239], ["QUALITY ASSURANCEStudy medications", "TREATMENT", 280, 314], ["hydroxychloroquine", "TREATMENT", 363, 381], ["This study", "TEST", 458, 468]]], ["All investigators must have received human subject protection and GCP training prior to human subject involvement.Institutional Review BoardPrior to the initiation of the study, the protocol, all informed consent forms and the participant Information materials will be submitted to and approved by the single IRB of record.", [["human", "ORGANISM", 37, 42], ["human", "ORGANISM", 88, 93], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 88, 93], ["human subject protection", "TREATMENT", 37, 61], ["GCP training", "TREATMENT", 66, 78], ["the study", "TEST", 167, 176]]], ["Likewise, any future amendments to the study protocol will be submitted and approved by the IRB before implementation.", [["the study protocol", "TEST", 35, 53]]], ["This protocol and any amendments will undergo review and approval by the Human Subjects Board at the University of Minnesota under DHHS Assurance FWA00000312.Informed Consent Process\u2022 Written informed consent will be obtained via an English-language, internet-based web form.", [["FWA00000312", "CHEMICAL", 146, 157], ["Human", "ORGANISM", 73, 78], ["Human", "SPECIES", 73, 78], ["This protocol", "TREATMENT", 0, 13]]], ["If potential participants have questions, they may contact faq.covid19@gmail.com to reach a study staff member to answer their questions about research, either via email or a phone call. \u2022 After completion of reading the form, participants will be assessed for comprehension, querying: \u25cb Concept of Randomization to hydroxychloroquine or vitamin placebo \u25cb Whether hydroxychloroquine is known to be effective in preventing disease \u25cb Duration of the study? (14 days) \u25cb Duration of taking the study medicine (5 days) \u25cb When follow up surveys will be sent (Days 1, 3, 5, 10 and 14) \u25cb If hydroxychloroquine can be shared?", [["hydroxychloroquine", "CHEMICAL", 316, 334], ["vitamin", "CHEMICAL", 338, 345], ["hydroxychloroquine", "CHEMICAL", 364, 382], ["hydroxychloroquine", "CHEMICAL", 583, 601], ["hydroxychloroquine", "CHEMICAL", 316, 334], ["vitamin placebo", "CHEMICAL", 338, 353], ["hydroxychloroquine", "CHEMICAL", 364, 382], ["hydroxychloroquine", "CHEMICAL", 583, 601], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 316, 334], ["vitamin", "SIMPLE_CHEMICAL", 338, 345], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 364, 382], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 583, 601], ["participants", "SPECIES", 13, 25], ["participants", "SPECIES", 227, 239], ["Randomization", "TREATMENT", 299, 312], ["hydroxychloroquine", "TREATMENT", 316, 334], ["vitamin placebo", "TREATMENT", 338, 353], ["hydroxychloroquine", "TREATMENT", 364, 382], ["the study", "TEST", 444, 453], ["the study medicine", "TREATMENT", 486, 504], ["follow up surveys", "TEST", 521, 538], ["hydroxychloroquine", "TREATMENT", 583, 601]]], ["(No)Informed Consent/Assent Process (in Case of a Minor)\u2022 Persons under 18 years of age are not eligible to participate.", [["Persons", "ORGANISM", 58, 65], ["Persons", "SPECIES", 58, 65]]], ["COVID19 has negligible mortality in children <10 years, and rate of progression to symptomatic disease may likely be different.", [["COVID19", "CHEMICAL", 0, 7], ["COVID19", "GENE_OR_GENE_PRODUCT", 0, 7], ["children", "ORGANISM", 36, 44], ["COVID19", "PROTEIN", 0, 7], ["children", "SPECIES", 36, 44], ["symptomatic disease", "PROBLEM", 83, 102], ["negligible", "OBSERVATION_MODIFIER", 12, 22], ["mortality", "OBSERVATION_MODIFIER", 23, 32], ["symptomatic", "OBSERVATION_MODIFIER", 83, 94], ["disease", "OBSERVATION", 95, 102], ["may likely be", "UNCERTAINTY", 103, 116], ["different", "OBSERVATION_MODIFIER", 117, 126]]], ["Furthermore, pediatric dosing is weight based, making remote administration more complicated with fixed dose 200mg tablets.Exclusion of Women, Minorities, and Children\u2022 Persons under 18 years of age are not eligible to participate.", [["Women", "SPECIES", 136, 141], ["Persons", "SPECIES", 169, 176], ["remote administration", "TREATMENT", 54, 75]]], ["COVID19 has 0% mortality in children and young adults. \u2022 Non-English speaking adults are not eligible as the webpage and consents will only be available in English.Subject Confidentiality\u2022 Interaction will be via internet-based RedCAP ECRFs conforming to required U.S. privacy and server security standards. \u2022 Clinical data will be entered into a study specific database by designated staff on a regular basis from completed electronic Case Record Forms (eCRF).", [["COVID19", "CHEMICAL", 0, 7], ["COVID19", "GENE_OR_GENE_PRODUCT", 0, 7], ["children", "ORGANISM", 28, 36], ["adults", "ORGANISM", 78, 84], ["children", "SPECIES", 28, 36]]], ["Access to database will be given to authorized personnel only (members of the immediate study team). eCRF and trial documents will be kept in a secure database. \u2022 Documentation, data and all other information generated will be held in strict confidence.", [["eCRF", "PROBLEM", 101, 105]]], ["No information concerning the study or the data will be released to any unauthorized third party, without prior written approval of the participant except as necessary for monitoring by the IRB or public health authorities \u2022 No participant identifying information will be disclosed in any publication or at any conference activities arising from the study.Future Use of Stored Specimens\u2022 No specimens are to be stored for future research.Data Management ResponsibilitiesInvestigators will maintain a REDCAP database of study records.", [["specimens", "ANATOMY", 391, 400], ["participant", "SPECIES", 228, 239], ["the study", "TEST", 26, 35], ["the study", "TEST", 346, 355], ["specimens", "OBSERVATION", 391, 400]]], ["Survey forms will be self-completed by study participants.Data Capture Methods\u2022 Data will be obtained via internet-based REDCAP forms.Types of Data\u2022 Participants will be asked to provide data regarding COVID19 exposure timing and location.", [["COVID19", "GENE_OR_GENE_PRODUCT", 202, 209], ["COVID19", "PROTEIN", 202, 209], ["participants", "SPECIES", 45, 57], ["Participants", "SPECIES", 149, 161], ["COVID19 exposure timing", "TREATMENT", 202, 225]]], ["They will also be asked to provide ongoing symptom reports during the follow-up period.Timing/Reports\u2022 An enrollment progress report will be generated monthly \u25cb Participants Enrolled \u25cb Participants on study \u25cb Participants completed the study \u25cb Lost to Follow Up \u25cb Cumulative COVID19 (pooled, both arms) \u25cb Cumulative Hospitalizations (pooled, both arms) \u2022 A data safety monitoring board (DSMB) will review data after every 100 participants complete 14 days of follow-up. \u2022 De-identified data will be shared with the research team members for analysis.Study Records Retention\u2022 No paper documents will be retained or stored.Study Records Retention\u2022 Digital records will be kept in a secure server setting.Protocol DeviationsProtocol violations will be reported to the IRB of record.", [["Participants", "SPECIES", 161, 173], ["Participants", "SPECIES", 185, 197], ["Participants", "SPECIES", 209, 221], ["participants", "SPECIES", 426, 438], ["the study", "TEST", 232, 241], ["Cumulative COVID19 (pooled, both arms)", "TREATMENT", 264, 302], ["analysis", "TEST", 541, 549]]]], "78b7a343a9ffffc005daf8a962cf9140f5dc8735": [["INTRODUCTIONTGEV, a member of Coronaviridae family, is an enveloped virus with a positive-sense single-stranded RNA genome (Weiss & Leibowitz, 2011) .", [["Coronaviridae", "GENE_OR_GENE_PRODUCT", 30, 43], ["Coronaviridae family", "PROTEIN", 30, 50], ["positive-sense single-stranded RNA genome", "DNA", 81, 122], ["an enveloped virus", "PROBLEM", 55, 73]]], ["TGEV infection primarily causes transmissible gastroenteritis (TGE) that is characterized by highly contagious and fatal gastroenteritis for pigs of all ages, especially for piglets under 2 weeks old (Chae et al., 2000; Kim & Chae, 2001) .INTRODUCTIONApoptosis is a process of self-destruction in response to a variety of stimuli such as viral infection.", [["TGEV infection", "DISEASE", 0, 14], ["transmissible gastroenteritis", "DISEASE", 32, 61], ["TGE", "DISEASE", 63, 66], ["gastroenteritis", "DISEASE", 121, 136], ["viral infection", "DISEASE", 338, 353], ["TGEV", "ORGANISM", 0, 4], ["pigs", "ORGANISM", 141, 145], ["piglets", "ORGANISM", 174, 181], ["TGEV", "SPECIES", 0, 4], ["pigs", "SPECIES", 141, 145], ["piglets", "SPECIES", 174, 181], ["TGEV", "SPECIES", 0, 4], ["pigs", "SPECIES", 141, 145], ["TGEV infection", "PROBLEM", 0, 14], ["transmissible gastroenteritis", "PROBLEM", 32, 61], ["highly contagious and fatal gastroenteritis", "PROBLEM", 93, 136], ["self-destruction", "PROBLEM", 277, 293], ["a variety of stimuli", "TREATMENT", 309, 329], ["viral infection", "PROBLEM", 338, 353], ["infection", "OBSERVATION", 5, 14], ["transmissible", "OBSERVATION_MODIFIER", 32, 45], ["gastroenteritis", "OBSERVATION", 46, 61], ["highly", "OBSERVATION_MODIFIER", 93, 99], ["contagious", "OBSERVATION_MODIFIER", 100, 110], ["fatal", "OBSERVATION_MODIFIER", 115, 120], ["gastroenteritis", "OBSERVATION", 121, 136], ["destruction", "OBSERVATION", 282, 293], ["viral", "OBSERVATION_MODIFIER", 338, 343], ["infection", "OBSERVATION", 344, 353]]], ["Infection of coronavirus such as porcine epidemic diarrhea virus (PEDV) (Kim & Lee, 2014) , infectious bronchitis virus (IBV) (Li, Tam & Liu, 2007) , severe acute respiratory syndrome coronavirus (SARS-CoV) (Krahling et al., 2009) , may result in host cell apoptosis.", [["cell", "ANATOMY", 252, 256], ["coronavirus", "DISEASE", 13, 24], ["porcine epidemic diarrhea virus", "DISEASE", 33, 64], ["infectious bronchitis virus", "DISEASE", 92, 119], ["acute respiratory syndrome coronavirus", "DISEASE", 157, 195], ["SARS-CoV)", "DISEASE", 197, 206], ["coronavirus", "ORGANISM", 13, 24], ["porcine epidemic diarrhea virus", "ORGANISM", 33, 64], ["PEDV", "ORGANISM", 66, 70], ["infectious bronchitis virus", "ORGANISM", 92, 119], ["IBV", "ORGANISM", 121, 124], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 150, 195], ["SARS-CoV", "ORGANISM", 197, 205], ["host cell", "CELL", 247, 256], ["coronavirus", "SPECIES", 13, 24], ["porcine epidemic diarrhea virus", "SPECIES", 33, 64], ["infectious bronchitis virus", "SPECIES", 92, 119], ["porcine epidemic diarrhea virus", "SPECIES", 33, 64], ["PEDV", "SPECIES", 66, 70], ["infectious bronchitis virus", "SPECIES", 92, 119], ["IBV", "SPECIES", 121, 124], ["severe acute respiratory syndrome coronavirus", "SPECIES", 150, 195], ["SARS-CoV", "SPECIES", 197, 205], ["Infection", "PROBLEM", 0, 9], ["coronavirus", "PROBLEM", 13, 24], ["porcine epidemic diarrhea virus (PEDV", "PROBLEM", 33, 70], ["infectious bronchitis virus", "PROBLEM", 92, 119], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 150, 195], ["host cell apoptosis", "PROBLEM", 247, 266], ["coronavirus", "OBSERVATION", 13, 24], ["infectious", "OBSERVATION_MODIFIER", 92, 102], ["bronchitis", "OBSERVATION", 103, 113], ["severe", "OBSERVATION_MODIFIER", 150, 156], ["acute", "OBSERVATION_MODIFIER", 157, 162], ["respiratory syndrome coronavirus", "OBSERVATION", 163, 195], ["host cell apoptosis", "OBSERVATION", 247, 266]]], ["We have reported that TGEV infection induced apoptosis via mitochondria mediated apoptotic pathway in PK-15 cells (Ding et al., 2012; Ding et al., 2013) .INTRODUCTIONmiRNAs are a class of small non-coding RNA molecules and may regulate gene expression at post-transcription level (Bartel, 2009) .", [["mitochondria", "ANATOMY", 59, 71], ["PK-15 cells", "ANATOMY", 102, 113], ["TGEV infection", "DISEASE", 22, 36], ["TGEV", "ORGANISM", 22, 26], ["mitochondria", "CELLULAR_COMPONENT", 59, 71], ["PK-15 cells", "CELL", 102, 113], ["PK-15 cells", "CELL_LINE", 102, 113], ["small non-coding RNA molecules", "PROTEIN", 188, 218], ["TGEV", "SPECIES", 22, 26], ["TGEV infection", "PROBLEM", 22, 36], ["apoptosis via mitochondria", "PROBLEM", 45, 71], ["PK", "TEST", 102, 104], ["small non-coding RNA molecules", "PROBLEM", 188, 218], ["TGEV", "OBSERVATION_MODIFIER", 22, 26], ["infection", "OBSERVATION", 27, 36], ["small", "OBSERVATION_MODIFIER", 188, 193], ["non-coding RNA molecules", "OBSERVATION", 194, 218], ["gene expression", "OBSERVATION", 236, 251]]], ["Numerous experimental studies have demonstrated that miRNAs play important roles in cell apoptosis (Wilson & Doudna, 2013) . miR-29b effectively inhibits apoptosis via directly targeting caspase-7 and nuclear apoptosis inducing factor 1 (NAIF1) in Madin-Darby Bovine Kidney (MDBK) cells infected with bovine viral diarrhea virus (BVDV) (Fu et al., 2014) . miR-27b promotes doxorubicin-induced apoptosis in hepatoblastoma cell line (HepG2) (Mu et al., 2015) .", [["cell", "ANATOMY", 84, 88], ["nuclear", "ANATOMY", 201, 208], ["Kidney (MDBK) cells", "ANATOMY", 267, 286], ["hepatoblastoma cell line", "ANATOMY", 406, 430], ["HepG2", "ANATOMY", 432, 437], ["miR-29b", "CHEMICAL", 125, 132], ["bovine viral diarrhea virus", "DISEASE", 301, 328], ["miR-27b", "CHEMICAL", 356, 363], ["doxorubicin", "CHEMICAL", 373, 384], ["hepatoblastoma", "DISEASE", 406, 420], ["doxorubicin", "CHEMICAL", 373, 384], ["cell", "CELL", 84, 88], ["miR-29b", "GENE_OR_GENE_PRODUCT", 125, 132], ["caspase-7", "GENE_OR_GENE_PRODUCT", 187, 196], ["nuclear apoptosis inducing factor 1", "GENE_OR_GENE_PRODUCT", 201, 236], ["NAIF1", "GENE_OR_GENE_PRODUCT", 238, 243], ["Madin-Darby Bovine Kidney (MDBK) cells", "CELL", 248, 286], ["bovine viral diarrhea virus", "ORGANISM", 301, 328], ["BVDV", "ORGANISM", 330, 334], ["miR-27b", "GENE_OR_GENE_PRODUCT", 356, 363], ["doxorubicin", "SIMPLE_CHEMICAL", 373, 384], ["hepatoblastoma cell line", "CELL", 406, 430], ["HepG2", "CELL", 432, 437], ["miR-29b", "DNA", 125, 132], ["caspase-7", "PROTEIN", 187, 196], ["nuclear apoptosis inducing factor 1", "PROTEIN", 201, 236], ["NAIF1", "PROTEIN", 238, 243], ["Madin-Darby Bovine Kidney (MDBK) cells", "CELL_LINE", 248, 286], ["miR-27b", "DNA", 356, 363], ["hepatoblastoma cell line", "CELL_LINE", 406, 430], ["HepG2", "CELL_LINE", 432, 437], ["bovine", "SPECIES", 301, 307], ["viral diarrhea virus", "SPECIES", 308, 328], ["MDBK", "SPECIES", 275, 279], ["bovine viral diarrhea virus", "SPECIES", 301, 328], ["BVDV", "SPECIES", 330, 334], ["Numerous experimental studies", "TEST", 0, 29], ["miR", "TEST", 125, 128], ["apoptosis", "PROBLEM", 154, 163], ["caspase", "TEST", 187, 194], ["nuclear apoptosis", "TEST", 201, 218], ["factor", "TEST", 228, 234], ["NAIF1", "TEST", 238, 243], ["Madin", "TREATMENT", 248, 253], ["Darby Bovine Kidney (MDBK) cells", "TREATMENT", 254, 286], ["bovine viral diarrhea virus", "PROBLEM", 301, 328], ["miR", "TEST", 356, 359], ["doxorubicin", "TREATMENT", 373, 384], ["apoptosis", "PROBLEM", 393, 402], ["hepatoblastoma cell line", "TREATMENT", 406, 430], ["cell apoptosis", "OBSERVATION", 84, 98], ["Kidney", "ANATOMY", 267, 273], ["doxorubicin", "OBSERVATION_MODIFIER", 373, 384], ["apoptosis", "OBSERVATION_MODIFIER", 393, 402], ["hepatoblastoma cell line", "OBSERVATION", 406, 430]]], ["Moreover, miR-27b is an endogenous inhibitory factor of apoptotic peptidase activating factor 1 (Apaf-1) expression and decreases the apoptotic rate of neurons (Chen et al., 2014) . miRNAs are also involved in regulating the process of virus-induced apoptosis (Smith et al., 2012; Zhang et al., 2013) .", [["neurons", "ANATOMY", 152, 159], ["miR-27b", "GENE_OR_GENE_PRODUCT", 10, 17], ["apoptotic peptidase activating factor 1", "GENE_OR_GENE_PRODUCT", 56, 95], ["Apaf-1", "GENE_OR_GENE_PRODUCT", 97, 103], ["neurons", "CELL", 152, 159], ["miR-27b", "PROTEIN", 10, 17], ["apoptotic peptidase activating factor 1 (Apaf-1", "PROTEIN", 56, 103], ["apoptotic peptidase activating factor", "TREATMENT", 56, 93], ["Apaf", "TEST", 97, 101], ["virus", "PROBLEM", 236, 241], ["virus", "OBSERVATION", 236, 241]]], ["Hs_154 promotes WNV-mediated apoptosis via inhibiting the expression of CCCTC-binding factor (CTCF) and the epidermal growth factor receptor (EGFR) (Smith et al., 2012) .", [["Hs_154", "GENE_OR_GENE_PRODUCT", 0, 6], ["WNV", "ORGANISM", 16, 19], ["CCCTC-binding factor", "GENE_OR_GENE_PRODUCT", 72, 92], ["CTCF", "GENE_OR_GENE_PRODUCT", 94, 98], ["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 108, 140], ["EGFR", "GENE_OR_GENE_PRODUCT", 142, 146], ["CCCTC", "PROTEIN", 72, 77], ["binding factor", "PROTEIN", 78, 92], ["CTCF", "PROTEIN", 94, 98], ["epidermal growth factor receptor", "PROTEIN", 108, 140], ["EGFR", "PROTEIN", 142, 146], ["WNV", "SPECIES", 16, 19], ["WNV", "PROBLEM", 16, 19], ["apoptosis", "PROBLEM", 29, 38], ["CCCTC-binding factor", "PROBLEM", 72, 92]]], ["Our previous studies showed that miR-27b was significantly down-regulated during TGEV-induced apoptosis (Song et al., 2015) .", [["miR-27b", "GENE_OR_GENE_PRODUCT", 33, 40], ["TGEV", "ORGANISM", 81, 85], ["miR-27b", "DNA", 33, 40], ["TGEV", "SPECIES", 81, 85], ["Our previous studies", "TEST", 0, 20], ["miR", "TEST", 33, 36], ["TGEV", "PROBLEM", 81, 85]]], ["Thus, we supposed that miR-27b may play a role in apoptosis induced by TGEV infection.", [["miR-27b", "CHEMICAL", 23, 30], ["TGEV infection", "DISEASE", 71, 85], ["miR-27b", "GENE_OR_GENE_PRODUCT", 23, 30], ["TGEV", "ORGANISM", 71, 75], ["miR-27b", "PROTEIN", 23, 30], ["TGEV", "SPECIES", 71, 75], ["apoptosis", "PROBLEM", 50, 59], ["TGEV infection", "PROBLEM", 71, 85], ["infection", "OBSERVATION", 76, 85]]], ["In the present study, we investigated the role of miR-27b in TGEV-induced apoptosis in PK-15 cells and demonstrated that the miR-27b attenuated TGEV-induced apoptosis by targeting RUNX1, suggesting TGEV may use miR-27b to regulate apoptosis in PK-15 cells.Antibodies, cells and virusMonoclonal RUNX1 (MAB23991) was purchased from R& D Systems (R& D Systems, Minneapolis, MN, USA).", [["PK-15 cells", "ANATOMY", 87, 98], ["PK-15 cells", "ANATOMY", 244, 255], ["cells", "ANATOMY", 268, 273], ["miR-27b", "CHEMICAL", 50, 57], ["miR-27b", "CHEMICAL", 125, 132], ["miR-27b", "GENE_OR_GENE_PRODUCT", 50, 57], ["TGEV", "ORGANISM", 61, 65], ["PK-15 cells", "CELL", 87, 98], ["miR-27b", "GENE_OR_GENE_PRODUCT", 125, 132], ["TGEV", "ORGANISM", 144, 148], ["RUNX1", "GENE_OR_GENE_PRODUCT", 180, 185], ["TGEV", "ORGANISM", 198, 202], ["miR-27b", "GENE_OR_GENE_PRODUCT", 211, 218], ["PK-15 cells", "CELL", 244, 255], ["cells", "CELL", 268, 273], ["RUNX1", "GENE_OR_GENE_PRODUCT", 294, 299], ["miR-27b", "PROTEIN", 50, 57], ["PK-15 cells", "CELL_LINE", 87, 98], ["miR-27b", "PROTEIN", 125, 132], ["RUNX1", "PROTEIN", 180, 185], ["miR-27b", "DNA", 211, 218], ["PK-15 cells", "CELL_LINE", 244, 255], ["virusMonoclonal RUNX1", "PROTEIN", 278, 299], ["MAB23991", "PROTEIN", 301, 309], ["TGEV", "SPECIES", 61, 65], ["TGEV", "SPECIES", 144, 148], ["TGEV", "SPECIES", 198, 202], ["miR", "TEST", 50, 53], ["TGEV", "PROBLEM", 61, 65], ["PK", "TEST", 87, 89], ["the miR", "TEST", 121, 128], ["TGEV", "PROBLEM", 144, 148], ["targeting RUNX1", "PROBLEM", 170, 185], ["TGEV", "PROBLEM", 198, 202], ["miR", "TEST", 211, 214], ["apoptosis", "TEST", 231, 240], ["PK", "TEST", 244, 246], ["Antibodies", "TEST", 256, 266], ["virusMonoclonal RUNX1", "PROBLEM", 278, 299]]], ["Monoclonal antibodies against Bax (sc-23959) and \u03b2-actin (sc-69879) were purchased from Santa Cruz Biotechnology (Santa Cruz, Inc., Santa Cruz, CA, USA).", [["sc-23959", "CHEMICAL", 35, 43], ["sc-69879", "CHEMICAL", 58, 66], ["Bax", "GENE_OR_GENE_PRODUCT", 30, 33], ["sc-23959", "GENE_OR_GENE_PRODUCT", 35, 43], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 49, 56], ["sc-69879", "GENE_OR_GENE_PRODUCT", 58, 66], ["Monoclonal antibodies", "PROTEIN", 0, 21], ["Bax", "PROTEIN", 30, 33], ["Monoclonal antibodies", "TEST", 0, 21], ["Bax", "TEST", 30, 33]]], ["Horseradish peroxidase (HRP)-conjugated secondary antibody was purchased from Pierce (Pierce, Rockford, IL, US).", [["Horseradish peroxidase", "SIMPLE_CHEMICAL", 0, 22], ["HRP", "SIMPLE_CHEMICAL", 24, 27], ["Horseradish peroxidase (HRP)-conjugated secondary antibody", "PROTEIN", 0, 58], ["Horseradish", "SPECIES", 0, 11], ["Horseradish peroxidase (HRP)", "TREATMENT", 0, 28], ["conjugated secondary antibody", "PROBLEM", 29, 58]]], ["PK-15 cells were obtained from ATCC (CCL-33) and cultured in Dulbecco's Minimal Essential Medium (DMEM) supplemented with 10% fetal bovine serum (Gibco BRL, Gaithersburg, MD, USA), 100 IU of penicillin, and 100 mg of streptomycin per ml, at 37 \u2022 C in a 5% CO 2 atmosphere incubator.", [["PK-15 cells", "ANATOMY", 0, 11], ["ATCC", "ANATOMY", 31, 35], ["CCL-33", "ANATOMY", 37, 43], ["fetal bovine serum", "ANATOMY", 126, 144], ["penicillin", "CHEMICAL", 191, 201], ["streptomycin", "CHEMICAL", 217, 229], ["penicillin", "CHEMICAL", 191, 201], ["streptomycin", "CHEMICAL", 217, 229], ["CO", "CHEMICAL", 256, 258], ["PK-15 cells", "CELL", 0, 11], ["ATCC", "CELL", 31, 35], ["CCL-33", "CELL", 37, 43], ["bovine", "ORGANISM", 132, 138], ["serum", "ORGANISM_SUBSTANCE", 139, 144], ["penicillin", "SIMPLE_CHEMICAL", 191, 201], ["streptomycin", "SIMPLE_CHEMICAL", 217, 229], ["PK-15 cells", "CELL_LINE", 0, 11], ["CCL-33", "CELL_LINE", 37, 43], ["bovine", "SPECIES", 132, 138], ["ATCC (CCL-33", "SPECIES", 31, 43], ["bovine", "SPECIES", 132, 138], ["PK", "TEST", 0, 2], ["ATCC", "TEST", 31, 35], ["CCL", "TEST", 37, 40], ["cultured", "TEST", 49, 57], ["Dulbecco", "TEST", 61, 69], ["penicillin", "TREATMENT", 191, 201], ["streptomycin", "TREATMENT", 217, 229], ["a 5% CO 2 atmosphere incubator", "TREATMENT", 251, 281]]], ["The TGEV Shaanxi strain was isolated from TGEV-infected piglets by Ding et al. (2011) .miRNAs quantification by real-time PCRTotal RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA) from PK-15 cells Reverse transcription reactions and real-time PCR were performed as described previously (Song et al., 2015) .", [["PK-15 cells", "ANATOMY", 207, 218], ["TGEV Shaanxi strain", "ORGANISM", 4, 23], ["TGEV", "ORGANISM", 42, 46], ["piglets", "ORGANISM", 56, 63], ["PK-15 cells", "CELL", 207, 218], ["PCRTotal RNA", "RNA", 122, 134], ["TGEV", "SPECIES", 4, 8], ["TGEV", "SPECIES", 42, 46], ["piglets", "SPECIES", 56, 63], ["TGEV", "SPECIES", 4, 8], ["TGEV", "SPECIES", 42, 46], ["The TGEV Shaanxi strain", "PROBLEM", 0, 23], ["TGEV", "PROBLEM", 42, 46], ["Trizol reagent", "TREATMENT", 155, 169], ["Invitrogen", "TEST", 171, 181], ["CA", "TEST", 193, 195], ["PK", "TEST", 207, 209], ["Reverse transcription reactions", "PROBLEM", 219, 250], ["real-time PCR", "TEST", 255, 268], ["infected", "OBSERVATION_MODIFIER", 47, 55]]], ["The relative quantification of miRNAs was normalized to U6 using the two-ddCt method (Livak & Schmittgen, 2001) .Flow cytometry analysisAnnexin V-FITC Apoptosis Kit (Invitrogen, Carlsbad, CA, USA) was used to detect apoptosis according to the manufacturer's protocol.", [["FITC", "CHEMICAL", 146, 150], ["Annexin V-FITC", "GENE_OR_GENE_PRODUCT", 136, 150], ["miRNAs", "RNA", 31, 37], ["U6", "DNA", 56, 58], ["Flow cytometry analysis", "TEST", 113, 136], ["Annexin V", "TEST", 136, 145], ["Invitrogen", "TEST", 166, 176], ["apoptosis", "PROBLEM", 216, 225], ["the manufacturer's protocol", "TREATMENT", 239, 266], ["miRNAs", "OBSERVATION", 31, 37], ["FITC Apoptosis", "OBSERVATION", 146, 160]]], ["Briefly, cells were washed twice with ice-cold PBS and resuspended in 500 \u00b5L 1\u00d7Annexin V binding buffer followed by adding 5 \u00b5L Annexin V-FITC and 5 \u00b5L PI.", [["cells", "ANATOMY", 9, 14], ["Annexin V", "CHEMICAL", 79, 88], ["FITC", "CHEMICAL", 138, 142], ["cells", "CELL", 9, 14], ["Annexin V", "GENE_OR_GENE_PRODUCT", 79, 88], ["Annexin V-FITC", "GENE_OR_GENE_PRODUCT", 128, 142], ["ice-cold PBS", "TREATMENT", 38, 50], ["Annexin V binding buffer", "TREATMENT", 79, 103], ["5 \u00b5L Annexin V-FITC and 5 \u00b5L PI", "TREATMENT", 123, 154]]], ["After incubation for 30 min at room temperature, analysis was done by flow cytometry (Beckman Coulter, CA, USA).Caspase activity assayCaspases activities were measured by colorimetric assay kits (Keygen Biotech, Nanjing, China) following the manufacture's protocol.", [["Caspase", "GENE_OR_GENE_PRODUCT", 112, 119], ["assayCaspases", "GENE_OR_GENE_PRODUCT", 129, 142], ["Caspase", "PROTEIN", 112, 119], ["analysis", "TEST", 49, 57], ["flow cytometry", "TEST", 70, 84], ["Caspase activity assayCaspases activities", "TEST", 112, 153], ["colorimetric assay kits", "TEST", 171, 194], ["the manufacture's protocol", "TREATMENT", 238, 264]]], ["Briefly, protein concentrations were measured by BCA Protein Assay Reagent (Vazyme Biotech Nanjing, China).", [["protein concentrations", "TEST", 9, 31]]], ["Then 200 mg protein of each sample was incubated with each caspase substrate at 37 \u2022 C in a microplate for 4 h.", [["sample", "ANATOMY", 28, 34], ["caspase", "GENE_OR_GENE_PRODUCT", 59, 66], ["each caspase substrate", "TREATMENT", 54, 76], ["a microplate", "TREATMENT", 90, 102]]], ["Absorbance at the wavelength of 405 nm was read in microplate spectrophotometer (Infinite 200 PRO NanoQuant; Tecan, Switzerland).Luciferase reporter experimentsThe 3 UTR sequence of RUNX1 mRNA containing the target sites of miR-27b was amplified by PCR using the primers of Table S1.", [["RUNX1", "GENE_OR_GENE_PRODUCT", 182, 187], ["miR-27b", "GENE_OR_GENE_PRODUCT", 224, 231], ["3 UTR sequence", "DNA", 164, 178], ["RUNX1 mRNA", "RNA", 182, 192], ["miR-27b", "DNA", 224, 231], ["microplate spectrophotometer", "TEST", 51, 79], ["The 3 UTR sequence", "TEST", 160, 178], ["RUNX1 mRNA", "PROBLEM", 182, 192], ["PCR", "TEST", 249, 252], ["RUNX1 mRNA", "OBSERVATION", 182, 192]]], ["The 3 UTR of RUNX1 mRNA was cloned into psiCHECK-2 (Promega, Madison, WI, USA) between Xho I and Not I cloning sites to obtain the wild type plasmid RUNX1-WT.", [["plasmid", "ANATOMY", 141, 148], ["RUNX1", "GENE_OR_GENE_PRODUCT", 13, 18], ["Xho I", "GENE_OR_GENE_PRODUCT", 87, 92], ["Not I", "GENE_OR_GENE_PRODUCT", 97, 102], ["RUNX1", "GENE_OR_GENE_PRODUCT", 149, 154], ["RUNX1 mRNA", "RNA", 13, 23], ["psiCHECK-2", "DNA", 40, 50], ["Xho I and Not I cloning sites", "DNA", 87, 116], ["wild type plasmid RUNX1", "DNA", 131, 154], ["The 3 UTR of RUNX1 mRNA", "TREATMENT", 0, 23], ["psiCHECK", "TEST", 40, 48]]], ["The binding sequences of miR-27b seed region in 3 UTR of RUNX1-WT were mutated following a mutagenesis protocol (Heckman & Pease, 2007) to generate RUNX1-mut. miR-27b mimics, miRNA mimics control, miR-27b inhibitors and miRNA inhibitors control were synthesized by Ribo Biotech (RiboBio, Guangzhou, China). miR-27b inhibitors were modified with 2 -O-methyl.", [["miR-27b", "CHEMICAL", 307, 314], ["2 -O-methyl", "CHEMICAL", 345, 356], ["2 -O-methyl", "CHEMICAL", 345, 356], ["miR-27b", "GENE_OR_GENE_PRODUCT", 25, 32], ["RUNX1", "GENE_OR_GENE_PRODUCT", 57, 62], ["RUNX1", "GENE_OR_GENE_PRODUCT", 148, 153], ["mut", "GENE_OR_GENE_PRODUCT", 154, 157], ["miR-27b", "GENE_OR_GENE_PRODUCT", 159, 166], ["miR-27b", "GENE_OR_GENE_PRODUCT", 197, 204], ["miR-27b", "GENE_OR_GENE_PRODUCT", 307, 314], ["2 -O-methyl", "SIMPLE_CHEMICAL", 345, 356], ["binding sequences", "DNA", 4, 21], ["miR-27b seed region", "DNA", 25, 44], ["UTR", "DNA", 50, 53], ["RUNX1", "DNA", 57, 62], ["RUNX1", "PROTEIN", 148, 153], ["mut", "DNA", 154, 157], ["miR-27b", "DNA", 159, 166], ["miR-27b seed region", "TREATMENT", 25, 44], ["a mutagenesis protocol", "TEST", 89, 111], ["miR", "TEST", 159, 162], ["miRNA mimics control", "TREATMENT", 175, 195], ["miR-27b inhibitors", "TREATMENT", 197, 215], ["miRNA inhibitors control", "TREATMENT", 220, 244], ["miR-27b inhibitors", "TREATMENT", 307, 325]]], ["The sequences of miRNA in this study were shown in Table S2 .", [["this study", "TEST", 26, 36], ["miRNA", "ANATOMY", 17, 22]]], ["For the luciferase reporter assay, PK-15 cells were grown in 24-well plates and then co-transfected with plasmid RUNX1-WT (or RUNX1-mut) and miR-27b mimics (or miR-27b inhibitors) using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA).", [["PK-15 cells", "ANATOMY", 35, 46], ["plasmid", "ANATOMY", 105, 112], ["luciferase", "GENE_OR_GENE_PRODUCT", 8, 18], ["PK-15 cells", "CELL", 35, 46], ["RUNX1", "GENE_OR_GENE_PRODUCT", 113, 118], ["RUNX1", "GENE_OR_GENE_PRODUCT", 126, 131], ["mut", "GENE_OR_GENE_PRODUCT", 132, 135], ["miR-27b", "GENE_OR_GENE_PRODUCT", 141, 148], ["miR-27b", "GENE_OR_GENE_PRODUCT", 160, 167], ["PK-15 cells", "CELL_LINE", 35, 46], ["plasmid RUNX1-WT", "DNA", 105, 121], ["RUNX1", "DNA", 126, 131], ["mut", "DNA", 132, 135], ["miR-27b mimics", "DNA", 141, 155], ["the luciferase reporter assay", "TEST", 4, 33], ["PK", "TEST", 35, 37], ["plasmid RUNX1", "TEST", 105, 118], ["WT", "TEST", 119, 121], ["RUNX1", "TEST", 126, 131], ["miR", "TEST", 141, 144], ["mimics", "TEST", 149, 155], ["miR", "TEST", 160, 163], ["Lipofectamine", "TREATMENT", 186, 199]]], ["The luciferase activities were detected at 48 h post transfection (hpt) using a Dual-Glo R Luciferase Assay System (Promega, Madison, WI, USA) following the manufacturer's manual.RNA interferenceThree siRNAs (siRUNX1-1, siRUNX1-2, siRUNX1-3) of RUNX1 were synthesized by GenePharma (GenePharma, Shanghai, China).", [["luciferase", "GENE_OR_GENE_PRODUCT", 4, 14], ["siRUNX1-1", "GENE_OR_GENE_PRODUCT", 209, 218], ["siRUNX1-2", "GENE_OR_GENE_PRODUCT", 220, 229], ["siRUNX1-3", "GENE_OR_GENE_PRODUCT", 231, 240], ["RUNX1", "GENE_OR_GENE_PRODUCT", 245, 250], ["luciferase", "PROTEIN", 4, 14], ["siRUNX1", "DNA", 209, 216], ["siRUNX1", "DNA", 220, 227], ["siRUNX1", "DNA", 231, 238], ["RUNX1", "DNA", 245, 250], ["The luciferase activities", "TEST", 0, 25], ["a Dual-Glo R Luciferase", "TREATMENT", 78, 101], ["the manufacturer", "TREATMENT", 153, 169], ["RNA interference", "PROBLEM", 179, 195], ["Three siRNAs", "TEST", 195, 207], ["siRUNX1", "TEST", 209, 216], ["siRUNX1", "TEST", 220, 227], ["RUNX1", "PROBLEM", 245, 250], ["siRNAs", "OBSERVATION", 201, 207], ["RUNX1", "ANATOMY", 245, 250]]], ["The most effective siRNA (si-RUNX1-2) was applied for the further experiments.", [["The most effective siRNA (si-RUNX1-2)", "TREATMENT", 0, 37], ["most", "OBSERVATION_MODIFIER", 4, 8], ["effective", "OBSERVATION_MODIFIER", 9, 18], ["siRNA", "OBSERVATION", 19, 24]]], ["PK-15 cells were transfected with 100 nM RUNX1specific siRUNX1-2 (Table S2 ) or irrelevant siRNA using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, US).Cell viability assayCell viability was detected using Cell Counting Kit-8 (CCK-8) (Vazyme Biotech Nanjing, China).", [["PK-15 cells", "ANATOMY", 0, 11], ["Cell", "ANATOMY", 153, 157], ["Cell", "ANATOMY", 207, 211], ["PK-15 cells", "CELL", 0, 11], ["siRUNX1-2", "GENE_OR_GENE_PRODUCT", 55, 64], ["Cell", "CELL", 153, 157], ["assayCell", "CELL", 168, 177], ["PK-15 cells", "CELL_LINE", 0, 11], ["RUNX1specific siRUNX1-2", "DNA", 41, 64], ["PK", "TEST", 0, 2], ["cells", "TEST", 6, 11], ["nM RUNX1specific siRUNX1", "TEST", 38, 62], ["irrelevant siRNA", "PROBLEM", 80, 96], ["Lipofectamine", "TREATMENT", 103, 116], ["Cell viability assayCell viability", "TEST", 153, 187], ["Cell Counting Kit", "TEST", 207, 224], ["CCK", "TEST", 228, 231]]], ["Briefly, cells were seeded in 96-well culture plate and cultured at 37 \u2022 C in a humidified atmosphere with 5% CO 2 .", [["cells", "ANATOMY", 9, 14], ["CO 2", "CHEMICAL", 110, 114], ["cells", "CELL", 9, 14], ["culture plate", "TEST", 38, 51], ["a humidified atmosphere", "TREATMENT", 78, 101]]], ["Twelve hours later, cells were transfected with 100 nM siRUNX1-2 or irrelevant siRNAs.", [["cells", "ANATOMY", 20, 25], ["cells", "CELL", 20, 25], ["siRUNX1-2", "GENE_OR_GENE_PRODUCT", 55, 64], ["cells", "TEST", 20, 25], ["nM siRUNX1", "TEST", 52, 62], ["irrelevant siRNAs", "PROBLEM", 68, 85], ["irrelevant siRNAs", "OBSERVATION", 68, 85]]], ["The cell viability was tested following the manufacturer's manual at 48 hpt.Vector constructionTo construct the RUNX1 expression plasmid, the full-length RUNX1 gene was amplified by PCR and was cloned into plasmid pCI-neo (Promega, Madison, WI, USA) between EcoR I and Not I cloning sites to gain pCI-neo-RUNX1.", [["cell", "ANATOMY", 4, 8], ["cell", "CELL", 4, 8], ["RUNX1", "GENE_OR_GENE_PRODUCT", 112, 117], ["RUNX1", "GENE_OR_GENE_PRODUCT", 154, 159], ["EcoR I", "GENE_OR_GENE_PRODUCT", 258, 264], ["Not I", "GENE_OR_GENE_PRODUCT", 269, 274], ["pCI", "GENE_OR_GENE_PRODUCT", 297, 300], ["RUNX1", "GENE_OR_GENE_PRODUCT", 305, 310], ["RUNX1 expression plasmid", "DNA", 112, 136], ["full-length RUNX1 gene", "DNA", 142, 164], ["pCI", "DNA", 214, 217], ["neo", "DNA", 218, 221], ["EcoR I and Not I cloning sites", "DNA", 258, 288], ["pCI", "DNA", 297, 300], ["RUNX1", "PROTEIN", 305, 310], ["Vector constructionTo", "TREATMENT", 76, 97], ["the RUNX1 expression plasmid", "TREATMENT", 108, 136], ["the full-length RUNX1 gene", "TREATMENT", 138, 164], ["plasmid pCI", "TREATMENT", 206, 217], ["neo", "TREATMENT", 218, 221], ["pCI", "TREATMENT", 297, 300], ["neo-RUNX1", "TREATMENT", 301, 310], ["cell viability", "OBSERVATION", 4, 18], ["RUNX1 expression plasmid", "OBSERVATION", 112, 136], ["neo-RUNX1", "OBSERVATION", 301, 310]]], ["The primer sequences of PCR are shown in Table S1 .", [["primer sequences", "DNA", 4, 20], ["The primer sequences of PCR", "TEST", 0, 27], ["S1", "ANATOMY", 47, 49]]], ["PK-15 cells were transfected with pCI-neo (control) or pCI-neo-RUNX1.", [["PK-15 cells", "ANATOMY", 0, 11], ["PK-15 cells", "CELL", 0, 11], ["pCI-neo", "GENE_OR_GENE_PRODUCT", 34, 41], ["pCI", "GENE_OR_GENE_PRODUCT", 55, 58], ["RUNX1", "GENE_OR_GENE_PRODUCT", 63, 68], ["PK-15 cells", "CELL_LINE", 0, 11], ["pCI", "PROTEIN", 34, 37], ["neo (control) or pCI-neo-RUNX1", "DNA", 38, 68], ["PK", "TEST", 0, 2], ["pCI", "TREATMENT", 34, 37], ["neo", "TREATMENT", 38, 41], ["pCI", "TREATMENT", 55, 58], ["neo-RUNX1", "TREATMENT", 59, 68], ["neo-RUNX1", "OBSERVATION", 59, 68]]], ["Cells were infected with TGEV at multiplicity of infection (MOI) of 1 at 48 h post infection (hpi).Quantification of mRNAs by real-time PCRThe total RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to manufacturer's instructions.", [["Cells", "ANATOMY", 0, 5], ["infection", "DISEASE", 49, 58], ["infection", "DISEASE", 83, 92], ["Cells", "CELL", 0, 5], ["TGEV", "ORGANISM", 25, 29], ["mRNAs", "RNA", 117, 122], ["TGEV", "SPECIES", 25, 29], ["TGEV", "PROBLEM", 25, 29], ["infection", "PROBLEM", 49, 58], ["infection", "PROBLEM", 83, 92], ["Trizol reagent", "TREATMENT", 173, 187], ["Invitrogen", "TREATMENT", 189, 199], ["Carlsbad", "TREATMENT", 201, 209], ["infection", "OBSERVATION", 49, 58], ["infection", "OBSERVATION", 83, 92]]], ["A total of 2 \u00b5g of RNA was transcribed into cDNA using the First-strand cDNA synthesis kit (Invitrogen, Carlsbad, CA, US).", [["cDNA", "DNA", 44, 48], ["A total of 2 \u00b5g of RNA", "TREATMENT", 0, 22]]], ["Real-time PCR was carried out using the AccuPower R 2\u00d7 Greenstar qPCR Master mix (Bioneer, Daejeon, Korea) on Bio-Rad iQ5 Real-Time PCR System.", [["time PCR", "TEST", 5, 13], ["the AccuPower R", "TREATMENT", 36, 51], ["Bio-Rad iQ5", "TREATMENT", 110, 121]]], ["The relative fold changes were calculated using the 2-ddCt method.", [["The relative fold changes", "PROBLEM", 0, 25], ["the 2-ddCt method", "TREATMENT", 48, 65], ["fold", "OBSERVATION_MODIFIER", 13, 17]]], ["The real-time PCR primers are shown in Table S3 .Western blot analysisCells were treated with Radioimmunoprecipitation Assay (RIPA) lysis buffer containing phenylmethyl sulfonylfluoride (PMSF).", [["Cells", "ANATOMY", 70, 75], ["phenylmethyl sulfonylfluoride", "CHEMICAL", 156, 185], ["phenylmethyl sulfonylfluoride", "CHEMICAL", 156, 185], ["PMSF", "CHEMICAL", 187, 191], ["Cells", "CELL", 70, 75], ["phenylmethyl sulfonylfluoride", "SIMPLE_CHEMICAL", 156, 185], ["PMSF", "SIMPLE_CHEMICAL", 187, 191], ["PCR primers", "DNA", 14, 25], ["The real-time PCR primers", "TEST", 0, 25], ["blot analysis", "TEST", 57, 70], ["Radioimmunoprecipitation Assay (RIPA) lysis buffer containing phenylmethyl sulfonylfluoride", "TREATMENT", 94, 185]]], ["Protein concentration was tested with BCA Protein Assay Reagent (Pierce, Rockford, IL, USA).", [["Protein concentration", "TEST", 0, 21]]], ["The proteins were separated on a 12% sodium dodecyl sulfate-polyacrylamide (SDS-PAGE) gel and subsequently transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore Corp, Atlanta, GA, USA).", [["sodium dodecyl sulfate-polyacrylamide", "CHEMICAL", 37, 74], ["SDS-PAGE", "CHEMICAL", 76, 84], ["sodium dodecyl sulfate", "CHEMICAL", 37, 59], ["polyacrylamide", "CHEMICAL", 60, 74], ["SDS-PAGE", "CHEMICAL", 76, 84], ["polyvinylidene difluoride", "CHEMICAL", 124, 149], ["PVDF", "CHEMICAL", 151, 155], ["sodium dodecyl sulfate-polyacrylamide", "SIMPLE_CHEMICAL", 37, 74], ["SDS-PAGE", "SIMPLE_CHEMICAL", 76, 84], ["a 12% sodium dodecyl sulfate", "TREATMENT", 31, 59], ["polyacrylamide (SDS", "TREATMENT", 60, 79], ["a polyvinylidene difluoride (PVDF) membrane", "TREATMENT", 122, 165]]], ["The membrane was blocked with 5% non-fat dry milk for 2 h at room temperature and then incubated with the primary antibodies overnight at 4 \u2022 C. The HRP-conjugated secondary antibodies were used to incubate for 1 h at room temperature.", [["membrane", "ANATOMY", 4, 12], ["milk", "ANATOMY", 45, 49], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["milk", "ORGANISM_SUBSTANCE", 45, 49], ["HRP", "SIMPLE_CHEMICAL", 149, 152], ["primary antibodies", "PROTEIN", 106, 124], ["HRP-conjugated secondary antibodies", "PROTEIN", 149, 184], ["The HRP", "TEST", 145, 152], ["conjugated secondary antibodies", "TREATMENT", 153, 184]]], ["The blotting was visualized using Enhanced Chemiluminescence (ECL) reagent.StatisticsAll data are representative of results from at least 3 separate experiments.", [["The blotting", "TEST", 0, 12], ["Enhanced Chemiluminescence (ECL) reagent", "TREATMENT", 34, 74]]], ["All data points are the average of triplicates, with error bars representing standard deviations.", [["standard deviations", "PROBLEM", 77, 96], ["standard deviations", "OBSERVATION", 77, 96]]], ["The difference between two groups was statistically analyzed by a two-tailed Student's t test using SPSS software.", [["SPSS software", "TEST", 100, 113]]], ["P value <0.05 was considered significant.miR-27b attenuates TGEV-induced apoptosisTo investigate whether miR-27b is involved in the apoptosis induced by TGEV, the cells were transfected with miR-27b mimics or miR-27b inhibitors and infected with TGEV at a MOI of 1 at 24 hpt.", [["cells", "ANATOMY", 163, 168], ["miR-27b", "CHEMICAL", 41, 48], ["miR-27b", "GENE_OR_GENE_PRODUCT", 41, 48], ["TGEV", "ORGANISM", 60, 64], ["miR-27b", "GENE_OR_GENE_PRODUCT", 105, 112], ["TGEV", "ORGANISM", 153, 157], ["cells", "CELL", 163, 168], ["miR-27b", "GENE_OR_GENE_PRODUCT", 191, 198], ["miR-27b", "GENE_OR_GENE_PRODUCT", 209, 216], ["TGEV", "ORGANISM", 246, 250], ["miR-27b", "DNA", 41, 48], ["miR-27b", "DNA", 105, 112], ["TGEV", "SPECIES", 60, 64], ["TGEV", "SPECIES", 153, 157], ["TGEV", "SPECIES", 246, 250], ["P value", "TEST", 0, 7], ["miR", "TEST", 41, 44], ["TGEV", "PROBLEM", 60, 64], ["the apoptosis", "PROBLEM", 128, 141], ["miR", "TEST", 191, 194], ["miR-27b inhibitors", "TREATMENT", 209, 227], ["TGEV", "PROBLEM", 246, 250]]], ["The apoptotic rate was analyzed by flow cytometry at 24 and 48 hpi.", [["The apoptotic rate", "TEST", 0, 18], ["flow cytometry", "TEST", 35, 49]]], ["The results showed that the over-expression of miR-27b led to a decrease of apoptotic rate and the down-expression of miR-27b increased apoptotic rate at 24 and 48 hpi (Fig. 1A) , indicating that miR-27b attenuated apoptosis induced by TGEV infection in PK-15 cells.", [["PK-15 cells", "ANATOMY", 254, 265], ["miR-27b", "CHEMICAL", 47, 54], ["miR-27b", "CHEMICAL", 196, 203], ["TGEV infection", "DISEASE", 236, 250], ["miR-27b", "GENE_OR_GENE_PRODUCT", 47, 54], ["miR-27b", "GENE_OR_GENE_PRODUCT", 118, 125], ["miR-27b", "GENE_OR_GENE_PRODUCT", 196, 203], ["TGEV", "ORGANISM", 236, 240], ["PK-15 cells", "CELL", 254, 265], ["miR-27b", "DNA", 47, 54], ["miR-27b", "PROTEIN", 118, 125], ["miR-27b", "PROTEIN", 196, 203], ["PK-15 cells", "CELL_LINE", 254, 265], ["TGEV", "SPECIES", 236, 240], ["apoptotic rate", "TEST", 76, 90], ["miR", "TEST", 118, 121], ["apoptotic rate", "TEST", 136, 150], ["miR", "TEST", 196, 199], ["attenuated apoptosis", "PROBLEM", 204, 224], ["TGEV infection", "PROBLEM", 236, 250], ["PK", "TEST", 254, 256], ["decrease", "OBSERVATION_MODIFIER", 64, 72], ["TGEV infection", "OBSERVATION", 236, 250]]], ["We previously found that TGEV infection could cause PK-15 cell apoptosis through mitochondria-mediated pathway and FasL-mediated apoptotic pathway ( Ding et al., 2012) .", [["PK-15 cell", "ANATOMY", 52, 62], ["mitochondria", "ANATOMY", 81, 93], ["TGEV infection", "DISEASE", 25, 39], ["TGEV", "ORGANISM", 25, 29], ["PK-15 cell", "CELL", 52, 62], ["mitochondria", "CELLULAR_COMPONENT", 81, 93], ["FasL", "GENE_OR_GENE_PRODUCT", 115, 119], ["FasL", "PROTEIN", 115, 119], ["TGEV", "SPECIES", 25, 29], ["TGEV infection", "PROBLEM", 25, 39], ["PK", "TEST", 52, 54], ["15 cell apoptosis", "PROBLEM", 55, 72], ["TGEV", "OBSERVATION_MODIFIER", 25, 29], ["infection", "OBSERVATION", 30, 39], ["15 cell apoptosis", "OBSERVATION", 55, 72]]], ["Therefore, we analyzed caspase-9 activity of mitochondria-mediated pathway and caspase-8 activity of FasL-mediated apoptotic pathway.", [["mitochondria", "ANATOMY", 45, 57], ["caspase-9", "GENE_OR_GENE_PRODUCT", 23, 32], ["mitochondria", "CELLULAR_COMPONENT", 45, 57], ["caspase-8", "GENE_OR_GENE_PRODUCT", 79, 88], ["FasL", "GENE_OR_GENE_PRODUCT", 101, 105], ["caspase-9", "PROTEIN", 23, 32], ["caspase-8", "PROTEIN", 79, 88], ["FasL", "PROTEIN", 101, 105], ["caspase", "TEST", 23, 30], ["mitochondria-mediated pathway", "TREATMENT", 45, 74], ["caspase", "TREATMENT", 79, 86], ["FasL-mediated apoptotic pathway", "TREATMENT", 101, 132]]], ["However, miR-27b did not affect the caspase-8 activity during TGEV infection (data not shown).", [["miR-27b", "CHEMICAL", 9, 16], ["TGEV infection", "DISEASE", 62, 76], ["miR-27b", "GENE_OR_GENE_PRODUCT", 9, 16], ["caspase-8", "GENE_OR_GENE_PRODUCT", 36, 45], ["TGEV", "ORGANISM", 62, 66], ["miR-27b", "DNA", 9, 16], ["caspase-8", "PROTEIN", 36, 45], ["TGEV", "SPECIES", 62, 66], ["the caspase", "TEST", 32, 43], ["TGEV infection", "PROBLEM", 62, 76]]], ["As expected, the caspase-9 activity was decreased by miR-27b mimics and up-regulated by miR-27b inhibitors in the TGEV-infected PK-15 cells (Fig. 1B) .", [["PK-15 cells", "ANATOMY", 128, 139], ["miR-27b", "CHEMICAL", 88, 95], ["caspase-9", "GENE_OR_GENE_PRODUCT", 17, 26], ["miR-27b", "GENE_OR_GENE_PRODUCT", 53, 60], ["miR-27b", "GENE_OR_GENE_PRODUCT", 88, 95], ["TGEV", "ORGANISM", 114, 118], ["PK-15 cells", "CELL", 128, 139], ["Fig. 1B", "CELL", 141, 148], ["caspase-9", "PROTEIN", 17, 26], ["TGEV-infected PK-15 cells", "CELL_LINE", 114, 139], ["TGEV", "SPECIES", 114, 118], ["the caspase", "TEST", 13, 24], ["miR-27b inhibitors", "TREATMENT", 88, 106], ["the TGEV", "TEST", 110, 118], ["infected PK", "TEST", 119, 130]]], ["Moreover, we investigated the effect of miR-27b on caspases-3 activity in TGEV-infected PK-15 cells.", [["PK-15 cells", "ANATOMY", 88, 99], ["miR-27b", "CHEMICAL", 40, 47], ["miR-27b", "GENE_OR_GENE_PRODUCT", 40, 47], ["caspases-3", "GENE_OR_GENE_PRODUCT", 51, 61], ["TGEV", "ORGANISM", 74, 78], ["PK-15 cells", "CELL", 88, 99], ["caspases-3", "PROTEIN", 51, 61], ["TGEV-infected PK-15 cells", "CELL_LINE", 74, 99], ["TGEV", "SPECIES", 74, 78], ["miR", "TEST", 40, 43], ["caspases", "TREATMENT", 51, 59], ["TGEV", "TEST", 74, 78]]], ["The caspase-3 activity was decreased by miR-27b mimics and increased by miR-27b inhibitors in the TGEV-infected cells compared with control (Fig. 1C) .", [["cells", "ANATOMY", 112, 117], ["miR-27b", "CHEMICAL", 40, 47], ["miR-27b", "CHEMICAL", 72, 79], ["caspase-3", "GENE_OR_GENE_PRODUCT", 4, 13], ["miR-27b", "GENE_OR_GENE_PRODUCT", 40, 47], ["miR-27b", "GENE_OR_GENE_PRODUCT", 72, 79], ["TGEV", "ORGANISM", 98, 102], ["cells", "CELL", 112, 117], ["caspase-3", "PROTEIN", 4, 13], ["TGEV-infected cells", "CELL_LINE", 98, 117], ["TGEV", "SPECIES", 98, 102], ["The caspase", "TREATMENT", 0, 11], ["miR-27b inhibitors", "TREATMENT", 72, 90], ["infected cells", "PROBLEM", 103, 117], ["infected cells", "OBSERVATION", 103, 117]]], ["Taken together, these results suggest that miR-27b plays a negative role in the TGEV-induced apoptosis in PK-15 cells via mitochondria-mediated pathway.RUNX1 is the direct target of miR-27bTo identify the targets that affect TGEV-induced apoptosis, we predicted the targets of miR-27b using TargetScan and miRanda and found that RUNX1 was a potential target of miR-27b (Song et al., 2015) .", [["PK-15 cells", "ANATOMY", 106, 117], ["mitochondria", "ANATOMY", 122, 134], ["miR-27b", "CHEMICAL", 43, 50], ["miR-27b", "GENE_OR_GENE_PRODUCT", 43, 50], ["TGEV", "ORGANISM", 80, 84], ["PK-15 cells", "CELL", 106, 117], ["mitochondria", "CELLULAR_COMPONENT", 122, 134], ["RUNX1", "GENE_OR_GENE_PRODUCT", 152, 157], ["miR-27b", "GENE_OR_GENE_PRODUCT", 182, 189], ["TGEV", "ORGANISM", 225, 229], ["miR-27b", "GENE_OR_GENE_PRODUCT", 277, 284], ["RUNX1", "GENE_OR_GENE_PRODUCT", 329, 334], ["miR-27b", "GENE_OR_GENE_PRODUCT", 361, 368], ["miR-27b", "PROTEIN", 43, 50], ["PK-15 cells", "CELL_LINE", 106, 117], ["RUNX1", "PROTEIN", 152, 157], ["miR-27b", "DNA", 182, 189], ["miR-27b", "DNA", 277, 284], ["RUNX1", "PROTEIN", 329, 334], ["miR-27b", "DNA", 361, 368], ["TGEV", "SPECIES", 80, 84], ["TGEV", "SPECIES", 225, 229], ["the TGEV", "PROBLEM", 76, 84], ["PK", "TEST", 106, 108], ["TGEV", "PROBLEM", 225, 229], ["apoptosis", "PROBLEM", 238, 247], ["TargetScan", "TEST", 291, 301]]], ["Moreover, RUNX1 was reported to regulate apoptosis (Wu et al., 2012) .", [["RUNX1", "GENE_OR_GENE_PRODUCT", 10, 15], ["RUNX1", "PROTEIN", 10, 15], ["RUNX1", "OBSERVATION", 10, 15], ["apoptosis", "OBSERVATION_MODIFIER", 41, 50]]], ["Thus, we investigated the direct interaction between miR-27b and 3 UTR of RUNX1 mRNA through dual-luciferase assay.", [["miR-27b", "GENE_OR_GENE_PRODUCT", 53, 60], ["3", "GENE_OR_GENE_PRODUCT", 65, 66], ["RUNX1", "GENE_OR_GENE_PRODUCT", 74, 79], ["luciferase", "GENE_OR_GENE_PRODUCT", 98, 108], ["miR-27b and 3 UTR", "DNA", 53, 70], ["RUNX1 mRNA", "RNA", 74, 84], ["luciferase", "PROTEIN", 98, 108], ["miR", "TEST", 53, 56], ["RUNX1 mRNA", "TEST", 74, 84], ["dual-luciferase assay", "TEST", 93, 114]]], ["The sequence of the 3 UTR of RUNX1 was obtained by PCR and the two binding sites of miR-27b seed region in the 3 UTR of RUNX1 were mutated with a 3-bp substitution.", [["RUNX1", "GENE_OR_GENE_PRODUCT", 29, 34], ["miR-27b", "GENE_OR_GENE_PRODUCT", 84, 91], ["RUNX1", "GENE_OR_GENE_PRODUCT", 120, 125], ["3 UTR", "DNA", 20, 25], ["RUNX1", "DNA", 29, 34], ["binding sites", "DNA", 67, 80], ["miR-27b seed region", "DNA", 84, 103], ["3 UTR", "DNA", 111, 116], ["RUNX1", "DNA", 120, 125], ["3-bp substitution", "DNA", 146, 163], ["PCR", "TEST", 51, 54], ["miR-27b seed region", "TREATMENT", 84, 103], ["a 3-bp substitution", "TREATMENT", 144, 163]]], ["The 3 UTR of RUNX1 and its mutational version were respectively sub-cloned into the 3 UTR of the Renilla luciferase dual-luciferase plasmid psiCHECK-2 ( Figs.", [["RUNX1", "GENE_OR_GENE_PRODUCT", 13, 18], ["luciferase", "GENE_OR_GENE_PRODUCT", 105, 115], ["luciferase", "GENE_OR_GENE_PRODUCT", 121, 131], ["psiCHECK-2", "GENE_OR_GENE_PRODUCT", 140, 150], ["3 UTR", "DNA", 4, 9], ["RUNX1", "DNA", 13, 18], ["3 UTR", "DNA", 84, 89], ["Renilla luciferase dual-luciferase plasmid psiCHECK-2", "DNA", 97, 150], ["The 3 UTR of RUNX1", "TREATMENT", 0, 18], ["the Renilla luciferase", "TEST", 93, 115], ["luciferase plasmid psiCHECK", "TEST", 121, 148], ["Renilla luciferase", "ANATOMY", 97, 115]]], ["The constructs were co-transfected into PK-15 cells with miR-27b mimics (or negative control) or miR-27b inhibitors (or negative control).", [["PK-15 cells", "ANATOMY", 40, 51], ["miR-27b", "CHEMICAL", 57, 64], ["PK-15 cells", "CELL", 40, 51], ["miR-27b", "GENE_OR_GENE_PRODUCT", 57, 64], ["miR-27b", "GENE_OR_GENE_PRODUCT", 97, 104], ["PK-15 cells", "CELL_LINE", 40, 51], ["PK", "TEST", 40, 42], ["miR", "TEST", 57, 60], ["miR-27b inhibitors", "TREATMENT", 97, 115]]], ["Compared with the miRNA mimics control, introduction of miR-27b mimics decreased the RUNX1-WT reporter activity (Fig. 2C) .", [["miR-27b", "CHEMICAL", 56, 63], ["miR-27b", "GENE_OR_GENE_PRODUCT", 56, 63], ["RUNX1", "GENE_OR_GENE_PRODUCT", 85, 90], ["miR-27b", "DNA", 56, 63], ["RUNX1", "PROTEIN", 85, 90], ["miR", "TEST", 56, 59]]], ["To determine whether miR-27b inhibits RUNX1 expression, miR-27b mimics or miRNA mimics control were transfected into PK-15 cells.", [["PK-15 cells", "ANATOMY", 117, 128], ["miR-27b", "GENE_OR_GENE_PRODUCT", 21, 28], ["RUNX1", "GENE_OR_GENE_PRODUCT", 38, 43], ["miR-27b", "GENE_OR_GENE_PRODUCT", 56, 63], ["PK-15 cells", "CELL", 117, 128], ["miR-27b", "DNA", 21, 28], ["RUNX1", "PROTEIN", 38, 43], ["PK-15 cells", "CELL_LINE", 117, 128], ["miR", "TEST", 21, 24], ["RUNX1 expression", "PROBLEM", 38, 54], ["miR", "TEST", 56, 59], ["miRNA mimics control", "TREATMENT", 74, 94], ["PK", "TEST", 117, 119]]], ["RUNX1 expression was assessed by western blot.", [["RUNX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["RUNX1", "PROTEIN", 0, 5], ["RUNX1 expression", "PROBLEM", 0, 16]]], ["The result showed that miR-27b decreased expression of RUNX1 in PK-15 cells compared with the control (Fig. 2D ).", [["PK-15 cells", "ANATOMY", 64, 75], ["miR-27b", "GENE_OR_GENE_PRODUCT", 23, 30], ["RUNX1", "GENE_OR_GENE_PRODUCT", 55, 60], ["PK-15 cells", "CELL", 64, 75], ["miR-27b", "PROTEIN", 23, 30], ["RUNX1", "PROTEIN", 55, 60], ["PK-15 cells", "CELL_LINE", 64, 75], ["miR", "TEST", 23, 26], ["RUNX1 in PK", "PROBLEM", 55, 66]]], ["Together, our data conclusively demonstrate that RUNX1 is a direct target of miR-27b in PK-15 cells.miR-27b attenuates apoptosis though regulating mitochondrial pathwayRUNX1 shows transactivate effect on Bax expression (Wu et al., 2012) .We previously found that TGEV infection could cause PK-15 cell apoptosis through mitochondria-mediated pathway (Ding et al., 2012) .", [["PK-15 cells", "ANATOMY", 88, 99], ["mitochondrial", "ANATOMY", 147, 160], ["PK-15 cell", "ANATOMY", 290, 300], ["mitochondria", "ANATOMY", 319, 331], ["miR-27b", "CHEMICAL", 100, 107], ["TGEV infection", "DISEASE", 263, 277], ["RUNX1", "GENE_OR_GENE_PRODUCT", 49, 54], ["miR-27b", "GENE_OR_GENE_PRODUCT", 77, 84], ["PK-15 cells", "CELL", 88, 99], ["miR-27b", "GENE_OR_GENE_PRODUCT", 100, 107], ["mitochondrial", "CELLULAR_COMPONENT", 147, 160], ["pathwayRUNX1", "GENE_OR_GENE_PRODUCT", 161, 173], ["Bax", "GENE_OR_GENE_PRODUCT", 204, 207], ["TGEV", "ORGANISM", 263, 267], ["PK-15 cell", "CELL", 290, 300], ["mitochondria", "CELLULAR_COMPONENT", 319, 331], ["RUNX1", "PROTEIN", 49, 54], ["miR-27b", "DNA", 77, 84], ["PK-15 cells", "CELL_LINE", 88, 99], ["miR-27b", "PROTEIN", 100, 107], ["mitochondrial pathwayRUNX1", "PROTEIN", 147, 173], ["Bax", "PROTEIN", 204, 207], ["TGEV", "SPECIES", 263, 267], ["our data", "TEST", 10, 18], ["miR", "TEST", 77, 80], ["miR", "TEST", 100, 103], ["attenuates apoptosis", "PROBLEM", 108, 128], ["transactivate effect", "PROBLEM", 180, 200], ["TGEV infection", "PROBLEM", 263, 277], ["PK", "TEST", 290, 292], ["15 cell apoptosis", "PROBLEM", 293, 310], ["RUNX1", "OBSERVATION", 49, 54], ["TGEV", "OBSERVATION_MODIFIER", 263, 267], ["infection", "OBSERVATION", 268, 277], ["15 cell apoptosis", "OBSERVATION", 293, 310]]], ["Therefore, we proposed a hypothesis that miR-27b could restrain TGEV-induced apoptosis of PK-15 through mitochondria-mediated pathway by decreasing expression of Bax.", [["mitochondria", "ANATOMY", 104, 116], ["miR-27b", "CHEMICAL", 41, 48], ["miR-27b", "GENE_OR_GENE_PRODUCT", 41, 48], ["TGEV", "ORGANISM", 64, 68], ["PK-15", "GENE_OR_GENE_PRODUCT", 90, 95], ["mitochondria", "CELLULAR_COMPONENT", 104, 116], ["Bax", "GENE_OR_GENE_PRODUCT", 162, 165], ["Bax", "PROTEIN", 162, 165], ["TGEV", "SPECIES", 64, 68], ["TGEV", "PROBLEM", 64, 68], ["PK", "TEST", 90, 92]]], ["In order to confirm this hypothesis, we analyzed the effect of miR-27b on Bax.", [["miR-27b", "GENE_OR_GENE_PRODUCT", 63, 70], ["Bax", "GENE_OR_GENE_PRODUCT", 74, 77], ["miR-27b", "PROTEIN", 63, 70], ["Bax", "PROTEIN", 74, 77], ["Bax", "TREATMENT", 74, 77]]], ["At 24 hpt of miR-27b mimics or miR-27b inhibitors, the cells were infected with TGEV at 1 MOI.", [["cells", "ANATOMY", 55, 60], ["miR-27b", "GENE_OR_GENE_PRODUCT", 13, 20], ["miR-27b", "GENE_OR_GENE_PRODUCT", 31, 38], ["cells", "CELL", 55, 60], ["TGEV", "ORGANISM", 80, 84], ["TGEV", "SPECIES", 80, 84], ["miR-27b inhibitors", "TREATMENT", 31, 49], ["the cells", "PROBLEM", 51, 60], ["TGEV", "PROBLEM", 80, 84]]], ["The mRNA and protein levels of Bax were analyzed by real-time PCR and western blotting at 24 and 48 hpi.", [["Bax", "GENE_OR_GENE_PRODUCT", 31, 34], ["Bax", "PROTEIN", 31, 34], ["The mRNA and protein levels", "TEST", 0, 27], ["Bax", "TEST", 31, 34], ["western blotting", "TEST", 70, 86]]], ["Over-expression of miR-27b resulted in a decrease of Bax at both mRNA and protein levels, down-expression of miR-27b increased the mRNA and protein expression of Bax (Figs.", [["miR-27b", "GENE_OR_GENE_PRODUCT", 19, 26], ["Bax", "GENE_OR_GENE_PRODUCT", 53, 56], ["miR-27b", "GENE_OR_GENE_PRODUCT", 109, 116], ["Bax", "GENE_OR_GENE_PRODUCT", 162, 165], ["miR-27b", "DNA", 19, 26], ["Bax", "PROTEIN", 53, 56], ["miR-27b", "PROTEIN", 109, 116], ["Bax", "PROTEIN", 162, 165], ["a decrease of Bax", "PROBLEM", 39, 56], ["protein levels", "TEST", 74, 88], ["miR", "TEST", 109, 112]]], ["Taken together, these results indicate that miR-27b attenuates TGEV-induced apoptosis by suppressing Bax.RUNX1 enhances TGEV-induced apoptosisTo investigate the effect of RUNX1 on apoptosis, we silenced and over-expressed RUNX1 respectively using siRUNX1 and pCI-neo-RUNX1.", [["miR-27b", "CHEMICAL", 44, 51], ["miR-27b", "GENE_OR_GENE_PRODUCT", 44, 51], ["TGEV", "ORGANISM", 63, 67], ["Bax", "GENE_OR_GENE_PRODUCT", 101, 104], ["RUNX1", "GENE_OR_GENE_PRODUCT", 105, 110], ["TGEV", "ORGANISM", 120, 124], ["RUNX1", "GENE_OR_GENE_PRODUCT", 171, 176], ["RUNX1", "GENE_OR_GENE_PRODUCT", 222, 227], ["siRUNX1", "GENE_OR_GENE_PRODUCT", 247, 254], ["pCI", "GENE_OR_GENE_PRODUCT", 259, 262], ["RUNX1", "GENE_OR_GENE_PRODUCT", 267, 272], ["Bax", "PROTEIN", 101, 104], ["RUNX1", "PROTEIN", 105, 110], ["RUNX1", "PROTEIN", 171, 176], ["RUNX1", "PROTEIN", 222, 227], ["siRUNX1", "PROTEIN", 247, 254], ["pCI", "PROTEIN", 259, 262], ["RUNX1", "PROTEIN", 267, 272], ["TGEV", "SPECIES", 63, 67], ["TGEV", "SPECIES", 120, 124], ["miR", "TEST", 44, 47], ["TGEV", "PROBLEM", 63, 67], ["TGEV", "PROBLEM", 120, 124], ["RUNX1 on apoptosis", "PROBLEM", 171, 189], ["siRUNX1", "TREATMENT", 247, 254], ["pCI", "TREATMENT", 259, 262], ["neo-RUNX1", "TREATMENT", 263, 272], ["TGEV", "OBSERVATION", 120, 124], ["neo-RUNX1", "OBSERVATION", 263, 272]]], ["The RUNX1 mRNA and protein levels were remarkably reduced by siRUNX1-2 (Figs.", [["RUNX1", "GENE_OR_GENE_PRODUCT", 4, 9], ["siRUNX1-2", "GENE_OR_GENE_PRODUCT", 61, 70], ["RUNX1 mRNA", "RNA", 4, 14], ["siRUNX1", "PROTEIN", 61, 68], ["The RUNX1 mRNA", "TEST", 0, 14], ["protein levels", "TEST", 19, 33], ["siRUNX1", "TEST", 61, 68], ["RUNX1 mRNA", "OBSERVATION", 4, 14]]], ["4A and 4B); however, the cell viability was For each schematic, the upper sequence is the binding site of miR-27b in 3 UTRs of swine RUNX1, the middle sequence is the mature miR-27b, and the lower sequence is the mutated sequence of 3 UTR.", [["cell", "ANATOMY", 25, 29], ["cell", "CELL", 25, 29], ["miR-27b", "GENE_OR_GENE_PRODUCT", 106, 113], ["swine", "ORGANISM", 127, 132], ["RUNX1", "GENE_OR_GENE_PRODUCT", 133, 138], ["miR-27b", "GENE_OR_GENE_PRODUCT", 174, 181], ["upper sequence", "DNA", 68, 82], ["binding site", "DNA", 90, 102], ["miR-27b", "DNA", 106, 113], ["UTRs", "DNA", 119, 123], ["swine RUNX1", "DNA", 127, 138], ["mature miR-27b", "DNA", 167, 181], ["mutated sequence of 3 UTR", "DNA", 213, 238], ["swine", "SPECIES", 127, 132], ["the cell viability", "TEST", 21, 39], ["cell viability", "OBSERVATION", 25, 39], ["upper", "ANATOMY_MODIFIER", 68, 73], ["middle", "ANATOMY_MODIFIER", 144, 150]]], ["The seed sequence is underlined.", [["seed sequence", "DNA", 4, 17], ["The seed sequence", "TEST", 0, 17]]], ["(B) Schematic drawing of the putative binding sites or mutations of miR-27b binding-sites in 3 UTR of RUNX1 mRNA.", [["miR-27b", "GENE_OR_GENE_PRODUCT", 68, 75], ["RUNX1", "GENE_OR_GENE_PRODUCT", 102, 107], ["putative binding sites", "DNA", 29, 51], ["miR-27b binding-sites", "DNA", 68, 89], ["RUNX1 mRNA", "RNA", 102, 112], ["the putative binding sites", "PROBLEM", 25, 51], ["mutations of miR-27b binding", "PROBLEM", 55, 83], ["RUNX1 mRNA", "PROBLEM", 102, 112], ["RUNX1 mRNA", "OBSERVATION", 102, 112]]], ["The locations of the potential binding sites or their mutations are presented by blank boxes.", [["potential binding sites", "DNA", 21, 44], ["blank boxes", "DNA", 81, 92], ["the potential binding sites", "PROBLEM", 17, 44], ["their mutations", "PROBLEM", 48, 63]]], ["(C) The RUNX1 luciferase reporter construct was co-transfected with miR-27b mimics (or negative control) or miR-27b inhibitors (or negative control) into PK-15 cells (normalized to the firefly luciferase activity).", [["PK-15 cells", "ANATOMY", 154, 165], ["RUNX1", "GENE_OR_GENE_PRODUCT", 8, 13], ["luciferase", "GENE_OR_GENE_PRODUCT", 14, 24], ["miR-27b", "GENE_OR_GENE_PRODUCT", 68, 75], ["miR-27b", "GENE_OR_GENE_PRODUCT", 108, 115], ["PK-15 cells", "CELL", 154, 165], ["luciferase", "GENE_OR_GENE_PRODUCT", 193, 203], ["RUNX1 luciferase reporter construct", "DNA", 8, 43], ["miR-27b mimics", "DNA", 68, 82], ["PK-15 cells", "CELL_LINE", 154, 165], ["luciferase", "PROTEIN", 193, 203], ["The RUNX1 luciferase reporter construct", "PROBLEM", 4, 43], ["miR", "TEST", 68, 71], ["miR-27b inhibitors", "TREATMENT", 108, 126], ["PK", "TEST", 154, 156]]], ["Data are expressed as relative luciferase activities to control.", [["luciferase", "GENE_OR_GENE_PRODUCT", 31, 41], ["luciferase", "PROTEIN", 31, 41]]], ["(D) Western blot analysis of RUNX1 in cells transfected with miR-27b mimics or mimics control.", [["cells", "ANATOMY", 38, 43], ["RUNX1", "GENE_OR_GENE_PRODUCT", 29, 34], ["cells", "CELL", 38, 43], ["miR-27b", "GENE_OR_GENE_PRODUCT", 61, 68], ["RUNX1", "PROTEIN", 29, 34], ["miR-27b", "DNA", 61, 68], ["blot analysis", "TEST", 12, 25], ["RUNX1 in cells", "PROBLEM", 29, 43], ["miR", "TEST", 61, 64]]], ["Data represent means \u00b1 S.D. of three independent experiments. * P < 0.05 in comparison with the control. * * P < 0.01 in comparison with the control. not affected in comparison with irrelevant siRNA (Fig. 4C) , indicating that the RUNX1 gene was knocked down in PK-15 cells by the siRUNX1-2.", [["PK-15 cells", "ANATOMY", 262, 273], ["RUNX1", "GENE_OR_GENE_PRODUCT", 231, 236], ["PK-15 cells", "CELL", 262, 273], ["siRUNX1-2", "GENE_OR_GENE_PRODUCT", 281, 290], ["RUNX1 gene", "DNA", 231, 241], ["PK-15 cells", "CELL_LINE", 262, 273], ["siRUNX1-2", "DNA", 281, 290], ["the RUNX1 gene", "PROBLEM", 227, 241], ["PK", "TEST", 262, 264], ["RUNX1", "ANATOMY", 231, 236]]], ["In addition, RUNX1 was notably over-expressed using pCI-neo-RUNX1 (Fig. 4D) .", [["RUNX1", "GENE_OR_GENE_PRODUCT", 13, 18], ["pCI", "GENE_OR_GENE_PRODUCT", 52, 55], ["RUNX1", "GENE_OR_GENE_PRODUCT", 60, 65], ["RUNX1", "PROTEIN", 13, 18], ["pCI", "PROTEIN", 52, 55], ["RUNX1", "PROTEIN", 60, 65], ["pCI", "TREATMENT", 52, 55], ["neo-RUNX1", "TREATMENT", 56, 65], ["RUNX1", "OBSERVATION", 13, 18]]], ["To determine the effect of RUNX1 on Bax, the RUNX1 were silenced with siRUNX1-2 and over-expressed by pCI-neo-RUNX1 followed by infection with TGEV.", [["infection", "DISEASE", 128, 137], ["RUNX1", "GENE_OR_GENE_PRODUCT", 27, 32], ["Bax", "GENE_OR_GENE_PRODUCT", 36, 39], ["RUNX1", "GENE_OR_GENE_PRODUCT", 45, 50], ["siRUNX1-2", "GENE_OR_GENE_PRODUCT", 70, 79], ["pCI", "GENE_OR_GENE_PRODUCT", 102, 105], ["RUNX1", "GENE_OR_GENE_PRODUCT", 110, 115], ["TGEV", "ORGANISM", 143, 147], ["RUNX1", "PROTEIN", 27, 32], ["Bax", "PROTEIN", 36, 39], ["RUNX1", "PROTEIN", 45, 50], ["siRUNX1", "PROTEIN", 70, 77], ["pCI", "PROTEIN", 102, 105], ["RUNX1", "PROTEIN", 110, 115], ["TGEV", "SPECIES", 143, 147], ["RUNX1 on Bax", "TREATMENT", 27, 39], ["pCI", "TREATMENT", 102, 105], ["neo-RUNX1", "TREATMENT", 106, 115], ["infection", "PROBLEM", 128, 137], ["TGEV", "PROBLEM", 143, 147], ["RUNX1", "ANATOMY", 45, 50], ["neo-RUNX1", "OBSERVATION", 106, 115], ["infection", "OBSERVATION", 128, 137]]], ["The Bax expression was decreased by knockdown of RUNX1 and up-regulated by over-expression of RUNX1 (Fig. 4E) .", [["Bax", "GENE_OR_GENE_PRODUCT", 4, 7], ["RUNX1", "GENE_OR_GENE_PRODUCT", 49, 54], ["RUNX1", "GENE_OR_GENE_PRODUCT", 94, 99], ["Fig. 4E", "GENE_OR_GENE_PRODUCT", 101, 108], ["Bax", "PROTEIN", 4, 7], ["RUNX1", "PROTEIN", 49, 54], ["RUNX1", "PROTEIN", 94, 99], ["Fig. 4E", "PROTEIN", 101, 108], ["The Bax expression", "TREATMENT", 0, 18], ["RUNX1", "TEST", 49, 54], ["Bax expression", "OBSERVATION", 4, 18], ["decreased", "OBSERVATION_MODIFIER", 23, 32]]], ["The activities of caspase-9 and -3 were respectively reduced and increased by silence and over-expression of RUNX1 (Figs.", [["caspase-9", "GENE_OR_GENE_PRODUCT", 18, 27], ["-3", "GENE_OR_GENE_PRODUCT", 32, 34], ["RUNX1", "GENE_OR_GENE_PRODUCT", 109, 114], ["caspase-9 and -3", "PROTEIN", 18, 34], ["RUNX1", "PROTEIN", 109, 114], ["caspase", "TEST", 18, 25]]], ["4F and 4G) .", [["4F", "GENE_OR_GENE_PRODUCT", 0, 2]]], ["Therefore, RUNX1 promoted TGEV-induced apoptosis of PK-15 cells.", [["PK-15 cells", "ANATOMY", 52, 63], ["RUNX1", "GENE_OR_GENE_PRODUCT", 11, 16], ["TGEV", "ORGANISM", 26, 30], ["PK-15 cells", "CELL", 52, 63], ["RUNX1", "PROTEIN", 11, 16], ["PK-15 cells", "CELL_LINE", 52, 63], ["TGEV", "SPECIES", 26, 30], ["TGEV", "PROBLEM", 26, 30], ["PK", "TEST", 52, 54], ["TGEV", "OBSERVATION", 26, 30]]], ["Taken together, our findings suggest that miR-27b shows a negative regulatory effect on TGEV-induced apoptosis of PK-15 cells via targeting RUNX1.DISCUSSIONAccumulating evidence has shown that miRNAs play an important role in apoptosis induced by virus infection (Fu et al., 2014; Guan et al., 2012; Smith et al., 2012) .", [["PK-15 cells", "ANATOMY", 114, 125], ["miR-27b", "CHEMICAL", 42, 49], ["infection", "DISEASE", 253, 262], ["miR-27b", "GENE_OR_GENE_PRODUCT", 42, 49], ["TGEV", "ORGANISM", 88, 92], ["PK-15 cells", "CELL", 114, 125], ["miR-27b", "PROTEIN", 42, 49], ["PK-15 cells", "CELL_LINE", 114, 125], ["TGEV", "SPECIES", 88, 92], ["miR", "TEST", 42, 45], ["TGEV", "PROBLEM", 88, 92], ["PK", "TEST", 114, 116], ["virus infection", "PROBLEM", 247, 262]]], ["We previously found that TGEV infection induced apoptosis in PK-15 cells via mitochondria-mediated apoptosis pathway (Ding et al., 2012) .", [["PK-15 cells", "ANATOMY", 61, 72], ["mitochondria", "ANATOMY", 77, 89], ["TGEV infection", "DISEASE", 25, 39], ["TGEV", "ORGANISM", 25, 29], ["PK-15 cells", "CELL", 61, 72], ["mitochondria", "CELLULAR_COMPONENT", 77, 89], ["PK-15 cells", "CELL_LINE", 61, 72], ["TGEV", "SPECIES", 25, 29], ["TGEV infection", "PROBLEM", 25, 39], ["apoptosis", "PROBLEM", 48, 57], ["PK", "TEST", 61, 63], ["TGEV", "OBSERVATION_MODIFIER", 25, 29], ["infection", "OBSERVATION", 30, 39]]], ["In addition, we reported that miR-27b was significantly downregulated during apoptosis triggered by TGEV infection in PK-15 cells (Song et al., 2015) .", [["PK-15 cells", "ANATOMY", 118, 129], ["TGEV infection", "DISEASE", 100, 114], ["miR-27b", "GENE_OR_GENE_PRODUCT", 30, 37], ["TGEV", "ORGANISM", 100, 104], ["PK-15 cells", "CELL", 118, 129], ["miR-27b", "DNA", 30, 37], ["PK-15 cells", "CELL_LINE", 118, 129], ["TGEV", "SPECIES", 100, 104], ["apoptosis", "PROBLEM", 77, 86], ["TGEV infection", "PROBLEM", 100, 114], ["PK", "TEST", 118, 120], ["infection", "OBSERVATION", 105, 114]]], ["However, the role of miR-27b in the process of apoptosis induced by TGEV infection is unclear.", [["TGEV infection", "DISEASE", 68, 82], ["miR-27b", "GENE_OR_GENE_PRODUCT", 21, 28], ["TGEV", "ORGANISM", 68, 72], ["miR-27b", "DNA", 21, 28], ["TGEV", "SPECIES", 68, 72], ["apoptosis", "PROBLEM", 47, 56], ["TGEV infection", "PROBLEM", 68, 82], ["apoptosis", "OBSERVATION", 47, 56], ["TGEV", "OBSERVATION_MODIFIER", 68, 72], ["infection", "OBSERVATION", 73, 82]]], ["Here we proved that miR-27b suppressed the TGEV-induced apoptosis via regulating mitochondrial pathway.DISCUSSIONDuring the viral infection, miRNAs may regulate the interaction between virus and host cell via targeting viral or cellular genes. miR-181c, which is down-regulated by HCV infection in hepatocytes, suppresses homeobox A1 expression (HOXA1) and its downstream molecules STAT3 and STAT5 to regulate cell growth by targeting E1 and NS5A sequences of HCV (Mukherjee et al., 2014) . miR-1236 represses HIV infection by inhibiting transcription of HIV-1 viral protein R-binding protein (VprBP) in monocytes (Ma et al., 2014) .", [["mitochondrial", "ANATOMY", 81, 94], ["cell", "ANATOMY", 200, 204], ["cellular", "ANATOMY", 228, 236], ["hepatocytes", "ANATOMY", 298, 309], ["cell", "ANATOMY", 410, 414], ["monocytes", "ANATOMY", 604, 613], ["miR-27b", "CHEMICAL", 20, 27], ["viral infection", "DISEASE", 124, 139], ["HCV infection", "DISEASE", 281, 294], ["miR-1236", "CHEMICAL", 491, 499], ["HIV infection", "DISEASE", 510, 523], ["miR-27b", "GENE_OR_GENE_PRODUCT", 20, 27], ["TGEV", "ORGANISM", 43, 47], ["mitochondrial", "CELLULAR_COMPONENT", 81, 94], ["host cell", "CELL", 195, 204], ["cellular", "CELL", 228, 236], ["miR-181c", "GENE_OR_GENE_PRODUCT", 244, 252], ["HCV", "ORGANISM", 281, 284], ["hepatocytes", "CELL", 298, 309], ["homeobox A1", "GENE_OR_GENE_PRODUCT", 322, 333], ["HOXA1", "GENE_OR_GENE_PRODUCT", 346, 351], ["STAT3", "GENE_OR_GENE_PRODUCT", 382, 387], ["STAT5", "GENE_OR_GENE_PRODUCT", 392, 397], ["cell", "CELL", 410, 414], ["E1", "GENE_OR_GENE_PRODUCT", 435, 437], ["NS5A", "GENE_OR_GENE_PRODUCT", 442, 446], ["HCV", "ORGANISM", 460, 463], ["miR-1236", "GENE_OR_GENE_PRODUCT", 491, 499], ["HIV", "ORGANISM", 510, 513], ["HIV-1 viral protein R-binding protein", "GENE_OR_GENE_PRODUCT", 555, 592], ["VprBP", "GENE_OR_GENE_PRODUCT", 594, 599], ["monocytes", "CELL", 604, 613], ["miR-27b", "PROTEIN", 20, 27], ["viral or cellular genes", "DNA", 219, 242], ["miR-181c", "DNA", 244, 252], ["hepatocytes", "CELL_TYPE", 298, 309], ["homeobox A1", "PROTEIN", 322, 333], ["HOXA1", "PROTEIN", 346, 351], ["STAT3", "PROTEIN", 382, 387], ["STAT5", "PROTEIN", 392, 397], ["E1 and NS5A sequences", "DNA", 435, 456], ["HIV-1 viral protein R-binding protein", "PROTEIN", 555, 592], ["VprBP", "PROTEIN", 594, 599], ["monocytes", "CELL_TYPE", 604, 613], ["HIV-1", "SPECIES", 555, 560], ["TGEV", "SPECIES", 43, 47], ["HCV", "SPECIES", 281, 284], ["HCV", "SPECIES", 460, 463], ["HIV", "SPECIES", 510, 513], ["HIV-1", "SPECIES", 555, 560], ["the TGEV", "PROBLEM", 39, 47], ["regulating mitochondrial pathway", "TREATMENT", 70, 102], ["the viral infection", "PROBLEM", 120, 139], ["the interaction between virus", "PROBLEM", 161, 190], ["host cell", "PROBLEM", 195, 204], ["targeting viral or cellular genes", "PROBLEM", 209, 242], ["miR", "TEST", 244, 247], ["HCV infection in hepatocytes", "PROBLEM", 281, 309], ["homeobox A1 expression (HOXA1)", "PROBLEM", 322, 352], ["its downstream molecules STAT3", "PROBLEM", 357, 387], ["HCV", "PROBLEM", 460, 463], ["HIV infection", "PROBLEM", 510, 523], ["HIV", "TEST", 555, 558], ["viral protein", "TEST", 561, 574], ["binding protein", "TEST", 577, 592], ["VprBP", "TEST", 594, 599], ["monocytes", "TEST", 604, 613], ["viral", "OBSERVATION_MODIFIER", 124, 129], ["infection", "OBSERVATION", 130, 139], ["host cell", "OBSERVATION", 195, 204], ["viral", "OBSERVATION", 219, 224], ["cellular genes", "OBSERVATION", 228, 242], ["HCV", "OBSERVATION_MODIFIER", 281, 284], ["infection", "OBSERVATION", 285, 294], ["hepatocytes", "ANATOMY", 298, 309], ["cell", "OBSERVATION", 410, 414], ["monocytes", "ANATOMY", 604, 613]]], ["We assessed the effects of miR-27b on the replication and transcription of TGEV genes and found that the replication and transcription of TGEV structural and non-structural genes were not affected by miR-27b (Data not shown).", [["miR-27b", "CHEMICAL", 27, 34], ["miR-27b", "GENE_OR_GENE_PRODUCT", 27, 34], ["TGEV", "ORGANISM", 75, 79], ["TGEV", "ORGANISM", 138, 142], ["miR-27b", "GENE_OR_GENE_PRODUCT", 200, 207], ["miR-27b", "DNA", 27, 34], ["TGEV genes", "DNA", 75, 85], ["TGEV structural and non-structural genes", "DNA", 138, 178], ["miR-27b", "DNA", 200, 207], ["TGEV", "SPECIES", 75, 79], ["TGEV", "SPECIES", 138, 142], ["the replication", "TREATMENT", 38, 53], ["TGEV genes", "TREATMENT", 75, 85], ["the replication", "TREATMENT", 101, 116], ["TGEV structural and non-structural genes", "PROBLEM", 138, 178]]], ["We tested the effects of miR-27b on apoptotic rate of TGEV-infected PK-15 cells.", [["PK-15 cells", "ANATOMY", 68, 79], ["miR-27b", "CHEMICAL", 25, 32], ["miR-27b", "GENE_OR_GENE_PRODUCT", 25, 32], ["TGEV", "ORGANISM", 54, 58], ["PK-15 cells", "CELL", 68, 79], ["miR-27b", "DNA", 25, 32], ["TGEV-infected PK-15 cells", "CELL_LINE", 54, 79], ["TGEV", "SPECIES", 54, 58], ["miR", "TEST", 25, 28], ["apoptotic rate", "TEST", 36, 50], ["TGEV", "TEST", 54, 58]]], ["The results showed that miR-27b decreased TGEV-induced apoptosis.", [["miR-27b", "CHEMICAL", 24, 31], ["miR-27b", "GENE_OR_GENE_PRODUCT", 24, 31], ["TGEV", "ORGANISM", 42, 46], ["miR-27b", "PROTEIN", 24, 31], ["TGEV", "SPECIES", 42, 46], ["miR", "TEST", 24, 27], ["TGEV", "PROBLEM", 42, 46], ["apoptosis", "PROBLEM", 55, 64], ["apoptosis", "OBSERVATION_MODIFIER", 55, 64]]], ["We previously reported that miR-27b was decreased by TGEV infection (Song et al., 2015) , so we propose that miR-27b may present an antagonistic effect with TGEV infection on apoptosis via regulating mitochondrial pathway.", [["mitochondrial", "ANATOMY", 200, 213], ["TGEV infection", "DISEASE", 53, 67], ["miR-27b", "CHEMICAL", 109, 116], ["infection", "DISEASE", 162, 171], ["miR-27b", "GENE_OR_GENE_PRODUCT", 28, 35], ["TGEV", "ORGANISM", 53, 57], ["miR-27b", "GENE_OR_GENE_PRODUCT", 109, 116], ["TGEV", "ORGANISM", 157, 161], ["mitochondrial", "CELLULAR_COMPONENT", 200, 213], ["miR-27b", "DNA", 28, 35], ["TGEV", "SPECIES", 53, 57], ["TGEV", "SPECIES", 157, 161], ["TGEV infection", "PROBLEM", 53, 67], ["TGEV infection", "PROBLEM", 157, 171], ["apoptosis via regulating mitochondrial pathway", "TREATMENT", 175, 221], ["infection", "OBSERVATION", 58, 67], ["infection", "OBSERVATION", 162, 171]]], ["An analogous situation has been reported that miR-27b alleviate hypoxia-induced neuronal apoptosis (Chen et al., 2014) .", [["neuronal", "ANATOMY", 80, 88], ["miR-27b", "CHEMICAL", 46, 53], ["hypoxia", "DISEASE", 64, 71], ["miR-27b", "GENE_OR_GENE_PRODUCT", 46, 53], ["neuronal", "CELL", 80, 88], ["miR-27b", "DNA", 46, 53], ["hypoxia", "PROBLEM", 64, 71], ["neuronal apoptosis", "PROBLEM", 80, 98], ["neuronal apoptosis", "OBSERVATION", 80, 98]]], ["It indicates that miR-27b not only down-regulates cancer cell apoptosis, it also suppresses virus-induced apoptosis.DISCUSSIONApoptosis is primarily modulated by two pathways, extrinsic pathway and intrinsic pathway (mitochondrion-mediated), which regulate cell death involving the continuous activation of caspases (Lavrik, 2010) .", [["cancer cell", "ANATOMY", 50, 61], ["mitochondrion", "ANATOMY", 217, 230], ["cell", "ANATOMY", 257, 261], ["miR-27b", "CHEMICAL", 18, 25], ["cancer", "DISEASE", 50, 56], ["apoptosis.DISCUSSIONApoptosis", "DISEASE", 106, 135], ["miR-27b", "GENE_OR_GENE_PRODUCT", 18, 25], ["cancer cell", "CELL", 50, 61], ["mitochondrion", "CELLULAR_COMPONENT", 217, 230], ["cell", "CELL", 257, 261], ["caspases", "GENE_OR_GENE_PRODUCT", 307, 315], ["miR-27b", "DNA", 18, 25], ["caspases", "PROTEIN", 307, 315], ["miR", "TEST", 18, 21], ["cancer cell apoptosis", "PROBLEM", 50, 71], ["cancer cell apoptosis", "OBSERVATION", 50, 71], ["cell death", "OBSERVATION", 257, 267]]], ["Caspase-8 and caspase-9 are factors of extrinsic pathway and mitochondrial pathway respectively (Sakamaki et al., 2015; Thornberry & Lazebnik, 1998) .", [["mitochondrial", "ANATOMY", 61, 74], ["Caspase-8", "GENE_OR_GENE_PRODUCT", 0, 9], ["caspase-9", "GENE_OR_GENE_PRODUCT", 14, 23], ["mitochondrial", "CELLULAR_COMPONENT", 61, 74], ["Caspase-8", "PROTEIN", 0, 9], ["caspase-9", "PROTEIN", 14, 23], ["Caspase", "TREATMENT", 0, 7], ["caspase", "TREATMENT", 14, 21]]], ["Bax, a member of the BCL-2 family, functions as an apoptotic activator to activate caspase-9 and -3 (Chipuk et al., 2010; Ding et al., 2012) .", [["Bax", "GENE_OR_GENE_PRODUCT", 0, 3], ["BCL-2", "GENE_OR_GENE_PRODUCT", 21, 26], ["caspase-9", "GENE_OR_GENE_PRODUCT", 83, 92], ["-3", "GENE_OR_GENE_PRODUCT", 97, 99], ["Bax", "PROTEIN", 0, 3], ["BCL-2 family", "PROTEIN", 21, 33], ["caspase-9 and -3", "PROTEIN", 83, 99], ["caspase", "TEST", 83, 90]]], ["In this study, we showed that miR-27b inhibited Bax expression and reduced the activities of caspase-9 and -3 during TGEV-induced apoptosis.", [["miR-27b", "GENE_OR_GENE_PRODUCT", 30, 37], ["Bax", "GENE_OR_GENE_PRODUCT", 48, 51], ["caspase-9", "GENE_OR_GENE_PRODUCT", 93, 102], ["-3", "GENE_OR_GENE_PRODUCT", 107, 109], ["TGEV", "ORGANISM", 117, 121], ["Bax", "PROTEIN", 48, 51], ["caspase-9 and -3", "PROTEIN", 93, 109], ["TGEV", "SPECIES", 117, 121], ["this study", "TEST", 3, 13], ["miR", "TEST", 30, 33], ["Bax expression", "PROBLEM", 48, 62], ["caspase", "TEST", 93, 100], ["TGEV", "PROBLEM", 117, 121], ["apoptosis", "PROBLEM", 130, 139], ["reduced", "OBSERVATION_MODIFIER", 67, 74], ["apoptosis", "OBSERVATION", 130, 139]]], ["We demonstrated that miR-27b regulated apoptosis via down-regulation the expression of Bax and activation of caspase-9 and caspase-3, implying that miR-27b are involved in regulating TGEV-induced apoptosis via regulating mitochondrial pathway.DISCUSSIONThe miRNAs suppress gene expression by imperfectly binding to the 3 UTR of target mRNA in mammalian cells.", [["mitochondrial", "ANATOMY", 221, 234], ["mammalian cells", "ANATOMY", 343, 358], ["miR-27b", "GENE_OR_GENE_PRODUCT", 21, 28], ["Bax", "GENE_OR_GENE_PRODUCT", 87, 90], ["caspase-9", "GENE_OR_GENE_PRODUCT", 109, 118], ["caspase-3", "GENE_OR_GENE_PRODUCT", 123, 132], ["miR-27b", "GENE_OR_GENE_PRODUCT", 148, 155], ["TGEV", "ORGANISM", 183, 187], ["mitochondrial", "CELLULAR_COMPONENT", 221, 234], ["mammalian cells", "CELL", 343, 358], ["miR-27b", "PROTEIN", 21, 28], ["Bax", "PROTEIN", 87, 90], ["caspase-9", "PROTEIN", 109, 118], ["caspase-3", "PROTEIN", 123, 132], ["miR-27b", "PROTEIN", 148, 155], ["3 UTR", "DNA", 319, 324], ["target mRNA", "RNA", 328, 339], ["mammalian cells", "CELL_TYPE", 343, 358], ["TGEV", "SPECIES", 183, 187], ["miR", "TEST", 21, 24], ["Bax", "TREATMENT", 87, 90], ["caspase", "TEST", 109, 116], ["caspase", "TREATMENT", 123, 130], ["regulating mitochondrial pathway", "TREATMENT", 210, 242], ["TGEV", "OBSERVATION", 183, 187], ["mammalian cells", "OBSERVATION", 343, 358]]], ["The imprecise binding make each miRNA has the ability to target multiple mRNAs.", [["multiple mRNAs", "RNA", 64, 78], ["The imprecise binding", "PROBLEM", 0, 21]]], ["For example, miR-27b could suppress adipogenesis in hMADS cells by targeting peroxisome proliferator-activated receptor gamma (PPAR\u03b3 ) (Karbiener et al., 2009 ) and promote differentiation of myeloblasts through targeting RUNX1 (Feng et al., 2009 ).", [["hMADS cells", "ANATOMY", 52, 63], ["myeloblasts", "ANATOMY", 192, 203], ["miR-27b", "CHEMICAL", 13, 20], ["miR-27b", "GENE_OR_GENE_PRODUCT", 13, 20], ["hMADS cells", "CELL", 52, 63], ["peroxisome proliferator-activated receptor gamma", "GENE_OR_GENE_PRODUCT", 77, 125], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 127, 132], ["myeloblasts", "CELL", 192, 203], ["RUNX1", "GENE_OR_GENE_PRODUCT", 222, 227], ["miR-27b", "DNA", 13, 20], ["hMADS cells", "CELL_LINE", 52, 63], ["peroxisome proliferator-activated receptor gamma", "PROTEIN", 77, 125], ["PPAR\u03b3", "PROTEIN", 127, 132], ["myeloblasts", "CELL_TYPE", 192, 203], ["RUNX1", "PROTEIN", 222, 227], ["miR", "TEST", 13, 16], ["adipogenesis in hMADS cells", "PROBLEM", 36, 63], ["peroxisome proliferator", "TEST", 77, 100], ["activated receptor gamma (PPAR\u03b3", "TREATMENT", 101, 132], ["peroxisome proliferator", "OBSERVATION", 77, 100]]], ["In the present study, we confirmed that RUNX1 is the target of miR-27b during TGEV infection, while whether miR-27b regulates apoptosis via RUNX1 is unclear.", [["infection", "DISEASE", 83, 92], ["RUNX1", "GENE_OR_GENE_PRODUCT", 40, 45], ["miR-27b", "GENE_OR_GENE_PRODUCT", 63, 70], ["TGEV", "ORGANISM", 78, 82], ["miR-27b", "GENE_OR_GENE_PRODUCT", 108, 115], ["RUNX1", "GENE_OR_GENE_PRODUCT", 140, 145], ["RUNX1", "PROTEIN", 40, 45], ["miR-27b", "DNA", 63, 70], ["miR-27b", "PROTEIN", 108, 115], ["RUNX1", "PROTEIN", 140, 145], ["TGEV", "SPECIES", 78, 82], ["the present study", "TEST", 3, 20], ["TGEV infection", "PROBLEM", 78, 92], ["miR", "TEST", 108, 111], ["apoptosis via RUNX1", "PROBLEM", 126, 145], ["RUNX1", "OBSERVATION", 40, 45], ["infection", "OBSERVATION", 83, 92]]], ["RUNX1 is a transcription factor, and play important roles in regulating the growth, development, and/or differentiation of multiple lineages of haematopoietic cells (Feng et al., 2009) .", [["haematopoietic cells", "ANATOMY", 144, 164], ["RUNX1", "GENE_OR_GENE_PRODUCT", 0, 5], ["haematopoietic cells", "CELL", 144, 164], ["RUNX1", "PROTEIN", 0, 5], ["transcription factor", "PROTEIN", 11, 31], ["haematopoietic cells", "CELL_TYPE", 144, 164], ["haematopoietic cells", "PROBLEM", 144, 164], ["haematopoietic cells", "OBSERVATION", 144, 164]]], ["We found over-expression of RUNX1 reduced Bax and decreased the activities of caspase-9 and -3, and silencing RUNX1 up-regulated Bax and increased the activities of caspase-9 and -3.", [["RUNX1", "GENE_OR_GENE_PRODUCT", 28, 33], ["Bax", "GENE_OR_GENE_PRODUCT", 42, 45], ["caspase-9", "GENE_OR_GENE_PRODUCT", 78, 87], ["-3", "GENE_OR_GENE_PRODUCT", 92, 94], ["RUNX1", "GENE_OR_GENE_PRODUCT", 110, 115], ["Bax", "GENE_OR_GENE_PRODUCT", 129, 132], ["caspase-9", "GENE_OR_GENE_PRODUCT", 165, 174], ["-3", "GENE_OR_GENE_PRODUCT", 179, 181], ["RUNX1", "PROTEIN", 28, 33], ["Bax", "PROTEIN", 42, 45], ["caspase-9 and -3", "PROTEIN", 78, 94], ["RUNX1", "PROTEIN", 110, 115], ["Bax", "PROTEIN", 129, 132], ["caspase-9 and -3", "PROTEIN", 165, 181], ["RUNX1 reduced Bax", "PROBLEM", 28, 45], ["caspase", "TEST", 78, 85], ["caspase", "TEST", 165, 172], ["RUNX1", "OBSERVATION", 28, 33], ["reduced Bax", "OBSERVATION", 34, 45], ["decreased", "OBSERVATION_MODIFIER", 50, 59], ["increased", "OBSERVATION_MODIFIER", 137, 146]]], ["This suggests that miR-27b regulates TGEV-induced apoptosis via targeting RUNX1, which is an important supplement of RUNX1 function.DISCUSSIONIn summary, our finding suggests miR-27b represses TGEV-induced apoptosis by directly targeting RUNX1, which may have potential for therapeutic strategies.", [["miR-27b", "CHEMICAL", 175, 182], ["miR-27b", "GENE_OR_GENE_PRODUCT", 19, 26], ["TGEV", "ORGANISM", 37, 41], ["RUNX1", "GENE_OR_GENE_PRODUCT", 74, 79], ["RUNX1", "GENE_OR_GENE_PRODUCT", 117, 122], ["miR-27b", "GENE_OR_GENE_PRODUCT", 175, 182], ["TGEV", "ORGANISM", 193, 197], ["RUNX1", "GENE_OR_GENE_PRODUCT", 238, 243], ["miR-27b", "PROTEIN", 19, 26], ["RUNX1", "PROTEIN", 74, 79], ["RUNX1", "PROTEIN", 117, 122], ["miR-27b", "DNA", 175, 182], ["RUNX1", "PROTEIN", 238, 243], ["TGEV", "SPECIES", 37, 41], ["TGEV", "SPECIES", 193, 197], ["miR", "TEST", 19, 22], ["TGEV", "PROBLEM", 37, 41], ["targeting RUNX1", "PROBLEM", 64, 79], ["TGEV", "PROBLEM", 193, 197], ["apoptosis", "PROBLEM", 206, 215], ["therapeutic strategies", "TREATMENT", 274, 296], ["RUNX1 function", "OBSERVATION", 117, 131]]]], "32272283047b962dd7b5e1f0dcd838e2511e9145": [["of small sequence insertions relative m the trypanosomes, but the lower gene density in Leishmania is mostly explained by its larger inter-CDS regions.", [["CDS regions", "DNA", 139, 150], ["small sequence insertions", "PROBLEM", 3, 28], ["the trypanosomes", "PROBLEM", 40, 56], ["the lower gene density in Leishmania", "PROBLEM", 62, 98], ["small", "OBSERVATION_MODIFIER", 3, 8], ["trypanosomes", "OBSERVATION_MODIFIER", 44, 56], ["lower gene", "OBSERVATION_MODIFIER", 66, 76], ["density", "OBSERVATION", 77, 84], ["Leishmania", "OBSERVATION", 88, 98], ["larger", "OBSERVATION_MODIFIER", 126, 132]]], ["Each species contains a number of gene families of varying size.", [["varying", "OBSERVATION_MODIFIER", 51, 58], ["size", "OBSERVATION_MODIFIER", 59, 63]]], ["Predicted functions have been ascribed to -40% of the protein-coding genes, but this has been confirmed experimentally for only -5% of the proteins.", [["protein-coding genes", "DNA", 54, 74], ["the protein", "TEST", 50, 61]]], ["Most of the remaining genes encode conserved hypothetical proteins, of which slightly more than half are found only in trypanosomatids.", [["hypothetical proteins", "PROBLEM", 45, 66], ["hypothetical proteins", "OBSERVATION", 45, 66]]], ["Interestingly, -2-3% of the Tritryp proteins are related to those found in prokaryotes but not other eukaryotes.", [["Tritryp proteins", "GENE_OR_GENE_PRODUCT", 28, 44], ["Tritryp proteins", "PROTEIN", 28, 44], ["the Tritryp proteins", "PROBLEM", 24, 44]]], ["The Tritryp genomes display a remarkable degree of synteny, with -75% of the genes in L. major having orthologues in both other species and >90% of these occurring in the same genomic context (see Table 1 ).", [["L. major", "ORGANISM", 86, 94], ["Tritryp genomes", "DNA", 4, 19], ["remarkable", "OBSERVATION_MODIFIER", 30, 40], ["degree", "OBSERVATION_MODIFIER", 41, 47]]], ["The proteins within this Tritryp \"core\" proteome exhibit an average 57% identity between T. brucei and T. cruzi, and 44% identity between L. major and the two other trypanosomes, reflecting the expected phylogenetic relationships.", [["Tritryp", "GENE_OR_GENE_PRODUCT", 25, 32], ["T. brucei", "ORGANISM", 89, 98], ["T. cruzi", "ORGANISM", 103, 111], ["L. major", "ORGANISM", 138, 146], ["T. brucei", "SPECIES", 89, 98], ["T. cruzi", "SPECIES", 103, 111], ["L. major", "SPECIES", 138, 146], ["T. brucei", "SPECIES", 89, 98], ["T. cruzi", "SPECIES", 103, 111], ["L. major", "SPECIES", 138, 146], ["The proteins", "TEST", 0, 12], ["T. brucei", "TEST", 89, 98], ["T. cruzi", "TEST", 103, 111], ["44% identity between L. major and the two other trypanosomes", "PROBLEM", 117, 177], ["phylogenetic relationships", "OBSERVATION", 203, 229]]], ["5'6 Interestingly, substantially fewer orthologues are shared only between L. major and T. brucei than between L. major and T. cruzi, perhaps reflecting the common intracellular environment of their mammalian stages.", [["intracellular", "ANATOMY", 164, 177], ["L. major", "ORGANISM", 75, 83], ["T. brucei", "ORGANISM", 88, 97], ["L. major", "ORGANISM", 111, 119], ["T. cruzi", "ORGANISM", 124, 132], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 164, 177], ["5'6", "PROTEIN", 0, 3], ["L. major", "SPECIES", 75, 83], ["T. brucei", "SPECIES", 88, 97], ["L. major", "SPECIES", 111, 119], ["T. cruzi", "SPECIES", 124, 132], ["L. major", "SPECIES", 75, 83], ["T. brucei", "SPECIES", 88, 97], ["L. major", "SPECIES", 111, 119], ["T. cruzi", "SPECIES", 124, 132], ["substantially", "OBSERVATION_MODIFIER", 19, 32], ["fewer orthologues", "OBSERVATION", 33, 50], ["T. brucei", "OBSERVATION", 88, 97], ["cruzi", "OBSERVATION", 127, 132]]], ["However, all three genomes contain a significant number of species-specific genes, which account for .-21% and 38% of the protein-coding genes in T. brucei and T. cruzi, respectively, but only -13% of the L. major genes.", [["T. brucei", "ORGANISM", 146, 155], ["T. cruzi", "ORGANISM", 160, 168], ["L. major", "ORGANISM", 205, 213], ["protein-coding genes", "DNA", 122, 142], ["L. major genes", "DNA", 205, 219], ["T. brucei", "SPECIES", 146, 155], ["T. cruzi", "SPECIES", 160, 168], ["T. brucei", "SPECIES", 146, 155], ["T. cruzi", "SPECIES", 160, 168], ["the protein", "TEST", 118, 129], ["coding genes in T. brucei", "PROBLEM", 130, 155], ["T. cruzi", "TEST", 160, 168], ["significant", "OBSERVATION_MODIFIER", 37, 48], ["number", "OBSERVATION_MODIFIER", 49, 55], ["species", "OBSERVATION", 59, 66]]], ["These species-speciflc genes (and pseudogenes) mostly encode large families of surface proteins, exemplified by the variant surface glycoproteins (VSGs) and Procyclic Acidic Repetitive Proteins (EP/PARP/procyclin) of T. brucei; the trans-sialidases, dispersed gene family protein 1 (DGF-1), mucins, and mucin-associated surface proteins (MASPs) of T. cruzi; and the amastins andpromastigote surface antigens (PSA-2) of L. major.", [["surface", "ANATOMY", 79, 86], ["speciflc", "GENE_OR_GENE_PRODUCT", 14, 22], ["variant surface glycoproteins", "GENE_OR_GENE_PRODUCT", 116, 145], ["VSGs", "GENE_OR_GENE_PRODUCT", 147, 151], ["Procyclic Acidic Repetitive Proteins", "GENE_OR_GENE_PRODUCT", 157, 193], ["PARP", "GENE_OR_GENE_PRODUCT", 198, 202], ["procyclin", "GENE_OR_GENE_PRODUCT", 203, 212], ["T. brucei", "ORGANISM", 217, 226], ["dispersed gene family protein 1", "GENE_OR_GENE_PRODUCT", 250, 281], ["DGF-1", "GENE_OR_GENE_PRODUCT", 283, 288], ["mucins", "GENE_OR_GENE_PRODUCT", 291, 297], ["mucin-associated surface proteins", "GENE_OR_GENE_PRODUCT", 303, 336], ["MASPs", "GENE_OR_GENE_PRODUCT", 338, 343], ["T. cruzi", "ORGANISM", 348, 356], ["amastins andpromastigote surface antigens", "GENE_OR_GENE_PRODUCT", 366, 407], ["PSA-2", "GENE_OR_GENE_PRODUCT", 409, 414], ["L. major", "ORGANISM", 419, 427], ["speciflc genes", "DNA", 14, 28], ["surface proteins", "PROTEIN", 79, 95], ["variant surface glycoproteins", "PROTEIN", 116, 145], ["VSGs", "PROTEIN", 147, 151], ["Procyclic Acidic Repetitive Proteins", "PROTEIN", 157, 193], ["EP", "PROTEIN", 195, 197], ["PARP", "PROTEIN", 198, 202], ["procyclin", "PROTEIN", 203, 212], ["trans-sialidases", "PROTEIN", 232, 248], ["dispersed gene family protein 1 (DGF-1", "PROTEIN", 250, 288], ["mucins", "PROTEIN", 291, 297], ["mucin-associated surface proteins", "PROTEIN", 303, 336], ["MASPs", "PROTEIN", 338, 343], ["amastins andpromastigote surface antigens", "PROTEIN", 366, 407], ["PSA", "PROTEIN", 409, 412], ["T. brucei", "SPECIES", 217, 226], ["T. cruzi", "SPECIES", 348, 356], ["L. major", "SPECIES", 419, 427], ["T. brucei", "SPECIES", 217, 226], ["T. cruzi", "SPECIES", 348, 356], ["L. major", "SPECIES", 419, 427], ["These species", "TEST", 0, 13], ["speciflc genes (and pseudogenes", "PROBLEM", 14, 45], ["surface proteins", "PROBLEM", 79, 95], ["VSGs", "TEST", 147, 151], ["Procyclic Acidic Repetitive Proteins", "TEST", 157, 193], ["EP", "TEST", 195, 197], ["/PARP/procyclin", "TREATMENT", 197, 212], ["T. brucei", "PROBLEM", 217, 226], ["the trans-sialidases", "TEST", 228, 248], ["family protein", "TEST", 265, 279], ["DGF", "TEST", 283, 286], ["mucins", "TEST", 291, 297], ["mucin-associated surface proteins", "TEST", 303, 336], ["MASPs", "TEST", 338, 343], ["T. cruzi", "PROBLEM", 348, 356], ["the amastins andpromastigote surface antigens", "TEST", 362, 407], ["PSA", "TEST", 409, 412], ["large", "OBSERVATION_MODIFIER", 61, 66]]], ["In addition to these species-speciflc genes, all three species demonstrate differential paralogous gene expansion or contraction, with the ESAG4 adenylate/guanylate cyclases and leucine-rich repeat proteins being over-represented in T. brucei; GP63 surface proteases and recombination hot spot (RHS) proteins in T. cruzi; and mitochondrial carrier protein, ATP-Binding Cassette (ABC) transporters, and Heat Shock Protein (HSP) 90 gene families in L. major.", [["mitochondrial", "ANATOMY", 326, 339], ["leucine", "CHEMICAL", 178, 185], ["ATP", "CHEMICAL", 357, 360], ["adenylate", "CHEMICAL", 145, 154], ["guanylate", "CHEMICAL", 155, 164], ["leucine", "CHEMICAL", 178, 185], ["ATP", "CHEMICAL", 357, 360], ["speciflc", "GENE_OR_GENE_PRODUCT", 29, 37], ["ESAG4 adenylate/guanylate cyclases", "GENE_OR_GENE_PRODUCT", 139, 173], ["leucine-rich repeat proteins", "GENE_OR_GENE_PRODUCT", 178, 206], ["T. brucei", "ORGANISM", 233, 242], ["GP63 surface proteases and recombination hot spot (RHS)", "GENE_OR_GENE_PRODUCT", 244, 299], ["T. cruzi", "ORGANISM", 312, 320], ["mitochondrial", "CELLULAR_COMPONENT", 326, 339], ["ATP-Binding Cassette (ABC) transporters", "GENE_OR_GENE_PRODUCT", 357, 396], ["Heat Shock Protein (HSP) 90", "GENE_OR_GENE_PRODUCT", 402, 429], ["L. major", "ORGANISM", 447, 455], ["speciflc genes", "DNA", 29, 43], ["ESAG4 adenylate/guanylate cyclases", "PROTEIN", 139, 173], ["leucine-rich repeat proteins", "PROTEIN", 178, 206], ["T. brucei; GP63 surface proteases", "PROTEIN", 233, 266], ["recombination hot spot (RHS) proteins", "PROTEIN", 271, 308], ["mitochondrial carrier protein", "PROTEIN", 326, 355], ["ATP-Binding Cassette (ABC) transporters", "PROTEIN", 357, 396], ["Heat Shock Protein (HSP) 90 gene families", "PROTEIN", 402, 443], ["T. brucei", "SPECIES", 233, 242], ["T. cruzi", "SPECIES", 312, 320], ["L. major", "SPECIES", 447, 455], ["T. brucei", "SPECIES", 233, 242], ["T. cruzi", "SPECIES", 312, 320], ["L. major", "SPECIES", 447, 455], ["these species", "TEST", 15, 28], ["speciflc genes", "PROBLEM", 29, 43], ["differential paralogous gene expansion", "PROBLEM", 75, 113], ["contraction", "PROBLEM", 117, 128], ["the ESAG4 adenylate/guanylate cyclases", "PROBLEM", 135, 173], ["leucine", "TEST", 178, 185], ["repeat proteins", "TEST", 191, 206], ["T. brucei", "PROBLEM", 233, 242], ["GP63 surface proteases", "TREATMENT", 244, 266], ["recombination hot spot (RHS) proteins in T. cruzi", "PROBLEM", 271, 320], ["mitochondrial carrier protein", "TEST", 326, 355], ["ATP", "TEST", 357, 360], ["Heat Shock Protein", "TEST", 402, 420], ["gene expansion", "OBSERVATION", 99, 113]]], ["Many of these species-speciflc genes or paralogous expansions occur in telomeric and sub-telomeric gene dusters, possibly reflecting similar strategies used for immune evasion.", [["telomeric", "ANATOMY", 71, 80], ["speciflc", "GENE_OR_GENE_PRODUCT", 22, 30], ["telomeric", "CELLULAR_COMPONENT", 71, 80], ["telomeric", "CELLULAR_COMPONENT", 89, 98], ["speciflc genes", "DNA", 22, 36], ["telomeric and sub-telomeric gene dusters", "DNA", 71, 111], ["these species", "PROBLEM", 8, 21], ["speciflc genes", "PROBLEM", 22, 36], ["paralogous expansions", "PROBLEM", 40, 61], ["telomeric and sub-telomeric gene dusters", "PROBLEM", 71, 111], ["immune evasion", "TREATMENT", 161, 175], ["species", "OBSERVATION", 14, 21], ["paralogous expansions", "OBSERVATION", 40, 61], ["possibly reflecting", "UNCERTAINTY", 113, 132], ["similar strategies", "OBSERVATION", 133, 151]]]], "e44284f191fc9522ccc675257354cb33cd9c2885": [["In children treated either in hospital or as an outpatient for community-acquired pneumonia, levofloxacin was as well-tolerated and as effective as standard-of-care antibiotics in infants and children Atkinson In children with non-severe pneumonia, there was no significant difference in outcome between the cotrimoxazole and the procaine penicillin group, and benzathine penicillin was not effective Co-trimoxazole was cost effectiveComparisons of dose and/or duration of the same antimicrobial agentHazir et al (2007)", [["pneumonia", "DISEASE", 82, 91], ["levofloxacin", "CHEMICAL", 93, 105], ["pneumonia", "DISEASE", 238, 247], ["cotrimoxazole", "CHEMICAL", 308, 321], ["procaine", "CHEMICAL", 330, 338], ["penicillin", "CHEMICAL", 339, 349], ["benzathine", "CHEMICAL", 361, 371], ["penicillin", "CHEMICAL", 372, 382], ["Co-trimoxazole", "CHEMICAL", 401, 415], ["levofloxacin", "CHEMICAL", 93, 105], ["cotrimoxazole", "CHEMICAL", 308, 321], ["procaine penicillin", "CHEMICAL", 330, 349], ["benzathine penicillin", "CHEMICAL", 361, 382], ["Co-trimoxazole", "CHEMICAL", 401, 415], ["children", "ORGANISM", 3, 11], ["levofloxacin", "SIMPLE_CHEMICAL", 93, 105], ["infants", "ORGANISM", 180, 187], ["children", "ORGANISM", 213, 221], ["cotrimoxazole", "SIMPLE_CHEMICAL", 308, 321], ["procaine penicillin", "SIMPLE_CHEMICAL", 330, 349], ["benzathine penicillin", "SIMPLE_CHEMICAL", 361, 382], ["Co-trimoxazole", "SIMPLE_CHEMICAL", 401, 415], ["children", "SPECIES", 3, 11], ["infants", "SPECIES", 180, 187], ["children", "SPECIES", 192, 200], ["children", "SPECIES", 213, 221], ["community-acquired pneumonia", "PROBLEM", 63, 91], ["levofloxacin", "TREATMENT", 93, 105], ["antibiotics", "TREATMENT", 165, 176], ["non-severe pneumonia", "PROBLEM", 227, 247], ["the cotrimoxazole", "TREATMENT", 304, 321], ["the procaine penicillin group", "TREATMENT", 326, 355], ["benzathine penicillin", "TREATMENT", 361, 382], ["Co-trimoxazole", "TREATMENT", 401, 415], ["the same antimicrobial agent", "TREATMENT", 473, 501], ["pneumonia", "OBSERVATION", 82, 91], ["non-severe", "OBSERVATION_MODIFIER", 227, 237], ["pneumonia", "OBSERVATION", 238, 247], ["no", "UNCERTAINTY", 259, 261], ["significant", "OBSERVATION_MODIFIER", 262, 273], ["difference", "OBSERVATION_MODIFIER", 274, 284]]]], "49fc8a68c880d2a64ead72c14613582e4fc10138": [["COVID-19 and dermatologic surgery: hazards of surgical plumeWe read with interest the article by Yang et al. 1 on the safety measures implemented for post COVID-19 resumption of dermatologic surgery services.", [["COVID-19", "CHEMICAL", 0, 8], ["dermatologic surgery", "TREATMENT", 13, 33], ["surgical plumeWe", "TREATMENT", 46, 62], ["dermatologic surgery services", "TREATMENT", 178, 207]]], ["Whilst we commend the authors for their work and comprehensive actions put in place, there was an omission of a critical factor highly pertinent to dermatologic surgery and potential COVID-19 transmission, namely surgical plume.", [["dermatologic surgery", "TREATMENT", 148, 168], ["surgical plume", "OBSERVATION", 213, 227]]], ["Whilst ablative lasers are not ubiquitous in dermatologic surgery departments, the use of cautery forms an integral part of the discipline.", [["ablative lasers", "TREATMENT", 7, 22], ["cautery", "TREATMENT", 90, 97], ["cautery", "OBSERVATION", 90, 97]]], ["Numerous studies have shown the hazards of surgical smoke containing toxic gases and metabolites harmful to both the operating dermatosurgeon as well as the patient, in addition to acting as a vector for infectious particles 2,3 .", [["patient", "ORGANISM", 157, 164], ["patient", "SPECIES", 157, 164], ["Numerous studies", "TEST", 0, 16], ["surgical smoke", "TREATMENT", 43, 57], ["toxic gases", "TEST", 69, 80], ["infectious particles", "PROBLEM", 204, 224], ["surgical smoke", "OBSERVATION", 43, 57], ["toxic gases", "OBSERVATION", 69, 80]]], ["COVID-19 has exposed new occupational hazards given the highly contagious nature of the virus through aerosolised procedures.", [["COVID-19", "CHEMICAL", 0, 8], ["the virus", "PROBLEM", 84, 93], ["aerosolised procedures", "TREATMENT", 102, 124], ["new", "OBSERVATION_MODIFIER", 21, 24]]], ["The use of surgical masks may offer partial protection to respiratory droplets; however fine aerosolised particles from surgical plume may continue to pose an infectious risk to patient and staff.", [["respiratory droplets", "ANATOMY", 58, 78], ["patient", "ORGANISM", 178, 185], ["patient", "SPECIES", 178, 185], ["surgical masks", "TREATMENT", 11, 25], ["partial protection to respiratory droplets", "TREATMENT", 36, 78], ["fine aerosolised particles", "TREATMENT", 88, 114], ["surgical plume", "TREATMENT", 120, 134], ["infectious", "OBSERVATION", 159, 169]]], ["The use of specialised masks able to filter particles smaller than 5 microns (the threshold size for surgical masks) such as laser-specific masks or N95 masks offer better protection to aerosolised particles 4, 5 .", [["specialised masks", "TREATMENT", 11, 28], ["surgical masks", "TREATMENT", 101, 115], ["laser-specific masks", "TREATMENT", 125, 145], ["N95 masks", "TREATMENT", 149, 158], ["size", "OBSERVATION_MODIFIER", 92, 96]]], ["It is recognised that particular diathermic instruments and parameters used can alter the composition of emitted plumes, with lower temperature This article is protected by copyright.", [["particular diathermic instruments", "TREATMENT", 22, 55], ["lower temperature", "PROBLEM", 126, 143], ["lower temperature", "OBSERVATION_MODIFIER", 126, 143]]], ["All rights reserved.COVID-19 and dermatologic surgery: hazards of surgical plumeplumes (such as those produced by ablative lasers) being more likely to harbour infectious material.", [["COVID-19", "CHEMICAL", 20, 28], ["COVID", "TEST", 20, 25], ["dermatologic surgery", "TREATMENT", 33, 53], ["surgical plumeplumes", "PROBLEM", 66, 86], ["ablative lasers", "TREATMENT", 114, 129], ["surgical plumeplumes", "OBSERVATION", 66, 86], ["more likely to", "UNCERTAINTY", 137, 151], ["infectious", "OBSERVATION", 160, 170]]], ["3 Dermatosurgeons may wish to consider using bipolar cautery, which causes lower concentrations of small aerosolised particles, 6 than monopolar cautery when operating with lower power settings.", [["bipolar", "DISEASE", 45, 52], ["bipolar cautery", "TREATMENT", 45, 60], ["lower concentrations of small aerosolised particles", "PROBLEM", 75, 126], ["monopolar cautery", "TREATMENT", 135, 152], ["lower concentrations", "OBSERVATION_MODIFIER", 75, 95], ["small", "OBSERVATION_MODIFIER", 99, 104]]], ["Additionally, measures to safely extract generated plume are required such as the use of appropriate plume extractor.", [["appropriate plume extractor", "TREATMENT", 89, 116]]], ["Air filtration in the surgical theatre should ideally constitute of air-conditioned medical high-efficiency particulate air or ultra-low particulate filter in addition to the above named measures 7, 8 .", [["Air filtration", "TREATMENT", 0, 14], ["the surgical theatre", "TREATMENT", 18, 38], ["ultra-low particulate filter", "TREATMENT", 127, 155], ["filtration", "OBSERVATION", 4, 14], ["surgical theatre", "OBSERVATION", 22, 38], ["low", "OBSERVATION_MODIFIER", 133, 136], ["particulate filter", "OBSERVATION", 137, 155]]], ["Given that many dermatologic surgical procedures involve the head and neck area, careful attention to hazards posed by surgical plume and ablative lasers and attempts to mitigate these are essential interventions in the COVID-19 era.", [["head", "ANATOMY", 61, 65], ["neck area", "ANATOMY", 70, 79], ["head", "ORGANISM_SUBDIVISION", 61, 65], ["neck", "ORGAN", 70, 74], ["many dermatologic surgical procedures", "TREATMENT", 11, 48], ["the head and neck area", "PROBLEM", 57, 79], ["surgical plume", "TREATMENT", 119, 133], ["ablative lasers", "TREATMENT", 138, 153], ["essential interventions", "TREATMENT", 189, 212], ["the COVID", "TEST", 216, 225], ["head", "ANATOMY", 61, 65], ["neck", "ANATOMY", 70, 74]]]], "PMC7380168": [["IntroductionViral diseases are a major threat to sustainable and productive agriculture worldwide, resulting in losses of several billion dollars every year (Mumford et al., 2016).", [["IntroductionViral diseases", "DISEASE", 0, 26], ["IntroductionViral diseases", "PROBLEM", 0, 26], ["productive", "OBSERVATION_MODIFIER", 65, 75]]], ["The highest impact occurs with emerging diseases, defined by a rapid increase in disease incidence, geographical range, and/or pathogenicity.", [["emerging diseases", "PROBLEM", 31, 48], ["a rapid increase in disease incidence", "PROBLEM", 61, 98], ["pathogenicity", "PROBLEM", 127, 140], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["rapid", "OBSERVATION_MODIFIER", 63, 68], ["increase", "OBSERVATION_MODIFIER", 69, 77], ["disease", "OBSERVATION", 81, 88], ["geographical", "OBSERVATION_MODIFIER", 100, 112], ["range", "OBSERVATION_MODIFIER", 113, 118]]], ["The main factors driving virus emergence are: i) the agricultural systems based on monocrops with low genetic diversity and high plant density, which are more vulnerable to pathogens and pests; ii) world trade of plant material (germplasm and live plants) that moves viruses, hosts, and vectors to new regions and environments; iii) the climate change affecting the distribution area of hosts and vectors; and iv) the ability of viruses for rapid evolution and adaptation (Anderson et al., 2004; Jones, 2009; Elena et al., 2014).IntroductionPresently, curing plants once they have been infected by a virus is not feasible, unlike bacteria or fungi that can be treated with antibacterial or antifungal agents, respectively.", [["the agricultural systems", "PROBLEM", 49, 73], ["monocrops", "TEST", 83, 92], ["low genetic diversity", "PROBLEM", 98, 119], ["high plant density", "PROBLEM", 124, 142], ["the climate change", "PROBLEM", 333, 351], ["a virus", "PROBLEM", 598, 605], ["bacteria", "PROBLEM", 630, 638], ["fungi", "PROBLEM", 642, 647], ["antibacterial", "TREATMENT", 673, 686], ["antifungal agents", "TREATMENT", 690, 707], ["main", "OBSERVATION_MODIFIER", 4, 8], ["high", "OBSERVATION_MODIFIER", 124, 128], ["plant density", "OBSERVATION", 129, 142], ["plant material", "OBSERVATION", 213, 227], ["bacteria", "OBSERVATION", 630, 638]]], ["So, disease management relies on preventing viruses from entering plants, or getting plants resistant to viral infection, using multiple strategies that must be developed specifically for each virus, host, and environment (pathosystem).", [["viral infection", "DISEASE", 105, 120], ["disease management", "TREATMENT", 4, 22], ["viruses", "PROBLEM", 44, 51], ["viral infection", "PROBLEM", 105, 120], ["multiple strategies", "TREATMENT", 128, 147], ["disease", "OBSERVATION", 4, 11], ["viral", "OBSERVATION_MODIFIER", 105, 110], ["infection", "OBSERVATION", 111, 120]]], ["Specific tools for virus diagnostics and identification are pivotal to set up and evaluate disease management.", [["virus diagnostics", "TEST", 19, 36], ["disease management", "TREATMENT", 91, 109]]], ["Here, the current state and progress of procedures used for virus detection are reviewed, discussing important features such as their sensitivity, specificity, versatility, portability, capacity for multiplexing, and virus quantification and designability.", [["procedures", "TREATMENT", 40, 50], ["virus detection", "TEST", 60, 75], ["multiplexing", "TEST", 199, 211], ["virus quantification", "TEST", 217, 237], ["designability", "PROBLEM", 242, 255]]], ["This review also includes basic concepts of genetic diversity and evolution of plant viruses and how they must be considered to improve detection.", [["genetic diversity", "PROBLEM", 44, 61], ["plant viruses", "PROBLEM", 79, 92], ["genetic diversity", "OBSERVATION", 44, 61], ["plant viruses", "OBSERVATION", 79, 92]]], ["Finally, the main strategies for disease control are described, showing both the more suitable detection methods and how genetic diversity and evolution of virus populations can affect the efficiency and durability of some control strategies.", [["disease control", "TREATMENT", 33, 48], ["virus populations", "PROBLEM", 156, 173], ["some control strategies", "TREATMENT", 218, 241], ["main", "OBSERVATION_MODIFIER", 13, 17], ["disease", "OBSERVATION", 33, 40], ["virus populations", "OBSERVATION", 156, 173]]], ["This review follows a pragmatic approach aimed to guide plant pathologists to design and apply more accurate detection procedures for a more efficient management of viral diseases.Genetic Variability and Evolution of Plant VirusesViruses have a great potential for high genetic variability due to their rapid replication and generation of large populations.", [["viral diseases", "DISEASE", 165, 179], ["accurate detection procedures", "TREATMENT", 100, 129], ["viral diseases", "PROBLEM", 165, 179], ["Genetic Variability", "PROBLEM", 180, 199], ["Plant VirusesViruses", "PROBLEM", 217, 237], ["high genetic variability", "PROBLEM", 265, 289], ["their rapid replication", "PROBLEM", 297, 320], ["large populations", "PROBLEM", 339, 356], ["viral diseases", "OBSERVATION", 165, 179], ["Variability", "OBSERVATION_MODIFIER", 188, 199], ["Plant Viruses", "OBSERVATION", 217, 230], ["large", "OBSERVATION_MODIFIER", 339, 344], ["populations", "OBSERVATION_MODIFIER", 345, 356]]], ["Viruses with RNA genomes, comprising most plant viruses, and viroids have the highest mutation rate of any group of replicons, since RNA polymerases lack a proofreading activity (Domingo et al., 1996; Drake and Holland, 1999; Gago et al., 2009).", [["RNA genomes", "DNA", 13, 24], ["RNA polymerases", "PROTEIN", 133, 148], ["Viruses", "PROBLEM", 0, 7], ["RNA genomes", "PROBLEM", 13, 24], ["most plant viruses", "PROBLEM", 37, 55], ["viroids", "TREATMENT", 61, 68], ["replicons", "TREATMENT", 116, 125], ["RNA polymerases", "PROBLEM", 133, 148], ["RNA genomes", "OBSERVATION", 13, 24], ["viruses", "OBSERVATION", 48, 55]]], ["The mutation rate is so high that replication from a single RNA molecule gives rise to a population of mutant sequences (haplotypes or variants) grouped around a master sequence, termed quasispecies (Holland et al., 1982; Moya et al., 2004).", [["mutant sequences", "DNA", 103, 119], ["master sequence", "DNA", 162, 177], ["The mutation rate", "TEST", 0, 17], ["a single RNA molecule", "PROBLEM", 51, 72], ["mutant sequences (haplotypes or variants", "PROBLEM", 103, 143]]], ["Populations of closely related viral or viroidal variants in individual plants have been reported (Ambr\u00f3s et al., 1999; Kong et al., 2000; Gand\u00eda et al., 2005).", [["closely related viral or viroidal variants", "PROBLEM", 15, 57], ["viral", "OBSERVATION", 31, 36], ["viroidal variants", "OBSERVATION", 40, 57]]], ["Viral populations in individual plants can be even more complex, since mixed infections with different virus species (Ju\u00e1rez et al., 2013) or divergent variants of the same virus species (Rubio et al., 2001; G\u00f3mez et al., 2009) are frequent as a consequence of successive inoculations by vectors (e.g., insects).", [["infections", "DISEASE", 77, 87], ["Viral populations", "PROBLEM", 0, 17], ["mixed infections", "PROBLEM", 71, 87], ["different virus species", "PROBLEM", 93, 116], ["divergent variants", "PROBLEM", 142, 160], ["the same virus species", "PROBLEM", 164, 186], ["successive inoculations", "PROBLEM", 261, 284], ["mixed", "OBSERVATION_MODIFIER", 71, 76], ["infections", "OBSERVATION", 77, 87]]], ["For example, a survey of seven tomato viruses in Sicily, Italy (Panno et al., 2012) showed that most plants (75.5%) presented multiple infections, whereas 17.8% were infected with a single virus, and only 6.7% were free of these viruses (Table 1).", [["infections", "DISEASE", 135, 145], ["tomato viruses", "ORGANISM", 31, 45], ["tomato", "SPECIES", 31, 37], ["multiple infections", "PROBLEM", 126, 145], ["a single virus", "PROBLEM", 180, 194], ["multiple", "OBSERVATION_MODIFIER", 126, 134], ["infections", "OBSERVATION", 135, 145], ["viruses", "OBSERVATION", 229, 236]]], ["Synergistic interactions between different viruses and viroids in mixed infection can lead to increased virulence (symptoms and/or viral accumulation) or even new diseases (Wang et al., 2002; Wintermantel, 2005; Murphy and Bowen, 2006; Untiveros et al., 2007; Syller, 2012; Moreno and L\u00f3pez-Moya, 2020).", [["infection", "DISEASE", 72, 81], ["Synergistic interactions", "PROBLEM", 0, 24], ["different viruses", "PROBLEM", 33, 50], ["viroids", "TREATMENT", 55, 62], ["mixed infection", "PROBLEM", 66, 81], ["increased virulence (symptoms", "PROBLEM", 94, 123], ["viral accumulation", "PROBLEM", 131, 149], ["new diseases", "PROBLEM", 159, 171], ["viruses", "OBSERVATION", 43, 50], ["mixed", "OBSERVATION_MODIFIER", 66, 71], ["infection", "OBSERVATION", 72, 81]]], ["Mixed infections of two viruses also enable recombination, which, in addition to mutation, is another source of genetic variation and emergence of new viruses.", [["infections", "DISEASE", 6, 16], ["Mixed infections of two viruses", "PROBLEM", 0, 31], ["mutation", "PROBLEM", 81, 89], ["genetic variation", "PROBLEM", 112, 129], ["new viruses", "PROBLEM", 147, 158], ["infections", "OBSERVATION", 6, 16], ["two", "OBSERVATION_MODIFIER", 20, 23], ["viruses", "OBSERVATION", 24, 31], ["new", "OBSERVATION_MODIFIER", 147, 150], ["viruses", "OBSERVATION", 151, 158]]], ["Recombinants have been described between different species of plant viruses (Padidam et al., 1999; Chare and Holmes, 2006; Codo\u00f1er and Elena, 2008; Davino et al., 2012) or divergent viral strains (Rubio et al., 2013; Lian et al., 2013; Ferriol et al., 2014).", [["divergent viral strains", "PROBLEM", 172, 195], ["plant viruses", "OBSERVATION", 62, 75]]], ["Recombination seems a frequent event coupled to virus replication (Froissart et al., 2005; Sztuba-Solinska et al., 2011), so that populations of different recombinants have been found in individual plants (Figure 1A) (Vives et al., 2005; Weng et al., 2007).", [["a frequent event", "PROBLEM", 20, 36]]], ["Recombination in RNA viruses is considered as a mechanism for rapid removal of many deleterious mutations produced during replication and regeneration of functional genomes (Moya et al., 2004).Genetic Variability and Evolution of Plant VirusesThe genetic variation produced by mutation and recombination is restricted and structured by the other three evolutionary forces: natural selection, genetic drift, and gene flow.", [["Recombination in RNA viruses", "PROBLEM", 0, 28], ["rapid removal", "TREATMENT", 62, 75], ["many deleterious mutations", "PROBLEM", 79, 105], ["Genetic Variability", "PROBLEM", 193, 212], ["Plant Viruses", "PROBLEM", 230, 243], ["natural selection", "TREATMENT", 373, 390], ["genetic drift", "TEST", 392, 405], ["RNA viruses", "OBSERVATION", 17, 28], ["Variability", "OBSERVATION_MODIFIER", 201, 212], ["Plant Viruses", "OBSERVATION", 230, 243], ["natural selection", "OBSERVATION", 373, 390], ["genetic drift", "OBSERVATION", 392, 405], ["gene flow", "OBSERVATION", 411, 420]]], ["Natural selection is a directional process by which the less fit virus variants will decrease their frequency in the population (negative or purifying selection) as a result of functional restrictions necessary for replication, movement between plant cells, transmission by vectors, and specific interactions between virus and host or virus and vector (Power, 2000; Schneider and Roossinck, 2001; Chare and Holmes, 2004).", [["cells", "ANATOMY", 251, 256], ["plant cells", "CELL", 245, 256], ["plant cells", "CELL_TYPE", 245, 256], ["Natural selection", "TREATMENT", 0, 17], ["a directional process", "PROBLEM", 21, 42], ["the less fit virus variants", "PROBLEM", 52, 79], ["replication", "TREATMENT", 215, 226], ["movement between plant cells", "PROBLEM", 228, 256], ["directional", "OBSERVATION_MODIFIER", 23, 34], ["virus", "OBSERVATION", 65, 70]]], ["Positive or adaptive selection consists in the frequency increase of the fittest variants carrying genetic changes required to become adapted to new hosts and/or vectors (Agudelo-Romero et al., 2008; Ohshima et al., 2009; Pe\u00f1a et al., 2014).", [["adaptive selection", "TREATMENT", 12, 30], ["genetic changes", "PROBLEM", 99, 114]]], ["Genetic drift consists of stochastic changes in the frequencies of genomic variants in a finite population due to random sampling occurred during reproduction (Moya et al., 2004).", [["Genetic drift", "PROBLEM", 0, 13], ["stochastic changes", "PROBLEM", 26, 44], ["genomic variants", "PROBLEM", 67, 83], ["a finite population", "PROBLEM", 87, 106], ["random sampling", "PROBLEM", 114, 129], ["drift", "OBSERVATION", 8, 13], ["stochastic changes", "OBSERVATION", 26, 44], ["genomic variants", "OBSERVATION", 67, 83]]], ["The effect is a reduction of genetic variability and fixation of selectively neutral variants that is more evident after a rapid reduction of the population size by population bottlenecks or founder events, which can occur in different steps of the virus life cycle, such as virus movement between plant cells and transmission by vectors (Sacrist\u00e1n et al., 2003; Ali et al., 2006; Betancourt et al., 2008; Ali and Roossinck, 2010).Figure 1Bshows genetic changes of citrus tristeza virus (CTV) isolates, revealed by single-strand conformation polymorphism analysis (explained below), after host change or vector transmission.", [["cells", "ANATOMY", 304, 309], ["plant cells", "CELL", 298, 309], ["citrus tristeza virus", "ORGANISM", 465, 486], ["plant cells", "CELL_TYPE", 298, 309], ["citrus tristeza virus", "SPECIES", 465, 486], ["citrus tristeza virus", "SPECIES", 465, 486], ["a reduction of genetic variability", "PROBLEM", 14, 48], ["fixation", "TREATMENT", 53, 61], ["selectively neutral variants", "PROBLEM", 65, 93], ["the virus life cycle", "TREATMENT", 245, 265], ["Figure", "TEST", 431, 437], ["genetic changes of citrus tristeza virus", "PROBLEM", 446, 486], ["single-strand conformation polymorphism analysis", "PROBLEM", 515, 563], ["reduction", "OBSERVATION_MODIFIER", 16, 25], ["genetic variability", "OBSERVATION", 29, 48], ["neutral variants", "OBSERVATION", 77, 93], ["rapid", "OBSERVATION_MODIFIER", 123, 128], ["reduction", "OBSERVATION_MODIFIER", 129, 138], ["population", "OBSERVATION_MODIFIER", 146, 156], ["size", "OBSERVATION_MODIFIER", 157, 161], ["plant cells", "OBSERVATION", 298, 309], ["citrus tristeza virus", "OBSERVATION", 465, 486]]], ["Finally, gene flow (migration) among viral populations from distinct geographic areas is another factor shaping the genetic structure and variation, so that high migration rates favor genetic uniformity between populations decreasing the global genetic diversity (Moya et al., 2004).", [["gene flow (migration", "TREATMENT", 9, 29], ["viral populations", "PROBLEM", 37, 54], ["high migration rates", "PROBLEM", 157, 177], ["genetic uniformity between populations", "PROBLEM", 184, 222], ["flow", "OBSERVATION_MODIFIER", 14, 18], ["distinct", "OBSERVATION_MODIFIER", 60, 68], ["geographic", "OBSERVATION_MODIFIER", 69, 79], ["genetic structure", "OBSERVATION", 116, 133], ["variation", "OBSERVATION_MODIFIER", 138, 147], ["high", "OBSERVATION_MODIFIER", 157, 161], ["migration", "OBSERVATION_MODIFIER", 162, 171], ["uniformity", "OBSERVATION_MODIFIER", 192, 202], ["populations", "OBSERVATION_MODIFIER", 211, 222], ["decreasing", "OBSERVATION_MODIFIER", 223, 233], ["global", "OBSERVATION_MODIFIER", 238, 244]]], ["The rapid evolution of plant viruses implies that epidemiological and evolutionary processes interplay, and they must be considered together to understand and prevent viral emergence.Serological and Molecular Techniques ::: Detection of Plant VirusesIn the last decades, rapid and specific serological (enzyme-linked immunosorbent assay, ELISA) and molecular techniques (molecular hybridization and DNA amplification) for the detection of plant viruses have been developed.", [["DNA", "CELLULAR_COMPONENT", 399, 402], ["plant viruses", "PROBLEM", 23, 36], ["viral emergence", "PROBLEM", 167, 182], ["specific serological", "TEST", 281, 301], ["enzyme", "TEST", 303, 309], ["immunosorbent assay", "TEST", 317, 336], ["ELISA", "TEST", 338, 343], ["molecular techniques", "TEST", 349, 369], ["molecular hybridization", "TREATMENT", 371, 394], ["DNA amplification", "TREATMENT", 399, 416], ["plant viruses", "PROBLEM", 439, 452], ["rapid", "OBSERVATION_MODIFIER", 4, 9], ["plant viruses", "OBSERVATION", 23, 36], ["plant viruses", "OBSERVATION", 439, 452]]], ["ELISA is based on specific binding of viral proteins with antibodies (Clark and Adams, 1977), and molecular hybridization, on binding viral nucleic acids with sequence-specific DNA or RNA probes, due to their sequence complementarity (Hull and Al-Hakim, 1988).", [["nucleic acids", "CHEMICAL", 140, 153], ["DNA", "CELLULAR_COMPONENT", 177, 180], ["viral proteins", "PROTEIN", 38, 52], ["antibodies", "PROTEIN", 58, 68], ["viral proteins", "PROBLEM", 38, 52], ["molecular hybridization", "PROBLEM", 98, 121], ["binding viral nucleic acids", "TEST", 126, 153], ["specific DNA", "PROBLEM", 168, 180], ["RNA probes", "TEST", 184, 194]]], ["These binding events are visualized by attached markers based on fluorescent dyes, enzymes producing colorimetric or chemiluminescent reactions, radioactivity, or others.Serological and Molecular Techniques ::: Detection of Plant VirusesDetection methods based on DNA amplification can be classified into two types: polymerase chain reaction (PCR) and isothermal amplification.", [["DNA", "CELLULAR_COMPONENT", 264, 267], ["These binding events", "PROBLEM", 0, 20], ["fluorescent dyes", "TEST", 65, 81], ["enzymes", "TEST", 83, 90], ["colorimetric or chemiluminescent reactions", "PROBLEM", 101, 143], ["Plant VirusesDetection methods", "TREATMENT", 224, 254], ["DNA amplification", "TREATMENT", 264, 281], ["polymerase chain reaction", "PROBLEM", 316, 341], ["PCR", "TEST", 343, 346], ["isothermal amplification", "TREATMENT", 352, 376]]], ["PCR makes millions of DNA copies of a specific region of the viral genome that are usually visualized by electrophoresis or by hybridization with fluorescent probes.", [["DNA", "CELLULAR_COMPONENT", 22, 25], ["viral genome", "DNA", 61, 73], ["PCR", "TEST", 0, 3], ["DNA copies", "PROBLEM", 22, 32], ["the viral genome", "PROBLEM", 57, 73], ["fluorescent probes", "TEST", 146, 164], ["viral genome", "OBSERVATION", 61, 73]]], ["PCR can use as template genomic DNA, or complementary DNA obtained after reverse transcription (RT) of viral RNA.", [["DNA", "CELLULAR_COMPONENT", 32, 35], ["DNA", "CELLULAR_COMPONENT", 54, 57], ["template genomic DNA", "DNA", 15, 35], ["complementary DNA", "DNA", 40, 57], ["viral RNA", "RNA", 103, 112], ["PCR", "TEST", 0, 3], ["template genomic DNA", "PROBLEM", 15, 35], ["complementary DNA", "PROBLEM", 40, 57], ["reverse transcription", "TREATMENT", 73, 94], ["viral RNA", "PROBLEM", 103, 112], ["viral RNA", "OBSERVATION", 103, 112]]], ["Amplification occurs in three steps: i) denaturation by heating at 90\u00b0C to 95\u00b0C to separate the double-stranded DNA (dsDNA) template into single strands; ii) annealing by cooling at 40\u00b0C to 60\u00b0C to allow the primers (two short DNA sequences of 15\u201340 nt) to bind the start and end of the target DNA; iii) extension by heating at 70\u00b0C to 75\u00b0C, in which a thermostable DNA polymerase synthesizes new DNA strands starting from the primers.", [["DNA", "CELLULAR_COMPONENT", 112, 115], ["DNA", "CELLULAR_COMPONENT", 227, 230], ["DNA", "CELLULAR_COMPONENT", 294, 297], ["DNA", "CELLULAR_COMPONENT", 366, 369], ["DNA", "CELLULAR_COMPONENT", 397, 400], ["double-stranded DNA (dsDNA) template", "DNA", 96, 132], ["short DNA sequences", "DNA", 221, 240], ["15\u201340 nt", "DNA", 244, 252], ["start and end", "DNA", 266, 279], ["target DNA", "DNA", 287, 297], ["thermostable DNA polymerase", "PROTEIN", 353, 380], ["the double-stranded DNA (dsDNA)", "TREATMENT", 92, 123], ["the primers", "TREATMENT", 204, 215], ["two short DNA sequences", "TREATMENT", 217, 240], ["a thermostable DNA polymerase", "TEST", 351, 380], ["new DNA strands", "PROBLEM", 393, 408], ["the primers", "TREATMENT", 423, 434], ["new", "OBSERVATION_MODIFIER", 393, 396], ["DNA strands", "OBSERVATION", 397, 408]]], ["These steps are repeated for 20 to 40 cycles, so the newly synthesized DNA segments serve as template in next cycles (Mullis and Faloona, 1987).", [["DNA", "CELLULAR_COMPONENT", 71, 74], ["DNA segments", "DNA", 71, 83], ["the newly synthesized DNA segments", "TREATMENT", 49, 83]]], ["The PCR product is visualized by electrophoresis, and it can be further characterized by Sanger sequencing (first-generation sequencing), enabling a more precise identification by comparison with known sequences from databases like GenBank (see below).", [["The PCR product", "TEST", 0, 15], ["electrophoresis", "TEST", 33, 48], ["Sanger sequencing", "TEST", 89, 106]]], ["Also, this approach is used to genotype virus populations, evaluate their genetic diversity, and study their evolution (see below).", [["genotype virus populations", "PROBLEM", 31, 57]]], ["Real-time quantitative PCR (qPCR) is a variant of this technique that monitors the reaction progress by detecting a fluorescent reporter that binds to the dsDNA or is released from sequence-specific probes of 15 to 30 nt.", [["dsDNA", "CELLULAR_COMPONENT", 155, 160], ["dsDNA", "DNA", 155, 160], ["this technique", "TREATMENT", 50, 64], ["specific probes", "TEST", 190, 205]]], ["This PCR variant can be used to quantify nucleic acids (see below).Serological and Molecular Techniques ::: Detection of Plant VirusesIsothermal amplification can be achieved by different approaches (Olmos et al., 2007): i) Helicase dependent amplification (HAD) uses a helicase to separate the strands of dsDNA, allowing primer binding and extension by DNA polymerase at a constant temperature of about 65\u00b0C. ii) Recombinase polymerase amplification (RPA) uses a recombinase which forms a complex with primers to initiate amplification at a temperature between 37\u00b0C and 42\u00b0C. iii) Nucleic acid sequence-based amplification method (NASBA) uses a modified primer with the bacteriophage T7 promoter region that attaches to the RNA template.", [["nucleic acids", "CHEMICAL", 41, 54], ["dsDNA", "CELLULAR_COMPONENT", 306, 311], ["DNA", "CELLULAR_COMPONENT", 354, 357], ["Recombinase polymerase", "GENE_OR_GENE_PRODUCT", 414, 436], ["PCR variant", "DNA", 5, 16], ["DNA polymerase", "PROTEIN", 354, 368], ["Recombinase polymerase", "PROTEIN", 414, 436], ["RPA", "PROTEIN", 452, 455], ["recombinase", "DNA", 464, 475], ["bacteriophage T7 promoter region", "DNA", 671, 703], ["RNA template", "DNA", 725, 737], ["This PCR variant", "TEST", 0, 16], ["nucleic acids", "TEST", 41, 54], ["Plant VirusesIsothermal amplification", "TREATMENT", 121, 158], ["Helicase dependent amplification", "TREATMENT", 224, 256], ["a helicase", "TREATMENT", 268, 278], ["dsDNA", "PROBLEM", 306, 311], ["primer binding", "PROBLEM", 322, 336], ["DNA polymerase", "PROBLEM", 354, 368], ["Recombinase polymerase amplification", "TREATMENT", 414, 450], ["a recombinase", "TREATMENT", 462, 475], ["a temperature", "TEST", 540, 553], ["Nucleic acid sequence", "TEST", 582, 603], ["a modified primer", "TREATMENT", 644, 661], ["the bacteriophage T7 promoter region", "TREATMENT", 667, 703]]], ["Reverse transcriptase and RNase H are used to synthesize complementary ds DNA, and a T7 RNA polymerase to synthesize complementary RNA strands resulting in amplification. iv) Loop-mediated isothermal amplification (LAMP) is based on auto cycling and high DNA strand displacement activity mediated by Bst polymerase from Geobacillus stearothermophilus, under isothermal conditions at 60\u00b0C to 65\u00b0C (Panno et al., 2020).", [["RNase H", "GENE_OR_GENE_PRODUCT", 26, 33], ["DNA", "CELLULAR_COMPONENT", 74, 77], ["DNA", "CELLULAR_COMPONENT", 255, 258], ["Bst polymerase", "GENE_OR_GENE_PRODUCT", 300, 314], ["Geobacillus stearothermophilus", "ORGANISM", 320, 350], ["Reverse transcriptase", "PROTEIN", 0, 21], ["RNase H", "PROTEIN", 26, 33], ["complementary ds DNA", "DNA", 57, 77], ["T7 RNA polymerase", "PROTEIN", 85, 102], ["complementary RNA strands", "RNA", 117, 142], ["Bst polymerase", "PROTEIN", 300, 314], ["Geobacillus stearothermophilus", "SPECIES", 320, 350], ["Geobacillus stearothermophilus", "SPECIES", 320, 350], ["Reverse transcriptase and RNase H", "TREATMENT", 0, 33], ["ds DNA", "PROBLEM", 71, 77], ["a T7 RNA polymerase", "TREATMENT", 83, 102], ["RNA strands", "PROBLEM", 131, 142], ["Loop-mediated isothermal amplification", "TREATMENT", 175, 213], ["auto cycling", "TEST", 233, 245], ["high DNA strand displacement activity", "PROBLEM", 250, 287], ["Geobacillus stearothermophilus", "PROBLEM", 320, 350], ["T7", "ANATOMY", 85, 87]]], ["Recently, new tools for molecular diagnosis have been developed based on prokaryotic clustered regularly interspaced short palindromic repeats (CRISPR) immunity system, widely applied for genome editing (Chertow, 2018).High-Throughput Sequencing ::: Detection of Plant VirusesThe advent of high-throughput sequencing (HTS) technologies, also known as next-generation sequencing, has led to a revolution in plant virus diagnosis (Maree et al., 2018; Villamor et al., 2019).", [["CRISPR", "DNA", 144, 150], ["prokaryotic clustered regularly interspaced short palindromic repeats (CRISPR) immunity system", "TREATMENT", 73, 167], ["Plant Viruses", "PROBLEM", 263, 276], ["Plant Viruses", "OBSERVATION", 263, 276]]], ["HTS does not require any previous knowledge of viral sequences and can sequence millions or billions of DNA molecules in parallel, enabling the detection of all viruses present in a plant (virome), including those still unknown (Roossinck, 2015).", [["DNA", "CELLULAR_COMPONENT", 104, 107], ["virome", "CANCER", 189, 195], ["viral sequences", "DNA", 47, 62], ["DNA molecules", "PROTEIN", 104, 117], ["viral sequences", "PROBLEM", 47, 62], ["DNA molecules", "PROBLEM", 104, 117], ["all viruses", "PROBLEM", 157, 168], ["viruses", "OBSERVATION", 161, 168]]], ["HTS allowed elucidating the elusive etiology of some diseases (Vives et al., 2013; He et al., 2015), but often it is not possible to find a direct association between the disease and a particular virus (Toma\u0161echov\u00e1 et al., 2020) among those detected in the infected plant.", [["some diseases", "PROBLEM", 48, 61], ["the disease", "PROBLEM", 167, 178], ["a particular virus", "PROBLEM", 183, 201], ["some", "OBSERVATION_MODIFIER", 48, 52], ["diseases", "OBSERVATION", 53, 61], ["disease", "OBSERVATION", 171, 178], ["infected plant", "OBSERVATION", 257, 271]]], ["In this case, the diagnostic must be established by fulfilling Koch\u2019s postulates, or at least by finding a tight association between the disease and the presence of a certain virus in field surveys (Mumo et al., 2020).High-Throughput Sequencing ::: Detection of Plant VirusesHTS can be divided into two types.", [["the disease", "PROBLEM", 133, 144], ["Plant VirusesHTS", "TREATMENT", 262, 278], ["disease", "OBSERVATION", 137, 144]]], ["Second-generation sequencing is based on the preparation of random libraries of DNA fragments when DNA is used as starting material, or of cDNA obtained by retrotranscription of the RNA with random primers or oligodT.", [["DNA", "CELLULAR_COMPONENT", 80, 83], ["DNA", "CELLULAR_COMPONENT", 99, 102], ["DNA fragments", "DNA", 80, 93], ["cDNA", "DNA", 139, 143], ["T.", "SPECIES", 215, 217], ["Second-generation sequencing", "TREATMENT", 0, 28], ["DNA fragments", "PROBLEM", 80, 93], ["DNA", "PROBLEM", 99, 102], ["cDNA", "TEST", 139, 143], ["random primers", "TREATMENT", 191, 205]]], ["These libraries are clonally amplified, bond to synthetic DNA adapters and sequenced in parallel.", [["DNA", "CELLULAR_COMPONENT", 58, 61], ["synthetic DNA adapters", "DNA", 48, 70], ["synthetic DNA adapters", "TREATMENT", 48, 70]]], ["This produces a large number of short sequence reads (100\u2013500 nt) that are assembled by connecting overlapping sequence reads according to nucleotide identity by informatic analysis, e.g., Geneious package (www.geneious.com).", [["nucleotide", "CHEMICAL", 139, 149], ["nucleotide", "CHEMICAL", 139, 149], ["informatic analysis", "TEST", 162, 181], ["large", "OBSERVATION_MODIFIER", 16, 21]]], ["Several platforms for second-generation sequencing have been developed by different companies such as Roche 454, Illumina, Solid and Ion Torrent (Bleidorn, 2016; Goodwin et al., 2016; Heather and Chain, 2016; Villamor et al., 2019).", [["second-generation sequencing", "TREATMENT", 22, 50]]], ["In addition to detection of new plant viruses and viroids, HTS is being used for studies on epidemiology, synergistic interactions between viruses, and genetic diversity and evolutionary mechanisms of virus populations (Kehoe et al., 2014; Hadidi et al., 2016; Pecman et al., 2017; Roossinck, 2017; Tan et al., 2019; Xu et al., 2019).High-Throughput Sequencing ::: Detection of Plant VirusesThird-generation sequencing is based on sequencing single molecules in real-time without the need for clonal amplification, thus shortening DNA preparation time and giving long reads of several kilobases (Goodwin et al., 2016; van Dijk et al., 2018).", [["DNA", "CELLULAR_COMPONENT", 531, 534], ["new plant viruses", "PROBLEM", 28, 45], ["viroids", "TREATMENT", 50, 57], ["HTS", "TREATMENT", 59, 62], ["synergistic interactions between viruses", "PROBLEM", 106, 146], ["virus populations", "PROBLEM", 201, 218], ["Plant Viruses", "PROBLEM", 378, 391], ["clonal amplification", "TREATMENT", 493, 513], ["shortening DNA preparation", "TREATMENT", 520, 546], ["new", "OBSERVATION_MODIFIER", 28, 31], ["plant viruses", "OBSERVATION", 32, 45]]], ["Long reads are more appropriate for genome sequencing, genotyping, and detecting recombination.", [["genome sequencing", "TEST", 36, 53], ["genotyping", "TEST", 55, 65]]], ["However, third-generation sequencing needs further improvement since error rates are still much higher than in second-generation sequencing.", [["error rates", "TEST", 69, 80]]], ["Several techniques are being developed by different companies such as single-molecule real-time (SMRT) and nanopore sequencing.", [["SMRT", "PROTEIN", 97, 101], ["nanopore sequencing", "TEST", 107, 126]]], ["SMRT sequencing uses a flow cell with millions of individual picolitre wells with transparent bottoms (zero-mode waveguides) with a DNA polymerase fixed.", [["cell", "ANATOMY", 28, 32], ["SMRT", "GENE_OR_GENE_PRODUCT", 0, 4], ["DNA", "CELLULAR_COMPONENT", 132, 135], ["SMRT", "PROTEIN", 0, 4], ["DNA polymerase", "PROTEIN", 132, 146], ["a flow cell", "TREATMENT", 21, 32], ["millions of individual picolitre wells", "TREATMENT", 38, 76], ["transparent bottoms (zero-mode waveguides", "TREATMENT", 82, 123], ["a DNA polymerase fixed", "PROBLEM", 130, 152], ["flow cell", "OBSERVATION", 23, 32]]], ["Incorporation on each single-molecule template per well is continuously visualized with a laser and camera system that records the color and duration of emitted light, as the labeled nucleotide momentarily pauses during incorporation at the bottom of the wells.", [["nucleotide", "CHEMICAL", 183, 193], ["nucleotide", "CHEMICAL", 183, 193], ["a laser and camera system", "TREATMENT", 88, 113], ["the labeled nucleotide momentarily pauses", "PROBLEM", 171, 212]]], ["Nanopore sequencing is based on translocating the DNA or RNA through a nanopore (in membrane proteins or synthetic materials such as silicon nitride and aluminum oxide), where an ionic current pass by setting a voltage.", [["membrane", "ANATOMY", 84, 92], ["silicon nitride", "CHEMICAL", 133, 148], ["aluminum oxide", "CHEMICAL", 153, 167], ["silicon nitride", "CHEMICAL", 133, 148], ["aluminum oxide", "CHEMICAL", 153, 167], ["DNA", "CELLULAR_COMPONENT", 50, 53], ["membrane", "CELLULAR_COMPONENT", 84, 92], ["silicon nitride", "SIMPLE_CHEMICAL", 133, 148], ["aluminum oxide", "SIMPLE_CHEMICAL", 153, 167], ["membrane proteins", "PROTEIN", 84, 101], ["Nanopore sequencing", "TREATMENT", 0, 19], ["the DNA", "PROBLEM", 46, 53], ["a nanopore (in membrane proteins", "TREATMENT", 69, 101], ["synthetic materials", "TREATMENT", 105, 124], ["silicon nitride and aluminum oxide", "TREATMENT", 133, 167]]], ["The DNA passing through the nanopore changes the current depending on the shape, size and length of the DNA sequence.", [["DNA", "CELLULAR_COMPONENT", 4, 7], ["DNA", "CELLULAR_COMPONENT", 104, 107], ["DNA sequence", "DNA", 104, 116], ["The DNA", "PROBLEM", 0, 7], ["the nanopore changes", "PROBLEM", 24, 44], ["the DNA sequence", "TEST", 100, 116], ["DNA", "OBSERVATION", 4, 7], ["shape", "OBSERVATION_MODIFIER", 74, 79], ["size", "OBSERVATION_MODIFIER", 81, 85]]], ["Nanopore sequencing has several advantages such as the relatively low cost compared to other HTS technologies, high mobility due to the sequencer small size and rapid sample processing, without the need for reverse transcription for RNA viruses (Kiselev et al., 2020).", [["sample", "ANATOMY", 167, 173], ["Nanopore sequencing", "TREATMENT", 0, 19], ["the relatively low cost", "PROBLEM", 51, 74], ["other HTS technologies", "TEST", 87, 109], ["high mobility", "PROBLEM", 111, 124], ["the sequencer small size", "PROBLEM", 132, 156], ["rapid sample processing", "PROBLEM", 161, 184], ["reverse transcription", "TREATMENT", 207, 228], ["RNA viruses", "PROBLEM", 233, 244], ["small", "OBSERVATION_MODIFIER", 146, 151], ["size", "OBSERVATION_MODIFIER", 152, 156]]], ["This technology has been recently used to detect some plant viruses, such as plum pox virus (PPV) and tomato yellow leaf curl virus (TYLCV), and discover new plant viruses (Bronzato Badial et al., 2018; Chalupowicz et al., 2019; Naito et al., 2019).Accuracy of Virus Diagnosis ::: Detection of Plant VirusesDetection procedures must be optimized for accuracy, measured as sensitivity and specificity, which are the statistical measures of performance of binary classification tests (Sharma et al., 2009).", [["plum pox virus", "ORGANISM", 77, 91], ["tomato yellow leaf curl virus", "ORGANISM", 102, 131], ["TYLCV", "ORGANISM", 133, 138], ["Virus", "ORGANISM", 261, 266], ["plum pox virus", "SPECIES", 77, 91], ["tomato", "SPECIES", 102, 108], ["yellow leaf curl virus", "SPECIES", 109, 131], ["plum pox virus", "SPECIES", 77, 91], ["PPV", "SPECIES", 93, 96], ["tomato yellow leaf curl virus", "SPECIES", 102, 131], ["TYLCV", "SPECIES", 133, 138], ["some plant viruses", "PROBLEM", 49, 67], ["plum pox virus", "PROBLEM", 77, 91], ["PPV", "TEST", 93, 96], ["tomato yellow leaf curl virus", "PROBLEM", 102, 131], ["Plant VirusesDetection procedures", "TREATMENT", 294, 327], ["accuracy", "TEST", 350, 358], ["binary classification tests", "TEST", 454, 481], ["viruses", "OBSERVATION", 60, 67], ["new", "OBSERVATION_MODIFIER", 154, 157], ["plant viruses", "OBSERVATION", 158, 171], ["Plant Viruses", "OBSERVATION", 294, 307]]], ["Sensitivity measures the proportion of actual positives which are classified as such (probability of true positives) and specificity measures the proportion of negatives which are correctly identified (probability of true negatives).", [["Sensitivity", "TEST", 0, 11], ["true positives", "PROBLEM", 101, 115]]], ["Other measures of accuracy are positive predictive value, defined as the proportion of positive samples correctly diagnosed, and negative predictive value, or proportion of samples with negative results correctly diagnosed (Table 2).", [["samples", "ANATOMY", 96, 103], ["samples", "ANATOMY", 173, 180], ["positive samples", "PROBLEM", 87, 103]]], ["However, the predictive values depend on the infection prevalence in the samples tested and do not apply universally (Olmos et al., 2007).Accuracy of Virus Diagnosis ::: Detection of Plant VirusesLow virus titer can limit sensitivity, producing false negatives when the virus concentration is under the technique detection threshold.", [["infection", "DISEASE", 45, 54], ["Virus", "ORGANISM", 150, 155], ["Plant Viruses", "ORGANISM", 183, 196], ["the predictive values", "TEST", 9, 30], ["the infection prevalence", "PROBLEM", 41, 65], ["the samples", "TEST", 69, 80], ["Plant VirusesLow virus titer", "PROBLEM", 183, 211], ["the virus concentration", "PROBLEM", 266, 289], ["infection", "OBSERVATION", 45, 54], ["Plant Viruses", "OBSERVATION", 183, 196]]], ["Usually, the molecular techniques are more sensitive than the serological ones.", [["the molecular techniques", "TEST", 9, 33]]], ["Conventional PCR is much more sensitive than molecular hybridization.", [["Conventional PCR", "TEST", 0, 16], ["molecular hybridization", "PROBLEM", 45, 68], ["hybridization", "OBSERVATION", 55, 68]]], ["Some modalities of PCR are even more sensitive, such as qPCR and nested PCR (this uses two successive runs of PCR with a second primer pair to amplify a secondary target within the product of the first run).", [["primer pair", "DNA", 128, 139], ["Some modalities of PCR", "TEST", 0, 22], ["qPCR", "TEST", 56, 60], ["nested PCR", "TEST", 65, 75], ["PCR", "TREATMENT", 110, 113], ["a second primer pair", "TREATMENT", 119, 139]]], ["LAMP exhibits a sensitivity in the order of qPCR and is less affected than PCR by inhibitors (phenols, tannins, and complex polysaccharides), which are often a cause of false negatives.", [["phenols, tannins", "CHEMICAL", 94, 110], ["phenols", "CHEMICAL", 94, 101], ["tannins", "CHEMICAL", 103, 110], ["phenols", "SIMPLE_CHEMICAL", 94, 101], ["tannins", "SIMPLE_CHEMICAL", 103, 110], ["LAMP", "TEST", 0, 4], ["a sensitivity", "PROBLEM", 14, 27], ["qPCR", "TEST", 44, 48], ["PCR", "TEST", 75, 78], ["tannins", "TREATMENT", 103, 110], ["false negatives", "PROBLEM", 169, 184], ["false negatives", "OBSERVATION", 169, 184]]], ["Paradoxically, the high sensitivity of the amplification techniques can be a problem, as contamination of reagents and instruments with amplicons from previous samples and cross-contamination between samples can produce false positives reducing specificity.Accuracy of Virus Diagnosis ::: Detection of Plant VirusesAn important factor affecting the accuracy of the serological and molecular detection methods is the genetic variability within each virus species and the genetic relationships with other virus species.", [["samples", "ANATOMY", 160, 167], ["samples", "ANATOMY", 200, 207], ["Virus", "ORGANISM", 269, 274], ["Plant VirusesAn important factor", "PROTEIN", 302, 334], ["the amplification techniques", "TEST", 39, 67], ["contamination of reagents", "TREATMENT", 89, 114], ["instruments with amplicons", "TREATMENT", 119, 145], ["previous samples", "TEST", 151, 167], ["cross-contamination between samples", "TEST", 172, 207], ["false positives reducing specificity", "PROBLEM", 220, 256], ["the serological", "TEST", 361, 376], ["molecular detection methods", "TEST", 381, 408], ["the genetic variability", "PROBLEM", 412, 435], ["each virus species", "PROBLEM", 443, 461], ["other virus species", "PROBLEM", 497, 516], ["high", "OBSERVATION_MODIFIER", 19, 23], ["Plant VirusesAn", "OBSERVATION", 302, 317]]], ["Since these methods are based on specific binding (protein with antibody or nucleic acids with probes or primers), some dissimilar virus variants can fail to react giving false negatives.", [["antibody", "PROTEIN", 64, 72], ["these methods", "TEST", 6, 19], ["nucleic acids", "TREATMENT", 76, 89], ["primers", "PROBLEM", 105, 112], ["some dissimilar virus variants", "PROBLEM", 115, 145], ["virus", "OBSERVATION", 131, 136]]], ["For example, universal detection of PPV by ELISA with monoclonal antibodies failed for some PPV isolates (Sheveleva et al., 2018).", [["PPV", "PROTEIN", 36, 39], ["monoclonal antibodies", "PROTEIN", 54, 75], ["universal detection", "TEST", 13, 32], ["PPV", "TEST", 36, 39], ["ELISA", "TEST", 43, 48], ["monoclonal antibodies", "TEST", 54, 75], ["some PPV isolates", "TREATMENT", 87, 104]]], ["On the other hand, false positives by cross-reactions of antibodies with related viruses have been described for some viruses, e.g., arabis mosaic virus (ArMV) (Frison and Stace-Smith, 1992).", [["arabis mosaic virus", "DISEASE", 133, 152], ["arabis mosaic virus", "ORGANISM", 133, 152], ["antibodies", "PROTEIN", 57, 67], ["arabis mosaic virus", "SPECIES", 133, 152], ["arabis mosaic virus", "SPECIES", 133, 152], ["ArMV", "SPECIES", 154, 158], ["false positives", "PROBLEM", 19, 34], ["cross-reactions of antibodies", "PROBLEM", 38, 67], ["related viruses", "PROBLEM", 73, 88], ["some viruses", "PROBLEM", 113, 125], ["arabis mosaic virus", "PROBLEM", 133, 152], ["false positives", "OBSERVATION", 19, 34], ["viruses", "OBSERVATION", 81, 88], ["viruses", "OBSERVATION", 118, 125], ["mosaic virus", "OBSERVATION", 140, 152]]], ["Unlike antibody production, primers and probes are better suited to be optimized by considering the genetic variability.", [["Unlike antibody production", "PROBLEM", 0, 26], ["antibody production", "OBSERVATION", 7, 26]]], ["However, genetic variation of viruses is often neglected, and accuracy is tested just with samples from local surveys harboring genetically similar virus isolates.", [["genetic variation of viruses", "PROBLEM", 9, 37], ["accuracy", "TEST", 62, 70], ["local surveys", "TEST", 104, 117], ["variation", "OBSERVATION_MODIFIER", 17, 26], ["viruses", "OBSERVATION", 30, 37]]], ["Thus, some detection protocols can fail when applied with the same reagents (probes or primers) in other geographical areas or after the emergence of divergent variants, e.g., pepino mosaic virus (PepMV) and apple chlorotic leafspot virus (ACLSV) (Mansilla et al., 2003; Spiegel et al., 2006).Accuracy of Virus Diagnosis ::: Detection of Plant VirusesTo design accurate probes or primers for a given virus, the first step is to get a picture of the genetic variation and structure by gathering as many nucleotide sequences as possible from isolates of that virus and from genetically related viruses.", [["nucleotide", "CHEMICAL", 502, 512], ["pepino mosaic virus", "ORGANISM", 176, 195], ["PepMV", "ORGANISM", 197, 202], ["apple chlorotic leafspot virus", "ORGANISM", 208, 238], ["Virus", "ORGANISM", 305, 310], ["pepino mosaic virus", "SPECIES", 176, 195], ["apple chlorotic leafspot virus", "SPECIES", 208, 238], ["pepino mosaic virus", "SPECIES", 176, 195], ["PepMV", "SPECIES", 197, 202], ["apple chlorotic leafspot virus", "SPECIES", 208, 238], ["ACLSV", "SPECIES", 240, 245], ["some detection protocols", "TEST", 6, 30], ["the same reagents", "TREATMENT", 58, 75], ["divergent variants", "PROBLEM", 150, 168], ["pepino mosaic virus", "PROBLEM", 176, 195], ["apple chlorotic leafspot virus", "PROBLEM", 208, 238], ["Plant Viruses", "PROBLEM", 338, 351], ["primers", "TREATMENT", 380, 387], ["a given virus", "PROBLEM", 392, 405], ["many nucleotide sequences", "TEST", 497, 522], ["that virus", "PROBLEM", 552, 562], ["genetically related viruses", "PROBLEM", 572, 599], ["chlorotic leafspot virus", "OBSERVATION", 214, 238], ["Plant Viruses", "OBSERVATION", 338, 351]]], ["Sequences of specific genomic regions or complete genomes can be determined from purified or cloned PCR products or by HTS from viral samples and retrieved from databases like GenBank (https://www.ncbi.nlm.nih.gov/).", [["samples", "ANATOMY", 134, 141], ["genomic regions", "DNA", 22, 37], ["cloned PCR products", "TREATMENT", 93, 112], ["viral samples", "TEST", 128, 141]]], ["The genetic diversity and structure can be estimated easily with the MEGA X software (Kumar et al., 2018), after alignment with the algorithm CLUSTALW (Higgins et al., 1994) implemented in MEGA.", [["genetic", "OBSERVATION_MODIFIER", 4, 11], ["diversity", "OBSERVATION", 12, 21]]], ["Nucleotide diversity is the mean distance (proportion of nucleotide differences) between sequence pairs and can be considered as a measure of the genetic variation within a virus population.", [["nucleotide", "CHEMICAL", 57, 67], ["Nucleotide diversity", "PROBLEM", 0, 20], ["nucleotide differences) between sequence pairs", "PROBLEM", 57, 103], ["a virus population", "PROBLEM", 171, 189], ["diversity", "OBSERVATION_MODIFIER", 11, 20]]], ["In this case, p-distance should be used instead of nucleotide substitution models as this analysis is aimed to know the actual genetic differences for application in diagnostic and not the evolutionary changes that occurred.", [["nucleotide", "CHEMICAL", 51, 61], ["nucleotide", "CHEMICAL", 51, 61], ["p-distance", "TREATMENT", 14, 24], ["nucleotide substitution models", "TREATMENT", 51, 81], ["this analysis", "TEST", 85, 98]]], ["The genetic structure can be visualized with phylogenetic trees, which can be inferred with different methods, such as Neighbor-Joining, Maximum Likelihood and Maximum Parsimony.", [["Maximum Parsimony", "OBSERVATION", 160, 177]]], ["As an illustration,Figure 2shows the nucleotide diversity and the phylogenetic relationships of randomly selected worldwide isolates of cucumber green mottle mosaic virus (CGMMV) and grapevine leafroll-associated virus 2 (GLRaV-2).", [["nucleotide", "CHEMICAL", 37, 47], ["nucleotide", "CHEMICAL", 37, 47], ["cucumber", "ORGANISM", 136, 144], ["green mottle mosaic virus", "ORGANISM", 145, 170], ["CGMMV", "ORGANISM", 172, 177], ["grapevine leafroll-associated virus 2", "ORGANISM", 183, 220], ["GLRaV-2", "GENE_OR_GENE_PRODUCT", 222, 229], ["cucumber", "SPECIES", 136, 144], ["green mottle mosaic virus", "SPECIES", 145, 170], ["grapevine leafroll-associated virus", "SPECIES", 183, 218], ["cucumber green mottle mosaic virus", "SPECIES", 136, 170], ["CGMMV", "SPECIES", 172, 177], ["grapevine leafroll-associated virus", "SPECIES", 183, 218], ["the nucleotide diversity", "PROBLEM", 33, 57], ["cucumber green mottle mosaic virus", "PROBLEM", 136, 170], ["CGMMV", "TEST", 172, 177], ["grapevine leafroll", "TEST", 183, 201], ["virus", "PROBLEM", 213, 218], ["mottle mosaic virus", "OBSERVATION", 151, 170]]], ["The nucleotide diversity of GLRaV-2 is higher, so it is more challenging to develop an accurate detection method for GLRaV-2 than for CGMMV.", [["nucleotide", "CHEMICAL", 4, 14], ["nucleotide", "CHEMICAL", 4, 14], ["GLRaV-2", "GENE_OR_GENE_PRODUCT", 28, 35], ["GLRaV-2", "GENE_OR_GENE_PRODUCT", 117, 124], ["GLRaV-2", "DNA", 28, 35], ["CGMMV", "SPECIES", 134, 139], ["GLRaV", "TEST", 117, 122], ["CGMMV", "TEST", 134, 139], ["diversity", "OBSERVATION_MODIFIER", 15, 24], ["higher", "OBSERVATION_MODIFIER", 39, 45]]], ["Since the viral population of GLRaV-2 is structured in eight groups or clades, at least one isolate per clade should be considered to develop detection and disease control procedures for this virus.Accuracy of Virus Diagnosis ::: Detection of Plant VirusesFor universal detection of a virus by PCR, primers should be designed from short sequence stretches with conserved nucleotide positions among all available sequences and they should be degenerated to cover possible genetic variation not found in the sequences analyzed (explained in Detection Levels).", [["nucleotide", "CHEMICAL", 371, 381], ["nucleotide", "CHEMICAL", 371, 381], ["GLRaV-2", "GENE_OR_GENE_PRODUCT", 30, 37], ["Virus", "ORGANISM", 210, 215], ["Plant Viruses", "ORGANISM", 243, 256], ["GLRaV", "PROTEIN", 30, 35], ["disease control procedures", "TREATMENT", 156, 182], ["this virus", "PROBLEM", 187, 197], ["Plant Viruses", "PROBLEM", 243, 256], ["universal detection", "TEST", 260, 279], ["a virus", "PROBLEM", 283, 290], ["genetic variation", "PROBLEM", 471, 488], ["viral", "OBSERVATION_MODIFIER", 10, 15], ["Plant Viruses", "OBSERVATION", 243, 256]]], ["For example, detection of PepMV by RT-PCR (Mansilla et al., 2003) failed for new PepMV isolates and universal detection was only achieved after designing primers targeting conserved sequence stretches among PepMV isolates (Ling et al., 2007).", [["PepMV", "GENE_OR_GENE_PRODUCT", 26, 31], ["PepMV", "DNA", 26, 31], ["PepMV", "SPECIES", 81, 86], ["PepMV", "TEST", 26, 31], ["RT", "TEST", 35, 37], ["PCR", "TEST", 38, 41], ["new PepMV isolates", "TREATMENT", 77, 95], ["universal detection", "TEST", 100, 119], ["designing primers targeting conserved sequence stretches", "PROBLEM", 144, 200], ["PepMV isolates", "TREATMENT", 207, 221]]], ["For molecular hybridization, different genomic regions should be considered for probe design since the genetic diversity can vary widely along the genome due to different selective pressures or recombination.", [["genomic regions", "DNA", 39, 54], ["molecular hybridization", "PROBLEM", 4, 27], ["different genomic regions", "PROBLEM", 29, 54], ["different selective pressures", "TREATMENT", 161, 190], ["hybridization", "OBSERVATION", 14, 27], ["selective", "OBSERVATION_MODIFIER", 171, 180], ["pressures", "OBSERVATION_MODIFIER", 181, 190]]], ["For example, broad bean wilt virus 1 (BBWV-1), with a bipartite single-stranded RNA (ssRNA) genome, showed the lowest nucleotide diversity in the 5\u2032 terminal sequence of RNA 1 (Ferriol et al., 2014).", [["nucleotide", "CHEMICAL", 118, 128], ["nucleotide", "CHEMICAL", 118, 128], ["bean wilt virus 1", "ORGANISM", 19, 36], ["BBWV-1", "ORGANISM", 38, 44], ["bipartite single-stranded RNA (ssRNA) genome", "DNA", 54, 98], ["5\u2032 terminal sequence", "DNA", 146, 166], ["bean wilt virus", "SPECIES", 19, 34], ["bean wilt virus 1", "SPECIES", 19, 36], ["BBWV", "SPECIES", 38, 42], ["broad bean wilt virus", "PROBLEM", 13, 34], ["BBWV", "TEST", 38, 42], ["a bipartite single-stranded RNA (ssRNA) genome", "PROBLEM", 52, 98], ["the lowest nucleotide diversity", "PROBLEM", 107, 138], ["stranded RNA", "OBSERVATION", 71, 83], ["lowest", "OBSERVATION_MODIFIER", 111, 117], ["nucleotide diversity", "OBSERVATION", 118, 138]]], ["Thus, only a DNA probe binding this genomic region allowed universal detection of BBWV-1 by molecular hybridization (Ferrer et al., 2008).Accuracy of Virus Diagnosis ::: Detection of Plant VirusesHTS enables accurate and unbiased identification of viruses unlike the other techniques (ELISA, molecular hybridization or amplification) requiring a specific binding that can fail to detect some genetic variants.", [["DNA", "CELLULAR_COMPONENT", 13, 16], ["BBWV-1", "GENE_OR_GENE_PRODUCT", 82, 88], ["Virus", "ORGANISM", 150, 155], ["DNA probe", "DNA", 13, 22], ["genomic region", "DNA", 36, 50], ["BBWV-1", "DNA", 82, 88], ["BBWV-1", "SPECIES", 82, 88], ["a DNA probe binding", "PROBLEM", 11, 30], ["BBWV", "TEST", 82, 86], ["Plant VirusesHTS", "TEST", 183, 199], ["viruses", "PROBLEM", 248, 255], ["ELISA", "TEST", 285, 290], ["some genetic variants", "PROBLEM", 387, 408]]], ["HTS generates hundreds of megabases to gigabases of nucleotide sequence reads in a single run providing a good sensitivity (Santala and Valkonen, 2018).", [["nucleotide", "CHEMICAL", 52, 62], ["nucleotide", "CHEMICAL", 52, 62], ["nucleotide sequence", "TEST", 52, 71]]], ["However, cross-contamination can produce false positives, so it is necessary validation with other techniques, such as PCR (Maree et al., 2018).Detection Levels ::: Detection of Plant VirusesDetection and identification of viruses are based on assigning a virus from a plant sample to a group of viruses sharing common characteristics.", [["cross-contamination", "PROBLEM", 9, 28], ["false positives", "PROBLEM", 41, 56], ["other techniques", "TREATMENT", 93, 109], ["Detection Levels", "TEST", 144, 160], ["Plant VirusesDetection", "TEST", 178, 200], ["viruses", "PROBLEM", 223, 230], ["a virus", "PROBLEM", 254, 261], ["false positives", "OBSERVATION", 41, 56], ["Plant Viruses", "OBSERVATION", 178, 191], ["viruses", "OBSERVATION", 223, 230]]], ["In most cases, the level of detection is the virus species, but it can also be set for higher taxonomic units such as genus or family, or lower units like strain (virus variants with distinctive biological or molecular characteristics).Detection Levels ::: Detection of Plant VirusesSerological techniques usually detect viruses to the species level and, in some cases, they allow discrimination between virus strains (serotypes) using monoclonal antibodies (Permar et al., 1990; Myrta et al., 2000; Sheveleva et al., 2018).", [["monoclonal antibodies", "PROTEIN", 436, 457], ["the virus species", "PROBLEM", 41, 58], ["lower units like strain (virus variants", "PROBLEM", 138, 177], ["Detection Levels", "TEST", 236, 252], ["Plant Viruses", "PROBLEM", 270, 283], ["Serological techniques", "TEST", 283, 305], ["viruses", "PROBLEM", 321, 328], ["the species level", "TEST", 332, 349], ["discrimination between virus strains", "PROBLEM", 381, 417]]], ["Molecular hybridization has been used mostly to detect virus species (Supplementary Table S1), but the detection level can be modified to a certain extent by using different probes and hybridization conditions.", [["Molecular hybridization", "PROBLEM", 0, 23], ["virus species", "PROBLEM", 55, 68], ["the detection level", "TEST", 99, 118], ["hybridization conditions", "TREATMENT", 185, 209]]], ["The stability of the hybrid complexes depends on the probe length and G-C content, the probe type (DNA or RNA), and the number of global or local mismatches (nucleotide distance) between target and probe.", [["nucleotide", "CHEMICAL", 158, 168], ["nucleotide", "CHEMICAL", 158, 168], ["G-C", "SIMPLE_CHEMICAL", 70, 73], ["DNA", "CELLULAR_COMPONENT", 99, 102], ["the hybrid complexes", "PROBLEM", 17, 37], ["the probe length", "TEST", 49, 65], ["G-C content", "PROBLEM", 70, 81], ["the probe type (DNA or RNA)", "PROBLEM", 83, 110], ["local mismatches (nucleotide distance)", "TREATMENT", 140, 178], ["stability", "OBSERVATION_MODIFIER", 4, 13], ["hybrid complexes", "OBSERVATION", 21, 37], ["global", "OBSERVATION_MODIFIER", 130, 136], ["local mismatches", "OBSERVATION", 140, 156]]], ["Therefore, the distribution of nucleotide variation along the virus genome should be considered to modulate the level of detection and to test for accuracy.", [["nucleotide", "CHEMICAL", 31, 41], ["nucleotide", "CHEMICAL", 31, 41], ["virus genome", "DNA", 62, 74], ["nucleotide variation", "PROBLEM", 31, 51], ["the virus genome", "TREATMENT", 58, 74], ["accuracy", "TEST", 147, 155], ["nucleotide variation", "OBSERVATION", 31, 51], ["virus genome", "OBSERVATION", 62, 74]]], ["Regarding the hybridization conditions, a more selective detection can be attained by using more stringent conditions (higher incubation temperature, lower salt concentration or adding denaturing agents like formamide), that reduce the number of mismatches permitted to occur.", [["formamide", "CHEMICAL", 208, 217], ["formamide", "CHEMICAL", 208, 217], ["formamide", "SIMPLE_CHEMICAL", 208, 217], ["the hybridization conditions", "PROBLEM", 10, 38], ["higher incubation temperature", "TREATMENT", 119, 148], ["lower salt concentration", "TREATMENT", 150, 174], ["denaturing agents", "TREATMENT", 185, 202], ["formamide", "TREATMENT", 208, 217], ["mismatches", "OBSERVATION", 246, 256]]], ["Thus, probes from variable genomic regions with stringent conditions have been used to discriminate between virus strains or isolates (Narv\u00e1ez et al., 2000; Ferrer et al., 2008).", [["variable genomic regions", "PROBLEM", 18, 42], ["stringent conditions", "PROBLEM", 48, 68], ["virus strains", "PROBLEM", 108, 121], ["stringent conditions", "OBSERVATION", 48, 68]]], ["Designing probes complementary to regions conserved within taxonomic units higher than species is challenging given the high nucleotide variation among species.", [["nucleotide", "CHEMICAL", 125, 135], ["nucleotide", "CHEMICAL", 125, 135], ["the high nucleotide variation among species", "PROBLEM", 116, 159]]], ["To our knowledge, only two cases have been reported: i) A single RNA probe derived from the 5\u2032 untranslated of BBWV-1 was able to hybridize with other members of the genus Fabavirus (Ferriol et al., 2015).", [["BBWV-1", "GENE_OR_GENE_PRODUCT", 111, 117], ["RNA probe", "DNA", 65, 74], ["5\u2032 untranslated", "DNA", 92, 107], ["BBWV-1", "DNA", 111, 117]]], ["This genomic region contains several perfect or near-perfect repeats of ten nucleotides that allow hybridization despite the low nucleotide identity between these virus species. ii) A polyprobe with seven conserved motifs of the genus Potyvirus allowed detection of 32 viruses of this genus by hybridizing at low stringency conditions (S\u00e1nchez-Navarro et al., 2018).Detection Levels ::: Detection of Plant VirusesPCR techniques are the most versatile and primers have been designed for different detection levels from families and genera (Supplementary Table S2) to strains and genetic variants (Ruiz-Ruiz et al., 2009b; Debreczeni et al., 2011), whereas isothermal amplification has been limited to the species level (Supplementary Table S3).", [["nucleotide", "CHEMICAL", 129, 139], ["nucleotide", "CHEMICAL", 129, 139], ["genomic region", "DNA", 5, 19], ["ten nucleotides", "PROBLEM", 72, 87], ["hybridization", "TREATMENT", 99, 112], ["the low nucleotide identity", "PROBLEM", 121, 148], ["these virus species", "PROBLEM", 157, 176], ["the genus Potyvirus", "PROBLEM", 225, 244], ["this genus", "PROBLEM", 280, 290], ["hybridizing at low stringency conditions", "PROBLEM", 294, 334], ["Detection Levels", "TEST", 366, 382], ["Plant VirusesPCR techniques", "TEST", 400, 427], ["different detection levels", "TEST", 486, 512], ["genetic variants", "TEST", 578, 594], ["Ruiz", "TEST", 596, 600], ["several", "OBSERVATION_MODIFIER", 29, 36], ["perfect", "OBSERVATION_MODIFIER", 37, 44], ["virus species", "OBSERVATION", 163, 176], ["genus Potyvirus", "OBSERVATION", 229, 244]]], ["Obtaining primers specific for genera or families is more challenging than for virus species given the increasing nucleotide diversity of higher taxons.", [["nucleotide", "CHEMICAL", 114, 124], ["nucleotide", "CHEMICAL", 114, 124], ["genera", "PROBLEM", 31, 37], ["virus species", "PROBLEM", 79, 92], ["the increasing nucleotide diversity of higher taxons", "PROBLEM", 99, 151], ["higher taxons", "OBSERVATION", 138, 151]]], ["Primer design requires searching for conserved nucleotide positions among the members of the genus or family, which usually correspond to sequence motifs with relevant biological functions, and therefore, subjected to strong negative selection.", [["nucleotide", "CHEMICAL", 47, 57], ["nucleotide", "CHEMICAL", 47, 57]]], ["The conserved positions can occur at the nucleotide level due to structural constraints, codon usage, or at sites where regulatory proteins bind (Koonin, 1991; Adams and Antoniw, 2004; Watters et al., 2017), but most are at amino acid level.", [["amino acid", "CHEMICAL", 224, 234], ["nucleotide", "CHEMICAL", 41, 51], ["amino acid", "CHEMICAL", 224, 234], ["amino acid", "AMINO_ACID", 224, 234], ["regulatory proteins", "PROTEIN", 120, 139], ["structural constraints", "PROBLEM", 65, 87], ["codon usage", "TREATMENT", 89, 100]]], ["For example, primers for the subfamily Comovirinae (composed of the genera Comovirus, Fabavirus and Nepovirus) were designed based on amino acid motifs of the RNA-dependent RNA polymerase: (T/V)YGDDN(V/L) and TSEG(Y/F)P (Koonin, 1991; Maliogka et al., 2004).Detection Levels ::: Detection of Plant VirusesTo design primers detecting the members of a genus or family, at least one sequence per each virus species should be used for alignment, preferably a codon-based or amino acid alignment.", [["amino acid", "CHEMICAL", 134, 144], ["amino acid", "CHEMICAL", 470, 480], ["amino acid", "CHEMICAL", 134, 144], ["amino acid", "CHEMICAL", 470, 480], ["Comovirinae", "GENE_OR_GENE_PRODUCT", 39, 50], ["Comovirus", "GENE_OR_GENE_PRODUCT", 75, 84], ["Nepovirus", "GENE_OR_GENE_PRODUCT", 100, 109], ["amino acid", "AMINO_ACID", 134, 144], ["amino acid", "AMINO_ACID", 470, 480], ["Nepovirus", "PROTEIN", 100, 109], ["amino acid motifs", "PROTEIN", 134, 151], ["RNA-dependent RNA polymerase", "PROTEIN", 159, 187], ["YGDDN", "PROTEIN", 194, 199], ["the genera Comovirus", "TREATMENT", 64, 84], ["amino acid motifs", "TREATMENT", 134, 151], ["the RNA", "TEST", 155, 162], ["Detection Levels", "TEST", 258, 274], ["Plant Viruses", "PROBLEM", 292, 305], ["design primers", "TEST", 308, 322], ["each virus species", "PROBLEM", 393, 411], ["a codon-based or amino acid alignment", "PROBLEM", 453, 490], ["acid alignment", "OBSERVATION", 476, 490]]], ["Since the genetic code is redundant, the primer must be degenerate, that is, composed of a mixture of almost identical primers differing in some positions and covering all possible nucleotide combinations for that protein sequence.", [["nucleotide", "CHEMICAL", 181, 191], ["nucleotide", "CHEMICAL", 181, 191], ["nucleotide combinations", "TREATMENT", 181, 204], ["that protein sequence", "TEST", 209, 230], ["redundant", "OBSERVATION", 26, 35]]], ["The degeneracy level should be reduced as much as possible due to its negative effect in sensitivity (only a small proportion of the primers would bind the target) and specificity (some primers can bind to nontarget sequences).", [["The degeneracy level", "PROBLEM", 0, 20], ["small", "OBSERVATION_MODIFIER", 109, 114]]], ["Several approaches can be used, such as i) limiting the degenerate sites to the last 9 to 12 nucleotides from the 3\u2032 terminus, which are critical for PCR amplification, whereas some mispairings at the 5\u2032 terminus are allowed; ii) choosing low degeneracy (one- or two-fold) codons, particularly at the 3\u2032 terminus; and iii) using modified nucleotides such as inosine (I) for four-fold degenerate sites that can base-pair with the four normal nucleotides: A, C, G and T. As an illustration,Figure 3shows conserved amino acid positions in the genus Fabavirus, which can be used for a hypothetical universal detection of viruses within this genus.", [["inosine", "CHEMICAL", 358, 365], ["amino acid", "CHEMICAL", 512, 522], ["nucleotides", "CHEMICAL", 93, 104], ["nucleotides", "CHEMICAL", 338, 349], ["inosine", "CHEMICAL", 358, 365], ["nucleotides", "CHEMICAL", 441, 452], ["amino acid", "CHEMICAL", 512, 522], ["inosine (I)", "GENE_OR_GENE_PRODUCT", 358, 369], ["amino acid", "AMINO_ACID", 512, 522], ["degenerate sites", "DNA", 56, 72], ["3\u2032 terminus", "DNA", 114, 125], ["5\u2032 terminus", "DNA", 201, 212], ["3\u2032 terminus", "PROTEIN", 301, 312], ["Several approaches", "TREATMENT", 0, 18], ["the degenerate sites", "PROBLEM", 52, 72], ["PCR amplification", "PROBLEM", 150, 167], ["low degeneracy", "PROBLEM", 239, 253], ["two-fold) codons", "PROBLEM", 263, 279], ["modified nucleotides", "TREATMENT", 329, 349], ["inosine (I)", "TREATMENT", 358, 369], ["four-fold degenerate sites", "TREATMENT", 374, 400], ["amino acid", "OBSERVATION", 512, 522], ["genus Fabavirus", "ANATOMY", 540, 555], ["viruses", "OBSERVATION", 617, 624]]], ["The PCR products obtained with conserved primers for a genus or family can be further purified and sequenced to identify the viral species or discover new ones (Zheng et al., 2010).", [["PCR products", "DNA", 4, 16], ["The PCR products", "TREATMENT", 0, 16], ["the viral species", "PROBLEM", 121, 138]]], ["In plants infected with two or more species of the same genus or family, it is necessary to clone the PCR products and sequence individual clones to identify each virus species.", [["PCR products", "DNA", 102, 114], ["the PCR products", "TREATMENT", 98, 114], ["sequence individual clones", "PROBLEM", 119, 145], ["each virus species", "PROBLEM", 158, 176], ["infected", "OBSERVATION", 10, 18]]], ["In some cases, the PCR products obtained with conserved primers are of distinct size for each virus species and can be easily discriminated by electrophoresis (James and Upton, 1999; Ferrer et al., 2007).Detection Levels ::: Detection of Plant VirusesTools to detect small genetic variations are also necessary given the great potential of viruses to generate high genetic and biological variation (genetic variants can display different properties, such as host range, virulence and resistance-breakdown).", [["PCR products", "DNA", 19, 31], ["the PCR products", "TEST", 15, 31], ["conserved primers", "TREATMENT", 46, 63], ["each virus species", "PROBLEM", 89, 107], ["Detection Levels", "TEST", 204, 220], ["Plant Viruses", "PROBLEM", 238, 251], ["small genetic variations", "PROBLEM", 267, 291], ["viruses", "PROBLEM", 340, 347], ["high genetic and biological variation (genetic variants", "PROBLEM", 360, 415], ["virulence", "PROBLEM", 470, 479], ["breakdown", "PROBLEM", 495, 504], ["distinct", "OBSERVATION_MODIFIER", 71, 79], ["size", "OBSERVATION_MODIFIER", 80, 84], ["Plant Viruses", "OBSERVATION", 238, 251], ["viruses", "OBSERVATION", 340, 347]]], ["Several techniques based on PCR or using PCR products as templates have been used for genotyping: i) Randomly amplified polymorphic DNA (RAPD)-PCR uses a single short primer with an arbitrary nucleotide sequence (8\u201312 nucleotides) to produce different random segments depending on the target amplified, which are visualized by electrophoresis.", [["nucleotide", "CHEMICAL", 192, 202], ["DNA", "CELLULAR_COMPONENT", 132, 135], ["PCR products", "DNA", 41, 53], ["Randomly amplified polymorphic DNA (RAPD)-PCR", "DNA", 101, 146], ["arbitrary nucleotide sequence", "DNA", 182, 211], ["Several techniques", "TREATMENT", 0, 18], ["PCR", "TEST", 28, 31], ["PCR products", "TREATMENT", 41, 53], ["templates", "TREATMENT", 57, 66], ["Randomly amplified polymorphic DNA (RAPD)-PCR", "PROBLEM", 101, 146], ["a single short primer", "PROBLEM", 152, 173], ["an arbitrary nucleotide sequence", "TEST", 179, 211], ["nucleotides", "TREATMENT", 218, 229], ["different random segments", "PROBLEM", 242, 267], ["electrophoresis", "TEST", 327, 342]]], ["This technique does not require knowledge of the target DNA sequence, but its reproducibility is low and has been applied only for few plant viruses (Williams et al., 1990; de Ara\u00fajo et al., 2007); ii) Restriction fragment length polymorphism (RFLP) analysis is based on digestion of the PCR products with restriction enzymes and electrophoretic separation of the resulting restriction fragments according to their length, revealing sequence differences within the restriction sites.", [["DNA", "CELLULAR_COMPONENT", 56, 59], ["target DNA sequence", "DNA", 49, 68], ["RFLP", "DNA", 244, 248], ["restriction enzymes", "PROTEIN", 306, 325], ["restriction fragments", "DNA", 374, 395], ["restriction sites", "DNA", 465, 482], ["the target DNA sequence", "TEST", 45, 68], ["Restriction fragment length polymorphism (RFLP) analysis", "PROBLEM", 202, 258], ["the PCR products", "TREATMENT", 284, 300], ["restriction enzymes", "TREATMENT", 306, 325], ["electrophoretic separation", "TREATMENT", 330, 356], ["the resulting restriction fragments", "PROBLEM", 360, 395], ["sequence differences within the restriction sites", "PROBLEM", 433, 482], ["low", "OBSERVATION_MODIFIER", 97, 100], ["fragment", "OBSERVATION_MODIFIER", 214, 222], ["length", "OBSERVATION_MODIFIER", 223, 229], ["restriction fragments", "OBSERVATION", 374, 395]]], ["This technique has been used to differentiate isolates of some plant viruses, such as prunus necrotic ringspot virus (PNRSV), TYLCV and CTV (Gillings et al., 1993; Hammond et al., 1998; Font et al., 2007); iii) Single-strand conformation polymorphism (SSCP) analysis is based on electrophoresis of denatured dsDNA in non-denaturing gels so migration of single-stranded DNA depends on its conformation determined by its nucleotide sequence and the electrophoretic conditions.", [["nucleotide", "CHEMICAL", 419, 429], ["nucleotide", "CHEMICAL", 419, 429], ["prunus necrotic ringspot virus", "ORGANISM", 86, 116], ["PNRSV", "ORGANISM", 118, 123], ["TYLCV", "ORGANISM", 126, 131], ["dsDNA", "CELLULAR_COMPONENT", 308, 313], ["DNA", "CELLULAR_COMPONENT", 369, 372], ["prunus necrotic ringspot virus", "SPECIES", 86, 116], ["prunus necrotic ringspot virus", "SPECIES", 86, 116], ["PNRSV", "SPECIES", 118, 123], ["TYLCV", "SPECIES", 126, 131], ["This technique", "TREATMENT", 0, 14], ["some plant viruses", "PROBLEM", 58, 76], ["prunus necrotic ringspot virus", "PROBLEM", 86, 116], ["Single-strand conformation polymorphism (SSCP) analysis", "PROBLEM", 211, 266], ["denatured dsDNA", "PROBLEM", 298, 313], ["non-denaturing gels", "TREATMENT", 317, 336], ["single-stranded DNA", "TREATMENT", 353, 372], ["its nucleotide sequence", "TEST", 415, 438], ["the electrophoretic conditions", "PROBLEM", 443, 473], ["plant viruses", "OBSERVATION", 63, 76], ["necrotic", "OBSERVATION_MODIFIER", 93, 101], ["ringspot virus", "OBSERVATION", 102, 116]]], ["This technique is very resolutive and can detect small differences, even of a single nucleotide, but it is very sensitive to minute changes in the electrophoretic conditions hindering reproducibility.", [["nucleotide", "CHEMICAL", 85, 95], ["nucleotide", "CHEMICAL", 85, 95], ["a single nucleotide", "TEST", 76, 95], ["the electrophoretic conditions", "PROBLEM", 143, 173], ["small", "OBSERVATION_MODIFIER", 49, 54]]], ["The main advantage of SSCP analysis is the ability to detect different genetic variants (visualized as electrophoretic bands) within a sample (plant), allowing to assess within-isolate genetic variation rapidly.", [["SSCP", "DNA", 22, 26], ["SSCP analysis", "TEST", 22, 35], ["different genetic variants", "PROBLEM", 61, 87], ["electrophoretic bands", "TEST", 103, 124], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["This technique followed by sequencing of the different haplotypes detected has been used to evaluate the genetic variation of some plant viruses, such as cucumber mosaic virus (CMV), citrus psorosis virus (CPsV) and CTV (Rubio et al., 1996; Rubio et al., 1999; Vives et al., 2002; Lin et al., 2003; Mart\u00edn et al., 2006). iv) Real-time qPCR has been used to differentiate virus strains by high resolution melting DNA curve analysis with SYBR Green or by using TaqMan\u2122 fluorescent probes specific for each strain (Varga and James, 2005; Ruiz-Ruiz et al., 2007; Bester et al., 2012).Detection Levels ::: Detection of Plant VirusesHTS techniques are the most powerful and versatile since the nucleotide sequences can be used not only to estimate the genetic variation and structure of virus populations but also to identify and ascribe a virus sample to different taxonomic levels or discover new virus species, genera or families (Kreuze et al., 2009; Wu et al., 2015; Pecman et al., 2017; Verdin et al., 2017), according to its nucleotide or amino acid identity with known sequences in databases (GenBank) or the presence of sequence motifs.", [["citrus psorosis", "DISEASE", 183, 198], ["nucleotide", "CHEMICAL", 1026, 1036], ["amino acid", "CHEMICAL", 1040, 1050], ["nucleotide", "CHEMICAL", 688, 698], ["nucleotide", "CHEMICAL", 1026, 1036], ["amino acid", "CHEMICAL", 1040, 1050], ["cucumber mosaic virus", "ORGANISM", 154, 175], ["CMV", "ORGANISM", 177, 180], ["citrus psorosis virus", "ORGANISM", 183, 204], ["DNA", "CELLULAR_COMPONENT", 412, 415], ["SYBR Green", "GENE_OR_GENE_PRODUCT", 436, 446], ["amino acid", "AMINO_ACID", 1040, 1050], ["nucleotide sequences", "DNA", 688, 708], ["cucumber mosaic virus", "SPECIES", 154, 175], ["citrus psorosis virus", "SPECIES", 183, 204], ["cucumber mosaic virus", "SPECIES", 154, 175], ["CMV", "SPECIES", 177, 180], ["citrus psorosis virus", "SPECIES", 183, 204], ["CPsV", "SPECIES", 206, 210], ["This technique", "TREATMENT", 0, 14], ["the different haplotypes", "PROBLEM", 41, 65], ["some plant viruses", "PROBLEM", 126, 144], ["cucumber mosaic virus (CMV)", "PROBLEM", 154, 181], ["citrus psorosis virus", "PROBLEM", 183, 204], ["virus strains", "PROBLEM", 371, 384], ["DNA curve analysis", "TEST", 412, 430], ["Detection Levels", "TEST", 580, 596], ["Plant VirusesHTS techniques", "TREATMENT", 614, 641], ["the nucleotide sequences", "TEST", 684, 708], ["virus populations", "PROBLEM", 781, 798], ["a virus sample", "PROBLEM", 832, 846], ["taxonomic levels", "TEST", 860, 876], ["new virus species", "PROBLEM", 889, 906], ["amino acid identity", "PROBLEM", 1040, 1059], ["plant viruses", "OBSERVATION", 131, 144], ["mosaic virus", "OBSERVATION", 163, 175], ["citrus psorosis", "OBSERVATION", 183, 198]]], ["This task can be easily carried out with the algorithm BLAST (https://www.ncbi.nlm.nih.gov/BLAST/), which compares the query sequence with all sequences from databases and find those that are more similar.Detection Levels ::: Detection of Plant VirusesRecombination can produce biological and genomic variants of a virus that can be very similar in one genome region and very divergent in other.", [["the algorithm BLAST", "TEST", 41, 60], ["all sequences from databases", "TEST", 139, 167], ["Plant VirusesRecombination", "PROBLEM", 239, 265], ["a virus", "PROBLEM", 313, 320], ["more similar", "OBSERVATION_MODIFIER", 192, 204], ["Plant VirusesRecombination", "OBSERVATION", 239, 265], ["genomic variants", "OBSERVATION", 293, 309], ["virus", "OBSERVATION", 315, 320], ["divergent", "OBSERVATION_MODIFIER", 376, 385]]], ["Thus, the complete genome or different regions of it should be analyzed for detection and identification of recombinant variants.", [["recombinant variants", "PROBLEM", 108, 128]]], ["Recombination can be detected by comparing nucleotide identity and/or phylogenetic relationships along the genome, which can be performed with different procedures implemented in the package RDP 4 (Martin et al., 2015).", [["nucleotide", "CHEMICAL", 43, 53], ["nucleotide", "CHEMICAL", 43, 53], ["nucleotide identity", "TEST", 43, 62], ["different procedures", "TREATMENT", 143, 163]]], ["For example, identification of CTV strains requires different sets of primers (Roy et al., 2010) as recombination has played an important role in shaping CTV genome (Mart\u00edn et al., 2009).", [["CTV", "CANCER", 31, 34], ["CTV genome", "DNA", 154, 164], ["CTV strains", "PROBLEM", 31, 42], ["CTV strains", "OBSERVATION", 31, 42]]], ["HTS can be useful to detect recombination since full-length or almost full-length viral genomes are sequenced rapidly, in a single analysis (Akinyemi et al., 2016; Silva et al., 2019), unlike genome walking that requires successive steps of PCR, Sanger sequencing and primer design.", [["viral genomes", "DNA", 82, 95], ["successive steps of PCR", "TREATMENT", 221, 244]]], ["Third-generation sequencing of single molecules seems more appropriate to identify recombination (Viehweger et al., 2019) than second-generation sequencing methods that can produce recombinant artifacts, as genomic sequences are assembled from short sequences.", [["genomic sequences", "DNA", 207, 224], ["single molecules", "PROBLEM", 31, 47], ["second-generation sequencing methods", "TREATMENT", 127, 163], ["recombinant artifacts", "PROBLEM", 181, 202], ["genomic sequences", "TEST", 207, 224]]], ["Nevertheless, it is convenient to confirm the recombinants by PCR followed by Sanger sequencing.Multiplexing ::: Detection of Plant VirusesProcedures to detect and identify various viruses or virus strains in a single assay simultaneously reduce time and cost of the analysis (see Pall\u00e1s et al., 2018 for a comprehensive review), and are especially suitable for evaluating mixed infections in individual plants.", [["infections", "DISEASE", 379, 389], ["PCR", "TEST", 62, 65], ["Plant VirusesProcedures", "TREATMENT", 126, 149], ["various viruses", "PROBLEM", 173, 188], ["virus strains", "PROBLEM", 192, 205], ["a single assay", "TEST", 209, 223], ["the analysis", "TEST", 263, 275], ["mixed infections in individual plants", "PROBLEM", 373, 410], ["infections", "OBSERVATION", 379, 389]]], ["The detection of individual viruses in a sample is mainly based on three approaches: i) spatial separation of detection sites (wells or spots); ii) separation of distinctly sized amplicons by electrophoresis; and iii) using a different label for each virus (Dincer et al., 2017).Multiplexing ::: Detection of Plant VirusesMultiplex PCR or RT-PCR is the amplification of multiple targets simultaneously in a single PCR by using several primer pairs specific for each target.", [["primer pairs", "DNA", 435, 447], ["individual viruses", "PROBLEM", 17, 35], ["a sample", "TEST", 39, 47], ["detection sites", "PROBLEM", 110, 125], ["distinctly sized amplicons", "PROBLEM", 162, 188], ["electrophoresis", "TEST", 192, 207], ["Plant VirusesMultiplex PCR", "TEST", 309, 335], ["RT-PCR", "TEST", 339, 345], ["a single PCR", "TEST", 405, 417], ["viruses", "OBSERVATION", 28, 35]]], ["Development of a multiplex PCR or RT-PCR assay is often complex since primers must comply with several conditions: i) similar melting temperatures (similar length and G-C content) so that all primers can function under the same PCR conditions; ii) compatibility, avoiding cross-binding and competition; iii) similar sensitivity; and iv) flanking genomic regions of different sizes so that the amplicons of each target can be separated and visualized by gel electrophoresis.", [["G-C", "GENE_OR_GENE_PRODUCT", 167, 170], ["flanking genomic regions", "DNA", 337, 361], ["a multiplex PCR", "TEST", 15, 30], ["RT-PCR assay", "TEST", 34, 46], ["similar melting temperatures", "PROBLEM", 118, 146], ["G-C content", "TREATMENT", 167, 178], ["all primers", "TREATMENT", 188, 199], ["iv) flanking genomic regions of different sizes", "PROBLEM", 333, 380], ["the amplicons of each target", "TREATMENT", 389, 417], ["gel electrophoresis", "TEST", 453, 472], ["different", "OBSERVATION_MODIFIER", 365, 374], ["sizes", "OBSERVATION_MODIFIER", 375, 380]]], ["The last constriction can be avoided by using primers labeled with different color fluorescent dyes or coupling the PCR with hybridization with specific probes (James et al., 2006).", [["different color fluorescent dyes", "PROBLEM", 67, 99], ["the PCR", "TEST", 112, 119], ["constriction", "OBSERVATION", 9, 21]]], ["Multiplex PCR or RT-PCR have been used to identify: i) the main viruses infecting a particular crop, such as tomato, tobacco, legumes, potato, ornamentals, cucumber and olive (Bariana et al., 1994; Bertolini et al., 2001; Dai et al., 2012; Panno et al., 2012; Ge et al., 2013; Ali et al., 2014; Pall\u00e1s et al., 2018); ii) viruses from the same genus (Uga and Tsuda, 2005; Hu et al., 2010; Panno et al., 2014); and iii) different strains of a viral species (Hammond et al., 1999; Nie and Singh, 2003; Huang et al., 2004; Alfaro-Fern\u00e1ndez et al., 2009; Bester et al., 2012).", [["tomato", "ORGANISM_SUBDIVISION", 109, 115], ["tobacco", "ORGANISM", 117, 124], ["legumes", "ORGANISM_SUBDIVISION", 126, 133], ["potato", "ORGANISM_SUBDIVISION", 135, 141], ["cucumber", "ORGANISM_SUBDIVISION", 156, 164], ["olive", "ORGANISM_SUBDIVISION", 169, 174], ["tomato", "SPECIES", 109, 115], ["tobacco", "SPECIES", 117, 124], ["potato", "SPECIES", 135, 141], ["cucumber", "SPECIES", 156, 164], ["tomato", "SPECIES", 109, 115], ["tobacco", "SPECIES", 117, 124], ["potato", "SPECIES", 135, 141], ["cucumber", "SPECIES", 156, 164], ["Multiplex PCR", "TEST", 0, 13], ["RT-PCR", "TEST", 17, 23], ["viruses", "PROBLEM", 321, 328], ["a viral species", "PROBLEM", 439, 454], ["main", "OBSERVATION_MODIFIER", 59, 63], ["viruses", "OBSERVATION", 64, 71], ["viral species", "OBSERVATION", 441, 454]]], ["Multiplex real-time qPCR with Taqman probes labeled with different fluorescent dyes have been used to identify viruses from the same crop (Abrahamian et al., 2013; L\u00f3pez-Fabuel et al., 2013; Malandraki et al., 2017), and strains or isolates from the same viral species (Varga and James, 2005; Debreczeni et al., 2011).", [["Taqman probes", "DNA", 30, 43], ["Taqman probes", "TREATMENT", 30, 43], ["different fluorescent dyes", "TREATMENT", 57, 83], ["viruses", "PROBLEM", 111, 118], ["L\u00f3pez", "TEST", 164, 169], ["strains", "PROBLEM", 221, 228], ["isolates", "PROBLEM", 232, 240], ["viral species", "OBSERVATION", 255, 268]]], ["The main problem of multiplex PCR is that only a limited number of targets can be amplified simultaneously since the more primers are used, the higher is the probability of incompatibility between some of them.", [["multiplex PCR", "TEST", 20, 33], ["incompatibility", "PROBLEM", 173, 188], ["main", "OBSERVATION_MODIFIER", 4, 8], ["multiplex PCR", "OBSERVATION", 20, 33], ["higher", "OBSERVATION_MODIFIER", 144, 150], ["incompatibility", "OBSERVATION", 173, 188]]], ["Also, there is a limitation in the number of products of different sizes that can be resolved by electrophoresis or the number of fluorescent dyes that can be used (Boonham et al., 2007).", [["fluorescent dyes", "TREATMENT", 130, 146], ["limitation", "OBSERVATION_MODIFIER", 17, 27], ["different", "OBSERVATION_MODIFIER", 57, 66], ["sizes", "OBSERVATION_MODIFIER", 67, 72]]], ["Multiplex LAMP has also been developed for the simultaneous detection of some plant viruses (Zhang J. et al., 2018; Wilisiani et al., 2019).", [["Multiplex LAMP", "TEST", 0, 14], ["the simultaneous detection", "TEST", 43, 69], ["some plant viruses", "PROBLEM", 73, 91], ["plant viruses", "OBSERVATION", 78, 91]]], ["Molecular hybridization with cocktails of probes or polyprobes (probes linked in tandem) has been used to detect different viruses affecting a crop (S\u00e1nchez-Navarro et al., 1999; Saade et al., 2000; Herranz et al., 2005; Aparicio et al., 2009; Minutillo et al., 2012), although further analyses are necessary to identify each virus.Multiplexing ::: Detection of Plant VirusesMicroarray analyses can screen many samples simultaneously.", [["samples", "ANATOMY", 411, 418], ["samples", "CANCER", 411, 418], ["polyprobes", "DNA", 52, 62], ["Molecular hybridization", "PROBLEM", 0, 23], ["cocktails of probes", "TREATMENT", 29, 48], ["polyprobes", "PROBLEM", 52, 62], ["different viruses", "PROBLEM", 113, 130], ["further analyses", "TEST", 278, 294], ["each virus", "PROBLEM", 321, 331], ["Plant VirusesMicroarray analyses", "TEST", 362, 394], ["viruses", "OBSERVATION", 123, 130]]], ["They can be based on serology, but most are based on molecular hybridization (Boonham et al., 2007; Boonham et al., 2014; Charlermroj et al., 2014).", [["serology", "TEST", 21, 29]]], ["Capture probes corresponding to different viruses and/or genomic regions are attached to a solid support (usually glass) and the sample to be examined is fluorescently labeled so the identity of the virus or viruses present in the sample is determined by the fluorescent positions on the array.", [["sample", "ANATOMY", 129, 135], ["sample", "ANATOMY", 231, 237], ["viruses and/or genomic regions", "DNA", 42, 72], ["Capture probes", "TREATMENT", 0, 14], ["different viruses", "PROBLEM", 32, 49], ["genomic regions", "PROBLEM", 57, 72], ["a solid support", "TREATMENT", 89, 104], ["the virus", "PROBLEM", 195, 204], ["viruses", "PROBLEM", 208, 215], ["different", "OBSERVATION_MODIFIER", 32, 41], ["viruses", "OBSERVATION", 42, 49], ["virus", "OBSERVATION", 199, 204], ["viruses", "OBSERVATION", 208, 215]]], ["Capture probes can be produced from PCR products (200\u20131000 bp in length) or synthetic oligonucleotides (20\u201370 nucleotides in length).", [["PCR products", "DNA", 36, 48], ["PCR products", "TREATMENT", 36, 48], ["bp in length)", "TREATMENT", 59, 72], ["synthetic oligonucleotides", "TREATMENT", 76, 102]]], ["Probe design must consider probe length, melting temperature, GC content, secondary structure caused by self-annealing and hybridization free energy since they affect sensitivity and specificity.", [["probe length", "TEST", 27, 39], ["melting temperature", "PROBLEM", 41, 60], ["GC content", "PROBLEM", 62, 72], ["secondary structure", "PROBLEM", 74, 93], ["self-annealing and hybridization free energy", "PROBLEM", 104, 148]]], ["Short oligonucleotides (15\u201325 bases) are better to discriminate small sequence differences but exhibit reduced sensitivity.", [["small sequence differences", "PROBLEM", 64, 90], ["reduced sensitivity", "PROBLEM", 103, 122], ["reduced", "OBSERVATION_MODIFIER", 103, 110]]], ["Oligoprobes can be designed for different detection levels (genus, species and strain) by choosing conserved or variable sequence stretches.", [["different detection levels", "TEST", 32, 58], ["variable sequence stretches", "PROBLEM", 112, 139]]], ["Sensitivity and specificity can be improved controlling the hybridization temperature and buffer composition (Boonham et al., 2007).", [["Sensitivity", "TEST", 0, 11]]], ["Microarrays have been used to detect: i) viruses infecting a particular crop, such as tomato, cucurbits, potato and grapevine (Bystricka et al., 2003; Engel et al., 2010; Sip et al., 2010; Tiberini et al., 2010; Tiberini and Barba, 2012); ii) different viral species of a genus (Wei et al., 2009); and iii) isolates or variants of the same virus (Deyong et al., 2005; Pasquini et al., 2008).", [["tomato", "ORGANISM", 86, 92], ["potato", "TISSUE", 105, 111], ["tomato", "SPECIES", 86, 92], ["potato", "SPECIES", 105, 111], ["grapevine", "SPECIES", 116, 125], ["tomato", "SPECIES", 86, 92], ["potato", "SPECIES", 105, 111], ["Microarrays", "TREATMENT", 0, 11], ["viruses", "PROBLEM", 41, 48], ["Tiberini", "TEST", 212, 220], ["different viral species", "PROBLEM", 243, 266], ["a genus", "PROBLEM", 270, 277], ["the same virus", "PROBLEM", 331, 345], ["viral species", "OBSERVATION", 253, 266]]], ["Microarrays have been improved to detect hundreds of plant viruses, including genus-specific oligoprobes (Zhang et al., 2010; Nicolaisen, 2011; Nam et al., 2014).Multiplexing ::: Detection of Plant VirusesMicrosphere technology, like Luminex xMAP, can detect up to 500 targets in a single sample.", [["Microarrays", "TEST", 0, 11], ["plant viruses", "PROBLEM", 53, 66], ["Luminex xMAP", "TEST", 234, 246], ["a single sample", "TEST", 280, 295], ["plant viruses", "OBSERVATION", 53, 66]]], ["It is based on microspheres (beads) coated with specific antibodies or oligonucleotides, which capture respectively viruses or PCR products obtained from their genetic material.", [["PCR products", "PROTEIN", 127, 139], ["microspheres (beads)", "TREATMENT", 15, 35], ["specific antibodies", "TEST", 48, 67], ["oligonucleotides", "PROBLEM", 71, 87], ["PCR products", "TEST", 127, 139]]], ["The beads have been dyed into spectrally distinct sets, or \u201cregions,\u201d allowing them to be individually identified.", [["The beads", "TREATMENT", 0, 9], ["spectrally", "OBSERVATION_MODIFIER", 30, 40], ["distinct", "OBSERVATION_MODIFIER", 41, 49], ["sets", "OBSERVATION_MODIFIER", 50, 54]]], ["After binding, the target is labeled by specific conjugated antibodies or probes which will give a fluorescent signal.", [["conjugated antibodies", "PROTEIN", 49, 70], ["a fluorescent signal", "TEST", 97, 117]]], ["The color code of the bead in combination with the fluorescent signal identifies a unique combination (Boonham et al., 2014).", [["the fluorescent signal", "TEST", 47, 69], ["color", "OBSERVATION_MODIFIER", 4, 9], ["bead", "OBSERVATION_MODIFIER", 22, 26]]], ["Luminex xMAP system has been used to detect viruses infecting a crop (Lim et al., 2016), viruses belonging to a genus (van Brunschot et al., 2014; Bald-Blume et al., 2017a), and strains or variants within a virus species (Bald-Blume et al., 2017b).Multiplexing ::: Detection of Plant VirusesHTS is the most powerful technique for multiplex detection as it can identify and discover an unlimited number of viruses and virus variants within a plant (Jones et al., 2017).Quantification ::: Detection of Plant VirusesEstimating the amount of a specific virus provides more precise information than just determining the presence or absence of that virus.", [["xMAP", "CHEMICAL", 8, 12], ["Plant Viruses", "ORGANISM", 500, 513], ["xMAP", "PROTEIN", 8, 12], ["Luminex xMAP system", "TEST", 0, 19], ["viruses", "PROBLEM", 44, 51], ["strains", "PROBLEM", 178, 185], ["variants", "PROBLEM", 189, 197], ["a virus species", "PROBLEM", 205, 220], ["multiplex detection", "TEST", 330, 349], ["viruses and virus variants", "PROBLEM", 405, 431], ["Plant Viruses", "PROBLEM", 500, 513], ["a specific virus", "PROBLEM", 538, 554], ["that virus", "PROBLEM", 638, 648], ["viruses", "OBSERVATION", 405, 412], ["Plant Viruses", "OBSERVATION", 500, 513]]], ["ELISA and molecular hybridization can be used for rough quantification of viral particles or nucleic acids based on the signal intensity (Rubio et al., 2003a; Rohrman et al., 2012).", [["nucleic acids", "CHEMICAL", 93, 106], ["nucleic acids", "SIMPLE_CHEMICAL", 93, 106], ["ELISA", "TEST", 0, 5], ["molecular hybridization", "TREATMENT", 10, 33], ["viral particles", "PROBLEM", 74, 89], ["nucleic acids", "PROBLEM", 93, 106], ["viral particles", "OBSERVATION", 74, 89]]], ["Real-time qPCR is a very accurate procedure to estimate virus titer with a wide dynamic range and great sensitivity.", [["a very accurate procedure", "TREATMENT", 18, 43], ["estimate virus titer", "PROBLEM", 47, 67]]], ["The principle is to monitor in each cycle the increase of fluorescence.", [["increase", "OBSERVATION_MODIFIER", 46, 54]]], ["The cycle at which amplification is observed (cycle threshold, CT) is related to the inverse Log of the quantity of target being amplified (Boonham et al., 2014).", [["CT", "TEST", 63, 65]]], ["Real-time qPCR or RT-qPCR has been developed for several plant viruses (Mumford et al., 2000; Pic\u00f3 et al., 2005; L\u00f3pez et al., 2006; Ling et al., 2007; Hongyun et al., 2008; Ruiz-Ruiz et al., 2009a; Debreczeni et al., 2011; Ferriol et al., 2011; Sharma and Dasgupta, 2012; MacKenzie et al., 2015; Herrera-V\u00e1squez et al., 2015).", [["RT-qPCR", "TEST", 18, 25], ["Ruiz", "TEST", 174, 178], ["Herrera", "TEST", 297, 304]]], ["It has been applied to evaluate some disease control methods such as i) study interactions between viruses in mixed infections (Mortimer-Jones et al., 2009; Abrahamian et al., 2013), which can be used for control based on cross protection (Ruiz-Ruiz et al., 2009b; Hanssen et al., 2010); ii) estimation of correlation between virus accumulation and transmission by insect vectors (Olmos et al., 2005; Rotenberg et al., 2009; Ferriol et al., 2013; Debreczeni et al., 2014), which can be used for epidemiological studies and disease control strategies based on restricting the dispersion of viruses by vectors; iii) evaluation of the resistance level to virus accumulation in plant breeding programs (Gil-Salas et al., 2009; Galipienso et al., 2013; Soler et al., 2015); and iv) estimation of fitness in competition and evolutionary experiments (Carrasco et al., 2007; Pe\u00f1a et al., 2014) which can be used for evolutionary and epidemiological studies, as well as for evaluation of resistance durability.", [["infections", "DISEASE", 116, 126], ["some disease control methods", "PROBLEM", 32, 60], ["mixed infections", "PROBLEM", 110, 126], ["virus accumulation", "PROBLEM", 326, 344], ["epidemiological studies", "TEST", 495, 518], ["disease control strategies", "TREATMENT", 523, 549], ["evaluation", "TEST", 614, 624], ["the resistance level", "PROBLEM", 628, 648], ["virus accumulation", "PROBLEM", 652, 670], ["epidemiological studies", "TEST", 925, 948], ["evaluation", "TEST", 965, 975], ["resistance durability", "PROBLEM", 979, 1000], ["mixed", "OBSERVATION_MODIFIER", 110, 115], ["infections", "OBSERVATION", 116, 126]]], ["HTS can be used for a relative quantification based on the number of reads for the same sequence, but it is still too expensive for these applications.Feasibility and Designability ::: Detection of Plant VirusesOther important features to be considered in the detection techniques are the costs, throughput screening (number of samples analyzed simultaneously) and easiness, not only during the application but also during the design or development (Table 3).Feasibility and Designability ::: Detection of Plant VirusesSample processing is a critical step and affects the rapidity, easiness and throughput of the detection process.", [["a relative quantification", "TEST", 20, 45], ["these applications", "TREATMENT", 132, 150], ["throughput screening", "TEST", 296, 316], ["Plant Viruses", "PROBLEM", 506, 519], ["the detection process", "TEST", 609, 630], ["Plant Viruses", "OBSERVATION", 506, 519]]], ["Molecular hybridization and PCR techniques require purification of total RNA or DNA from plants to remove substances inhibiting the detection process (yielding false negatives) or producing a background signal (yielding false positives).", [["DNA", "CELLULAR_COMPONENT", 80, 83], ["total RNA", "RNA", 67, 76], ["Molecular hybridization", "TEST", 0, 23], ["PCR techniques", "TEST", 28, 42], ["total RNA", "TREATMENT", 67, 76], ["DNA", "PROBLEM", 80, 83], ["substances", "TREATMENT", 106, 116], ["the detection process", "TEST", 128, 149]]], ["Inhibition of PCR can be avoided or minimized by diluting the extracts or by immunocapture (Olmos et al., 2007).", [["extracts", "ANATOMY", 62, 70], ["extracts", "ORGANISM_SUBSTANCE", 62, 70], ["Inhibition of PCR", "TREATMENT", 0, 17]]], ["HTS also requires purification of DNA or RNA from plants.", [["DNA", "CELLULAR_COMPONENT", 34, 37], ["DNA", "PROBLEM", 34, 37]]], ["Libraries can be enriched in viral sequences by using as starting material preparations from which host nucleic acids have been removed by subtractive hybridization or using purified viral particles, double-stranded RNAs (dsRNAs) preparations, which are enriched in replicative intermediates of RNA viruses, or small RNAs resulting from RNA silencing that is a plant response to virus infection (Kreuze et al., 2009; Singh et al., 2012; Kesanakurti et al., 2016; Pecman et al., 2017; Czotter et al., 2018).Feasibility and Designability ::: Detection of Plant VirusesExtracts obtained by just grinding plant tissue in buffer can be used for ELISA and LAMP.", [["Extracts", "ANATOMY", 566, 574], ["tissue", "ANATOMY", 607, 613], ["nucleic acids", "CHEMICAL", 104, 117], ["infection", "DISEASE", 385, 394], ["double-stranded RNAs", "GENE_OR_GENE_PRODUCT", 200, 220], ["tissue", "TISSUE", 607, 613], ["viral sequences", "DNA", 29, 44], ["double-stranded RNAs", "RNA", 200, 220], ["dsRNAs", "DNA", 222, 228], ["RNA viruses", "RNA", 295, 306], ["small RNAs", "RNA", 311, 321], ["Libraries", "TREATMENT", 0, 9], ["viral sequences", "TREATMENT", 29, 44], ["material preparations", "TREATMENT", 66, 87], ["host nucleic acids", "TREATMENT", 99, 117], ["subtractive hybridization", "TREATMENT", 139, 164], ["purified viral particles", "TREATMENT", 174, 198], ["double-stranded RNAs (dsRNAs) preparations", "TREATMENT", 200, 242], ["RNA viruses", "PROBLEM", 295, 306], ["small RNAs", "PROBLEM", 311, 321], ["RNA silencing", "PROBLEM", 337, 350], ["virus infection", "PROBLEM", 379, 394], ["Plant VirusesExtracts", "PROBLEM", 553, 574], ["ELISA", "TEST", 640, 645], ["RNA viruses", "OBSERVATION", 295, 306], ["small RNAs", "OBSERVATION", 311, 321], ["Plant Viruses", "OBSERVATION", 553, 566]]], ["For some viruses, tissue-prints made by cutting leaf petioles or rolled leaf blades transversely and gently pressing the fresh cut onto nitrocellulose membranes have been analyzed directly with ELISA or molecular hybridization (Narv\u00e1ez et al., 2000; Rubio et al., 2003b; Ferrer et al., 2008).", [["tissue", "ANATOMY", 18, 24], ["leaf petioles", "ANATOMY", 48, 61], ["leaf blades", "ANATOMY", 72, 83], ["membranes", "ANATOMY", 151, 160], ["nitrocellulose", "CHEMICAL", 136, 150], ["tissue", "TISSUE", 18, 24], ["leaf petioles", "MULTI-TISSUE_STRUCTURE", 48, 61], ["membranes", "CELLULAR_COMPONENT", 151, 160], ["some viruses", "PROBLEM", 4, 16], ["rolled leaf blades", "TREATMENT", 65, 83], ["the fresh cut onto nitrocellulose membranes", "TREATMENT", 117, 160], ["viruses", "OBSERVATION", 9, 16]]], ["An alternative to passive incubation of probes with the targets immobilized onto membranes in solution is the flow-through hybridization, based on directing a probe flow towards the targets immobilized on the membrane, reducing the hybridization time from hours to a few minutes (Ferriol et al., 2015).Feasibility and Designability ::: Detection of Plant VirusesOn-site detection of plant viruses is an interesting feature allowing a prompt response.", [["membranes", "ANATOMY", 81, 90], ["membrane", "ANATOMY", 209, 217], ["membranes", "CELLULAR_COMPONENT", 81, 90], ["membrane", "CELLULAR_COMPONENT", 209, 217], ["passive incubation of probes", "TREATMENT", 18, 46], ["membranes in solution", "TREATMENT", 81, 102], ["a probe flow", "TREATMENT", 157, 169], ["the membrane", "TREATMENT", 205, 217], ["Plant VirusesOn", "TEST", 349, 364], ["plant viruses", "PROBLEM", 383, 396], ["plant viruses", "OBSERVATION", 383, 396]]], ["Lateral flow assay (LFA) consists of a chromatographic test strip where crude plant extracts are dropped and move capillarily.", [["extracts", "ANATOMY", 84, 92], ["extracts", "ORGANISM_SUBSTANCE", 84, 92], ["Lateral flow assay", "TEST", 0, 18], ["a chromatographic test strip", "TEST", 37, 65], ["crude plant extracts", "TEST", 72, 92]]], ["The virus is detected when a stained band appears by binding virions with labeled antibodies or viral nucleic acids with labeled DNA or RNA probes (Drygin et al., 2012; Zhang et al., 2014; Koczula and Gallotta, 2016).", [["nucleic acids", "CHEMICAL", 102, 115], ["DNA", "CELLULAR_COMPONENT", 129, 132], ["labeled antibodies", "PROTEIN", 74, 92], ["The virus", "PROBLEM", 0, 9], ["a stained band", "PROBLEM", 27, 41], ["binding virions", "PROBLEM", 53, 68], ["labeled antibodies", "TEST", 74, 92], ["viral nucleic acids", "PROBLEM", 96, 115], ["labeled DNA", "PROBLEM", 121, 132], ["RNA probes", "TEST", 136, 146], ["virus", "OBSERVATION", 4, 9]]], ["This procedure takes only about 15 to 30 min.", [["This procedure", "TREATMENT", 0, 14]]], ["LFA has been used for multiplex detection of potato viruses (Safenkova et al., 2016) and relative quantification (Rohrman et al., 2012).", [["LFA", "GENE_OR_GENE_PRODUCT", 0, 3], ["potato viruses", "ORGANISM", 45, 59], ["LFA", "PROTEIN", 0, 3], ["potato viruses", "SPECIES", 45, 59], ["LFA", "TEST", 0, 3], ["potato viruses", "PROBLEM", 45, 59], ["potato viruses", "OBSERVATION", 45, 59]]], ["RPA and LAMP isothermal amplification can be performed with crude plant extracts in portable hot blocks and results can be displayed with a portable fluorescence reader or a lateral flow strip so the whole process can take about 45 min.", [["extracts", "ANATOMY", 72, 80], ["RPA", "GENE_OR_GENE_PRODUCT", 0, 3], ["extracts", "ORGANISM_SUBSTANCE", 72, 80], ["RPA", "PROTEIN", 0, 3], ["RPA", "TEST", 0, 3], ["LAMP isothermal amplification", "TEST", 8, 37], ["portable hot blocks", "TEST", 84, 103], ["a portable fluorescence", "TEST", 138, 161], ["a lateral flow strip", "TREATMENT", 172, 192]]], ["Oxford Nanopore Technologies has developed MinION, a portable nanopore sequencing device, that can be used for the detection of plant viruses in the field (Boykin et al., 2018; Filloux et al., 2018; Shaffer, 2019), but it is still too expensive for most routine uses.Feasibility and Designability ::: Detection of Plant VirusesThe ability to develop rapidly new assays is very important given the continuous emergence of new plant viruses.", [["Plant Viruses", "ORGANISM", 314, 327], ["a portable nanopore sequencing device", "TREATMENT", 51, 88], ["plant viruses", "PROBLEM", 128, 141], ["Plant Viruses", "PROBLEM", 314, 327], ["rapidly new assays", "PROBLEM", 350, 368], ["new plant viruses", "PROBLEM", 421, 438], ["plant viruses", "OBSERVATION", 128, 141], ["Plant Viruses", "OBSERVATION", 314, 327], ["plant viruses", "OBSERVATION", 425, 438]]], ["In contrast, the setup of molecular detection methods is a directed process that is cheap, fast and versatile, enabling to address different detection levels and consider the genetic variability of virus populations.", [["molecular detection methods", "TREATMENT", 26, 53], ["different detection levels", "TEST", 131, 157], ["virus populations", "PROBLEM", 198, 215]]], ["They can be easily designed with many available software algorithms, such as Prime3 (http://bioinfo.ut.ee/primer3-0.4.0/) and Primer Express (Thermofisher) for PCR, or Primer Explorer (https://primerexplorer.jp/e/), LAMP Designer (Optigene) and LAVA (Torres et al., 2011) for LAMP.Immunization Measures ::: Disease ManagementIntrogression of resistance genes from cultivated or wild species into susceptible related crops by backcrossing (plant breeding) is the most widely-used immunization method.", [["Prime3", "DNA", 77, 83], ["resistance genes", "DNA", 342, 358], ["PCR", "PROBLEM", 160, 163], ["Disease Management", "TREATMENT", 307, 325], ["resistance genes", "PROBLEM", 342, 358], ["wild species", "PROBLEM", 378, 390], ["immunization method", "TREATMENT", 479, 498], ["resistance genes", "OBSERVATION", 342, 358]]], ["There are two types: i) active resistance driven by resistance proteins, encoded by dominant alleles, which recognize specifically a sequence or conformational pattern of a virus gene (avirulence determinant, Avr) and induces death of the infected cells (hypersensitive response), precluding virus movement to adjacent cells and systemic infection (De Ronde et al., 2014; Peir\u00f3 et al., 2014); and ii) passive resistance, conferred by resistance recessive alleles encoding host factors critical for viral infection, mostly eukaryotic translation initiation factors (eIF) 4E and 4G, and their isoforms (Truniger and Aranda, 2009; Hashimoto et al., 2016).Immunization Measures ::: Disease ManagementPlant breeders usually aim at complete resistance, in which the virus cannot establish a systemic infection.", [["cells", "ANATOMY", 248, 253], ["cells", "ANATOMY", 319, 324], ["death of the infected", "DISEASE", 226, 247], ["systemic infection", "DISEASE", 329, 347], ["viral infection", "DISEASE", 498, 513], ["infection", "DISEASE", 794, 803], ["Avr", "GENE_OR_GENE_PRODUCT", 209, 212], ["cells", "CELL", 248, 253], ["cells", "CELL", 319, 324], ["eukaryotic translation initiation factors (eIF) 4E", "GENE_OR_GENE_PRODUCT", 522, 572], ["4G", "GENE_OR_GENE_PRODUCT", 577, 579], ["resistance proteins", "PROTEIN", 52, 71], ["virus gene", "DNA", 173, 183], ["Avr", "PROTEIN", 209, 212], ["infected cells", "CELL_TYPE", 239, 253], ["adjacent cells", "CELL_TYPE", 310, 324], ["host factors", "PROTEIN", 472, 484], ["eukaryotic translation initiation factors", "PROTEIN", 522, 563], ["eIF", "PROTEIN", 565, 568], ["4G", "PROTEIN", 577, 579], ["active resistance", "PROBLEM", 24, 41], ["resistance proteins", "PROBLEM", 52, 71], ["a sequence", "TEST", 131, 141], ["a virus gene (avirulence determinant", "PROBLEM", 171, 207], ["Avr", "TREATMENT", 209, 212], ["the infected cells", "PROBLEM", 235, 253], ["hypersensitive response)", "PROBLEM", 255, 279], ["virus movement to adjacent cells", "PROBLEM", 292, 324], ["systemic infection", "PROBLEM", 329, 347], ["passive resistance", "PROBLEM", 401, 419], ["resistance recessive alleles encoding host factors", "PROBLEM", 434, 484], ["viral infection", "PROBLEM", 498, 513], ["Disease Management", "TREATMENT", 678, 696], ["Plant breeders", "TREATMENT", 696, 710], ["the virus", "PROBLEM", 756, 765], ["a systemic infection", "PROBLEM", 783, 803], ["active", "OBSERVATION_MODIFIER", 24, 30], ["resistance", "OBSERVATION", 31, 41], ["infected cells", "OBSERVATION", 239, 253], ["systemic", "OBSERVATION_MODIFIER", 329, 337], ["infection", "OBSERVATION", 338, 347], ["infection", "OBSERVATION", 504, 513], ["systemic", "OBSERVATION_MODIFIER", 785, 793], ["infection", "OBSERVATION", 794, 803]]], ["ELISA and molecular hybridization have been used to test germplasm and cultivars for resistance since a good number of plants can be analyzed simultaneously (Rubio et al., 2003a; Soler et al., 2015).", [["ELISA", "TEST", 0, 5], ["molecular hybridization", "PROBLEM", 10, 33], ["resistance", "PROBLEM", 85, 95]]], ["When a complete resistance is not possible, breeding for relative or partial resistance (reduction of virus accumulation) or tolerance (reduction of virus damage without affecting virus multiplication) can be a good alternative.", [["partial resistance", "PROBLEM", 69, 87], ["virus accumulation", "PROBLEM", 102, 120], ["virus damage", "PROBLEM", 149, 161], ["virus multiplication", "TREATMENT", 180, 200], ["not possible", "UNCERTAINTY", 30, 42]]], ["The most precise technique to evaluate the level of relative resistance is real-time qPCR (Gil-Salas et al., 2009; Galipienso et al., 2013; Soler et al., 2015).", [["resistance", "OBSERVATION", 61, 71]]], ["Time-course assays can be used to evaluate relative resistance (that can be measured by ELISA or molecular hybridization) and relative tolerance (measured by observation of symptoms as a proxy of damage).", [["relative resistance", "PROBLEM", 43, 62], ["symptoms", "PROBLEM", 173, 181]]], ["The levels of resistance or tolerance can be estimated as the probability of no infection or no symptoms, respectively, by survival analyses (Kaplan and Meier, 1958).Immunization Measures ::: Disease ManagementHowever, breeding resistant cultivars is unsuitable for many crops and viruses because of the scarcity of resistance genes found in genetically compatible relatives.", [["infection", "DISEASE", 80, 89], ["resistance genes", "DNA", 316, 332], ["infection", "PROBLEM", 80, 89], ["symptoms", "PROBLEM", 96, 104], ["Disease ManagementHowever", "PROBLEM", 192, 217], ["breeding resistant cultivars", "PROBLEM", 219, 247], ["many crops and viruses", "PROBLEM", 266, 288], ["resistance genes", "PROBLEM", 316, 332], ["no", "UNCERTAINTY", 77, 79], ["infection", "OBSERVATION", 80, 89]]], ["An alternative may be to change the specificity or range of known resistance genes by artificial evolution so they can confer resistance to novel viruses or virus strains.", [["resistance genes", "DNA", 66, 82], ["known resistance genes", "PROBLEM", 60, 82], ["novel viruses", "PROBLEM", 140, 153], ["virus strains", "PROBLEM", 157, 170]]], ["This approach is based on generating large populations of random mutants from a resistance gene by PCR with a high error rate, followed by the selection of those variants showing the desired resistance properties.", [["resistance gene", "DNA", 80, 95], ["random mutants", "PROBLEM", 58, 72], ["PCR", "TEST", 99, 102], ["large", "OBSERVATION_MODIFIER", 37, 42], ["populations", "OBSERVATION", 43, 54], ["desired resistance", "OBSERVATION", 183, 201]]], ["Resistance is evaluated by Agrobacterium-mediated transient co-expression of each resistance gene mutant and the Avr from the challenge virus in Nicotiana benthamiana leaves so the resistance response is observed as a necrotic lesion.", [["leaves", "ANATOMY", 167, 173], ["necrotic lesion", "ANATOMY", 218, 233], ["necrotic", "DISEASE", 218, 226], ["Avr", "GENE_OR_GENE_PRODUCT", 113, 116], ["Nicotiana benthamiana", "ORGANISM", 145, 166], ["leaves", "ORGANISM", 167, 173], ["necrotic lesion", "CANCER", 218, 233], ["resistance gene mutant", "DNA", 82, 104], ["Avr", "DNA", 113, 116], ["Nicotiana benthamiana", "SPECIES", 145, 166], ["Nicotiana benthamiana", "SPECIES", 145, 166], ["each resistance gene mutant", "PROBLEM", 77, 104], ["the Avr", "TREATMENT", 109, 116], ["the challenge virus", "TREATMENT", 122, 141], ["Nicotiana benthamiana leaves", "TREATMENT", 145, 173], ["a necrotic lesion", "PROBLEM", 216, 233], ["necrotic", "OBSERVATION_MODIFIER", 218, 226], ["lesion", "OBSERVATION", 227, 233]]], ["This approach has been used to broaden the resistance specificity of the potato gene Rx (Farnham and Baulcombe, 2006; Harris et al., 2013), but its use has not become widespread since most mutants are nonfunctional and screening is time-consuming.Immunization Measures ::: Disease ManagementGenome editing, like the CRISPR-Cas9 system, could be used to implement in crops the resistance genes obtained by artificial evolution and to mutagenize directly host genes involved in recessive resistance to prevent interaction with viruses (Piron et al., 2010; Chandrasekaran et al., 2016; Pyott et al., 2016).", [["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 316, 327], ["CRISPR", "DNA", 316, 322], ["resistance genes", "DNA", 376, 392], ["host genes", "DNA", 453, 463], ["potato", "SPECIES", 73, 79], ["potato", "SPECIES", 73, 79], ["Disease Management", "TREATMENT", 273, 291], ["Genome editing", "PROBLEM", 291, 305], ["recessive resistance", "PROBLEM", 476, 496]]], ["However, the mutagenized plant genes could be involved in important biological functions, so the mutations may also have unexpected adverse effects in plant development or physiology.Immunization Measures ::: Disease ManagementResistance can be ineffective for some virus variants or be overcome by i) interaction with other viruses in mixed infections (Desbiez et al., 2003; Garc\u00eda-Cano et al., 2006), ii) positive selection of punctual mutations (Weber et al., 1993; H\u00e9brard et al., 2006; L\u00f3pez et al., 2011) or iii) recombination or reassortment events (Qiu and Moyer, 1999; Miras et al., 2014).", [["infections", "DISEASE", 342, 352], ["mutagenized plant genes", "DNA", 13, 36], ["Disease ManagementResistance", "PROBLEM", 209, 237], ["some virus variants", "PROBLEM", 261, 280], ["plant genes", "OBSERVATION", 25, 36], ["punctual mutations", "OBSERVATION", 429, 447]]], ["Plant genes conferring dominant resistance usually target viral protein domains whose function is essential for the virus biology (replication, movement, transmission) and are under strong negative selection.", [["Plant genes", "DNA", 0, 11], ["viral protein domains", "PROTEIN", 58, 79], ["dominant resistance", "PROBLEM", 23, 42], ["viral protein domains", "PROBLEM", 58, 79], ["dominant resistance", "OBSERVATION", 23, 42]]], ["Thus, it is difficult for the virus to fix the mutations producing resistance breakdown.", [["the virus", "PROBLEM", 26, 35], ["the mutations", "PROBLEM", 43, 56], ["resistance breakdown", "PROBLEM", 67, 87], ["resistance", "OBSERVATION_MODIFIER", 67, 77], ["breakdown", "OBSERVATION_MODIFIER", 78, 87]]], ["In some cases, overcoming the resistance implemented in a cultivar by plant breeding involves a tradeoff leading to a loss of the virus fitness in non-resistant hosts, thus limiting the cases of emergence and spread of resistance-breaking isolates in the field (Garc\u00eda-Arenal and McDonald, 2003).", [["a cultivar", "TREATMENT", 56, 66], ["a loss of the virus fitness in non-resistant hosts", "PROBLEM", 116, 166], ["breaking isolates", "PROBLEM", 230, 247], ["virus", "OBSERVATION", 130, 135]]], ["Polygenic resistance is more durable, but resistance implemented in most breeding programs is monogenic because its introgression in the crops is easier (Palloix et al., 2009).", [["monogenic", "DISEASE", 94, 103], ["Polygenic resistance", "PROBLEM", 0, 20], ["monogenic", "PROBLEM", 94, 103], ["resistance", "OBSERVATION", 10, 20], ["more durable", "OBSERVATION_MODIFIER", 24, 36]]], ["Understanding the molecular, evolutionary and epidemiological factors involved in the emergence of resistance-breaking virus isolates is progressing (Garc\u00eda-Arenal and McDonald, 2003; Elena et al., 2014), but predicting the durability of new resistances remains elusive and it needs to be tested in the field.Immunization Measures ::: Disease ManagementPlant breeders are keen on the host genetic variability, but often they neglect the virus genetic variability, which should be considered when new resistance genes are tested to minimize the possibility of resistance breakdown.", [["resistance genes", "DNA", 500, 516], ["breaking virus isolates", "PROBLEM", 110, 133], ["new resistances", "PROBLEM", 238, 253], ["Disease Management", "TREATMENT", 335, 353], ["the virus genetic variability", "PROBLEM", 433, 462], ["new resistance genes", "PROBLEM", 496, 516], ["resistance breakdown", "PROBLEM", 559, 579], ["new", "OBSERVATION_MODIFIER", 238, 241], ["resistances", "OBSERVATION", 242, 253], ["breeders", "OBSERVATION", 359, 367], ["resistance", "OBSERVATION_MODIFIER", 559, 569], ["breakdown", "OBSERVATION", 570, 579]]], ["Multiplex real-time qPCR is well-suited to evaluate the effect of mixed infections in overcoming resistance.", [["infections", "DISEASE", 72, 82], ["Multiplex real-time qPCR", "TEST", 0, 24], ["mixed infections", "PROBLEM", 66, 82], ["mixed", "OBSERVATION_MODIFIER", 66, 71], ["infections", "OBSERVATION", 72, 82]]], ["Detection of virus variants with punctual mutations leading to resistance breakdown would be a valuable tool to monitor the dispersion of these variants.", [["virus variants", "PROBLEM", 13, 27], ["punctual mutations", "PROBLEM", 33, 51], ["resistance breakdown", "PROBLEM", 63, 83], ["virus variants", "OBSERVATION", 13, 27]]], ["However, this has proved to be a difficult task as in most cases resistance breakdown occurs by only one nucleotide substitution (producing one amino acid change).", [["nucleotide", "CHEMICAL", 105, 115], ["amino acid", "CHEMICAL", 144, 154], ["nucleotide", "CHEMICAL", 105, 115], ["amino acid", "CHEMICAL", 144, 154], ["amino acid", "AMINO_ACID", 144, 154], ["a difficult task", "PROBLEM", 31, 47], ["resistance breakdown", "PROBLEM", 65, 85], ["one nucleotide substitution", "TREATMENT", 101, 128], ["one amino acid change", "TREATMENT", 140, 161]]], ["The presence of other neutral substitutions around the critical mutation hinders the design of molecular markers for resistance breakdown.", [["other neutral substitutions", "PROBLEM", 16, 43], ["the critical mutation", "PROBLEM", 51, 72], ["resistance breakdown", "PROBLEM", 117, 137], ["neutral substitutions", "OBSERVATION", 22, 43]]], ["Real-time qPCR with Taqman probes has been developed to detect single nucleotide polymorphisms associated with resistance breakdown for beet necrotic yellow vein virus (BNYVV) and tomato spotted wilt virus (TSWV) (Acosta-Leal and Rush, 2007; di Rienzo et al., 2018);.", [["nucleotide", "CHEMICAL", 70, 80], ["beet necrotic yellow vein virus", "ORGANISM", 136, 167], ["BNYVV", "ORGANISM", 169, 174], ["tomato spotted wilt virus", "ORGANISM", 180, 205], ["TSWV", "ORGANISM", 207, 211], ["Taqman probes", "DNA", 20, 33], ["yellow vein virus", "SPECIES", 150, 167], ["tomato spotted wilt virus", "SPECIES", 180, 205], ["beet necrotic yellow vein virus", "SPECIES", 136, 167], ["BNYVV", "SPECIES", 169, 174], ["tomato spotted wilt virus", "SPECIES", 180, 205], ["TSWV", "SPECIES", 207, 211], ["Taqman probes", "TEST", 20, 33], ["single nucleotide polymorphisms", "PROBLEM", 63, 94], ["resistance breakdown", "PROBLEM", 111, 131], ["beet necrotic yellow vein virus", "PROBLEM", 136, 167], ["tomato spotted wilt virus", "PROBLEM", 180, 205], ["necrotic", "OBSERVATION_MODIFIER", 141, 149], ["yellow vein virus", "OBSERVATION", 150, 167]]], ["However, there is no guarantee that these techniques are universal for all isolates of each virus species, since other polymorphic sites nearby can affect the detection process or have epistatic interactions affecting resistance.Immunization Measures ::: Disease ManagementAnother strategy to obtain resistant plants is based on the RNA silencing mechanism.", [["polymorphic sites", "DNA", 119, 136], ["each virus species", "PROBLEM", 87, 105], ["other polymorphic sites", "PROBLEM", 113, 136], ["epistatic interactions affecting resistance", "PROBLEM", 185, 228], ["Disease Management", "TREATMENT", 255, 273], ["resistant plants", "PROBLEM", 300, 316], ["no", "UNCERTAINTY", 18, 20]]], ["RNA silencing is a regulatory mechanism of gene expression in eukaryotes and a natural antiviral defense mechanism.", [["RNA silencing", "PROBLEM", 0, 13], ["a natural antiviral defense mechanism", "TREATMENT", 77, 114], ["gene expression", "OBSERVATION", 43, 58], ["antiviral defense", "OBSERVATION", 87, 104]]], ["The host RNA silencing machinery targets dsRNA that arise from replicative viral intermediates or secondary structures in the genomic RNA due to internal complementarity, which are detected by RNases (Dicer-like proteins) and cleaved into small RNA duplexes (siRNA or miRNAs) of 21\u201324 nucleotides (nt) in length.", [["nucleotides", "CHEMICAL", 285, 296], ["RNases", "GENE_OR_GENE_PRODUCT", 193, 199], ["Dicer-like proteins", "GENE_OR_GENE_PRODUCT", 201, 220], ["genomic RNA", "RNA", 126, 137], ["RNases", "PROTEIN", 193, 199], ["Dicer", "PROTEIN", 201, 206], ["like proteins", "PROTEIN", 207, 220], ["small RNA duplexes", "RNA", 239, 257], ["siRNA", "RNA", 259, 264], ["miRNAs", "RNA", 268, 274], ["21\u201324 nucleotides", "DNA", 279, 296], ["The host RNA silencing machinery targets dsRNA", "TREATMENT", 0, 46], ["replicative viral intermediates", "PROBLEM", 63, 94], ["secondary structures in the genomic RNA", "PROBLEM", 98, 137], ["internal complementarity", "PROBLEM", 145, 169], ["small RNA duplexes", "PROBLEM", 239, 257], ["nucleotides (nt) in length", "PROBLEM", 285, 311], ["host", "OBSERVATION_MODIFIER", 4, 8], ["RNA silencing", "OBSERVATION", 9, 22], ["replicative", "OBSERVATION_MODIFIER", 63, 74], ["viral intermediates", "OBSERVATION", 75, 94], ["secondary structures", "OBSERVATION", 98, 118], ["genomic RNA", "OBSERVATION", 126, 137], ["internal complementarity", "OBSERVATION", 145, 169], ["small", "OBSERVATION_MODIFIER", 239, 244], ["RNA duplexes", "OBSERVATION", 245, 257]]], ["One of the two strands of the small RNAs is recruited to the RNA-induced silencing complex (RISC) that subsequently cleaves cognate viral RNAs in a sequence-specific manner.", [["RNA-induced silencing complex", "GENE_OR_GENE_PRODUCT", 61, 90], ["RISC", "GENE_OR_GENE_PRODUCT", 92, 96], ["small RNAs", "RNA", 30, 40], ["RNA-induced silencing complex", "PROTEIN", 61, 90], ["RISC", "PROTEIN", 92, 96], ["viral RNAs", "RNA", 132, 142], ["the small RNAs", "PROBLEM", 26, 40], ["two", "OBSERVATION_MODIFIER", 11, 14], ["strands", "OBSERVATION_MODIFIER", 15, 22], ["small RNAs", "OBSERVATION", 30, 40]]], ["These cleaved RNAs are recognized by RNA dependent RNA polymerase (RDR), which amplifies the dsRNA molecules, thus contributing to the amplification of the host defense mechanism that results in effective inhibition of local and systemic viral infection (Kaldis et al., 2017).", [["viral infection", "DISEASE", 238, 253], ["RNA dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 37, 65], ["RDR", "GENE_OR_GENE_PRODUCT", 67, 70], ["cleaved RNAs", "RNA", 6, 18], ["RNA dependent RNA polymerase", "PROTEIN", 37, 65], ["RDR", "PROTEIN", 67, 70], ["dsRNA molecules", "PROTEIN", 93, 108], ["These cleaved RNAs", "PROBLEM", 0, 18], ["RNA dependent RNA polymerase", "PROBLEM", 37, 65], ["the dsRNA molecules", "PROBLEM", 89, 108], ["the host defense mechanism", "PROBLEM", 152, 178], ["local and systemic viral infection", "PROBLEM", 219, 253], ["RNAs", "OBSERVATION", 14, 18], ["systemic", "OBSERVATION_MODIFIER", 229, 237], ["viral infection", "OBSERVATION", 238, 253]]], ["To counteract this defensive mechanism, many viruses encode RNA silencing suppressors (Voinnet et al., 1999), which can act in different steps of the silencing pathway, either by binding siRNA duplex or by directly interacting with key components of the RNA silencing machinery.", [["this defensive mechanism", "PROBLEM", 14, 38]]], ["Some synergetic interactions between coinfecting viruses (increasing viral accumulation or symptoms) are caused by the cumulative effect of the silencing suppressors of both viruses (Syller, 2012).", [["Some synergetic interactions", "PROBLEM", 0, 28], ["coinfecting viruses", "PROBLEM", 37, 56], ["increasing viral accumulation", "PROBLEM", 58, 87], ["symptoms", "PROBLEM", 91, 99], ["the silencing suppressors", "TREATMENT", 140, 165], ["synergetic", "OBSERVATION_MODIFIER", 5, 15], ["viruses", "OBSERVATION", 49, 56], ["viral accumulation", "OBSERVATION", 69, 87]]], ["Resistance can be obtained by plant transformation, introducing into plants DNA constructs to produce viral dsRNAs or ssRNA with some degree of secondary structure to trigger RNA silencing.", [["DNA", "CELLULAR_COMPONENT", 76, 79], ["plants DNA constructs", "DNA", 69, 90], ["viral dsRNAs", "RNA", 102, 114], ["plants DNA constructs", "TREATMENT", 69, 90], ["viral dsRNAs", "PROBLEM", 102, 114], ["ssRNA", "PROBLEM", 118, 123], ["secondary structure to trigger RNA silencing", "PROBLEM", 144, 188], ["plant transformation", "OBSERVATION", 30, 50], ["viral dsRNAs", "OBSERVATION", 102, 114], ["secondary structure", "OBSERVATION", 144, 163], ["RNA silencing", "OBSERVATION", 175, 188]]], ["Since RNA silencing requires a certain nucleotide identity between the targeted virus and the transgene, it is necessary to evaluate the nucleotide variation of the virus population as explained above.", [["nucleotide", "CHEMICAL", 137, 147], ["nucleotide", "CHEMICAL", 39, 49], ["nucleotide", "CHEMICAL", 137, 147], ["RNA silencing", "PROBLEM", 6, 19], ["the targeted virus", "TREATMENT", 67, 85], ["the virus population", "TREATMENT", 161, 181], ["virus", "OBSERVATION", 165, 170]]], ["The best technique to evaluate the efficiency of the RNA silencing-based resistances is real-time qPCR.Immunization Measures ::: Disease ManagementSilencing resistance breakdown can occur by mutation and selection (de Haan et al., 1992) or by mixed infection with other viruses (Syller, 2012).", [["infection", "DISEASE", 249, 258], ["the RNA silencing", "PROBLEM", 49, 66], ["Disease Management", "TREATMENT", 129, 147], ["Silencing resistance breakdown", "PROBLEM", 147, 177], ["mixed infection", "PROBLEM", 243, 258], ["RNA silencing", "OBSERVATION", 53, 66], ["mixed", "OBSERVATION_MODIFIER", 243, 248], ["infection", "OBSERVATION", 249, 258]]], ["Transgenic plants with multiple constructs from different viral genomes (from the same species and/or different species) can be used to minimize the risk of resistance breakdown (Bucher et al., 2006; Duan et al., 2012).", [["viral genomes", "DNA", 58, 71], ["Transgenic plants", "PROBLEM", 0, 17], ["multiple constructs", "PROBLEM", 23, 42], ["different viral genomes", "PROBLEM", 48, 71], ["the same species", "PROBLEM", 78, 94], ["resistance breakdown", "PROBLEM", 157, 177], ["multiple", "OBSERVATION_MODIFIER", 23, 31], ["viral genomes", "OBSERVATION", 58, 71]]], ["Another strategy is using a transgene mimicking the secondary structure of endogenous miRNA precursors (involved in plant gene expression and development) to express artificial miRNAS (amiRNAs) targeting viral sequences (Niu et al., 2006; Qu et al., 2007; Liu et al., 2017).", [["miRNAS", "GENE_OR_GENE_PRODUCT", 177, 183], ["amiRNAs", "GENE_OR_GENE_PRODUCT", 185, 192], ["miRNAS", "PROTEIN", 177, 183], ["amiRNAs", "PROTEIN", 185, 192], ["viral sequences", "DNA", 204, 219], ["endogenous miRNA precursors", "PROBLEM", 75, 102], ["viral sequences", "TEST", 204, 219], ["endogenous miRNA precursors", "OBSERVATION", 75, 102]]], ["The main advantage is that the short sequence of amiRNAs makes it easier to find conserved sequences that are more difficult to overcome (they are usually under strong negative selective pressure) and can be used for broad range targets (genera and families).", [["amiRNAs", "GENE_OR_GENE_PRODUCT", 49, 56], ["amiRNAs", "PROTEIN", 49, 56], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["However, the amiRNA resistance can be also overcome by mutation and selection (Sim\u00f3n-Mateo and Garc\u00eda, 2006; Lin et al., 2009; Lafforgue et al., 2011) or interaction with co-infecting viruses (Pacheco et al., 2012; Mart\u00ednez et al., 2013).", [["amiRNA", "CHEMICAL", 13, 19], ["amiRNA", "GENE_OR_GENE_PRODUCT", 13, 19], ["the amiRNA resistance", "PROBLEM", 9, 30]]], ["A strategy to obtain more durable resistances is to express multiple amiRNAs to target different regions within a single viral genome (Fahim et al., 2012; Kung et al., 2012; Lafforgue et al., 2013; Kis et al., 2016).", [["amiRNAs", "GENE_OR_GENE_PRODUCT", 69, 76], ["amiRNAs", "PROTEIN", 69, 76], ["viral genome", "DNA", 121, 133], ["viral genome", "OBSERVATION", 121, 133]]], ["Synthetic trans-acting small interfering RNAs (syn-tasiRNAs) is another class of artificial small RNAs engineered in plants, which are especially suited to target multiple sites within a viral genome or different unrelated viruses (Carbonell et al., 2016; Chen et al., 2016; Carbonell and Dar\u00f2s, 2019; Carbonell et al., 2019).", [["syn-tasiRNAs", "GENE_OR_GENE_PRODUCT", 47, 59], ["trans-acting small interfering RNAs", "RNA", 10, 45], ["syn-tasiRNAs", "DNA", 47, 59], ["viral genome", "DNA", 187, 199], ["small interfering RNAs (syn-tasiRNAs", "PROBLEM", 23, 59], ["artificial small RNAs", "PROBLEM", 81, 102], ["a viral genome", "PROBLEM", 185, 199], ["small", "OBSERVATION_MODIFIER", 23, 28], ["interfering RNAs", "OBSERVATION", 29, 45], ["small", "OBSERVATION_MODIFIER", 92, 97], ["RNAs engineered", "OBSERVATION", 98, 113], ["viral genome", "OBSERVATION", 187, 199]]], ["The durability of these resistances can be evaluated by experimental evolution based on successive passages of the virus in the resistant plants.", [["the virus", "PROBLEM", 111, 120], ["durability", "OBSERVATION_MODIFIER", 4, 14], ["resistant plants", "OBSERVATION", 128, 144]]], ["Resistance-breakdown can be detected by qPCR as an increase in virus accumulation (Carrasco et al., 2007; Pe\u00f1a et al., 2014).", [["Resistance-breakdown", "PROBLEM", 0, 20], ["an increase in virus accumulation", "PROBLEM", 48, 81], ["increase", "OBSERVATION_MODIFIER", 51, 59]]], ["The mutations fixed after the passages can be detected by PCR followed by cloning and Sanger sequencing or HTS.", [["The mutations", "PROBLEM", 0, 13], ["the passages", "TREATMENT", 26, 38], ["PCR", "TEST", 58, 61]]], ["Identification of the mutations leading to resistance breakdown is possible if infectious clones exist, so that each mutation can be tested for the increase of virus accumulation.", [["clones", "CELL", 90, 96], ["the mutations", "PROBLEM", 18, 31], ["resistance breakdown", "PROBLEM", 43, 63], ["infectious clones", "PROBLEM", 79, 96], ["each mutation", "PROBLEM", 112, 125], ["virus accumulation", "PROBLEM", 160, 178], ["virus accumulation", "OBSERVATION", 160, 178]]], ["An alternative to transgenic plants is the exogeneous application of in vitro-produced dsRNAs from viral sequences onto plants (Tenllado and D\u00edaz-Ruiz, 2001; Kaldis et al., 2017; Niehl et al., 2018).", [["dsRNAs", "DNA", 87, 93], ["viral sequences", "DNA", 99, 114], ["vitro-produced dsRNAs", "TREATMENT", 72, 93]]], ["The efficacy of this technique of immunization can be improved by high-pressure spraying plants (Dalakouras et al., 2016), using cell-penetrating peptides (Numata et al., 2014) or clay nanoparticles stabilizing dsRNAs (Mitter et al., 2017).Immunization Measures ::: Disease ManagementAnother immunization method is cross-protection based on inoculating mild or attenuated viral strains to protect plants against severe strains of the same virus.", [["cell", "ANATOMY", 129, 133], ["cell", "CELL", 129, 133], ["clay nanoparticles", "SIMPLE_CHEMICAL", 180, 198], ["this technique of immunization", "TREATMENT", 16, 46], ["high-pressure spraying plants", "TREATMENT", 66, 95], ["cell-penetrating peptides", "TREATMENT", 129, 154], ["Disease Management", "TREATMENT", 266, 284], ["Another immunization method", "TREATMENT", 284, 311], ["inoculating mild or attenuated viral strains", "PROBLEM", 341, 385], ["severe strains of the same virus", "PROBLEM", 412, 444]]], ["Cross-protection has been applied to several viruses and crops, such as PepMV in tomato and CTV in citrus crops (Pechinger et al., 2019).", [["PepMV", "CHEMICAL", 72, 77], ["PepMV", "GENE_OR_GENE_PRODUCT", 72, 77], ["tomato", "ORGANISM", 81, 87], ["CTV", "CANCER", 92, 95], ["tomato", "SPECIES", 81, 87], ["tomato", "SPECIES", 81, 87], ["Cross-protection", "TREATMENT", 0, 16], ["crops", "TREATMENT", 57, 62], ["PepMV", "TREATMENT", 72, 77], ["several", "OBSERVATION_MODIFIER", 37, 44], ["viruses", "OBSERVATION", 45, 52], ["citrus crops", "OBSERVATION", 99, 111]]], ["The mechanism of cross-protection is poorly understood and several models have been proposed: prevention of virus entry into cells; competition for host factors for replication, interference with disassembly, translation or replication; and induction of RNA silencing leading to sequence-specific degradation of the superinfecting virus (Ziebell and Carr, 2010; Folimonova, 2013).", [["cells", "ANATOMY", 125, 130], ["cells", "CELL", 125, 130], ["host factors", "PROTEIN", 148, 160], ["virus entry into cells", "PROBLEM", 108, 130], ["replication", "TREATMENT", 224, 235], ["RNA silencing", "PROBLEM", 254, 267], ["the superinfecting virus", "PROBLEM", 312, 336]]], ["It has been suggested that cross-protection in some viruses might be an active virus-controlled function involving virus-coded proteins (Folimonova, 2013).", [["virus-coded proteins", "PROTEIN", 115, 135], ["cross-protection", "TREATMENT", 27, 43], ["some viruses", "PROBLEM", 47, 59], ["an active virus", "PROBLEM", 69, 84], ["viruses", "OBSERVATION", 52, 59], ["active", "OBSERVATION_MODIFIER", 72, 78], ["virus", "OBSERVATION", 79, 84]]], ["A recent model proposed that cross-protection is a mechanism that prevents the virus progeny to replicate in the cells to minimize mutation rate and collaterally targets highly homologous superinfecting viruses that are indistinguishable from progeny viruses (Zhang X. et al., 2018).", [["cells", "ANATOMY", 113, 118], ["cells", "CELL", 113, 118], ["the virus progeny", "PROBLEM", 75, 92], ["mutation rate", "PROBLEM", 131, 144], ["highly homologous superinfecting viruses", "PROBLEM", 170, 210]]], ["To apply cross-protection it is necessary to evaluate the genetic and biological variability of the local virus population and search for mild isolates genetically close to the severe ones (Hanssen et al., 2010).", [["cross-protection", "TREATMENT", 9, 25], ["the local virus population", "PROBLEM", 96, 122], ["mild isolates", "PROBLEM", 138, 151]]], ["Mild or attenuated strains can also be generated by thermal treatment, random mutagenesis by using chemicals as nitrous acids and selection or directed mutagenesis in viral RNA silencing suppressors (Ziebell and Carr, 2010).", [["nitrous acids", "CHEMICAL", 112, 125], ["nitrous acids", "CHEMICAL", 112, 125], ["nitrous acids", "SIMPLE_CHEMICAL", 112, 125], ["Mild or attenuated strains", "PROBLEM", 0, 26], ["thermal treatment", "TREATMENT", 52, 69], ["random mutagenesis", "TREATMENT", 71, 89], ["chemicals", "TREATMENT", 99, 108], ["nitrous acids", "TREATMENT", 112, 125], ["selection", "TREATMENT", 130, 139], ["directed mutagenesis", "TREATMENT", 143, 163], ["viral RNA silencing suppressors", "TREATMENT", 167, 198], ["attenuated", "OBSERVATION_MODIFIER", 8, 18], ["strains", "OBSERVATION", 19, 26]]], ["Cross-protection assays can be evaluated by real-time qPCR with probes specific for each virus variant (Ruiz-Ruiz et al., 2009b; Hanssen et al., 2010) and SSCP analysis (Sambade et al., 2002).", [["Cross-protection assays", "TEST", 0, 23], ["each virus variant", "PROBLEM", 84, 102], ["Ruiz", "TEST", 104, 108], ["SSCP analysis", "TEST", 155, 168]]], ["However, the protection exerted by the mild isolate can be overcome and even a more severe disease can emerge by transmission to a different host species, interaction with other viruses in mixed infections, or recombination between divergent strains or viruses (Fulton, 1986).", [["infections", "DISEASE", 195, 205], ["the mild isolate", "PROBLEM", 35, 51], ["a more severe disease", "PROBLEM", 77, 98], ["a different host species", "PROBLEM", 129, 153], ["other viruses", "PROBLEM", 172, 185], ["mixed infections", "PROBLEM", 189, 205], ["divergent strains", "PROBLEM", 232, 249], ["viruses", "PROBLEM", 253, 260], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["disease", "OBSERVATION", 91, 98], ["mixed", "OBSERVATION_MODIFIER", 189, 194], ["infections", "OBSERVATION", 195, 205]]], ["Therefore cross-protection should be used only for devastating diseases when other protection measures fail, and the process should be monitored closely.Prophylactic Measures ::: Disease ManagementQuarantine (control of borders) and sanitary certification of virus-free germplasm (seeds or asexual propagative tissues) are the first measures to prevent the introduction and emergence of new viruses in a geographical area.", [["seeds", "ANATOMY", 281, 286], ["propagative tissues", "ANATOMY", 298, 317], ["propagative tissues", "TISSUE", 298, 317], ["cross-protection", "TREATMENT", 10, 26], ["devastating diseases", "PROBLEM", 51, 71], ["other protection measures", "TREATMENT", 77, 102], ["Disease ManagementQuarantine (control of borders)", "TREATMENT", 179, 228], ["virus", "PROBLEM", 259, 264], ["free germplasm (seeds", "TREATMENT", 265, 286], ["asexual propagative tissues", "TREATMENT", 290, 317], ["new viruses", "PROBLEM", 387, 398], ["free germplasm", "OBSERVATION", 265, 279], ["new", "OBSERVATION_MODIFIER", 387, 390], ["viruses", "OBSERVATION", 391, 398]]], ["Virus detection should be based on sensitive and broad-spectrum methods, since discarding healthy material is preferable to the risk of spreading new diseases.", [["Virus", "ORGANISM", 0, 5], ["Virus detection", "TEST", 0, 15], ["broad-spectrum methods", "TREATMENT", 49, 71], ["healthy material", "PROBLEM", 90, 106], ["spreading new diseases", "PROBLEM", 136, 158], ["spreading", "OBSERVATION_MODIFIER", 136, 145], ["new", "OBSERVATION_MODIFIER", 146, 149], ["diseases", "OBSERVATION", 150, 158]]], ["On-site detection devices can be useful to make decisions quickly, thus preventing importation and exportation delays.", [["site detection devices", "TREATMENT", 3, 25]]], ["HTS is the most powerful detection procedure since it can detect all the viruses (known and unknown) present in a plant in an unbiased way.", [["powerful detection procedure", "TREATMENT", 16, 44], ["all the viruses", "PROBLEM", 65, 80], ["viruses", "OBSERVATION", 73, 80]]], ["Its use in quarantine and clean plant programs is increasing as it is becoming more economically affordable (Villamor et al., 2019).", [["clean plant programs", "TREATMENT", 26, 46]]], ["Phytosanitary certificates should be based on propagative material free from only harmful viruses, since plants can harbor many viruses (Maree et al., 2018).Prophylactic Measures ::: Disease ManagementSince epidemiology and evolution are coupled in viruses, phylogeographic studies, comparing genetic variation in space and time, can provide useful information on the introduction sites of new viruses and the dispersal paths (G\u00f3mez et al., 2012; Davino et al., 2013).", [["Phytosanitary certificates", "TREATMENT", 0, 26], ["propagative material", "PROBLEM", 46, 66], ["harmful viruses", "PROBLEM", 82, 97], ["Disease Management", "TREATMENT", 183, 201], ["phylogeographic studies", "TEST", 258, 281], ["new viruses", "PROBLEM", 390, 401], ["new", "OBSERVATION_MODIFIER", 390, 393], ["viruses", "OBSERVATION", 394, 401]]], ["As an illustration,Figure 4shows the migration paths of one of the strains in the first introduction of CTV in Sicily, Italy (Davino et al., 2013), which were inferred by Bayesian phylogeographic analysis with the program BEAST v1.6.2 (Drummond and Rambaut, 2007).", [["the strains", "PROBLEM", 63, 74], ["Bayesian phylogeographic analysis", "TEST", 171, 204], ["migration", "OBSERVATION_MODIFIER", 37, 46]]], ["Phylogenetic analyses showed that these Sicilian CTV isolates were genetically close to CTV isolates from mainland Italy and California.Prophylactic Measures ::: Disease ManagementSanitation, that is, removing viruses from valuable cultivars, is necessary when no healthy plants are available.", [["Sicilian CTV", "ORGANISM", 40, 52], ["Phylogenetic analyses", "TEST", 0, 21], ["these Sicilian CTV isolates", "PROBLEM", 34, 61], ["CTV isolates", "TEST", 88, 100], ["Disease ManagementSanitation", "PROBLEM", 162, 190], ["California", "OBSERVATION_MODIFIER", 125, 135]]], ["Virus-free plants are usually produced by thermotherapy, chemotherapy, electrotherapy, and tissue culture alone or combined (Naik and Buckseth, 2018).", [["tissue culture", "ANATOMY", 91, 105], ["Virus", "ORGANISM", 0, 5], ["Virus-free plants", "TREATMENT", 0, 17], ["thermotherapy", "TREATMENT", 42, 55], ["chemotherapy", "TREATMENT", 57, 69], ["electrotherapy", "TREATMENT", 71, 85], ["tissue culture", "TEST", 91, 105], ["free plants", "OBSERVATION", 6, 17]]], ["Thermotherapy could inactivate viruses by viral RNA breakage, viral particle disruption or coat protein rupture, viral replicase inactivation, virus movement inhibition and/or translation reduction (Hull, 2002).", [["coat protein", "PROTEIN", 91, 103], ["Thermotherapy", "TREATMENT", 0, 13], ["viruses", "PROBLEM", 31, 38], ["viral RNA breakage", "PROBLEM", 42, 60], ["viral particle disruption", "PROBLEM", 62, 87], ["coat protein rupture", "PROBLEM", 91, 111], ["viral replicase inactivation", "TREATMENT", 113, 141], ["virus movement inhibition", "TREATMENT", 143, 168], ["translation reduction", "TREATMENT", 176, 197], ["viral RNA breakage", "OBSERVATION", 42, 60], ["viral particle disruption", "OBSERVATION", 62, 87], ["protein rupture", "OBSERVATION", 96, 111]]], ["Chemotherapy is based on antiviral drugs to inhibit or disrupt specific steps of the virus life cycle, e.g., nucleoside analogs inhibiting replication and protease inhibitors preventing protein processing.", [["nucleoside", "CHEMICAL", 109, 119], ["nucleoside", "CHEMICAL", 109, 119], ["nucleoside analogs", "SIMPLE_CHEMICAL", 109, 127], ["Chemotherapy", "TREATMENT", 0, 12], ["antiviral drugs", "TREATMENT", 25, 40], ["the virus life cycle", "TREATMENT", 81, 101], ["nucleoside analogs", "TREATMENT", 109, 127], ["replication", "TREATMENT", 139, 150], ["protease inhibitors", "TREATMENT", 155, 174], ["protein processing", "TREATMENT", 186, 204]]], ["Antiviral drugs are costly and are used only to regenerate healthy mother plants for vegetative propagation or seed production (Panattoni et al., 2013).", [["seed", "ANATOMY", 111, 115], ["seed", "DEVELOPING_ANATOMICAL_STRUCTURE", 111, 115], ["Antiviral drugs", "TREATMENT", 0, 15], ["vegetative propagation", "PROBLEM", 85, 107]]], ["The sanitated plants must be evaluated and confirmed to be virus-free with very sensitive techniques such as real-time qPCR.", [["The sanitated plants", "TREATMENT", 0, 20], ["virus", "PROBLEM", 59, 64]]], ["Nucleoside analogs can also be used to increase the already high mutation rate of RNA viruses, so that the excess of mutations would lead to a loss of genetic information and virus extinction (lethal mutagenesis or error catastrophe).", [["Nucleoside", "CHEMICAL", 0, 10], ["error catastrophe", "DISEASE", 215, 232], ["Nucleoside", "CHEMICAL", 0, 10], ["Nucleoside analogs", "SIMPLE_CHEMICAL", 0, 18], ["Nucleoside analogs", "TREATMENT", 0, 18], ["RNA viruses", "PROBLEM", 82, 93], ["the excess of mutations", "PROBLEM", 103, 126], ["a loss of genetic information", "PROBLEM", 141, 170], ["virus extinction (lethal mutagenesis", "PROBLEM", 175, 211], ["error catastrophe", "PROBLEM", 215, 232], ["RNA viruses", "OBSERVATION", 82, 93]]], ["This approach has been assayed recently with a plant virus, tobacco mosaic virus (TMV), resulting in a loss of viral infectivity (D\u00edaz-Mart\u00ednez et al., 2018).Prophylactic Measures ::: Disease ManagementAn agronomical practice to limit virus dispersal consists of removing virus-infected plants from crops or weeds acting as inoculum source.", [["loss of viral infectivity", "DISEASE", 103, 128], ["tobacco mosaic virus", "ORGANISM", 60, 80], ["TMV", "ORGANISM", 82, 85], ["tobacco mosaic virus", "SPECIES", 60, 80], ["tobacco mosaic virus", "SPECIES", 60, 80], ["TMV", "SPECIES", 82, 85], ["a plant virus", "PROBLEM", 45, 58], ["tobacco mosaic virus", "PROBLEM", 60, 80], ["a loss of viral infectivity", "PROBLEM", 101, 128], ["Disease ManagementAn agronomical practice", "TREATMENT", 184, 225], ["removing virus", "PROBLEM", 263, 277], ["infected plants", "PROBLEM", 278, 293], ["mosaic virus", "OBSERVATION", 68, 80], ["viral infectivity", "OBSERVATION", 111, 128], ["infected", "OBSERVATION", 278, 286]]], ["This requires rapid and specific detection techniques able to analyze many samples from the field, such as ELISA and molecular hybridization, especially using tissue-prints (Rubio et al., 1999; Rubio et al., 2003b).", [["tissue", "ANATOMY", 159, 165], ["tissue", "TISSUE", 159, 165], ["specific detection techniques", "TEST", 24, 53], ["ELISA", "TEST", 107, 112]]], ["Roguing is effective only if the virus incidence is low after a recent introduction or in isolated areas.", [["the virus incidence", "PROBLEM", 29, 48], ["a recent introduction", "TREATMENT", 62, 83], ["low", "OBSERVATION_MODIFIER", 52, 55]]], ["Other practices consist of interrupting the virus transmission chain.", [["virus", "OBSERVATION", 44, 49]]], ["Many seed-borne viruses (carried on the seed coat) can be removed with chemical disinfectants such as sodium hypochlorite, trisodium phosphate, hydrochloric acid and ozone, whereas some seed-transmitted viruses (infecting the seed embryo) can be eliminated by thermotherapy (Ling, 2010; Paylan et al., 2014).", [["embryo", "ANATOMY", 231, 237], ["sodium hypochlorite", "CHEMICAL", 102, 121], ["trisodium phosphate", "CHEMICAL", 123, 142], ["hydrochloric acid", "CHEMICAL", 144, 161], ["ozone", "CHEMICAL", 166, 171], ["sodium hypochlorite", "CHEMICAL", 102, 121], ["trisodium phosphate", "CHEMICAL", 123, 142], ["hydrochloric acid", "CHEMICAL", 144, 161], ["ozone", "CHEMICAL", 166, 171], ["sodium hypochlorite", "SIMPLE_CHEMICAL", 102, 121], ["trisodium phosphate", "SIMPLE_CHEMICAL", 123, 142], ["hydrochloric acid", "SIMPLE_CHEMICAL", 144, 161], ["ozone", "SIMPLE_CHEMICAL", 166, 171], ["seed embryo", "MULTI-TISSUE_STRUCTURE", 226, 237], ["Many seed-borne viruses", "PROBLEM", 0, 23], ["chemical disinfectants", "TREATMENT", 71, 93], ["sodium hypochlorite", "TREATMENT", 102, 121], ["trisodium phosphate", "TREATMENT", 123, 142], ["hydrochloric acid", "TREATMENT", 144, 161], ["ozone", "TREATMENT", 166, 171], ["transmitted viruses", "PROBLEM", 191, 210], ["borne viruses", "OBSERVATION", 10, 23], ["viruses", "OBSERVATION", 203, 210]]], ["Multiplex (RT)-PCR to detect simultaneously the seed-transmitted and seed-borne viruses for a crop can be a useful tool (Panno et al., 2012).", [["Multiplex (RT)-PCR", "TEST", 0, 18], ["the seed", "PROBLEM", 44, 52], ["transmitted and seed-borne viruses", "PROBLEM", 53, 87]]], ["Incidence of plant viruses mechanically transmissible by contact, like those of the genus Tobamovirus, can be reduced by hygienic measures such as using disposable gloves or washing hands with disinfectant, heat sterilization of tools and debris and limiting the access to crops (Broadbent, 1976).", [["plant viruses", "PROBLEM", 13, 26], ["disposable gloves", "TREATMENT", 153, 170], ["washing hands", "TREATMENT", 174, 187], ["disinfectant", "TREATMENT", 193, 205], ["heat sterilization", "TREATMENT", 207, 225], ["debris", "PROBLEM", 239, 245], ["plant viruses", "OBSERVATION", 13, 26], ["genus Tobamovirus", "OBSERVATION", 84, 101], ["debris", "OBSERVATION", 239, 245]]], ["Most plant viruses are transmitted by arthropod vectors, mainly aphids, whiteflies, and thrips.", [["Most plant viruses", "PROBLEM", 0, 18], ["viruses", "OBSERVATION", 11, 18]]], ["Three strategies to prevent the spread of plant viruses by vectors have been used (Antignus, 2012; Fereres and Raccah, 2015): i) Reducing vector populations by pesticides; biological control with natural enemies such as arthropod predators and parasitoids (T\u00e9llez et al., 2017) or entomopathogenic fungi, nematodes, bacteria and viruses (Kalha et al., 2014); and biotechnology-based approaches based on protease inhibitors, neurotoxins, or RNA silencing of genes essential for insect development or metabolism (Fereres and Raccah, 2015; Nandety et al., 2015; Vogel et al., 2019). ii) Preventing the vector from reaching the crop with barriers (greenhouses and barrier plants), by interference of the insect vision with UV-absorbing plastics and reflective surfaces, by agronomical practices such as changing the planting or sowing dates to avoid high vector populations, or imposing a time gap between crops and/or space gap between plots to break the transmission cycle (Antignus, 2012; Fereres and Raccah, 2015). iii) Interfering with the transmission process by spraying mineral oils, synthetic peptides or modified proteins to outcompete virus-encoded proteins needed for virus attachment to insect receptors (Lecoq and Desbiez, 2012; Blanc et al., 2014).Prophylactic Measures ::: Disease ManagementThe rate of insect transmission can be evaluated using different detection techniques, such as ELISA, molecular hybridization and PCR, to detect the virus in the receptor plants and real-time qPCR to estimate the virus titer in the source plants, which affects transmissibility (Olmos et al., 2005; Rotenberg et al., 2009; Ferriol et al., 2013; Debreczeni et al., 2014).Conclusions and Future TrendsThe main challenge of agriculture in this century is to produce nutritious food for the growing world population in a sustainable manner while protecting the environment and human health (Pretty, 2008; Pretty et al., 2010).", [["plant viruses", "DISEASE", 42, 55], ["human", "ORGANISM", 1876, 1881], ["virus-encoded proteins", "PROTEIN", 1142, 1164], ["insect receptors", "PROTEIN", 1196, 1212], ["human", "SPECIES", 1876, 1881], ["human", "SPECIES", 1876, 1881], ["natural enemies", "TREATMENT", 196, 211], ["entomopathogenic fungi", "PROBLEM", 281, 303], ["nematodes", "PROBLEM", 305, 314], ["bacteria", "PROBLEM", 316, 324], ["viruses", "PROBLEM", 329, 336], ["protease inhibitors", "TREATMENT", 403, 422], ["neurotoxins", "PROBLEM", 424, 435], ["the vector", "TREATMENT", 595, 605], ["barriers (greenhouses", "TREATMENT", 634, 655], ["barrier plants", "TREATMENT", 660, 674], ["UV", "TREATMENT", 719, 721], ["plastics", "TREATMENT", 732, 740], ["the planting", "TREATMENT", 808, 820], ["high vector populations", "PROBLEM", 846, 869], ["space gap between plots", "PROBLEM", 915, 938], ["the transmission process", "TREATMENT", 1037, 1061], ["spraying mineral oils", "TREATMENT", 1065, 1086], ["synthetic peptides", "TREATMENT", 1088, 1106], ["modified proteins", "PROBLEM", 1110, 1127], ["outcompete virus", "PROBLEM", 1131, 1147], ["virus attachment", "PROBLEM", 1176, 1192], ["Disease Management", "TREATMENT", 1285, 1303], ["different detection techniques", "TEST", 1358, 1388], ["ELISA", "TEST", 1398, 1403], ["molecular hybridization", "TEST", 1405, 1428], ["PCR", "TEST", 1433, 1436], ["the virus", "PROBLEM", 1448, 1457], ["the virus titer", "PROBLEM", 1512, 1527], ["plant viruses", "OBSERVATION", 42, 55], ["main", "OBSERVATION_MODIFIER", 1706, 1710]]], ["Damages caused by pests and diseases have a considerable negative economic impact in agriculture, being emergent viral diseases particularly important (Anderson et al., 2004; Mumford et al., 2016).Conclusions and Future TrendsThe correct identification of viruses is critical for disease management.", [["Damages", "DISEASE", 0, 7], ["pests and diseases", "DISEASE", 18, 36], ["viral diseases", "DISEASE", 113, 127], ["diseases", "PROBLEM", 28, 36], ["emergent viral diseases", "PROBLEM", 104, 127], ["viruses", "PROBLEM", 256, 263], ["disease management", "TREATMENT", 280, 298], ["economic", "OBSERVATION_MODIFIER", 66, 74], ["viral diseases", "OBSERVATION", 113, 127], ["viruses", "OBSERVATION", 256, 263]]], ["However, the great ability of viruses to evolve and generate molecular and biological variation is a major difficulty for virus detection and disease management.", [["viruses", "PROBLEM", 30, 37], ["virus detection", "TREATMENT", 122, 137], ["disease management", "TREATMENT", 142, 160], ["viruses", "OBSERVATION", 30, 37]]], ["Presently, when a new virus-like disease appears, the first approach is to test for known viruses with well-established techniques (Figure 5A).", [["a new virus-like disease", "PROBLEM", 16, 40], ["known viruses", "PROBLEM", 84, 97], ["new", "OBSERVATION_MODIFIER", 18, 21], ["virus", "OBSERVATION", 22, 27], ["disease", "OBSERVATION", 33, 40], ["viruses", "OBSERVATION", 90, 97]]], ["ELISA is the most popular for routine analysis because of historical reasons, easiness to perform with little training and commercial availability of antibodies specific for the main plant viruses.", [["antibodies", "PROTEIN", 150, 160], ["routine analysis", "TEST", 30, 46], ["little training", "TREATMENT", 103, 118], ["antibodies", "TREATMENT", 150, 160], ["plant viruses", "OBSERVATION", 183, 196]]], ["However, antibody production is expensive, time-consuming, and unpredictable, and it cannot be designed to cope with viral variability.", [["antibody production", "PROBLEM", 9, 28], ["viral variability", "PROBLEM", 117, 134], ["viral variability", "OBSERVATION", 117, 134]]], ["In contrast, the development of molecular techniques is fast and cheap, making them more appropriate to cope with the frequent cases of new virus emergence (Boonham et al., 2014).", [["new virus emergence", "PROBLEM", 136, 155]]], ["PCR techniques are the most widely used because of the easy design, versatility, and low cost of primers.", [["PCR techniques", "TREATMENT", 0, 14], ["low cost of primers", "TREATMENT", 85, 104], ["most widely", "OBSERVATION_MODIFIER", 23, 34], ["low", "OBSERVATION_MODIFIER", 85, 88]]], ["Real-time qPCR is becoming the molecular method of choice for routine virus analysis (especially for new viruses for which antibodies are not available or with low accumulation levels) and quantification.", [["antibodies", "PROTEIN", 123, 133], ["routine virus analysis", "TEST", 62, 84], ["new viruses", "PROBLEM", 101, 112], ["antibodies", "TEST", 123, 133], ["low accumulation levels", "PROBLEM", 160, 183]]], ["On-site detection techniques by LFA and isothermal amplification (RPA and LAMP) allow an almost immediate response and are rapidly developing.", [["LFA", "PROTEIN", 32, 35], ["isothermal amplification", "TREATMENT", 40, 64], ["rapidly", "OBSERVATION_MODIFIER", 123, 130]]], ["When these techniques fail to detect the virus causing disease, the best approach is to use HTS, which can identify all the viruses in one plant, albeit infectivity assays or field surveys are necessary to determine which of the viruses detected is likely the disease causal agent (Figure 5A).", [["these techniques", "TEST", 5, 21], ["the virus", "PROBLEM", 37, 46], ["disease", "PROBLEM", 55, 62], ["HTS", "TREATMENT", 92, 95], ["field surveys", "TEST", 175, 188], ["the viruses", "PROBLEM", 225, 236], ["viruses", "OBSERVATION", 124, 131], ["viruses", "OBSERVATION", 229, 236]]], ["In some cases, such as quarantine, using HTS as first approach for virus detection can be more profitable than testing many viruses with ELISA or molecular detection techniques.", [["HTS", "TREATMENT", 41, 44], ["virus detection", "PROBLEM", 67, 82], ["ELISA", "TEST", 137, 142]]], ["However, HTS is still too expensive for most routine analyses and it is necessary to develop rapid and accurate detection techniques for each virus, being PCR the easiest to develop.", [["most routine analyses", "TEST", 40, 61], ["each virus", "PROBLEM", 137, 147], ["PCR", "TEST", 155, 158]]], ["The design of primers or probes for accurate detection requires to evaluate the genetic diversity of viral populations by analysis of nucleotide sequences.", [["nucleotide", "CHEMICAL", 134, 144], ["nucleotide", "CHEMICAL", 134, 144], ["nucleotide sequences", "DNA", 134, 154], ["accurate detection", "TEST", 36, 54], ["viral populations", "PROBLEM", 101, 118], ["nucleotide sequences", "TEST", 134, 154], ["viral populations", "OBSERVATION", 101, 118]]], ["(Figure 5B).Conclusions and Future TrendsPresently, disease management relies on preventing introduction of new viruses by border control and certification of virus-free propagative material (e.g., seeds) and preventing virus dispersal in the field.", [["disease management", "TREATMENT", 52, 70], ["new viruses", "TREATMENT", 108, 119], ["border control", "TREATMENT", 123, 137], ["virus", "PROBLEM", 159, 164], ["free propagative material", "TREATMENT", 165, 190], ["virus dispersal", "TREATMENT", 220, 235], ["disease", "OBSERVATION", 52, 59], ["virus dispersal", "OBSERVATION", 220, 235]]], ["Quarantine and certification require sensitive and broad-spectrum detection methods to minimize escapes such as the use of conserved primers specific for virus genera or families and multiplex procedures (Figure 5C).", [["Quarantine", "CHEMICAL", 0, 10], ["broad-spectrum detection methods", "TREATMENT", 51, 83], ["escapes", "PROBLEM", 96, 103], ["conserved primers", "TREATMENT", 123, 140], ["virus genera", "TREATMENT", 154, 166], ["multiplex procedures", "TREATMENT", 183, 203]]], ["HTS is the best procedure and it is becoming affordable in quarantine facilities given the devastating consequences of introducing new pathogens.", [["the best procedure", "TREATMENT", 7, 25], ["introducing new pathogens", "PROBLEM", 119, 144], ["new", "OBSERVATION_MODIFIER", 131, 134], ["pathogens", "OBSERVATION", 135, 144]]], ["Prophylactic measures to prevent or minimize virus dispersal require information on the virus biology (host range, transmission way, etc.), virus incidence and epidemiology.", [["Prophylactic measures", "TREATMENT", 0, 21], ["virus dispersal", "PROBLEM", 45, 60]]], ["Obtaining this information needs using high-throughput screening techniques able to analyze a high number of samples such as ELISA and molecular hybridization (Figure 5C).", [["samples", "ANATOMY", 109, 116], ["high-throughput screening techniques", "TREATMENT", 39, 75], ["ELISA", "TEST", 125, 130]]], ["The other keystone for plant disease control is the obtention of resistant cultivars, which is performed mainly by plant breeding and commercialized by seed companies.", [["plant disease", "DISEASE", 23, 36], ["plant disease control", "TREATMENT", 23, 44], ["resistant cultivars", "PROBLEM", 65, 84], ["keystone", "OBSERVATION_MODIFIER", 10, 18], ["disease", "OBSERVATION", 29, 36]]], ["However, apart from the important effort involved in breeding programs, resistance is not available for most crops and viruses.", [["breeding programs", "TREATMENT", 53, 70]]], ["Genetic engineering, despite the great potential and some remarkable successes (Fuchs and Gonsalves, 2007), faces heavy opposition in some countries due to the public concern on the potential ecological impact of transgenic plants (Jones, 2006).", [["transgenic plants", "OBSERVATION", 213, 230]]], ["Resistant plants should be evaluated with specific methods, as resistance depends on host and virus genotypes.", [["Resistant plants", "PROBLEM", 0, 16], ["specific methods", "TREATMENT", 42, 58], ["host and virus genotypes", "TREATMENT", 85, 109]]], ["Partial resistance can be evaluated by real-time qPCR (Figure 5C).", [["Partial resistance", "PROBLEM", 0, 18], ["resistance", "OBSERVATION", 8, 18]]], ["Genome editing by CRISPR and the application of dsRNA-loaded clay particles to trigger RNA silencing are promising research fields.", [["CRISPR", "DNA", 18, 24], ["dsRNA-loaded clay particles", "TREATMENT", 48, 75], ["RNA silencing", "OBSERVATION", 87, 100]]], ["In any case, to aim at more durable and effective protection, it is necessary to characterize the genetic variability and relationships of plant viruses, as well as the factors and mechanisms involved in genetic change.Conclusions and Future TrendsHTS excels for its broad-spectrum and multiplex detection, sensitivity, and precise quantification.", [["plant viruses", "PROBLEM", 139, 152], ["Conclusions", "TEST", 219, 230], ["Future TrendsHTS excels", "TEST", 235, 258], ["multiplex detection", "TEST", 286, 305], ["sensitivity", "TEST", 307, 318], ["plant viruses", "OBSERVATION", 139, 152]]], ["No previous knowledge is required, enabling unbiased detection and discovery of new viruses.", [["unbiased detection", "TEST", 44, 62], ["new viruses", "PROBLEM", 80, 91], ["new", "OBSERVATION_MODIFIER", 80, 83], ["viruses", "OBSERVATION", 84, 91]]], ["The sequences obtained allow a precise taxonomic assignation and an estimation of genetic relationships with other viruses and viral isolates.", [["The sequences", "TEST", 0, 13], ["a precise taxonomic assignation", "TEST", 29, 60], ["other viruses and viral isolates", "PROBLEM", 109, 141]]], ["It is reasonable to expect that HTS, especially portable nanopore sequencing devices, will become the standard diagnostic procedure as costs will be dropping and analytical procedures improving.Author ContributionsLR conceived the idea.", [["portable nanopore sequencing devices", "TREATMENT", 48, 84], ["the standard diagnostic procedure", "TREATMENT", 98, 131], ["analytical procedures", "TEST", 162, 183]]], ["LR and IF designed the figures.", [["LR", "PROTEIN", 0, 2], ["IF", "PROTEIN", 7, 9], ["LR", "TREATMENT", 0, 2]]], ["All authors contributed to the article and approved the submitted version.FundingThis work was partially funded by grants RTA2017-00061-C03-02 from Spanish Ministerio de Ciencia e Innovaci\u00f3n co-financed by FEDER and 51912 from IVIA.", [["RTA2017-00061-C03-02", "CHEMICAL", 122, 142], ["C03", "TEST", 136, 139]]], ["IF acknowledges financial support from the Spanish Ministerio de Economia y Competitividad, through the \u201cSevero Ochoa Programme for Centers of Excellence in R&D\u201d 2016-2019 (SEV-2015-0533).DisclaimerThe opinions expressed, and arguments employed in this paper are the sole responsibility of the authors and do not necessarily reflect those of the OECD or of the governments of its Member countries.Conflict of InterestThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [["SEV-2015-0533", "CHEMICAL", 173, 186]]]], "52d81ba3dc04ff9d0faf98da41bc899bcc7bc410": [["IntroductionOn January 31st, 2020, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) a \"public health emergency of international concern\" [1] .", [["coronavirus disease", "DISEASE", 80, 99], ["coronavirus", "ORGANISM", 80, 91], ["coronavirus disease", "PROBLEM", 80, 99], ["coronavirus disease", "OBSERVATION", 80, 99]]], ["The virus causing it is highly homologous to the coronavirus (CoV) that caused an outbreak of Severe Acute Respiratory Syndrome (SARS) in 2003 and is named SARS-CoV-2 [2] .", [["Acute Respiratory Syndrome", "DISEASE", 101, 127], ["SARS", "DISEASE", 129, 133], ["coronavirus", "ORGANISM", 49, 60], ["CoV", "ORGANISM", 62, 65], ["coronavirus", "SPECIES", 49, 60], ["CoV", "SPECIES", 62, 65], ["Severe Acute Respiratory Syndrome (SARS)", "SPECIES", 94, 134], ["SARS-CoV", "SPECIES", 156, 164], ["The virus", "PROBLEM", 0, 9], ["the coronavirus", "PROBLEM", 45, 60], ["Severe Acute Respiratory Syndrome", "PROBLEM", 94, 127], ["virus", "OBSERVATION", 4, 9], ["outbreak", "OBSERVATION_MODIFIER", 82, 90], ["Severe", "OBSERVATION_MODIFIER", 94, 100], ["Acute", "OBSERVATION_MODIFIER", 101, 106], ["Respiratory Syndrome", "OBSERVATION", 107, 127]]], ["Further, in 2011, the world also experienced outbreaks of a coronavirus infection that threatened to become a global pandemic called Middle East Respiratory Syndrome (MERS).", [["coronavirus infection", "DISEASE", 60, 81], ["Middle East Respiratory Syndrome", "DISEASE", 133, 165], ["MERS", "DISEASE", 167, 171], ["coronavirus", "ORGANISM", 60, 71], ["coronavirus", "SPECIES", 60, 71], ["a coronavirus infection", "PROBLEM", 58, 81], ["Middle East Respiratory Syndrome", "PROBLEM", 133, 165], ["coronavirus infection", "OBSERVATION", 60, 81], ["Middle", "ANATOMY_MODIFIER", 133, 139], ["Respiratory Syndrome", "OBSERVATION", 145, 165]]], ["In both cases, the causative agents (SARS-CoV and MERS-CoV, respectively) were newly identified coronaviruses from the genus Betacoronavirus having zoonotic origin [3] .", [["SARS-CoV", "ORGANISM", 37, 45], ["MERS-CoV", "ORGANISM", 50, 58], ["coronaviruses", "ORGANISM", 96, 109], ["SARS-CoV", "SPECIES", 37, 45], ["MERS-CoV", "SPECIES", 50, 58]]], ["Another lung disorder associated with CoV is the Acute Respiratory Distress Syndrome (ARDS) that developed in several patients causing pathological changes in the lungs such as diffuse alveolar damage leading to fibrotic lesions [4, 5] .IntroductionTherapeutic clinical and preclinical studies using cultured cells are on the rise.", [["lung", "ANATOMY", 8, 12], ["lungs", "ANATOMY", 163, 168], ["alveolar", "ANATOMY", 185, 193], ["fibrotic lesions", "ANATOMY", 212, 228], ["cells", "ANATOMY", 309, 314], ["lung disorder", "DISEASE", 8, 21], ["Respiratory Distress Syndrome", "DISEASE", 55, 84], ["ARDS", "DISEASE", 86, 90], ["alveolar damage", "DISEASE", 185, 200], ["lung", "ORGAN", 8, 12], ["patients", "ORGANISM", 118, 126], ["lungs", "ORGAN", 163, 168], ["alveolar", "TISSUE", 185, 193], ["fibrotic lesions", "PATHOLOGICAL_FORMATION", 212, 228], ["cells", "CELL", 309, 314], ["cultured cells", "CELL_LINE", 300, 314], ["patients", "SPECIES", 118, 126], ["Another lung disorder", "PROBLEM", 0, 21], ["CoV", "PROBLEM", 38, 41], ["the Acute Respiratory Distress Syndrome", "PROBLEM", 45, 84], ["ARDS", "PROBLEM", 86, 90], ["pathological changes in the lungs", "PROBLEM", 135, 168], ["diffuse alveolar damage", "PROBLEM", 177, 200], ["fibrotic lesions", "PROBLEM", 212, 228], ["preclinical studies", "TEST", 274, 293], ["cultured cells", "TEST", 300, 314], ["lung", "ANATOMY", 8, 12], ["disorder", "OBSERVATION", 13, 21], ["CoV", "OBSERVATION", 38, 41], ["Acute", "OBSERVATION_MODIFIER", 49, 54], ["Respiratory Distress Syndrome", "OBSERVATION", 55, 84], ["ARDS", "OBSERVATION", 86, 90], ["pathological", "OBSERVATION", 135, 147], ["lungs", "ANATOMY", 163, 168], ["diffuse", "OBSERVATION_MODIFIER", 177, 184], ["alveolar damage", "OBSERVATION", 185, 200], ["fibrotic", "OBSERVATION_MODIFIER", 212, 220], ["lesions", "OBSERVATION", 221, 228]]], ["Models for respiratory virus infections and relevant clinical studies related to the administration of stem cells in patients are essential to define the patient population that can benefit from cell therapy [6] .", [["stem cells", "ANATOMY", 103, 113], ["cell", "ANATOMY", 195, 199], ["respiratory virus infections", "DISEASE", 11, 39], ["respiratory virus", "ORGANISM", 11, 28], ["stem cells", "CELL", 103, 113], ["patients", "ORGANISM", 117, 125], ["patient", "ORGANISM", 154, 161], ["cell", "CELL", 195, 199], ["stem cells", "CELL_TYPE", 103, 113], ["patients", "SPECIES", 117, 125], ["patient", "SPECIES", 154, 161], ["respiratory virus", "SPECIES", 11, 28], ["respiratory virus infections", "PROBLEM", 11, 39], ["relevant clinical studies", "TEST", 44, 69], ["stem cells", "TREATMENT", 103, 113], ["cell therapy", "TREATMENT", 195, 207], ["respiratory virus", "OBSERVATION", 11, 28], ["stem cells", "OBSERVATION", 103, 113]]], ["Thus, this study aims to review the outcomes of ongoing clinical studies on stem cells in SARS, ARDS, and MERS.", [["stem cells", "ANATOMY", 76, 86], ["SARS", "DISEASE", 90, 94], ["ARDS", "DISEASE", 96, 100], ["stem cells", "CELL", 76, 86], ["stem cells", "CELL_TYPE", 76, 86], ["this study", "TEST", 6, 16], ["ongoing clinical studies", "TEST", 48, 72], ["stem cells", "PROBLEM", 76, 86], ["SARS", "PROBLEM", 90, 94], ["ARDS", "PROBLEM", 96, 100], ["stem cells", "OBSERVATION", 76, 86], ["ARDS", "OBSERVATION", 96, 100]]], ["The results will be associated with possible applications to COVID-19.IntroductionFernanda Majolo and Guilherme Liberato da Silva contributed equally to this work.Stem Cells and Respiratory DiseasesStem cells are specialized cells that differentiate into other cell types [7] .", [["Stem Cells", "ANATOMY", 163, 173], ["Respiratory DiseasesStem cells", "ANATOMY", 178, 208], ["cells", "ANATOMY", 225, 230], ["cell", "ANATOMY", 261, 265], ["COVID-19", "CHEMICAL", 61, 69], ["Stem Cells", "CELL", 163, 173], ["Respiratory DiseasesStem cells", "CELL", 178, 208], ["cells", "CELL", 225, 230], ["cell", "CELL", 261, 265], ["Stem Cells", "CELL_TYPE", 163, 173], ["Respiratory DiseasesStem cells", "CELL_TYPE", 178, 208], ["COVID", "TEST", 61, 66], ["IntroductionFernanda Majolo", "TREATMENT", 70, 97], ["Guilherme Liberato da Silva", "TREATMENT", 102, 129], ["Stem Cells", "TEST", 163, 173], ["Respiratory DiseasesStem cells", "PROBLEM", 178, 208], ["Respiratory DiseasesStem cells", "OBSERVATION", 178, 208], ["cell types", "OBSERVATION", 261, 271]]], ["In certain organs, the stem cells produce descendants that maintain tissue homeostasis and also have the same function as the cells that are not generated from this differentiation [8] .", [["organs", "ANATOMY", 11, 17], ["stem cells", "ANATOMY", 23, 33], ["tissue", "ANATOMY", 68, 74], ["cells", "ANATOMY", 126, 131], ["organs", "ORGAN", 11, 17], ["stem cells", "CELL", 23, 33], ["tissue", "TISSUE", 68, 74], ["cells", "CELL", 126, 131], ["stem cells", "CELL_TYPE", 23, 33], ["organs", "ANATOMY", 11, 17], ["stem cells", "OBSERVATION", 23, 33]]], ["This class of cells depicts a revolution in such studies enabling their application in patients with various disorders, including lung diseases, thus allowing to study cell-based therapies for their treatment.", [["cells", "ANATOMY", 14, 19], ["lung", "ANATOMY", 130, 134], ["cell", "ANATOMY", 168, 172], ["lung diseases", "DISEASE", 130, 143], ["cells", "CELL", 14, 19], ["patients", "ORGANISM", 87, 95], ["lung", "ORGAN", 130, 134], ["cell", "CELL", 168, 172], ["patients", "SPECIES", 87, 95], ["such studies", "TEST", 44, 56], ["various disorders", "PROBLEM", 101, 118], ["lung diseases", "PROBLEM", 130, 143], ["cell-based therapies", "TREATMENT", 168, 188], ["their treatment", "TREATMENT", 193, 208], ["cells", "OBSERVATION", 14, 19], ["lung", "ANATOMY", 130, 134], ["diseases", "OBSERVATION", 135, 143]]], ["For the treatment of ARDS and sepsis, various cell types are used such as headStartembryonic stem cellsheadEnd (ESCs), headStartmesenchymal stem cellsheadEnd (MSCs), and epithelial progenitor cells (EpPCs).", [["cell", "ANATOMY", 46, 50], ["head", "ANATOMY", 74, 78], ["ESCs", "ANATOMY", 112, 116], ["MSCs", "ANATOMY", 159, 163], ["epithelial progenitor cells", "ANATOMY", 170, 197], ["EpPCs", "ANATOMY", 199, 204], ["ARDS", "DISEASE", 21, 25], ["sepsis", "DISEASE", 30, 36], ["cell", "CELL", 46, 50], ["headStartembryonic stem cellsheadEnd", "CELL", 74, 110], ["ESCs", "CELL", 112, 116], ["headStartmesenchymal stem cellsheadEnd", "CELL", 119, 157], ["MSCs", "CELL", 159, 163], ["epithelial progenitor cells", "CELL", 170, 197], ["EpPCs", "CELL", 199, 204], ["headStartembryonic stem cellsheadEnd", "CELL_LINE", 74, 110], ["ESCs", "CELL_LINE", 112, 116], ["headStartmesenchymal stem cellsheadEnd", "CELL_LINE", 119, 157], ["MSCs", "CELL_LINE", 159, 163], ["epithelial progenitor cells", "CELL_TYPE", 170, 197], ["EpPCs", "CELL_TYPE", 199, 204], ["ARDS", "PROBLEM", 21, 25], ["sepsis", "PROBLEM", 30, 36], ["various cell types", "PROBLEM", 38, 56], ["epithelial progenitor cells", "PROBLEM", 170, 197], ["ARDS", "OBSERVATION", 21, 25], ["sepsis", "OBSERVATION", 30, 36], ["various cell types", "OBSERVATION", 38, 56], ["epithelial progenitor cells", "OBSERVATION", 170, 197]]], ["Currently, most of the preclinical studies are using MSCs, though headStartinduced pluripotent stem cellsheadEnd (iPSC) for the treatment of ARDS [9] are also being used.Stem Cells and Respiratory DiseasesThe lungs were previously thought to be \"post-mitotic\" and unable to regenerate, while the stem cell populations, such as bone marrow, intestinal mucosa, and skin are considered regenerative.", [["MSCs", "ANATOMY", 53, 57], ["head", "ANATOMY", 66, 70], ["iPSC", "ANATOMY", 114, 118], ["Stem Cells", "ANATOMY", 170, 180], ["lungs", "ANATOMY", 209, 214], ["stem cell populations", "ANATOMY", 296, 317], ["bone marrow", "ANATOMY", 327, 338], ["intestinal mucosa", "ANATOMY", 340, 357], ["skin", "ANATOMY", 363, 367], ["ARDS", "DISEASE", 141, 145], ["Respiratory Diseases", "DISEASE", 185, 205], ["MSCs", "CELL", 53, 57], ["headStartinduced pluripotent stem cellsheadEnd", "CELL", 66, 112], ["iPSC", "CELL", 114, 118], ["Stem Cells", "CELL", 170, 180], ["lungs", "ORGAN", 209, 214], ["stem cell populations", "CELL", 296, 317], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 327, 338], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 340, 357], ["skin", "ORGAN", 363, 367], ["MSCs", "CELL_TYPE", 53, 57], ["headStartinduced pluripotent stem cellsheadEnd", "CELL_LINE", 66, 112], ["iPSC", "CELL_LINE", 114, 118], ["stem cell populations", "CELL_TYPE", 296, 317], ["the preclinical studies", "TEST", 19, 42], ["MSCs", "TREATMENT", 53, 57], ["ARDS", "PROBLEM", 141, 145], ["Stem Cells", "PROBLEM", 170, 180], ["Respiratory Diseases", "PROBLEM", 185, 205], ["post-mitotic\"", "PROBLEM", 246, 259], ["the stem cell populations", "TEST", 292, 317], ["ARDS", "OBSERVATION", 141, 145], ["Respiratory Diseases", "OBSERVATION", 185, 205], ["lungs", "ANATOMY", 209, 214], ["thought to be", "UNCERTAINTY", 231, 244], ["stem cell populations", "OBSERVATION", 296, 317], ["bone marrow", "ANATOMY", 327, 338], ["intestinal mucosa", "ANATOMY", 340, 357], ["skin", "ANATOMY", 363, 367]]], ["Yet it is known that different regions in the lungs are dependent on different cell populations, such as the endogenous stem cell complex for tissue repair demonstrating regenerative characteristics [10].", [["lungs", "ANATOMY", 46, 51], ["cell", "ANATOMY", 79, 83], ["stem cell", "ANATOMY", 120, 129], ["tissue", "ANATOMY", 142, 148], ["lungs", "ORGAN", 46, 51], ["cell populations", "CELL", 79, 95], ["stem cell", "CELL", 120, 129], ["tissue", "TISSUE", 142, 148], ["endogenous stem cell complex", "PROTEIN", 109, 137], ["different cell populations", "PROBLEM", 69, 95], ["tissue repair", "TREATMENT", 142, 155], ["different", "OBSERVATION_MODIFIER", 21, 30], ["lungs", "ANATOMY", 46, 51], ["dependent", "OBSERVATION_MODIFIER", 56, 65], ["different cell populations", "OBSERVATION", 69, 95], ["endogenous stem cell", "OBSERVATION", 109, 129], ["tissue repair", "OBSERVATION", 142, 155], ["regenerative", "OBSERVATION_MODIFIER", 170, 182]]], ["For example, idiopathic pulmonary fibrosis (IPF) is a fatal form of the disease characterized by scar tissue formation in the interstitial lungs with extracellular matrix deposited over time.", [["pulmonary", "ANATOMY", 24, 33], ["scar tissue", "ANATOMY", 97, 108], ["interstitial lungs", "ANATOMY", 126, 144], ["extracellular matrix", "ANATOMY", 150, 170], ["idiopathic pulmonary fibrosis", "DISEASE", 13, 42], ["IPF", "DISEASE", 44, 47], ["pulmonary", "ORGAN", 24, 33], ["scar tissue", "TISSUE", 97, 108], ["interstitial lungs", "MULTI-TISSUE_STRUCTURE", 126, 144], ["extracellular matrix", "CELLULAR_COMPONENT", 150, 170], ["idiopathic pulmonary fibrosis", "PROBLEM", 13, 42], ["the disease", "PROBLEM", 68, 79], ["scar tissue formation in the interstitial lungs", "PROBLEM", 97, 144], ["extracellular matrix", "PROBLEM", 150, 170], ["idiopathic", "OBSERVATION_MODIFIER", 13, 23], ["pulmonary", "ANATOMY", 24, 33], ["fibrosis", "OBSERVATION", 34, 42], ["IPF", "OBSERVATION", 44, 47], ["fatal", "OBSERVATION_MODIFIER", 54, 59], ["disease", "OBSERVATION", 72, 79], ["scar tissue", "OBSERVATION", 97, 108], ["interstitial", "ANATOMY_MODIFIER", 126, 138], ["lungs", "ANATOMY", 139, 144], ["extracellular matrix", "OBSERVATION", 150, 170]]], ["The symptoms include cough, exertional dyspnea, functional and exercise limitation, acute respiratory failure, and death.Stem Cells and Respiratory DiseasesWith the emergence of stem cell therapy in treating diseases, the murine bleomycin model became the bestcharacterized one, in which the administration of allogeneic bone marrow-derived-MSCs (BM-MSCs) reduces inflammation and collagen deposition [11] [12] [13] .", [["respiratory", "ANATOMY", 90, 101], ["Stem Cells", "ANATOMY", 121, 131], ["stem cell", "ANATOMY", 178, 187], ["bone marrow-derived-MSCs", "ANATOMY", 321, 345], ["BM-MSCs", "ANATOMY", 347, 354], ["cough", "DISEASE", 21, 26], ["exertional dyspnea", "DISEASE", 28, 46], ["acute respiratory failure", "DISEASE", 84, 109], ["death", "DISEASE", 115, 120], ["Respiratory DiseasesWith", "DISEASE", 136, 160], ["bleomycin", "CHEMICAL", 229, 238], ["inflammation", "DISEASE", 364, 376], ["bleomycin", "CHEMICAL", 229, 238], ["Stem Cells", "CELL", 121, 131], ["stem cell", "CELL", 178, 187], ["murine", "ORGANISM", 222, 228], ["bleomycin", "SIMPLE_CHEMICAL", 229, 238], ["bone marrow-derived-MSCs", "CELL", 321, 345], ["BM-MSCs", "CELL", 347, 354], ["collagen", "GENE_OR_GENE_PRODUCT", 381, 389], ["allogeneic bone marrow-derived-MSCs", "CELL_LINE", 310, 345], ["BM", "CELL_TYPE", 347, 349], ["MSCs", "CELL_TYPE", 350, 354], ["collagen", "PROTEIN", 381, 389], ["murine", "SPECIES", 222, 228], ["The symptoms", "PROBLEM", 0, 12], ["cough", "PROBLEM", 21, 26], ["exertional dyspnea", "PROBLEM", 28, 46], ["functional and exercise limitation", "PROBLEM", 48, 82], ["acute respiratory failure", "PROBLEM", 84, 109], ["death", "PROBLEM", 115, 120], ["Stem Cells", "PROBLEM", 121, 131], ["stem cell therapy", "TREATMENT", 178, 195], ["treating diseases", "PROBLEM", 199, 216], ["the murine bleomycin model", "TREATMENT", 218, 244], ["allogeneic bone marrow", "TREATMENT", 310, 332], ["inflammation", "PROBLEM", 364, 376], ["collagen deposition", "TEST", 381, 400], ["cough", "OBSERVATION", 21, 26], ["exertional", "OBSERVATION_MODIFIER", 28, 38], ["dyspnea", "OBSERVATION", 39, 46], ["acute", "OBSERVATION_MODIFIER", 84, 89], ["respiratory failure", "OBSERVATION", 90, 109], ["Respiratory DiseasesWith", "OBSERVATION", 136, 160], ["stem cell therapy", "OBSERVATION", 178, 195]]], ["Also, it was observed that stem cells from the placenta and human umbilical cord demonstrated reduced lung tissue damage in the mouse bleomycin models [14] [15] [16] .Stem Cells and Respiratory DiseasesAnother example of stem cells applied to lung disease is chronic obstructive pulmonary disease (COPD), a major devastating disease worldwide.", [["stem cells", "ANATOMY", 27, 37], ["placenta", "ANATOMY", 47, 55], ["umbilical cord", "ANATOMY", 66, 80], ["lung tissue", "ANATOMY", 102, 113], ["Stem Cells", "ANATOMY", 167, 177], ["stem cells", "ANATOMY", 221, 231], ["lung", "ANATOMY", 243, 247], ["pulmonary", "ANATOMY", 279, 288], ["tissue damage", "DISEASE", 107, 120], ["bleomycin", "CHEMICAL", 134, 143], ["Respiratory Diseases", "DISEASE", 182, 202], ["lung disease", "DISEASE", 243, 255], ["chronic obstructive pulmonary disease", "DISEASE", 259, 296], ["COPD", "DISEASE", 298, 302], ["bleomycin", "CHEMICAL", 134, 143], ["stem cells", "CELL", 27, 37], ["placenta", "ORGAN", 47, 55], ["human", "ORGANISM", 60, 65], ["umbilical cord", "ORGAN", 66, 80], ["lung tissue", "TISSUE", 102, 113], ["mouse", "ORGANISM", 128, 133], ["bleomycin", "SIMPLE_CHEMICAL", 134, 143], ["Stem Cells", "CELL", 167, 177], ["stem cells", "CELL", 221, 231], ["lung", "ORGAN", 243, 247], ["pulmonary", "ORGAN", 279, 288], ["stem cells", "CELL_TYPE", 27, 37], ["stem cells", "CELL_TYPE", 221, 231], ["human", "SPECIES", 60, 65], ["mouse", "SPECIES", 128, 133], ["human", "SPECIES", 60, 65], ["mouse", "SPECIES", 128, 133], ["stem cells", "PROBLEM", 27, 37], ["the placenta and human umbilical cord", "TEST", 43, 80], ["reduced lung tissue damage", "PROBLEM", 94, 120], ["the mouse bleomycin models", "TEST", 124, 150], ["Stem Cells", "PROBLEM", 167, 177], ["Respiratory Diseases", "PROBLEM", 182, 202], ["stem cells", "PROBLEM", 221, 231], ["lung disease", "PROBLEM", 243, 255], ["chronic obstructive pulmonary disease", "PROBLEM", 259, 296], ["COPD", "PROBLEM", 298, 302], ["a major devastating disease worldwide", "PROBLEM", 305, 342], ["stem cells", "OBSERVATION", 27, 37], ["placenta", "ANATOMY", 47, 55], ["umbilical cord", "ANATOMY", 66, 80], ["reduced", "OBSERVATION_MODIFIER", 94, 101], ["lung", "ANATOMY", 102, 106], ["tissue", "OBSERVATION", 107, 113], ["Stem Cells", "OBSERVATION", 167, 177], ["Respiratory Diseases", "OBSERVATION", 182, 202], ["stem cells", "OBSERVATION", 221, 231], ["lung", "ANATOMY", 243, 247], ["disease", "OBSERVATION", 248, 255], ["chronic", "OBSERVATION_MODIFIER", 259, 266], ["obstructive", "OBSERVATION_MODIFIER", 267, 278], ["pulmonary", "ANATOMY", 279, 288], ["disease", "OBSERVATION", 289, 296], ["COPD", "OBSERVATION", 298, 302], ["major", "OBSERVATION_MODIFIER", 307, 312], ["devastating", "OBSERVATION_MODIFIER", 313, 324], ["disease", "OBSERVATION", 325, 332]]], ["COPD is characterized by chronic small airway inflammation, commonly known as chronic bronchitis, causing progressive poor airflow leading to damage of lung tissues (emphysema).", [["airway", "ANATOMY", 39, 45], ["lung tissues", "ANATOMY", 152, 164], ["emphysema", "ANATOMY", 166, 175], ["COPD", "DISEASE", 0, 4], ["airway inflammation", "DISEASE", 39, 58], ["bronchitis", "DISEASE", 86, 96], ["emphysema", "DISEASE", 166, 175], ["airway", "MULTI-TISSUE_STRUCTURE", 39, 45], ["lung tissues", "TISSUE", 152, 164], ["emphysema", "ORGAN", 166, 175], ["COPD", "PROBLEM", 0, 4], ["chronic small airway inflammation", "PROBLEM", 25, 58], ["chronic bronchitis", "PROBLEM", 78, 96], ["progressive poor airflow", "PROBLEM", 106, 130], ["damage of lung tissues", "PROBLEM", 142, 164], ["emphysema", "PROBLEM", 166, 175], ["chronic", "OBSERVATION_MODIFIER", 25, 32], ["small", "OBSERVATION_MODIFIER", 33, 38], ["airway", "ANATOMY", 39, 45], ["inflammation", "OBSERVATION", 46, 58], ["chronic", "OBSERVATION_MODIFIER", 78, 85], ["bronchitis", "OBSERVATION", 86, 96], ["progressive", "OBSERVATION_MODIFIER", 106, 117], ["poor airflow", "OBSERVATION", 118, 130], ["lung tissues", "ANATOMY", 152, 164], ["emphysema", "OBSERVATION", 166, 175]]], ["MSCs, as a therapy, are considered a strong candidate in headStartclinical trialsheadEnd to repair damaged lung tissue in COPD or any other chronic lung disease [17] [18] [19] .Stem Cells and Respiratory DiseasesStem cells, particularly pluripotent cells such as ESCs or iPSCs, offer the potential to differentiate into lung cells reprogramming the immune response to reduce destructive inflammatory elements and directly replace damaged cells and tissues [20] .", [["MSCs", "ANATOMY", 0, 4], ["head", "ANATOMY", 57, 61], ["lung tissue", "ANATOMY", 107, 118], ["lung", "ANATOMY", 148, 152], ["Stem Cells", "ANATOMY", 177, 187], ["Respiratory DiseasesStem cells", "ANATOMY", 192, 222], ["pluripotent cells", "ANATOMY", 237, 254], ["ESCs", "ANATOMY", 263, 267], ["iPSCs", "ANATOMY", 271, 276], ["lung cells", "ANATOMY", 320, 330], ["cells", "ANATOMY", 438, 443], ["tissues", "ANATOMY", 448, 455], ["COPD", "DISEASE", 122, 126], ["chronic lung disease", "DISEASE", 140, 160], ["MSCs", "CELL", 0, 4], ["head", "ORGANISM_SUBDIVISION", 57, 61], ["lung tissue", "TISSUE", 107, 118], ["lung", "ORGAN", 148, 152], ["Stem Cells", "CELL", 177, 187], ["Respiratory DiseasesStem cells", "CELL", 192, 222], ["pluripotent cells", "CELL", 237, 254], ["ESCs", "CELL", 263, 267], ["iPSCs", "CELL", 271, 276], ["lung cells", "CELL", 320, 330], ["cells", "CELL", 438, 443], ["tissues", "TISSUE", 448, 455], ["MSCs", "CELL_TYPE", 0, 4], ["Stem Cells", "CELL_TYPE", 177, 187], ["Respiratory DiseasesStem cells", "CELL_TYPE", 192, 222], ["pluripotent cells", "CELL_TYPE", 237, 254], ["ESCs", "CELL_TYPE", 263, 267], ["iPSCs", "CELL_TYPE", 271, 276], ["lung cells", "CELL_TYPE", 320, 330], ["inflammatory elements", "DNA", 387, 408], ["damaged cells", "CELL_TYPE", 430, 443], ["MSCs", "PROBLEM", 0, 4], ["a therapy", "TREATMENT", 9, 18], ["repair damaged lung tissue", "PROBLEM", 92, 118], ["COPD", "PROBLEM", 122, 126], ["any other chronic lung disease", "PROBLEM", 130, 160], ["Stem Cells", "TEST", 177, 187], ["Respiratory DiseasesStem cells", "PROBLEM", 192, 222], ["pluripotent cells", "PROBLEM", 237, 254], ["ESCs", "PROBLEM", 263, 267], ["iPSCs", "PROBLEM", 271, 276], ["lung cells", "PROBLEM", 320, 330], ["destructive inflammatory elements", "PROBLEM", 375, 408], ["repair", "OBSERVATION_MODIFIER", 92, 98], ["damaged", "OBSERVATION_MODIFIER", 99, 106], ["lung", "ANATOMY", 107, 111], ["tissue", "OBSERVATION", 112, 118], ["COPD", "OBSERVATION", 122, 126], ["chronic", "OBSERVATION_MODIFIER", 140, 147], ["lung", "ANATOMY", 148, 152], ["disease", "OBSERVATION", 153, 160], ["Respiratory", "ANATOMY", 192, 203], ["DiseasesStem cells", "OBSERVATION", 204, 222], ["pluripotent cells", "OBSERVATION", 237, 254], ["lung", "ANATOMY", 320, 324], ["destructive", "OBSERVATION_MODIFIER", 375, 386]]], ["Thus, it can be a promising novel therapeutic strategy in ARDS to repair and resolve a lung injury restoring the whole epithelial and endothelial function [21] .", [["lung", "ANATOMY", 87, 91], ["whole epithelial", "ANATOMY", 113, 129], ["endothelial", "ANATOMY", 134, 145], ["ARDS", "DISEASE", 58, 62], ["lung injury", "DISEASE", 87, 98], ["lung", "ORGAN", 87, 91], ["epithelial", "TISSUE", 119, 129], ["endothelial", "CELL", 134, 145], ["ARDS", "PROBLEM", 58, 62], ["repair", "TREATMENT", 66, 72], ["a lung injury", "PROBLEM", 85, 98], ["lung", "ANATOMY", 87, 91], ["injury", "OBSERVATION", 92, 98], ["epithelial", "ANATOMY_MODIFIER", 119, 129], ["endothelial", "ANATOMY", 134, 145]]], ["They can also attenuate bacterial sepsis, directly associated with ARDS, via several mechanisms, such as improving the phagocytic ability, secreting anti-microbial peptides [22] , and increasing bacterial clearance [23] .", [["sepsis", "DISEASE", 34, 40], ["ARDS", "DISEASE", 67, 71], ["bacterial sepsis", "PROBLEM", 24, 40], ["ARDS", "PROBLEM", 67, 71], ["secreting anti-microbial peptides", "TEST", 139, 172], ["increasing bacterial clearance", "PROBLEM", 184, 214], ["bacterial", "OBSERVATION_MODIFIER", 24, 33], ["sepsis", "OBSERVATION", 34, 40], ["ARDS", "OBSERVATION", 67, 71]]], ["Furthermore, MSCs demonstrated a great potential when reducing the endotoxin-induced injury to explanted human lungs [24] .Mesenchymal Stem CellsheadStartMesenchymal stem cellsheadEnd can be isolated from bone marrow and expanded extensively in vitro.", [["MSCs", "ANATOMY", 13, 17], ["lungs", "ANATOMY", 111, 116], ["Mesenchymal Stem Cellshead", "ANATOMY", 123, 149], ["stem cellshead", "ANATOMY", 166, 180], ["bone marrow", "ANATOMY", 205, 216], ["endotoxin", "CHEMICAL", 67, 76], ["MSCs", "CELL", 13, 17], ["endotoxin", "SIMPLE_CHEMICAL", 67, 76], ["human", "ORGANISM", 105, 110], ["lungs", "ORGAN", 111, 116], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 205, 216], ["MSCs", "CELL_TYPE", 13, 17], ["endotoxin", "PROTEIN", 67, 76], ["StartMesenchymal stem cellshead", "CELL_LINE", 149, 180], ["human", "SPECIES", 105, 110], ["human", "SPECIES", 105, 110], ["the endotoxin", "TREATMENT", 63, 76], ["bone marrow", "TEST", 205, 216], ["lungs", "ANATOMY", 111, 116], ["Stem Cellshead", "OBSERVATION", 135, 149], ["stem cellshead", "OBSERVATION", 166, 180], ["bone", "ANATOMY", 205, 209], ["marrow", "OBSERVATION", 210, 216]]], ["They play an important role in the repair process or may engraft the injured lung [25, 26] .", [["lung", "ANATOMY", 77, 81], ["lung", "ORGAN", 77, 81], ["the repair process", "TREATMENT", 31, 49], ["repair", "OBSERVATION", 35, 41], ["injured", "OBSERVATION", 69, 76], ["lung", "ANATOMY", 77, 81]]], ["Engraftment may initiate simultaneously, where MSCs differentiate into lung epithelial cells and can directly replace the damaged cells in alveoli during the treatment of ARDS [27, 28] .", [["MSCs", "ANATOMY", 47, 51], ["lung epithelial cells", "ANATOMY", 71, 92], ["cells", "ANATOMY", 130, 135], ["alveoli", "ANATOMY", 139, 146], ["ARDS", "DISEASE", 171, 175], ["MSCs", "CELL", 47, 51], ["lung epithelial cells", "CELL", 71, 92], ["cells", "CELL", 130, 135], ["alveoli", "MULTI-TISSUE_STRUCTURE", 139, 146], ["MSCs", "CELL_TYPE", 47, 51], ["lung epithelial cells", "CELL_TYPE", 71, 92], ["damaged cells", "CELL_TYPE", 122, 135], ["Engraftment", "TREATMENT", 0, 11], ["lung epithelial cells", "PROBLEM", 71, 92], ["the damaged cells", "TREATMENT", 118, 135], ["ARDS", "PROBLEM", 171, 175], ["lung", "ANATOMY", 71, 75], ["epithelial cells", "OBSERVATION", 76, 92], ["damaged cells", "OBSERVATION", 122, 135], ["alveoli", "ANATOMY_MODIFIER", 139, 146], ["ARDS", "OBSERVATION", 171, 175]]], ["Their applicability has been reported in treating cardiovascular and pulmonary diseases [26, 29] along with severe inflammation [30, 31] .", [["cardiovascular", "ANATOMY", 50, 64], ["pulmonary", "ANATOMY", 69, 78], ["cardiovascular and pulmonary diseases", "DISEASE", 50, 87], ["inflammation", "DISEASE", 115, 127], ["cardiovascular", "ANATOMICAL_SYSTEM", 50, 64], ["pulmonary", "ORGAN", 69, 78], ["cardiovascular and pulmonary diseases", "PROBLEM", 50, 87], ["severe inflammation", "PROBLEM", 108, 127], ["pulmonary", "ANATOMY", 69, 78], ["diseases", "OBSERVATION", 79, 87], ["severe", "OBSERVATION_MODIFIER", 108, 114], ["inflammation", "OBSERVATION", 115, 127]]], ["These properties are also very attractive due to the immunosuppressive/ immunomodulatory abilities [32, 33] influencing an increase in Keratinocyte growth factor (KGF) on epithelial cells, and in the study models of lung injury.", [["epithelial cells", "ANATOMY", 171, 187], ["lung", "ANATOMY", 216, 220], ["lung injury", "DISEASE", 216, 227], ["Keratinocyte growth factor", "GENE_OR_GENE_PRODUCT", 135, 161], ["KGF", "GENE_OR_GENE_PRODUCT", 163, 166], ["epithelial cells", "CELL", 171, 187], ["lung", "ORGAN", 216, 220], ["Keratinocyte growth factor", "PROTEIN", 135, 161], ["KGF", "PROTEIN", 163, 166], ["epithelial cells", "CELL_TYPE", 171, 187], ["the immunosuppressive/ immunomodulatory abilities", "PROBLEM", 49, 98], ["an increase in Keratinocyte growth factor", "PROBLEM", 120, 161], ["epithelial cells", "PROBLEM", 171, 187], ["lung injury", "PROBLEM", 216, 227], ["increase", "OBSERVATION_MODIFIER", 123, 131], ["Keratinocyte growth", "OBSERVATION", 135, 154], ["epithelial cells", "OBSERVATION", 171, 187], ["lung", "ANATOMY", 216, 220], ["injury", "OBSERVATION", 221, 227]]], ["Thus, they play a protective role in inducing type II cell proliferation and edema clearance [34] .", [["type II cell", "ANATOMY", 46, 58], ["edema", "ANATOMY", 77, 82], ["edema", "DISEASE", 77, 82], ["type II cell", "CELL", 46, 58], ["edema", "PATHOLOGICAL_FORMATION", 77, 82], ["type II cell proliferation", "PROBLEM", 46, 72], ["edema clearance", "PROBLEM", 77, 92], ["cell proliferation", "OBSERVATION", 54, 72], ["edema", "OBSERVATION", 77, 82]]], ["Additionally, KGF could upregulate alveolar fluid clearance in ex vivo human lungs injured by an endotoxin [24] .", [["alveolar fluid", "ANATOMY", 35, 49], ["lungs", "ANATOMY", 77, 82], ["endotoxin", "CHEMICAL", 97, 106], ["KGF", "GENE_OR_GENE_PRODUCT", 14, 17], ["alveolar fluid", "TISSUE", 35, 49], ["human", "ORGANISM", 71, 76], ["lungs", "ORGAN", 77, 82], ["KGF", "PROTEIN", 14, 17], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 71, 76], ["alveolar fluid clearance", "TEST", 35, 59], ["alveolar", "ANATOMY_MODIFIER", 35, 43], ["fluid clearance", "OBSERVATION", 44, 59], ["lungs", "ANATOMY", 77, 82]]], ["MSCs play an anti-inflammatory role secreting several mediators that down-regulate the inflammatory process [35] and secrete growth factors, including KGF [36, 37] .Mesenchymal Stem CellsIn animal models with lung injury, intravenous MSCs led to favorable outcomes, such as reduction in inflammation, proinflammatory cytokines, and lung edema [38] .", [["MSCs", "ANATOMY", 0, 4], ["Mesenchymal", "ANATOMY", 165, 176], ["lung", "ANATOMY", 209, 213], ["intravenous MSCs", "ANATOMY", 222, 238], ["lung", "ANATOMY", 332, 336], ["lung injury", "DISEASE", 209, 220], ["inflammation", "DISEASE", 287, 299], ["lung edema", "DISEASE", 332, 342], ["MSCs", "CELL", 0, 4], ["KGF", "GENE_OR_GENE_PRODUCT", 151, 154], ["lung", "ORGAN", 209, 213], ["MSCs", "CELL", 234, 238], ["lung", "ORGAN", 332, 336], ["MSCs", "CELL_TYPE", 0, 4], ["growth factors", "PROTEIN", 125, 139], ["KGF", "PROTEIN", 151, 154], ["intravenous MSCs", "CELL_TYPE", 222, 238], ["proinflammatory cytokines", "PROTEIN", 301, 326], ["MSCs", "TREATMENT", 0, 4], ["the inflammatory process", "PROBLEM", 83, 107], ["secrete growth factors", "PROBLEM", 117, 139], ["KGF", "TEST", 151, 154], ["lung injury", "PROBLEM", 209, 220], ["intravenous MSCs", "TREATMENT", 222, 238], ["inflammation", "PROBLEM", 287, 299], ["proinflammatory cytokines", "PROBLEM", 301, 326], ["lung edema", "PROBLEM", 332, 342], ["inflammatory", "OBSERVATION_MODIFIER", 87, 99], ["Stem CellsIn", "OBSERVATION", 177, 189], ["lung", "ANATOMY", 209, 213], ["injury", "OBSERVATION", 214, 220], ["reduction", "OBSERVATION_MODIFIER", 274, 283], ["inflammation", "OBSERVATION", 287, 299], ["proinflammatory cytokines", "OBSERVATION", 301, 326], ["lung", "ANATOMY", 332, 336], ["edema", "OBSERVATION", 337, 342]]], ["In mouse models, the treatment involving MSCs reduced pulmonary edema and extended survival in Escherichia coli endotoxininduced lung injury [39] .", [["MSCs", "ANATOMY", 41, 45], ["pulmonary", "ANATOMY", 54, 63], ["lung", "ANATOMY", 129, 133], ["pulmonary edema", "DISEASE", 54, 69], ["lung injury", "DISEASE", 129, 140], ["mouse", "ORGANISM", 3, 8], ["MSCs", "CELL", 41, 45], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 54, 69], ["Escherichia coli", "ORGANISM", 95, 111], ["lung", "ORGAN", 129, 133], ["MSCs", "CELL_TYPE", 41, 45], ["mouse", "SPECIES", 3, 8], ["Escherichia coli", "SPECIES", 95, 111], ["mouse", "SPECIES", 3, 8], ["Escherichia coli", "SPECIES", 95, 111], ["the treatment", "TREATMENT", 17, 30], ["MSCs", "PROBLEM", 41, 45], ["pulmonary edema", "PROBLEM", 54, 69], ["Escherichia coli endotoxininduced lung injury", "PROBLEM", 95, 140], ["pulmonary", "ANATOMY", 54, 63], ["edema", "OBSERVATION", 64, 69], ["Escherichia coli", "OBSERVATION", 95, 111], ["lung", "ANATOMY", 129, 133], ["injury", "OBSERVATION", 134, 140]]], ["The outcomes of involving MSCs in experimental models of ALI/ARDS have been promising as a cell-based therapy [40] .Mesenchymal Stem CellsPreviously, ARDS was defined within two simple concepts, namely [1] the pro-inflammatory (leading to host damage) and [2] fibrotic (repair and fibrosis) phase.", [["MSCs", "ANATOMY", 26, 30], ["cell", "ANATOMY", 91, 95], ["Mesenchymal", "ANATOMY", 116, 127], ["ALI", "DISEASE", 57, 60], ["ARDS", "DISEASE", 61, 65], ["ARDS", "DISEASE", 150, 154], ["fibrosis", "DISEASE", 281, 289], ["MSCs", "CELL", 26, 30], ["cell", "CELL", 91, 95], ["MSCs", "CELL_TYPE", 26, 30], ["MSCs", "PROBLEM", 26, 30], ["ALI", "PROBLEM", 57, 60], ["ARDS", "PROBLEM", 61, 65], ["a cell-based therapy", "TREATMENT", 89, 109], ["ARDS", "PROBLEM", 150, 154], ["the pro-inflammatory", "PROBLEM", 206, 226], ["host damage)", "PROBLEM", 239, 251], ["fibrotic (repair", "TREATMENT", 260, 276], ["fibrosis) phase", "PROBLEM", 281, 296], ["ALI", "ANATOMY", 57, 60], ["ARDS", "OBSERVATION", 61, 65], ["Stem CellsPreviously", "OBSERVATION", 128, 148], ["ARDS", "OBSERVATION", 150, 154], ["fibrotic", "OBSERVATION_MODIFIER", 260, 268], ["fibrosis", "OBSERVATION", 281, 289]]], ["These two phases make the disease progression more complex [41] .", [["the disease progression", "PROBLEM", 22, 45]]], ["Moreover, the mechanism of action of MSCs is also unknown due to the diverse array of paracrine mediators which are directly associated with the therapeutic effects [42] .", [["MSCs", "ANATOMY", 37, 41], ["MSCs", "CELL", 37, 41], ["MSCs", "CELL_TYPE", 37, 41], ["MSCs", "PROBLEM", 37, 41], ["paracrine mediators", "TREATMENT", 86, 105]]], ["Several factors that influence these effects are [1] differences between the cell surface epitopes and genomic stability between mice and humans involved in the studies [43] ; [2] different inflammatory environment [44] ; and [3] the heterogeneity of MSCs and their subtypes [45] .", [["cell surface", "ANATOMY", 77, 89], ["MSCs", "ANATOMY", 251, 255], ["cell", "CELL", 77, 81], ["mice", "ORGANISM", 129, 133], ["humans", "ORGANISM", 138, 144], ["MSCs", "CELL", 251, 255], ["cell surface epitopes", "PROTEIN", 77, 98], ["MSCs", "CELL_TYPE", 251, 255], ["mice", "SPECIES", 129, 133], ["humans", "SPECIES", 138, 144], ["mice", "SPECIES", 129, 133], ["humans", "SPECIES", 138, 144], ["Several factors", "PROBLEM", 0, 15], ["the cell surface epitopes", "TREATMENT", 73, 98], ["the studies", "TEST", 157, 168], ["different inflammatory environment", "PROBLEM", 180, 214], ["the heterogeneity of MSCs", "PROBLEM", 230, 255], ["genomic stability", "OBSERVATION", 103, 120], ["inflammatory", "OBSERVATION_MODIFIER", 190, 202]]], ["However, the complete success of MSCs as a cell therapy for patients with ARDS will probably depend on a better understanding of their mechanism of action and on defining the best strategies for their use in a clinical setting [46] .Mesenchymal Stem CellsThe benefit of MSCs utilization is directly related to paracrine soluble factors, transfer of mitochondria, and histologically active microvesicles [47] . siRNA knockdown was utilized to analyze the paracrine soluble factors in cultured human type 2 cells during in vitro MSCs treatment and it was found that angiopoietin-1 secretion was partially responsible for the beneficial effect of MSCs [48] [49] [50] .", [["MSCs", "ANATOMY", 33, 37], ["cell", "ANATOMY", 43, 47], ["Mesenchymal Stem Cells", "ANATOMY", 233, 255], ["MSCs", "ANATOMY", 270, 274], ["mitochondria", "ANATOMY", 349, 361], ["microvesicles", "ANATOMY", 389, 402], ["type 2 cells", "ANATOMY", 498, 510], ["MSCs", "ANATOMY", 527, 531], ["MSCs", "ANATOMY", 644, 648], ["ARDS", "DISEASE", 74, 78], ["MSCs", "CELL", 33, 37], ["cell", "CELL", 43, 47], ["patients", "ORGANISM", 60, 68], ["Mesenchymal Stem Cells", "CELL", 233, 255], ["MSCs", "CELL", 270, 274], ["mitochondria", "CELLULAR_COMPONENT", 349, 361], ["microvesicles", "CELL", 389, 402], ["human", "ORGANISM", 492, 497], ["type 2 cells", "CELL", 498, 510], ["MSCs", "CELL", 527, 531], ["angiopoietin-1", "GENE_OR_GENE_PRODUCT", 564, 578], ["MSCs", "CELL", 644, 648], ["MSCs", "CELL_TYPE", 33, 37], ["MSCs", "CELL_TYPE", 270, 274], ["paracrine soluble factors", "PROTEIN", 310, 335], ["paracrine soluble factors", "PROTEIN", 454, 479], ["cultured human type 2 cells", "CELL_LINE", 483, 510], ["MSCs", "CELL_TYPE", 527, 531], ["angiopoietin", "PROTEIN", 564, 576], ["MSCs", "CELL_TYPE", 644, 648], ["patients", "SPECIES", 60, 68], ["human", "SPECIES", 492, 497], ["human", "SPECIES", 492, 497], ["MSCs", "TREATMENT", 33, 37], ["a cell therapy", "TREATMENT", 41, 55], ["ARDS", "PROBLEM", 74, 78], ["Mesenchymal Stem Cells", "PROBLEM", 233, 255], ["MSCs utilization", "TREATMENT", 270, 286], ["paracrine soluble factors", "TREATMENT", 310, 335], ["siRNA knockdown", "TREATMENT", 410, 425], ["the paracrine soluble factors", "TREATMENT", 450, 479], ["vitro MSCs treatment", "TREATMENT", 521, 541], ["angiopoietin", "TEST", 564, 576], ["Stem Cells", "OBSERVATION", 245, 255]]], ["The presence of MSCs upregulates lipoxin A4, a pro-resolving lipid mediator which could play an important role in MSCmediated healing of lung injury [49, 50] .", [["MSCs", "ANATOMY", 16, 20], ["lung", "ANATOMY", 137, 141], ["lung injury", "DISEASE", 137, 148], ["MSCs", "CELL", 16, 20], ["lipoxin A4", "GENE_OR_GENE_PRODUCT", 33, 43], ["lung", "ORGAN", 137, 141], ["MSCs", "CELL_TYPE", 16, 20], ["lipoxin A4", "PROTEIN", 33, 43], ["MSCs upregulates lipoxin A4", "TREATMENT", 16, 43], ["a pro-resolving lipid mediator", "TREATMENT", 45, 75], ["lung injury", "PROBLEM", 137, 148], ["MSCs upregulates", "OBSERVATION", 16, 32], ["lipoxin A4", "OBSERVATION", 33, 43], ["healing", "OBSERVATION_MODIFIER", 126, 133], ["lung", "ANATOMY", 137, 141], ["injury", "OBSERVATION", 142, 148]]], ["Additionally, MSCs mediate the release of microvesicles during cell-tocell communication [51] .Mesenchymal Stem CellsThe resistance of pulmonary epithelial cells during inflammation is an important tool to combat pulmonary edema.", [["MSCs", "ANATOMY", 14, 18], ["microvesicles", "ANATOMY", 42, 55], ["cell", "ANATOMY", 63, 67], ["tocell", "ANATOMY", 68, 74], ["Mesenchymal Stem Cells", "ANATOMY", 95, 117], ["pulmonary epithelial cells", "ANATOMY", 135, 161], ["pulmonary", "ANATOMY", 213, 222], ["inflammation", "DISEASE", 169, 181], ["pulmonary edema", "DISEASE", 213, 228], ["MSCs", "CELL", 14, 18], ["microvesicles", "CELL", 42, 55], ["cell", "CELL", 63, 67], ["tocell", "CELL", 68, 74], ["Mesenchymal Stem Cells", "CELL", 95, 117], ["pulmonary epithelial cells", "CELL", 135, 161], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 213, 228], ["MSCs", "CELL_TYPE", 14, 18], ["microvesicles", "CELL_TYPE", 42, 55], ["pulmonary epithelial cells", "CELL_TYPE", 135, 161], ["Mesenchymal Stem Cells", "PROBLEM", 95, 117], ["pulmonary epithelial cells", "PROBLEM", 135, 161], ["inflammation", "PROBLEM", 169, 181], ["pulmonary edema", "PROBLEM", 213, 228], ["Stem Cells", "OBSERVATION", 107, 117], ["resistance", "OBSERVATION_MODIFIER", 121, 131], ["pulmonary", "ANATOMY", 135, 144], ["epithelial cells", "OBSERVATION", 145, 161], ["inflammation", "OBSERVATION", 169, 181], ["pulmonary", "ANATOMY", 213, 222], ["edema", "OBSERVATION", 223, 228]]], ["The interaction between epithelial cells and MSCs in an inflammatory process represents a critical information point in revealing the mechanism of MSC-mediated therapeutic effects, thus allowing to design a better practical protocol to manage these cells [52] .", [["epithelial cells", "ANATOMY", 24, 40], ["MSCs", "ANATOMY", 45, 49], ["MSC", "ANATOMY", 147, 150], ["cells", "ANATOMY", 249, 254], ["epithelial cells", "CELL", 24, 40], ["MSCs", "CELL", 45, 49], ["MSC", "CELL", 147, 150], ["cells", "CELL", 249, 254], ["epithelial cells", "CELL_TYPE", 24, 40], ["MSCs", "CELL_TYPE", 45, 49], ["MSC", "CELL_TYPE", 147, 150], ["epithelial cells", "PROBLEM", 24, 40], ["MSCs", "PROBLEM", 45, 49], ["an inflammatory process", "PROBLEM", 53, 76], ["MSC", "PROBLEM", 147, 150], ["a better practical protocol", "TREATMENT", 205, 232], ["epithelial cells", "OBSERVATION", 24, 40], ["MSCs", "ANATOMY", 45, 49], ["inflammatory", "OBSERVATION", 56, 68]]], ["However, the genetic manipulation to improve the therapeutic efficacy of MSCs, so that they could work at the low level of trophic factors in the damaged host tissue, remains a permanent challenge [53] .MSCs-derived MicrovesiclesAmong the MSC-derived extracellular vesicles (EVs) or microvesicles, the best-characterized ones are the exosomes.", [["MSCs", "ANATOMY", 73, 77], ["tissue", "ANATOMY", 159, 165], ["MSCs", "ANATOMY", 203, 207], ["MSC", "ANATOMY", 239, 242], ["extracellular vesicles", "ANATOMY", 251, 273], ["EVs", "ANATOMY", 275, 278], ["microvesicles", "ANATOMY", 283, 296], ["exosomes", "ANATOMY", 334, 342], ["MSCs", "CELL", 73, 77], ["tissue", "TISSUE", 159, 165], ["MSCs", "CELL", 203, 207], ["MicrovesiclesAmong", "CELL", 216, 234], ["MSC", "CELL", 239, 242], ["extracellular vesicles", "CELLULAR_COMPONENT", 251, 273], ["EVs", "CELL", 275, 278], ["microvesicles", "CELL", 283, 296], ["exosomes", "CELL", 334, 342], ["MSCs", "CELL_TYPE", 73, 77], ["trophic factors", "PROTEIN", 123, 138], ["MSCs", "CELL_TYPE", 203, 207], ["MSC", "CELL_TYPE", 239, 242], ["EVs", "CELL_TYPE", 275, 278], ["microvesicles", "CELL_TYPE", 283, 296], ["exosomes", "CELL_TYPE", 334, 342], ["MSCs", "PROBLEM", 73, 77], ["a permanent challenge", "TREATMENT", 175, 196], ["MSCs", "TEST", 203, 207], ["microvesicles", "PROBLEM", 283, 296], ["trophic factors", "OBSERVATION", 123, 138], ["host tissue", "OBSERVATION", 154, 165], ["MSC", "ANATOMY", 239, 242], ["extracellular vesicles", "OBSERVATION", 251, 273], ["microvesicles", "OBSERVATION", 283, 296], ["exosomes", "OBSERVATION", 334, 342]]], ["They have a conserved protein group known as tetraspanins which is important for cell targeting.", [["cell", "ANATOMY", 81, 85], ["tetraspanins", "GENE_OR_GENE_PRODUCT", 45, 57], ["cell", "CELL", 81, 85], ["conserved protein group", "PROTEIN", 12, 35], ["tetraspanins", "PROTEIN", 45, 57], ["tetraspanins", "TREATMENT", 45, 57], ["cell targeting", "TREATMENT", 81, 95]]], ["These vesicles are rich in integrins, flotillins (lipid raft-associated), and cholesterol [54] .", [["vesicles", "ANATOMY", 6, 14], ["raft", "ANATOMY", 56, 60], ["cholesterol", "CHEMICAL", 78, 89], ["cholesterol", "CHEMICAL", 78, 89], ["vesicles", "CELLULAR_COMPONENT", 6, 14], ["integrins", "GENE_OR_GENE_PRODUCT", 27, 36], ["flotillins", "GENE_OR_GENE_PRODUCT", 38, 48], ["lipid raft", "CELLULAR_COMPONENT", 50, 60], ["cholesterol", "SIMPLE_CHEMICAL", 78, 89], ["integrins", "PROTEIN", 27, 36], ["flotillins", "PROTEIN", 38, 48], ["flotillins (lipid raft", "TREATMENT", 38, 60], ["cholesterol", "TEST", 78, 89], ["vesicles", "ANATOMY", 6, 14], ["rich", "OBSERVATION_MODIFIER", 19, 23]]], ["An important role of microvesicles is cell-cell-mediated communication and they are composed of small circular membrane fragments released from the endosomal cell membrane [33, 55] .", [["microvesicles", "ANATOMY", 21, 34], ["cell", "ANATOMY", 38, 42], ["cell", "ANATOMY", 43, 47], ["membrane fragments", "ANATOMY", 111, 129], ["endosomal cell membrane", "ANATOMY", 148, 171], ["microvesicles", "CELL", 21, 34], ["cell", "CELL", 38, 42], ["cell", "CELL", 43, 47], ["membrane fragments", "CELLULAR_COMPONENT", 111, 129], ["endosomal cell membrane", "CELLULAR_COMPONENT", 148, 171], ["microvesicles", "CELL_TYPE", 21, 34], ["small circular membrane fragments", "PROTEIN", 96, 129], ["small circular membrane fragments", "PROBLEM", 96, 129], ["microvesicles", "OBSERVATION", 21, 34], ["small", "OBSERVATION_MODIFIER", 96, 101], ["circular", "OBSERVATION_MODIFIER", 102, 110], ["membrane fragments", "OBSERVATION", 111, 129], ["endosomal cell membrane", "OBSERVATION", 148, 171]]], ["MSC-derived EVs contain RNAs that are involved in transcription control, cell proliferation, and immune regulation [56] , and interact using different mechanisms with the cell surface receptors [54, 57] .", [["MSC", "ANATOMY", 0, 3], ["EVs", "ANATOMY", 12, 15], ["cell", "ANATOMY", 73, 77], ["cell surface", "ANATOMY", 171, 183], ["MSC", "CELL", 0, 3], ["EVs", "CELL", 12, 15], ["cell", "CELL", 73, 77], ["cell", "CELL", 171, 175], ["MSC", "CELL_TYPE", 0, 3], ["EVs", "CELL_TYPE", 12, 15], ["RNAs", "RNA", 24, 28], ["cell surface receptors", "PROTEIN", 171, 193], ["MSC", "PROBLEM", 0, 3], ["cell proliferation", "TEST", 73, 91], ["cell proliferation", "OBSERVATION", 73, 91]]], ["These exosomes activate molecules between the cells through the transfer of genetic material and specific organelles such as mitochondria [58] .", [["exosomes", "ANATOMY", 6, 14], ["cells", "ANATOMY", 46, 51], ["organelles", "ANATOMY", 106, 116], ["mitochondria", "ANATOMY", 125, 137], ["exosomes", "CELL", 6, 14], ["cells", "CELL", 46, 51], ["organelles", "CELLULAR_COMPONENT", 106, 116], ["mitochondria", "CELLULAR_COMPONENT", 125, 137], ["exosomes", "CELL_TYPE", 6, 14]]], ["Microvesicles derived from MSCs play an important role in the repair of lung injury in ARDS [59] .", [["Microvesicles", "ANATOMY", 0, 13], ["MSCs", "ANATOMY", 27, 31], ["lung", "ANATOMY", 72, 76], ["lung injury", "DISEASE", 72, 83], ["ARDS", "DISEASE", 87, 91], ["MSCs", "CELL", 27, 31], ["lung", "ORGAN", 72, 76], ["Microvesicles", "CELL_TYPE", 0, 13], ["MSCs", "CELL_TYPE", 27, 31], ["Microvesicles", "PROBLEM", 0, 13], ["MSCs", "TREATMENT", 27, 31], ["the repair", "TREATMENT", 58, 68], ["lung injury", "PROBLEM", 72, 83], ["ARDS", "PROBLEM", 87, 91], ["repair", "OBSERVATION", 62, 68], ["lung", "ANATOMY", 72, 76], ["injury", "OBSERVATION", 77, 83], ["ARDS", "OBSERVATION", 87, 91]]], ["Zhu et al. [51] observed a decrease in lung edema and neutrophil counts by utilizing microvesicles from human bone marrow MSCs with an increased expression of KGF in this induced lung injury.", [["lung edema", "ANATOMY", 39, 49], ["neutrophil", "ANATOMY", 54, 64], ["microvesicles", "ANATOMY", 85, 98], ["bone marrow MSCs", "ANATOMY", 110, 126], ["lung", "ANATOMY", 179, 183], ["edema", "DISEASE", 44, 49], ["lung injury", "DISEASE", 179, 190], ["lung", "ORGAN", 39, 43], ["edema", "PATHOLOGICAL_FORMATION", 44, 49], ["neutrophil", "CELL", 54, 64], ["microvesicles", "CELL", 85, 98], ["human", "ORGANISM", 104, 109], ["bone marrow MSCs", "CELL", 110, 126], ["KGF", "GENE_OR_GENE_PRODUCT", 159, 162], ["lung", "ORGAN", 179, 183], ["microvesicles", "CELL_TYPE", 85, 98], ["human bone marrow MSCs", "CELL_TYPE", 104, 126], ["KGF", "PROTEIN", 159, 162], ["human", "SPECIES", 104, 109], ["human", "SPECIES", 104, 109], ["a decrease in lung edema", "PROBLEM", 25, 49], ["neutrophil counts", "TEST", 54, 71], ["human bone marrow MSCs", "PROBLEM", 104, 126], ["an increased expression of KGF", "PROBLEM", 132, 162], ["this induced lung injury", "PROBLEM", 166, 190], ["decrease", "OBSERVATION_MODIFIER", 27, 35], ["lung", "ANATOMY", 39, 43], ["edema", "OBSERVATION", 44, 49], ["neutrophil counts", "OBSERVATION", 54, 71], ["bone", "ANATOMY", 110, 114], ["marrow MSCs", "OBSERVATION", 115, 126], ["increased", "OBSERVATION_MODIFIER", 135, 144], ["KGF", "OBSERVATION", 159, 162], ["lung", "ANATOMY", 179, 183], ["injury", "OBSERVATION", 184, 190]]], ["Evidence from several studies supports the role of microvesicles in cell-based therapies associated with respiratory diseases [55, 60] .", [["microvesicles", "ANATOMY", 51, 64], ["cell", "ANATOMY", 68, 72], ["respiratory", "ANATOMY", 105, 116], ["respiratory diseases", "DISEASE", 105, 125], ["microvesicles", "CELL", 51, 64], ["cell", "CELL", 68, 72], ["microvesicles", "CELL_TYPE", 51, 64], ["several studies", "TEST", 14, 29], ["cell-based therapies", "TREATMENT", 68, 88], ["respiratory diseases", "PROBLEM", 105, 125], ["respiratory diseases", "OBSERVATION", 105, 125]]], ["Furthermore, microvesicles from adult MSCs protect against acute tubular injury ischemia-reperfusion-induced acute and chronic kidney injury [61, 62] .MSCs-derived MicrovesiclesIn relation to cell-free therapeutics in lung diseases, Monsel et al. [63] displayed various advantages of using MSC-derived extracellular vesicles compared to the MSCs.", [["microvesicles", "ANATOMY", 13, 26], ["MSCs", "ANATOMY", 38, 42], ["tubular", "ANATOMY", 65, 72], ["kidney", "ANATOMY", 127, 133], ["MSCs", "ANATOMY", 151, 155], ["cell", "ANATOMY", 192, 196], ["lung", "ANATOMY", 218, 222], ["MSC", "ANATOMY", 290, 293], ["extracellular vesicles", "ANATOMY", 302, 324], ["MSCs", "ANATOMY", 341, 345], ["chronic kidney injury", "DISEASE", 119, 140], ["lung diseases", "DISEASE", 218, 231], ["microvesicles", "CELL", 13, 26], ["MSCs", "CELL", 38, 42], ["tubular", "MULTI-TISSUE_STRUCTURE", 65, 72], ["kidney", "ORGAN", 127, 133], ["MSCs", "CELL", 151, 155], ["MicrovesiclesIn", "CELL", 164, 179], ["cell", "CELL", 192, 196], ["lung", "ORGAN", 218, 222], ["MSC", "CELL", 290, 293], ["extracellular vesicles", "CELLULAR_COMPONENT", 302, 324], ["MSCs", "CELL", 341, 345], ["microvesicles", "CELL_TYPE", 13, 26], ["adult MSCs", "CELL_TYPE", 32, 42], ["MSCs", "CELL_TYPE", 151, 155], ["MSC", "CELL_TYPE", 290, 293], ["MSCs", "CELL_TYPE", 341, 345], ["adult MSCs", "TREATMENT", 32, 42], ["acute tubular injury ischemia-reperfusion", "PROBLEM", 59, 100], ["acute and chronic kidney injury", "PROBLEM", 109, 140], ["MSCs", "PROBLEM", 151, 155], ["lung diseases", "PROBLEM", 218, 231], ["MSC-derived extracellular vesicles", "TREATMENT", 290, 324], ["microvesicles", "OBSERVATION", 13, 26], ["adult MSCs", "OBSERVATION_MODIFIER", 32, 42], ["acute", "OBSERVATION_MODIFIER", 59, 64], ["tubular", "ANATOMY_MODIFIER", 65, 72], ["injury", "OBSERVATION", 73, 79], ["acute", "OBSERVATION_MODIFIER", 109, 114], ["chronic", "OBSERVATION_MODIFIER", 119, 126], ["kidney", "ANATOMY", 127, 133], ["injury", "OBSERVATION", 134, 140], ["lung", "ANATOMY", 218, 222], ["diseases", "OBSERVATION", 223, 231], ["extracellular vesicles", "OBSERVATION", 302, 324]]], ["The advantages are as follows: they are non-self-replicating, have reduced risk of iatrogenic tumor formation, can be stored without DMSO at \u2212 80\u00baC to maintain a biologically active state, they do not express MHC I or II antigens, nor can be induced to express them, and they allow allogeneic transplantation.Induced Pluripotent Stem CellsThe headStartinduced pluripotent stem cellsheadEnd (iPSCs) produced by the method of Takahashi & Yamanaka [64] are based on the reprogramming of adult cells to a \"stem cell state\" through a gene transfection technique by manipulating them to undergo cellular differentiation, plasticity and behavioral transformation [64, 65] .Induced Pluripotent Stem CellsThere is a great potential of using iPSCs in ARDS and sepsis [9] .", [["tumor", "ANATOMY", 94, 99], ["Stem Cells", "ANATOMY", 329, 339], ["headStartinduced pluripotent stem cellsheadEnd", "ANATOMY", 343, 389], ["iPSCs", "ANATOMY", 391, 396], ["adult cells", "ANATOMY", 484, 495], ["stem cell", "ANATOMY", 502, 511], ["cellular", "ANATOMY", 589, 597], ["Stem Cells", "ANATOMY", 686, 696], ["iPSCs", "ANATOMY", 732, 737], ["tumor", "DISEASE", 94, 99], ["DMSO", "CHEMICAL", 133, 137], ["ARDS", "DISEASE", 741, 745], ["sepsis", "DISEASE", 750, 756], ["DMSO", "CHEMICAL", 133, 137], ["tumor", "CANCER", 94, 99], ["DMSO", "SIMPLE_CHEMICAL", 133, 137], ["MHC I", "GENE_OR_GENE_PRODUCT", 209, 214], ["II antigens", "GENE_OR_GENE_PRODUCT", 218, 229], ["Pluripotent Stem Cells", "CELL", 317, 339], ["headStartinduced pluripotent stem cellsheadEnd", "CELL", 343, 389], ["iPSCs", "CELL", 391, 396], ["adult cells", "CELL", 484, 495], ["stem cell", "CELL", 502, 511], ["cellular", "CELL", 589, 597], ["Pluripotent Stem Cells", "CELL", 674, 696], ["iPSCs", "CELL", 732, 737], ["MHC I or II antigens", "PROTEIN", 209, 229], ["headStartinduced pluripotent stem cellsheadEnd", "CELL_LINE", 343, 389], ["iPSCs", "CELL_LINE", 391, 396], ["adult cells", "CELL_TYPE", 484, 495], ["iPSCs", "CELL_TYPE", 732, 737], ["iatrogenic tumor formation", "PROBLEM", 83, 109], ["DMSO", "TREATMENT", 133, 137], ["allogeneic transplantation", "TREATMENT", 282, 308], ["Induced Pluripotent Stem Cells", "PROBLEM", 309, 339], ["adult cells", "PROBLEM", 484, 495], ["a gene transfection technique", "TREATMENT", 527, 556], ["Induced Pluripotent Stem Cells", "PROBLEM", 666, 696], ["ARDS", "PROBLEM", 741, 745], ["sepsis", "PROBLEM", 750, 756], ["iatrogenic", "OBSERVATION_MODIFIER", 83, 93], ["tumor", "OBSERVATION", 94, 99], ["Pluripotent Stem Cells", "OBSERVATION", 317, 339], ["pluripotent stem", "OBSERVATION", 360, 376], ["stem cell", "OBSERVATION", 502, 511], ["cellular differentiation", "OBSERVATION", 589, 613], ["Pluripotent Stem Cells", "OBSERVATION", 674, 696], ["great", "OBSERVATION_MODIFIER", 707, 712], ["ARDS", "OBSERVATION", 741, 745], ["sepsis", "OBSERVATION", 750, 756]]], ["However, the associated problems arising from their use are unclear, and also their low efficiency during differentiation and the reprogramming process might be a concern.", [["the associated problems", "PROBLEM", 9, 32], ["their low efficiency", "PROBLEM", 78, 98], ["the reprogramming process", "PROBLEM", 126, 151], ["low efficiency", "OBSERVATION_MODIFIER", 84, 98]]], ["Thus, a possible genomic modification may be considered to address these drawbacks [66] .Embryonic Stem CellsThe human headStartembryonic stem cellsheadEnd (ESCs) derived from the inner cell mass of blastocysts are pluripotent and able to differentiate into all three primary germ layers.", [["Stem Cells", "ANATOMY", 99, 109], ["headStartembryonic stem cellsheadEnd", "ANATOMY", 119, 155], ["ESCs", "ANATOMY", 157, 161], ["inner cell mass", "ANATOMY", 180, 195], ["blastocysts", "ANATOMY", 199, 210], ["germ layers", "ANATOMY", 276, 287], ["Embryonic Stem Cells", "CELL", 89, 109], ["human", "ORGANISM", 113, 118], ["headStartembryonic stem cellsheadEnd", "CELL", 119, 155], ["ESCs", "CELL", 157, 161], ["inner cell", "CELL", 180, 190], ["blastocysts", "CELL", 199, 210], ["germ layers", "TISSUE", 276, 287], ["human headStartembryonic stem cellsheadEnd", "CELL_LINE", 113, 155], ["ESCs", "CELL_LINE", 157, 161], ["human", "SPECIES", 113, 118], ["human", "SPECIES", 113, 118], ["genomic modification", "TREATMENT", 17, 37], ["Embryonic Stem Cells", "PROBLEM", 89, 109], ["the inner cell mass of blastocysts", "PROBLEM", 176, 210], ["Stem Cells", "OBSERVATION", 99, 109], ["inner", "ANATOMY_MODIFIER", 180, 185], ["cell", "ANATOMY", 186, 190], ["mass", "OBSERVATION", 191, 195], ["blastocysts", "OBSERVATION", 199, 210], ["primary germ layers", "OBSERVATION", 268, 287]]], ["Their capacity to self-renew makes them a viable treatment option for tissue regeneration [67] .", [["tissue", "ANATOMY", 70, 76], ["tissue", "TISSUE", 70, 76], ["a viable treatment option", "TREATMENT", 40, 65], ["tissue regeneration", "PROBLEM", 70, 89]]], ["These ESCs promote the MSCs through reprogramming and differentiation with demonstrated efficacy in murine endotoxin and bleomycin-induced lung injury [68] .", [["ESCs", "ANATOMY", 6, 10], ["MSCs", "ANATOMY", 23, 27], ["lung", "ANATOMY", 139, 143], ["endotoxin", "CHEMICAL", 107, 116], ["bleomycin", "CHEMICAL", 121, 130], ["lung injury", "DISEASE", 139, 150], ["bleomycin", "CHEMICAL", 121, 130], ["ESCs", "CELL", 6, 10], ["MSCs", "CELL", 23, 27], ["murine", "ORGANISM", 100, 106], ["endotoxin", "SIMPLE_CHEMICAL", 107, 116], ["bleomycin", "SIMPLE_CHEMICAL", 121, 130], ["lung", "ORGAN", 139, 143], ["ESCs", "CELL_TYPE", 6, 10], ["MSCs", "CELL_TYPE", 23, 27], ["murine", "SPECIES", 100, 106], ["the MSCs", "TREATMENT", 19, 27], ["murine endotoxin", "TREATMENT", 100, 116], ["bleomycin", "TREATMENT", 121, 130], ["lung injury", "PROBLEM", 139, 150], ["lung", "ANATOMY", 139, 143], ["injury", "OBSERVATION", 144, 150]]], ["To develop cell-based strategies for repairing lung injury, Banerjee et al. [69] differentiated human headStartembryonic stem cellsheadEnd (hES) into lung epithelial lineage-specific cells.", [["cell", "ANATOMY", 11, 15], ["lung", "ANATOMY", 47, 51], ["headStartembryonic stem cellsheadEnd", "ANATOMY", 102, 138], ["hES", "ANATOMY", 140, 143], ["lung epithelial lineage", "ANATOMY", 150, 173], ["cells", "ANATOMY", 183, 188], ["lung injury", "DISEASE", 47, 58], ["cell", "CELL", 11, 15], ["lung", "ORGAN", 47, 51], ["human", "ORGANISM", 96, 101], ["headStartembryonic stem cellsheadEnd", "CELL", 102, 138], ["hES", "CELL", 140, 143], ["lung epithelial lineage-specific cells", "CELL", 150, 188], ["human headStartembryonic stem cellsheadEnd", "CELL_LINE", 96, 138], ["hES", "CELL_LINE", 140, 143], ["lung epithelial lineage-specific cells", "CELL_TYPE", 150, 188], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 96, 101], ["cell-based strategies", "TREATMENT", 11, 32], ["repairing lung injury", "PROBLEM", 37, 58], ["lung", "ANATOMY", 47, 51], ["injury", "OBSERVATION", 52, 58], ["head", "ANATOMY", 102, 106], ["lung", "ANATOMY", 150, 154], ["epithelial", "ANATOMY_MODIFIER", 155, 165], ["specific cells", "OBSERVATION", 174, 188]]], ["According to the authors, the study indicated an increase in progenitor cell numbers in the airway and significantly reduced the collagen content in bleomycin-treated mice, after the transplantation of differentiated hES cells.Clinical TrialsOnly three headStartclinical trialsheadEnd related to stem cells are considered complete, whereby two are in Phase 1 and one is in Phase 2.", [["progenitor cell", "ANATOMY", 61, 76], ["airway", "ANATOMY", 92, 98], ["hES cells", "ANATOMY", 217, 226], ["stem cells", "ANATOMY", 296, 306], ["bleomycin", "CHEMICAL", 149, 158], ["bleomycin", "CHEMICAL", 149, 158], ["progenitor cell", "CELL", 61, 76], ["airway", "ORGAN", 92, 98], ["collagen", "GENE_OR_GENE_PRODUCT", 129, 137], ["bleomycin", "SIMPLE_CHEMICAL", 149, 158], ["mice", "ORGANISM", 167, 171], ["hES cells", "CELL", 217, 226], ["stem cells", "CELL", 296, 306], ["collagen", "PROTEIN", 129, 137], ["differentiated hES cells", "CELL_LINE", 202, 226], ["stem cells", "CELL_TYPE", 296, 306], ["mice", "SPECIES", 167, 171], ["mice", "SPECIES", 167, 171], ["the study", "TEST", 26, 35], ["an increase in progenitor cell numbers in the airway", "PROBLEM", 46, 98], ["bleomycin", "TREATMENT", 149, 158], ["the transplantation", "TREATMENT", 179, 198], ["differentiated hES cells", "PROBLEM", 202, 226], ["stem cells", "PROBLEM", 296, 306], ["increase", "OBSERVATION_MODIFIER", 49, 57], ["progenitor cell numbers", "OBSERVATION", 61, 84], ["airway", "ANATOMY", 92, 98], ["significantly", "OBSERVATION_MODIFIER", 103, 116], ["reduced", "OBSERVATION_MODIFIER", 117, 124], ["collagen content", "OBSERVATION", 129, 145], ["stem cells", "OBSERVATION", 296, 306]]], ["All the completed studies were associated with ARDS in the United States (USA) ( Table 1) .", [["ARDS", "DISEASE", 47, 51], ["All the completed studies", "TEST", 0, 25], ["ARDS", "PROBLEM", 47, 51]]], ["Wilson et al. [70] conducted a Phase 1 trial, where no adverse events were reported in the nine patients evaluated.", [["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["adverse events", "PROBLEM", 55, 69]]], ["However, in three patients, serious adverse events were observed weeks after the infusion, but none were MSC-related.", [["MSC", "ANATOMY", 105, 108], ["patients", "ORGANISM", 18, 26], ["MSC", "CELL", 105, 108], ["patients", "SPECIES", 18, 26], ["serious adverse events", "PROBLEM", 28, 50], ["the infusion", "TREATMENT", 77, 89]]], ["The study was considered for an extension trial by Matthay et al. [71] .", [["The study", "TEST", 0, 9], ["an extension trial", "TREATMENT", 29, 47]]], ["These researchers carried out a Phase 2 trial in a double-blind study with placebo-control and allogeneic bone marrow-derived-MSCs in a 2 (MSCs):1(Placebo) randomization.", [["bone marrow", "ANATOMY", 106, 117], ["MSCs", "ANATOMY", 126, 130], ["MSCs", "ANATOMY", 139, 143], ["bone marrow-derived-MSCs", "CELL", 106, 130], ["MSCs", "CELL", 139, 143], ["allogeneic bone marrow-derived-MSCs", "CELL_LINE", 95, 130], ["a double-blind study", "TEST", 49, 69], ["placebo-control", "TREATMENT", 75, 90], ["allogeneic bone marrow", "TREATMENT", 95, 117], ["MSCs", "PROBLEM", 126, 130], ["randomization", "TREATMENT", 156, 169], ["bone marrow", "ANATOMY", 106, 117]]], ["The MSC group had significantly higher mean scores than the placebo group for Acute Physiology and Chronic Health Evaluation III (APACHE III) ( Table 1) .", [["MSC", "ANATOMY", 4, 7], ["Acute Physiology and Chronic Health Evaluation III", "DISEASE", 78, 128], ["MSC", "CELL", 4, 7], ["significantly higher mean scores", "PROBLEM", 18, 50], ["Acute Physiology", "PROBLEM", 78, 94], ["Chronic Health Evaluation", "TEST", 99, 124], ["Chronic", "OBSERVATION_MODIFIER", 99, 106]]], ["No results were posted in NCT02804945 by the authors.Clinical TrialsThe ongoing headStartclinical trialsheadEnd related to stem cells for various respiratory disorders such as SARS, MERS, and ARDS are presented in Table 2 .", [["stem cells", "ANATOMY", 123, 133], ["respiratory", "ANATOMY", 146, 157], ["respiratory disorders", "DISEASE", 146, 167], ["SARS", "DISEASE", 176, 180], ["MERS", "DISEASE", 182, 186], ["ARDS", "DISEASE", 192, 196], ["stem cells", "CELL", 123, 133], ["stem cells", "CELL_TYPE", 123, 133], ["stem cells", "PROBLEM", 123, 133], ["various respiratory disorders", "PROBLEM", 138, 167], ["SARS", "PROBLEM", 176, 180], ["MERS", "PROBLEM", 182, 186], ["ARDS", "PROBLEM", 192, 196], ["stem cells", "OBSERVATION", 123, 133], ["respiratory disorders", "OBSERVATION", 146, 167], ["ARDS", "OBSERVATION", 192, 196]]], ["Six studies related to coronavirus are in Phase 1, and four studies are already in Phase 2.", [["coronavirus", "DISEASE", 23, 34], ["coronavirus", "ORGANISM", 23, 34], ["Six studies", "TEST", 0, 11], ["coronavirus", "PROBLEM", 23, 34], ["four studies", "TEST", 55, 67]]], ["Basically, the ongoing studies on coronavirus are using MSCs derived from bone marrow or the umbilical cord to demonstrate their feasibility, safety, and tolerability.Clinical TrialsThe studies not related to coronavirus are all in ARDS conditions; four of them are in Phase 1 and three in Phase 2.", [["MSCs", "ANATOMY", 56, 60], ["bone marrow", "ANATOMY", 74, 85], ["umbilical cord", "ANATOMY", 93, 107], ["coronavirus", "DISEASE", 209, 220], ["ARDS", "DISEASE", 232, 236], ["coronavirus", "ORGANISM", 34, 45], ["MSCs", "CELL", 56, 60], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 74, 85], ["umbilical cord", "ORGAN", 93, 107], ["coronavirus", "ORGANISM", 209, 220], ["MSCs", "CELL_TYPE", 56, 60], ["the ongoing studies", "TEST", 11, 30], ["coronavirus", "PROBLEM", 34, 45], ["MSCs", "PROBLEM", 56, 60], ["bone marrow", "TEST", 74, 85], ["Clinical Trials", "TEST", 167, 182], ["The studies", "TEST", 182, 193], ["coronavirus", "PROBLEM", 209, 220], ["ARDS conditions", "PROBLEM", 232, 247], ["umbilical cord", "ANATOMY", 93, 107]]], ["Two particularly interesting situations are being developed in Phase 1, where firstly, menstrual blood stem cells are utilized to determine whether these cells are effective in the treatment of infection, and secondly, another study is testing the drug administration of HCR040 (drug based on allogeneic adiposederived adult headStartmesenchymal stem cellsheadEnd, expanded and pulsed with H 2 O 2 ) (Fig. 1) .Clinical TrialsEmukah et al. [72] conducted a systematic review on the effects of mesenchymal stromal cell conditioned media (CdM) on many lung diseases.", [["menstrual blood stem cells", "ANATOMY", 87, 113], ["cells", "ANATOMY", 154, 159], ["head", "ANATOMY", 325, 329], ["mesenchymal stromal cell", "ANATOMY", 492, 516], ["CdM", "ANATOMY", 536, 539], ["lung", "ANATOMY", 549, 553], ["infection", "DISEASE", 194, 203], ["HCR040", "CHEMICAL", 271, 277], ["lung diseases", "DISEASE", 549, 562], ["HCR040", "CHEMICAL", 271, 277], ["H 2 O 2", "CHEMICAL", 390, 397], ["menstrual blood stem cells", "CELL", 87, 113], ["cells", "CELL", 154, 159], ["HCR040", "SIMPLE_CHEMICAL", 271, 277], ["headStartmesenchymal stem cellsheadEnd", "CELL", 325, 363], ["mesenchymal stromal cell", "CELL", 492, 516], ["CdM", "MULTI-TISSUE_STRUCTURE", 536, 539], ["lung", "ORGAN", 549, 553], ["menstrual blood stem cells", "CELL_TYPE", 87, 113], ["allogeneic adiposederived adult headStartmesenchymal stem cellsheadEnd", "CELL_LINE", 293, 363], ["menstrual blood stem cells", "PROBLEM", 87, 113], ["these cells", "PROBLEM", 148, 159], ["infection", "PROBLEM", 194, 203], ["another study", "TEST", 219, 232], ["HCR040 (drug", "TREATMENT", 271, 283], ["allogeneic adiposederived adult headStartmesenchymal stem cellsheadEnd", "TREATMENT", 293, 363], ["mesenchymal stromal cell conditioned media", "TREATMENT", 492, 534], ["many lung diseases", "PROBLEM", 544, 562], ["infection", "OBSERVATION", 194, 203], ["mesenchymal stromal cell", "OBSERVATION", 492, 516], ["lung", "ANATOMY", 549, 553], ["diseases", "OBSERVATION", 554, 562]]], ["The findings were enthusiastic because it was demonstrated that CdM improved inflammation and was as effective as MSCs.", [["MSCs", "ANATOMY", 114, 118], ["CdM", "CHEMICAL", 64, 67], ["inflammation", "DISEASE", 77, 89], ["CdM", "CHEMICAL", 64, 67], ["CdM", "SIMPLE_CHEMICAL", 64, 67], ["MSCs", "CELL", 114, 118], ["MSCs", "CELL_TYPE", 114, 118], ["CdM improved inflammation", "PROBLEM", 64, 89], ["MSCs", "PROBLEM", 114, 118], ["CdM", "OBSERVATION_MODIFIER", 64, 67], ["improved", "OBSERVATION_MODIFIER", 68, 76], ["inflammation", "OBSERVATION", 77, 89]]], ["Further studies must be conducted to determine the ideal site of CdM delivery, dosage, and timing of the treatment according to the lung disease [72] .", [["lung", "ANATOMY", 132, 136], ["lung disease", "DISEASE", 132, 144], ["CdM", "SIMPLE_CHEMICAL", 65, 68], ["lung", "ORGAN", 132, 136], ["Further studies", "TEST", 0, 15], ["CdM delivery", "TREATMENT", 65, 77], ["the treatment", "TREATMENT", 101, 114], ["the lung disease", "PROBLEM", 128, 144], ["CdM", "OBSERVATION", 65, 68], ["lung", "ANATOMY", 132, 136], ["disease", "OBSERVATION", 137, 144]]], ["Zhao et al. [73] also conducted a systematic review and metaanalysis evaluating the safety of cell therapies and the clinical variables critical for these lung disorders.", [["cell", "ANATOMY", 94, 98], ["lung", "ANATOMY", 155, 159], ["lung disorders", "DISEASE", 155, 169], ["cell", "CELL", 94, 98], ["lung", "ORGAN", 155, 159], ["metaanalysis", "TREATMENT", 56, 68], ["cell therapies", "TREATMENT", 94, 108], ["these lung disorders", "PROBLEM", 149, 169], ["lung", "ANATOMY", 155, 159], ["disorders", "OBSERVATION", 160, 169]]], ["The authors concluded that the cell therapies do not cause complications in gas exchange, spirometry, quality of life, cardiopulmonary circulation, and immune system of those suffering from the lung disease.", [["cell", "ANATOMY", 31, 35], ["cardiopulmonary", "ANATOMY", 119, 134], ["immune system", "ANATOMY", 152, 165], ["lung", "ANATOMY", 194, 198], ["lung disease", "DISEASE", 194, 206], ["cell", "CELL", 31, 35], ["lung", "ORGAN", 194, 198], ["the cell therapies", "TREATMENT", 27, 45], ["complications in gas exchange", "PROBLEM", 59, 88], ["cardiopulmonary circulation", "PROBLEM", 119, 146], ["the lung disease", "PROBLEM", 190, 206], ["gas exchange", "OBSERVATION", 76, 88], ["cardiopulmonary circulation", "ANATOMY", 119, 146], ["lung", "ANATOMY", 194, 198], ["disease", "OBSERVATION", 199, 206]]], ["Phases 2 and 3 are very important to determine the efficacy of the cell therapies related to dosage and safety approaches.", [["cell", "ANATOMY", 67, 71], ["cell", "CELL", 67, 71], ["the cell therapies", "TREATMENT", 63, 81], ["safety approaches", "TREATMENT", 104, 121]]], ["Moreover, death rate was lower in the MSCstreated group than in the non-MSCs-treated patients [73] .", [["death", "DISEASE", 10, 15], ["non-MSCs", "CHEMICAL", 68, 76], ["MSCstreated", "CANCER", 38, 49], ["non-MSCs", "CANCER", 68, 76], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["death rate", "TEST", 10, 20], ["lower", "OBSERVATION_MODIFIER", 25, 30]]], ["Preclinical studies examined the efficacy of MSCs-treatment compared to the control group across different animals and acute lung injury induction models [74] .", [["MSCs", "ANATOMY", 45, 49], ["lung", "ANATOMY", 125, 129], ["acute lung injury", "DISEASE", 119, 136], ["MSCs", "CELL", 45, 49], ["lung", "ORGAN", 125, 129], ["MSCs", "CELL_TYPE", 45, 49], ["Preclinical studies", "TEST", 0, 19], ["MSCs", "PROBLEM", 45, 49], ["treatment", "TREATMENT", 50, 59], ["acute lung injury", "PROBLEM", 119, 136], ["acute", "OBSERVATION_MODIFIER", 119, 124], ["lung", "ANATOMY", 125, 129], ["injury", "OBSERVATION", 130, 136]]], ["A reduced number of deaths was also shown in acute lung injury (ALI) studies of preclinical models [74] .Cytokines StormLymphopenia and higher levels of cytokines are features of COVID-19-patients, being potential biomarkers for disease progression.", [["lung", "ANATOMY", 51, 55], ["deaths", "DISEASE", 20, 26], ["acute lung injury", "DISEASE", 45, 62], ["ALI", "DISEASE", 64, 67], ["lung", "ORGAN", 51, 55], ["patients", "ORGANISM", 188, 196], ["Cytokines", "PROTEIN", 105, 114], ["cytokines", "PROTEIN", 153, 162], ["patients", "SPECIES", 188, 196], ["acute lung injury", "PROBLEM", 45, 62], ["Cytokines StormLymphopenia", "PROBLEM", 105, 131], ["higher levels of cytokines", "PROBLEM", 136, 162], ["COVID", "TEST", 179, 184], ["disease progression", "PROBLEM", 229, 248], ["reduced", "OBSERVATION_MODIFIER", 2, 9], ["number", "OBSERVATION_MODIFIER", 10, 16], ["acute", "OBSERVATION_MODIFIER", 45, 50], ["lung", "ANATOMY", 51, 55], ["injury", "OBSERVATION", 56, 62], ["higher", "OBSERVATION_MODIFIER", 136, 142], ["levels", "OBSERVATION_MODIFIER", 143, 149]]], ["In severely ill patients, a \"cytokine storm\" is induced due to the high levels of cytokines, and consequently, numerous adverse reactions in the human body are observed [75] .", [["body", "ANATOMY", 151, 155], ["patients", "ORGANISM", 16, 24], ["human", "ORGANISM", 145, 150], ["body", "ORGANISM_SUBDIVISION", 151, 155], ["cytokine", "PROTEIN", 29, 37], ["cytokines", "PROTEIN", 82, 91], ["patients", "SPECIES", 16, 24], ["human", "SPECIES", 145, 150], ["human", "SPECIES", 145, 150], ["a \"cytokine storm", "PROBLEM", 26, 43], ["the high levels of cytokines", "PROBLEM", 63, 91], ["numerous adverse reactions in the human body", "PROBLEM", 111, 155], ["severely", "OBSERVATION_MODIFIER", 3, 11], ["ill", "OBSERVATION_MODIFIER", 12, 15], ["numerous", "OBSERVATION_MODIFIER", 111, 119], ["adverse", "OBSERVATION_MODIFIER", 120, 127], ["reactions", "OBSERVATION", 128, 137], ["human body", "ANATOMY", 145, 155]]], ["Cytokine storms include the interleukins IL-1\u03b2, IL-2, IL-6, IL-7, IL-8, IL-10, Granulocyte colony stimulating factor (G-CSF), Granulocyte-macrophage colony-stimulating factor (GM-CSF), Interferon gamma inducible protein 10 kD (IP10), Monocyte chemoattractant protein-1 (MCP1), Macrophage inflammatory protein-1 alpha (MIP-1\u03b1), IFN-\u03b3 and TNF-\u03b1 [75] [76] [77] [78] [79] .", [["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 41, 46], ["IL-2", "GENE_OR_GENE_PRODUCT", 48, 52], ["IL-6", "GENE_OR_GENE_PRODUCT", 54, 58], ["IL-7", "GENE_OR_GENE_PRODUCT", 60, 64], ["IL-8", "GENE_OR_GENE_PRODUCT", 66, 70], ["IL-10", "GENE_OR_GENE_PRODUCT", 72, 77], ["Granulocyte colony stimulating factor", "GENE_OR_GENE_PRODUCT", 79, 116], ["G-CSF", "GENE_OR_GENE_PRODUCT", 118, 123], ["Granulocyte-macrophage colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 126, 174], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 176, 182], ["Interferon gamma inducible protein 10 kD", "GENE_OR_GENE_PRODUCT", 185, 225], ["IP10", "GENE_OR_GENE_PRODUCT", 227, 231], ["Monocyte chemoattractant protein-1", "GENE_OR_GENE_PRODUCT", 234, 268], ["MCP1", "GENE_OR_GENE_PRODUCT", 270, 274], ["Macrophage inflammatory protein-1 alpha", "GENE_OR_GENE_PRODUCT", 277, 316], ["MIP-1\u03b1", "GENE_OR_GENE_PRODUCT", 318, 324], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 327, 332], ["TNF-\u03b1 [75] [76] [77] [78] [79]", "SIMPLE_CHEMICAL", 337, 367], ["interleukins", "PROTEIN", 28, 40], ["IL-7, IL-8", "PROTEIN", 60, 70], ["IL-10", "PROTEIN", 72, 77], ["Granulocyte colony stimulating factor", "PROTEIN", 79, 116], ["CSF", "PROTEIN", 120, 123], ["Granulocyte-macrophage colony-stimulating factor", "PROTEIN", 126, 174], ["GM", "PROTEIN", 176, 178], ["CSF", "PROTEIN", 179, 182], ["Interferon gamma inducible protein 10 kD", "PROTEIN", 185, 225], ["IP10", "PROTEIN", 227, 231], ["Monocyte chemoattractant protein-1", "PROTEIN", 234, 268], ["MCP1", "PROTEIN", 270, 274], ["Macrophage inflammatory protein-1 alpha", "PROTEIN", 277, 316], ["MIP", "PROTEIN", 318, 321], ["\u03b1", "PROTEIN", 323, 324], ["IFN", "PROTEIN", 327, 330], ["TNF", "PROTEIN", 337, 340], ["Cytokine storms", "TEST", 0, 15], ["the interleukins IL", "TEST", 24, 43], ["IL", "TEST", 48, 50], ["IL", "TEST", 54, 56], ["IL", "TEST", 60, 62], ["IL", "TEST", 66, 68], ["IL", "TEST", 72, 74], ["Granulocyte colony stimulating factor", "TEST", 79, 116], ["G-CSF", "TEST", 118, 123], ["Granulocyte", "TEST", 126, 137], ["macrophage colony", "TEST", 138, 155], ["stimulating factor", "TEST", 156, 174], ["GM", "TEST", 176, 178], ["CSF", "TEST", 179, 182], ["Interferon gamma inducible protein", "TEST", 185, 219], ["kD", "TEST", 223, 225], ["IP10", "TEST", 227, 231], ["Monocyte chemoattractant protein", "TEST", 234, 266], ["MCP1", "TEST", 270, 274], ["Macrophage inflammatory protein", "TEST", 277, 308], ["alpha", "TEST", 311, 316], ["MIP", "TEST", 318, 321], ["IFN", "TEST", 327, 330], ["TNF", "TEST", 337, 340], ["Granulocyte", "ANATOMY", 79, 90], ["Granulocyte", "ANATOMY", 126, 137]]], ["For COVID-19, IL-6 serves as a key mediator cytokine in cytokine storm development [80] .", [["COVID-19", "GENE_OR_GENE_PRODUCT", 4, 12], ["IL-6", "GENE_OR_GENE_PRODUCT", 14, 18], ["IL-6", "PROTEIN", 14, 18], ["cytokine", "PROTEIN", 44, 52], ["cytokine", "PROTEIN", 56, 64], ["COVID", "TEST", 4, 9], ["IL", "TREATMENT", 14, 16]]], ["After infection, CD4 + T cells can be quickly activated in pathogenic helper T cells (Th) 1 secreting GM-CSF, which further induces CD14+, CD16 + monocytes providing high levels of IL-6, accelerating the inflammation process [75, 81] .Cytokines Stormto the pathogenesis of HCoV-19, activating the Spike protein (S).", [["CD4 + T cells", "ANATOMY", 17, 30], ["helper T cells", "ANATOMY", 70, 84], ["CD14+, CD16 + monocytes", "ANATOMY", 132, 155], ["infection", "DISEASE", 6, 15], ["inflammation", "DISEASE", 204, 216], ["CD4", "GENE_OR_GENE_PRODUCT", 17, 20], ["helper T cells", "CELL", 70, 84], ["Th) 1", "GENE_OR_GENE_PRODUCT", 86, 91], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 102, 108], ["CD14", "GENE_OR_GENE_PRODUCT", 132, 136], ["CD16", "GENE_OR_GENE_PRODUCT", 139, 143], ["IL-6", "GENE_OR_GENE_PRODUCT", 181, 185], ["HCoV-19", "CELL", 273, 280], ["Spike", "GENE_OR_GENE_PRODUCT", 297, 302], ["CD4", "PROTEIN", 17, 20], ["T cells", "CELL_TYPE", 23, 30], ["pathogenic helper T cells", "CELL_TYPE", 59, 84], ["CSF", "PROTEIN", 105, 108], ["CD14", "PROTEIN", 132, 136], ["CD16", "PROTEIN", 139, 143], ["IL-6", "PROTEIN", 181, 185], ["Cytokines", "PROTEIN", 235, 244], ["Spike protein", "PROTEIN", 297, 310], ["S", "PROTEIN", 312, 313], ["HCoV-19", "SPECIES", 273, 280], ["infection", "PROBLEM", 6, 15], ["CD4", "TEST", 17, 20], ["T cells", "PROBLEM", 23, 30], ["secreting GM-CSF", "TEST", 92, 108], ["CD14", "TEST", 132, 136], ["CD16", "TEST", 139, 143], ["monocytes", "TEST", 146, 155], ["IL", "TEST", 181, 183], ["the inflammation process", "PROBLEM", 200, 224], ["Cytokines", "TEST", 235, 244], ["HCoV", "TEST", 273, 277], ["infection", "OBSERVATION", 6, 15], ["inflammation", "OBSERVATION", 204, 216]]], ["Since many cells of the immune system are negative for ACE2, immune therapy may be an alternative in the treatment of infected patients [83] .Cytokines StormAccording to the results of the above-mentioned study, MSCs have a natural immunity to HCoV-19, being ACE2or TMPRSS2-negative according to transplant analyses.", [["cells", "ANATOMY", 11, 16], ["immune system", "ANATOMY", 24, 37], ["MSCs", "ANATOMY", 212, 216], ["cells", "CELL", 11, 16], ["immune system", "ANATOMICAL_SYSTEM", 24, 37], ["ACE2", "GENE_OR_GENE_PRODUCT", 55, 59], ["patients", "ORGANISM", 127, 135], ["MSCs", "CELL", 212, 216], ["HCoV-19", "CELL", 244, 251], ["ACE2or", "GENE_OR_GENE_PRODUCT", 259, 265], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 266, 273], ["ACE2", "PROTEIN", 55, 59], ["Cytokines", "PROTEIN", 142, 151], ["MSCs", "CELL_TYPE", 212, 216], ["TMPRSS2", "PROTEIN", 266, 273], ["patients", "SPECIES", 127, 135], ["HCoV-19", "SPECIES", 244, 251], ["the immune system", "TEST", 20, 37], ["ACE2", "PROBLEM", 55, 59], ["immune therapy", "TREATMENT", 61, 75], ["the above-mentioned study", "TEST", 185, 210], ["HCoV", "TEST", 244, 248], ["TMPRSS2", "TEST", 266, 273], ["transplant analyses", "TEST", 296, 315]]], ["Thus, especially for patients critically ill with COVID-19 pneumonia, transplantation of MSCs was a safe and effective treatment regulating the inflammatory response and promoting tissue repair and regeneration [82] .Cytokines StormInterferon-stimulated genes (ISGs) present in MSCs may explain why these cells are resistant to viral infections.", [["MSCs", "ANATOMY", 89, 93], ["tissue", "ANATOMY", 180, 186], ["MSCs", "ANATOMY", 278, 282], ["cells", "ANATOMY", 305, 310], ["critically ill", "DISEASE", 30, 44], ["pneumonia", "DISEASE", 59, 68], ["viral infections", "DISEASE", 328, 344], ["patients", "ORGANISM", 21, 29], ["MSCs", "CELL", 89, 93], ["tissue", "TISSUE", 180, 186], ["StormInterferon-stimulated genes", "GENE_OR_GENE_PRODUCT", 227, 259], ["ISGs", "GENE_OR_GENE_PRODUCT", 261, 265], ["MSCs", "CELL", 278, 282], ["cells", "CELL", 305, 310], ["MSCs", "CELL_TYPE", 89, 93], ["Cytokines StormInterferon-stimulated genes", "DNA", 217, 259], ["ISGs", "DNA", 261, 265], ["MSCs", "CELL_TYPE", 278, 282], ["patients", "SPECIES", 21, 29], ["COVID", "TREATMENT", 50, 55], ["pneumonia", "PROBLEM", 59, 68], ["transplantation of MSCs", "TREATMENT", 70, 93], ["a safe and effective treatment", "TREATMENT", 98, 128], ["the inflammatory response", "PROBLEM", 140, 165], ["promoting tissue repair", "TREATMENT", 170, 193], ["Cytokines StormInterferon", "TREATMENT", 217, 242], ["these cells", "PROBLEM", 299, 310], ["viral infections", "PROBLEM", 328, 344], ["pneumonia", "OBSERVATION", 59, 68], ["inflammatory", "OBSERVATION_MODIFIER", 144, 156], ["tissue repair", "OBSERVATION", 180, 193], ["viral infections", "OBSERVATION", 328, 344]]], ["MSCs, for example, express several ISGs, some of which are known to show typical antiviral responses.", [["MSCs", "ANATOMY", 0, 4], ["MSCs", "CELL", 0, 4], ["MSCs", "CELL_TYPE", 0, 4], ["ISGs", "PROTEIN", 35, 39], ["MSCs", "PROBLEM", 0, 4]]], ["The member proteins of the Interferon Induced Transmembrane Family (IFITM) are peculiar because they prevent infection before the virus can cross the lipid bilayer on cells [84] .", [["lipid bilayer", "ANATOMY", 150, 163], ["cells", "ANATOMY", 167, 172], ["infection", "DISEASE", 109, 118], ["Interferon Induced Transmembrane Family", "GENE_OR_GENE_PRODUCT", 27, 66], ["IFITM", "GENE_OR_GENE_PRODUCT", 68, 73], ["lipid bilayer", "CELLULAR_COMPONENT", 150, 163], ["cells", "CELL", 167, 172], ["member proteins", "PROTEIN", 4, 19], ["Interferon Induced Transmembrane Family", "PROTEIN", 27, 66], ["IFITM", "PROTEIN", 68, 73], ["the Interferon Induced Transmembrane Family (IFITM)", "TREATMENT", 23, 74], ["infection", "PROBLEM", 109, 118], ["the virus", "PROBLEM", 126, 135], ["infection", "OBSERVATION", 109, 118]]], ["Cells cultivated by viruses such as SARS coronavirus, Ebola virus, influenza A and dengue were not infected because of the assigned activity to IFITM proteins [85] .", [["Cells", "ANATOMY", 0, 5], ["SARS coronavirus", "DISEASE", 36, 52], ["Ebola virus", "DISEASE", 54, 65], ["influenza A", "DISEASE", 67, 78], ["dengue", "DISEASE", 83, 89], ["Cells", "CELL", 0, 5], ["SARS coronavirus", "ORGANISM", 36, 52], ["Ebola virus", "ORGANISM", 54, 65], ["influenza A", "ORGANISM", 67, 78], ["dengue", "ORGANISM", 83, 89], ["IFITM", "GENE_OR_GENE_PRODUCT", 144, 149], ["IFITM proteins", "PROTEIN", 144, 158], ["SARS coronavirus", "SPECIES", 36, 52], ["Ebola virus", "SPECIES", 54, 65], ["influenza A and dengue", "SPECIES", 67, 89], ["SARS coronavirus", "SPECIES", 36, 52], ["Ebola virus", "SPECIES", 54, 65], ["dengue", "SPECIES", 83, 89], ["Cells", "TEST", 0, 5], ["viruses", "PROBLEM", 20, 27], ["SARS coronavirus", "PROBLEM", 36, 52], ["Ebola virus", "PROBLEM", 54, 65], ["influenza A", "PROBLEM", 67, 78], ["dengue", "PROBLEM", 83, 89], ["IFITM proteins", "TEST", 144, 158], ["viruses", "OBSERVATION", 20, 27]]], ["Therefore, in this scenario of the COVID-19 respiratory viral infection, as suggested by Rajarshi et al. [84] , the unique antiviral mechanisms of MSCs include constitutive elevation of MSC-specific ISG levels acting as regulators of antiviral protection and secondary response to IFN, which induces ISG, offering broad viral resistance [84] .Cytokines StormIn the case of hematopoietic stem / progenitor cells (HSPCs), evidence suggests that the SARS-CoV-2 virus input receptor (ACE2) and the angiotensin II receptor (AT1) are expressed and functional on the surface of these cells [86, 87] .", [["MSCs", "ANATOMY", 147, 151], ["MSC", "ANATOMY", 186, 189], ["hematopoietic stem / progenitor cells", "ANATOMY", 373, 410], ["HSPCs", "ANATOMY", 412, 417], ["surface", "ANATOMY", 560, 567], ["cells", "ANATOMY", 577, 582], ["respiratory viral infection", "DISEASE", 44, 71], ["IFN", "CHEMICAL", 281, 284], ["angiotensin II", "CHEMICAL", 494, 508], ["COVID-19 respiratory viral", "ORGANISM", 35, 61], ["MSCs", "CELL", 147, 151], ["MSC", "CELL", 186, 189], ["ISG", "GENE_OR_GENE_PRODUCT", 199, 202], ["IFN", "GENE_OR_GENE_PRODUCT", 281, 284], ["ISG", "GENE_OR_GENE_PRODUCT", 300, 303], ["StormIn", "GENE_OR_GENE_PRODUCT", 353, 360], ["hematopoietic stem / progenitor cells", "CELL", 373, 410], ["HSPCs", "CELL", 412, 417], ["SARS-CoV-2 virus input receptor", "GENE_OR_GENE_PRODUCT", 447, 478], ["ACE2", "GENE_OR_GENE_PRODUCT", 480, 484], ["angiotensin II receptor", "GENE_OR_GENE_PRODUCT", 494, 517], ["AT1", "GENE_OR_GENE_PRODUCT", 519, 522], ["surface", "CELLULAR_COMPONENT", 560, 567], ["cells", "CELL", 577, 582], ["MSCs", "CELL_TYPE", 147, 151], ["MSC", "CELL_TYPE", 186, 189], ["IFN", "PROTEIN", 281, 284], ["Cytokines", "PROTEIN", 343, 352], ["hematopoietic stem / progenitor cells", "CELL_TYPE", 373, 410], ["HSPCs", "CELL_TYPE", 412, 417], ["SARS-CoV-2 virus input receptor", "PROTEIN", 447, 478], ["ACE2", "PROTEIN", 480, 484], ["angiotensin II receptor", "PROTEIN", 494, 517], ["AT1", "PROTEIN", 519, 522], ["CoV-2 virus", "SPECIES", 452, 463], ["SARS-CoV-2 virus", "SPECIES", 447, 463], ["the COVID", "TEST", 31, 40], ["respiratory viral infection", "PROBLEM", 44, 71], ["the unique antiviral mechanisms of MSCs", "TREATMENT", 112, 151], ["constitutive elevation of MSC", "PROBLEM", 160, 189], ["antiviral protection", "TREATMENT", 234, 254], ["secondary response to IFN", "PROBLEM", 259, 284], ["hematopoietic stem / progenitor cells", "PROBLEM", 373, 410], ["the SARS", "TEST", 443, 451], ["CoV", "TEST", 452, 455], ["ACE2", "TEST", 480, 484], ["the angiotensin II receptor (AT1)", "TREATMENT", 490, 523], ["respiratory", "ANATOMY", 44, 55], ["viral infection", "OBSERVATION", 56, 71], ["hematopoietic stem", "OBSERVATION", 373, 391], ["progenitor cells", "OBSERVATION", 394, 410]]], ["Therefore, it is possible for SARS-CoV-2 upon binding to ACE2 via the Spike protein to directly activate the Nlrp3 inflammasome, contributing to the cytokine storm, affecting the mitochondrial function, leading to cell death by pyroptosis [87] [88] [89] [90] [91] [92] [93] .", [["mitochondrial", "ANATOMY", 179, 192], ["cell", "ANATOMY", 214, 218], ["SARS", "DISEASE", 30, 34], ["death", "DISEASE", 219, 224], ["pyroptosis", "DISEASE", 228, 238], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 30, 40], ["ACE2", "GENE_OR_GENE_PRODUCT", 57, 61], ["Spike", "GENE_OR_GENE_PRODUCT", 70, 75], ["Nlrp3", "GENE_OR_GENE_PRODUCT", 109, 114], ["mitochondrial", "CELLULAR_COMPONENT", 179, 192], ["cell", "CELL", 214, 218], ["pyroptosis [87] [88] [89] [90] [91] [92] [93]", "SIMPLE_CHEMICAL", 228, 273], ["ACE2", "PROTEIN", 57, 61], ["Spike protein", "PROTEIN", 70, 83], ["Nlrp3 inflammasome", "PROTEIN", 109, 127], ["cytokine", "PROTEIN", 149, 157], ["SARS-CoV", "SPECIES", 30, 38], ["SARS", "PROBLEM", 30, 34], ["CoV", "TEST", 35, 38], ["ACE2", "TREATMENT", 57, 61], ["the Spike protein", "TREATMENT", 66, 83], ["the Nlrp3 inflammasome", "TREATMENT", 105, 127], ["the cytokine storm", "PROBLEM", 145, 163], ["cell death", "PROBLEM", 214, 224], ["pyroptosis", "TEST", 228, 238], ["cytokine storm", "OBSERVATION", 149, 163]]], ["The Nlrp3 inflammasome, which can affect various tissues and organs as well as potentially hematopoiesis [93] , may be responsible for certain complications during a SARS-CoV-2 infection.Cytokines StormIn 2014, Min et al. [94] evaluated the therapeutic effects of human umbilical cord MSCs in the presence of a n g i o t e n s i n c o n v e r t i n g e n z y m e 2 g e n e ( A C E 2 ; ACE2uMSCs) using bleomycin (BLM)induced lung injury and pulmonary fibrosis in mice.", [["tissues", "ANATOMY", 49, 56], ["organs", "ANATOMY", 61, 67], ["umbilical cord MSCs", "ANATOMY", 270, 289], ["lung", "ANATOMY", 425, 429], ["pulmonary", "ANATOMY", 441, 450], ["SARS-CoV-2 infection", "DISEASE", 166, 186], ["bleomycin", "CHEMICAL", 402, 411], ["BLM", "CHEMICAL", 413, 416], ["lung injury", "DISEASE", 425, 436], ["pulmonary fibrosis", "DISEASE", 441, 459], ["bleomycin", "CHEMICAL", 402, 411], ["BLM", "CHEMICAL", 413, 416], ["Nlrp3", "GENE_OR_GENE_PRODUCT", 4, 9], ["tissues", "TISSUE", 49, 56], ["organs", "ORGAN", 61, 67], ["SARS-CoV-2", "ORGANISM", 166, 176], ["human", "ORGANISM", 264, 269], ["umbilical cord MSCs", "CELL", 270, 289], ["A C E 2 ; ACE2uMSCs", "SIMPLE_CHEMICAL", 375, 394], ["bleomycin", "SIMPLE_CHEMICAL", 402, 411], ["BLM", "SIMPLE_CHEMICAL", 413, 416], ["lung", "ORGAN", 425, 429], ["pulmonary", "ORGAN", 441, 450], ["mice", "ORGANISM", 463, 467], ["Nlrp3 inflammasome", "PROTEIN", 4, 22], ["human umbilical cord MSCs", "CELL_TYPE", 264, 289], ["human", "SPECIES", 264, 269], ["mice", "SPECIES", 463, 467], ["human", "SPECIES", 264, 269], ["mice", "SPECIES", 463, 467], ["The Nlrp3 inflammasome", "PROBLEM", 0, 22], ["hematopoiesis", "PROBLEM", 91, 104], ["certain complications", "PROBLEM", 135, 156], ["a SARS-CoV-2 infection", "PROBLEM", 164, 186], ["human umbilical cord MSCs", "TREATMENT", 264, 289], ["A C E", "TEST", 375, 380], ["ACE2uMSCs", "TEST", 385, 394], ["bleomycin (BLM", "TREATMENT", 402, 416], ["lung injury", "PROBLEM", 425, 436], ["pulmonary fibrosis in mice", "PROBLEM", 441, 467], ["Nlrp3 inflammasome", "OBSERVATION", 4, 22], ["may be responsible for", "UNCERTAINTY", 112, 134], ["infection", "OBSERVATION", 177, 186], ["umbilical cord", "ANATOMY", 270, 284], ["lung", "ANATOMY", 425, 429], ["injury", "OBSERVATION", 430, 436], ["pulmonary", "ANATOMY", 441, 450], ["fibrosis", "OBSERVATION", 451, 459]]], ["The injection of ACE2-uMSC demonstrated significantly more effective results in the treatment of bleomycin-induced pulmonary fibrosis in vivo compared to those of the ACE2 and uMSC treatments alone.", [["pulmonary", "ANATOMY", 115, 124], ["bleomycin", "CHEMICAL", 97, 106], ["pulmonary fibrosis", "DISEASE", 115, 133], ["uMSC", "CHEMICAL", 176, 180], ["bleomycin", "CHEMICAL", 97, 106], ["ACE2", "GENE_OR_GENE_PRODUCT", 17, 21], ["bleomycin", "SIMPLE_CHEMICAL", 97, 106], ["pulmonary", "ORGAN", 115, 124], ["ACE2", "GENE_OR_GENE_PRODUCT", 167, 171], ["uMSC", "SIMPLE_CHEMICAL", 176, 180], ["ACE2", "PROTEIN", 17, 21], ["uMSC", "PROTEIN", 22, 26], ["ACE2", "PROTEIN", 167, 171], ["ACE2", "TEST", 17, 21], ["bleomycin", "TREATMENT", 97, 106], ["pulmonary fibrosis", "PROBLEM", 115, 133], ["the ACE2 and uMSC treatments", "TREATMENT", 163, 191], ["bleomycin", "OBSERVATION", 97, 106], ["pulmonary", "ANATOMY", 115, 124], ["fibrosis", "OBSERVATION", 125, 133]]], ["Thus, according to the authors suggestions, the synergistic effect of ACE2 and uMSCs may be used as a promising novel treatment for lung injury [94] .Cytokines StormAs suggested by Ulrich & Pillat [95] , it is possible that CD147, the second incoming receptor for SARS-CoV-2, is expressed by untransformed lung stem and progenitor cells, but there is still no experimental evidence.", [["lung", "ANATOMY", 132, 136], ["lung stem", "ANATOMY", 306, 315], ["progenitor cells", "ANATOMY", 320, 336], ["uMSCs", "CHEMICAL", 79, 84], ["lung injury", "DISEASE", 132, 143], ["ACE2", "GENE_OR_GENE_PRODUCT", 70, 74], ["uMSCs", "SIMPLE_CHEMICAL", 79, 84], ["lung", "ORGAN", 132, 136], ["StormAs", "GENE_OR_GENE_PRODUCT", 160, 167], ["CD147", "GENE_OR_GENE_PRODUCT", 224, 229], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 264, 274], ["lung stem", "CELL", 306, 315], ["progenitor cells", "CELL", 320, 336], ["ACE2", "PROTEIN", 70, 74], ["Cytokines", "PROTEIN", 150, 159], ["CD147", "PROTEIN", 224, 229], ["untransformed lung stem and progenitor cells", "CELL_TYPE", 292, 336], ["ACE2 and uMSCs", "TREATMENT", 70, 84], ["a promising novel treatment", "TREATMENT", 100, 127], ["lung injury", "PROBLEM", 132, 143], ["Cytokines StormAs", "TEST", 150, 167], ["SARS", "PROBLEM", 264, 268], ["CoV", "TEST", 269, 272], ["lung", "ANATOMY", 132, 136], ["injury", "OBSERVATION", 137, 143], ["lung", "ANATOMY", 306, 310], ["stem", "ANATOMY_MODIFIER", 311, 315], ["progenitor cells", "OBSERVATION", 320, 336], ["no", "UNCERTAINTY", 357, 359], ["experimental", "OBSERVATION", 360, 372]]], ["This bone marrow receptor can be expressed by tissue-specific stem cells [96] .", [["bone marrow", "ANATOMY", 5, 16], ["tissue-specific stem cells", "ANATOMY", 46, 72], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 5, 16], ["tissue", "TISSUE", 46, 52], ["stem cells", "CELL", 62, 72], ["bone marrow receptor", "PROTEIN", 5, 25], ["stem cells", "CELL_TYPE", 62, 72], ["bone", "ANATOMY", 5, 9], ["marrow", "OBSERVATION", 10, 16]]], ["Soon, it is realized that the loss of airway epithelial cells caused by infection and viral replication suggests another possibility for the lack of cell regeneration considering that regenerating cells and stem cells can be equally lost or infected [95] .Final ConsiderationsAnti-inflammatory therapies for patients with ARDS have been developed using stem cells offering a great promise for managing ARDS [70, 97, 98] .", [["airway epithelial cells", "ANATOMY", 38, 61], ["cell", "ANATOMY", 149, 153], ["cells", "ANATOMY", 197, 202], ["stem cells", "ANATOMY", 207, 217], ["stem cells", "ANATOMY", 353, 363], ["infection", "DISEASE", 72, 81], ["ARDS", "DISEASE", 322, 326], ["ARDS", "DISEASE", 402, 406], ["airway epithelial cells", "CELL", 38, 61], ["cell", "CELL", 149, 153], ["cells", "CELL", 197, 202], ["stem cells", "CELL", 207, 217], ["patients", "ORGANISM", 308, 316], ["stem cells", "CELL", 353, 363], ["airway epithelial cells", "CELL_TYPE", 38, 61], ["regenerating cells", "CELL_TYPE", 184, 202], ["stem cells", "CELL_TYPE", 207, 217], ["stem cells", "CELL_TYPE", 353, 363], ["patients", "SPECIES", 308, 316], ["the loss of airway epithelial cells", "PROBLEM", 26, 61], ["infection", "PROBLEM", 72, 81], ["viral replication", "PROBLEM", 86, 103], ["cell regeneration", "PROBLEM", 149, 166], ["regenerating cells", "PROBLEM", 184, 202], ["stem cells", "PROBLEM", 207, 217], ["Anti-inflammatory therapies", "TREATMENT", 276, 303], ["ARDS", "PROBLEM", 322, 326], ["stem cells", "TREATMENT", 353, 363], ["managing ARDS", "PROBLEM", 393, 406], ["airway epithelial cells", "OBSERVATION", 38, 61], ["infection", "OBSERVATION", 72, 81], ["viral replication", "OBSERVATION", 86, 103], ["suggests another possibility for", "UNCERTAINTY", 104, 136], ["cell regeneration", "OBSERVATION", 149, 166], ["stem cells", "OBSERVATION", 207, 217], ["inflammatory", "OBSERVATION_MODIFIER", 281, 293], ["ARDS", "OBSERVATION", 322, 326], ["stem cells", "OBSERVATION", 353, 363]]], ["MSCs related cell-therapies demonstrate high efficacy in preclinical data allowing their clinical usage [99] .", [["MSCs", "ANATOMY", 0, 4], ["cell", "ANATOMY", 13, 17], ["MSCs", "CELL", 0, 4], ["cell", "CELL", 13, 17], ["MSCs", "CELL_TYPE", 0, 4], ["MSCs", "PROBLEM", 0, 4], ["cell-therapies", "TREATMENT", 13, 27], ["high efficacy in preclinical data", "PROBLEM", 40, 73], ["high", "OBSERVATION_MODIFIER", 40, 44]]], ["For COVID-19 research and headStartclinical trialsheadEnd, it is important to consider the blood biomarkers involved in the pathophysiology of the disease which provide therapeutic targets and thus improve the clinical care.", [["blood", "ANATOMY", 91, 96], ["blood", "ORGANISM_SUBSTANCE", 91, 96], ["COVID", "TEST", 4, 9], ["the blood biomarkers", "TEST", 87, 107], ["the disease", "PROBLEM", 143, 154], ["head", "ANATOMY", 26, 30], ["disease", "OBSERVATION", 147, 154]]], ["Moreover, it is essential to understand the role of endogenous lung progenitor cells during the repair of lung injury and also the mechanism of lung development for developing novel therapeutic strategies [100, 101] .", [["lung progenitor cells", "ANATOMY", 63, 84], ["lung", "ANATOMY", 106, 110], ["lung", "ANATOMY", 144, 148], ["lung injury", "DISEASE", 106, 117], ["lung progenitor cells", "CELL", 63, 84], ["lung", "ORGAN", 106, 110], ["lung", "ORGAN", 144, 148], ["endogenous lung progenitor cells", "CELL_TYPE", 52, 84], ["endogenous lung progenitor cells", "TREATMENT", 52, 84], ["the repair", "TREATMENT", 92, 102], ["lung injury", "PROBLEM", 106, 117], ["lung", "ANATOMY", 63, 67], ["progenitor cells", "OBSERVATION", 68, 84], ["lung", "ANATOMY", 106, 110], ["injury", "OBSERVATION", 111, 117], ["lung", "ANATOMY", 144, 148]]], ["Han et al. [102] mentioned some obstacles in clinical practice that must be considered for COVID-19 as, for example, the low mobilization of transplanted MSCs at the injury site and their low survival rate.", [["MSCs", "ANATOMY", 154, 158], ["MSCs", "CELL", 154, 158], ["transplanted MSCs", "CELL_TYPE", 141, 158], ["COVID", "TEST", 91, 96], ["transplanted MSCs", "PROBLEM", 141, 158], ["the injury site", "PROBLEM", 162, 177], ["transplanted MSCs", "OBSERVATION", 141, 158], ["injury", "OBSERVATION", 166, 172], ["low survival", "OBSERVATION_MODIFIER", 188, 200]]], ["The comprehensive interaction between MSCs and the host tissue is a key to the successful therapeutic application whereby experimental studies play a major role in developing lung diseases in clinical translation [37] .", [["MSCs", "ANATOMY", 38, 42], ["tissue", "ANATOMY", 56, 62], ["lung", "ANATOMY", 175, 179], ["lung diseases", "DISEASE", 175, 188], ["MSCs", "CELL", 38, 42], ["tissue", "TISSUE", 56, 62], ["lung", "ORGAN", 175, 179], ["MSCs", "CELL_TYPE", 38, 42], ["experimental studies", "TEST", 122, 142], ["developing lung diseases", "PROBLEM", 164, 188], ["lung", "ANATOMY", 175, 179], ["diseases", "OBSERVATION", 180, 188]]], ["Since we know that the mitochondrial disorder caused by the overactivation of Nlrp3 inflammasome is determinant to the pathogenesis of SARS-CoV-2, Nlrp3 inflammasome inhibitors must be taken into account regarding their therapeutic applicability [87] [88] [89] 92 ].", [["mitochondrial", "ANATOMY", 23, 36], ["mitochondrial disorder", "DISEASE", 23, 45], ["SARS", "DISEASE", 135, 139], ["mitochondrial", "CELLULAR_COMPONENT", 23, 36], ["Nlrp3", "GENE_OR_GENE_PRODUCT", 78, 83], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 135, 145], ["Nlrp3", "GENE_OR_GENE_PRODUCT", 147, 152], ["Nlrp3 inflammasome", "PROTEIN", 78, 96], ["the mitochondrial disorder", "PROBLEM", 19, 45], ["Nlrp3 inflammasome", "PROBLEM", 78, 96], ["SARS", "PROBLEM", 135, 139], ["CoV", "TEST", 140, 143], ["Nlrp3 inflammasome inhibitors", "TREATMENT", 147, 176]]], ["An example for this inhibitory potential is the MCC950 molecule which could affect the binding of SARS-CoV-2 to cells and inhibit the amplification of the intracellular virus, and also the ComC inhibitors that assist in modulating the activity of the innate immune system [93] .", [["cells", "ANATOMY", 112, 117], ["intracellular", "ANATOMY", 155, 168], ["MCC950", "GENE_OR_GENE_PRODUCT", 48, 54], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 98, 108], ["cells", "CELL", 112, 117], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 155, 168], ["virus", "ORGANISM", 169, 174], ["ComC", "GENE_OR_GENE_PRODUCT", 189, 193], ["MCC950 molecule", "PROTEIN", 48, 63], ["SARS", "PROBLEM", 98, 102], ["the intracellular virus", "PROBLEM", 151, 174], ["the ComC inhibitors", "TREATMENT", 185, 204], ["intracellular virus", "OBSERVATION", 155, 174]]], ["Another possible inhibition therapy against SARS-CoV-2 is the use of ACE2 + MSC-derived small extracellular vesicles (sEVs) overexpressed, as suggested by Inal [103] .Final ConsiderationsRegarding the combat against the cytokine storm in the lungs during viral pneumonia, some studies highlighted that the leukemia inhibitor factor (LIF) released by the MSCs may not be expressed enough to supply the damage caused by the disease [104, 105] .", [["MSC", "ANATOMY", 76, 79], ["extracellular vesicles", "ANATOMY", 94, 116], ["sEVs", "ANATOMY", 118, 122], ["lungs", "ANATOMY", 242, 247], ["MSCs", "ANATOMY", 354, 358], ["SARS", "DISEASE", 44, 48], ["pneumonia", "DISEASE", 261, 270], ["leukemia", "DISEASE", 306, 314], ["SARS-CoV-2", "ORGANISM", 44, 54], ["ACE2 + MSC-derived small extracellular vesicles", "CELLULAR_COMPONENT", 69, 116], ["sEVs", "CELLULAR_COMPONENT", 118, 122], ["lungs", "ORGAN", 242, 247], ["leukemia inhibitor factor", "GENE_OR_GENE_PRODUCT", 306, 331], ["LIF", "GENE_OR_GENE_PRODUCT", 333, 336], ["MSCs", "CELL", 354, 358], ["ACE2", "PROTEIN", 69, 73], ["MSC", "CELL_TYPE", 76, 79], ["cytokine", "PROTEIN", 220, 228], ["leukemia inhibitor factor", "PROTEIN", 306, 331], ["LIF", "PROTEIN", 333, 336], ["MSCs", "CELL_TYPE", 354, 358], ["SARS-CoV", "SPECIES", 44, 52], ["inhibition therapy", "TREATMENT", 17, 35], ["SARS", "PROBLEM", 44, 48], ["CoV", "TEST", 49, 52], ["ACE2", "TEST", 69, 73], ["small extracellular vesicles", "PROBLEM", 88, 116], ["the cytokine storm in the lungs", "PROBLEM", 216, 247], ["viral pneumonia", "PROBLEM", 255, 270], ["some studies", "TEST", 272, 284], ["the leukemia inhibitor factor", "PROBLEM", 302, 331], ["the damage", "PROBLEM", 397, 407], ["the disease", "PROBLEM", 418, 429], ["possible", "UNCERTAINTY", 8, 16], ["inhibition therapy", "OBSERVATION", 17, 35], ["small", "OBSERVATION_MODIFIER", 88, 93], ["extracellular vesicles", "OBSERVATION", 94, 116], ["cytokine storm", "OBSERVATION", 220, 234], ["lungs", "ANATOMY", 242, 247], ["viral", "OBSERVATION_MODIFIER", 255, 260], ["pneumonia", "OBSERVATION", 261, 270], ["leukemia", "OBSERVATION", 306, 314]]], ["As an innovative and technological alternative, there are MSCs with \"LIFNano\", nanotechnology that represents a 1000-fold increase in power compared to not using nanotechnology.", [["MSCs", "ANATOMY", 58, 62], ["MSCs", "CELL", 58, 62], ["MSCs", "CELL_TYPE", 58, 62]]], ["\"LIFNano\" acts on damaged tissues and reduces the cytokine storm.", [["tissues", "ANATOMY", 26, 33], ["LIFNano", "SIMPLE_CHEMICAL", 1, 8], ["tissues", "TISSUE", 26, 33], ["cytokine", "PROTEIN", 50, 58], ["the cytokine storm", "PROBLEM", 46, 64], ["cytokine storm", "OBSERVATION", 50, 64]]], ["Therefore, it represents a therapeutic agent ready to act beneficially against viral pneumonia [106] .Final ConsiderationsSignificant advances have been made in threedimensional (3D) cell culture to develop organoids.", [["cell", "ANATOMY", 183, 187], ["organoids", "ANATOMY", 207, 216], ["viral pneumonia", "DISEASE", 79, 94], ["cell", "CELL", 183, 187], ["organoids", "CELL", 207, 216], ["threedimensional (3D) cell culture", "CELL_LINE", 161, 195], ["a therapeutic agent", "TREATMENT", 25, 44], ["viral pneumonia", "PROBLEM", 79, 94], ["cell culture", "TEST", 183, 195], ["organoids", "PROBLEM", 207, 216], ["pneumonia", "OBSERVATION", 85, 94]]], ["These are able to recapitulate the complexity and functionality of different organs.", [["organs", "ANATOMY", 77, 83], ["organs", "ORGAN", 77, 83]]], ["Human lung organoids and bud tip progenitor organoids are composed of cells that are highly similar to the developing human lung.", [["lung organoids", "ANATOMY", 6, 20], ["bud tip progenitor organoids", "ANATOMY", 25, 53], ["cells", "ANATOMY", 70, 75], ["lung", "ANATOMY", 124, 128], ["Human", "ORGANISM", 0, 5], ["lung organoids", "CELL", 6, 20], ["bud tip progenitor organoids", "CELL", 25, 53], ["cells", "CELL", 70, 75], ["human", "ORGANISM", 118, 123], ["lung", "ORGAN", 124, 128], ["Human lung organoids", "CELL_TYPE", 0, 20], ["bud tip progenitor organoids", "CELL_TYPE", 25, 53], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 118, 123], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 118, 123], ["Human lung organoids", "PROBLEM", 0, 20], ["bud tip progenitor organoids", "TREATMENT", 25, 53], ["lung", "ANATOMY", 6, 10], ["organoids", "OBSERVATION", 11, 20], ["bud", "OBSERVATION_MODIFIER", 25, 28], ["tip", "OBSERVATION_MODIFIER", 29, 32], ["progenitor organoids", "OBSERVATION", 33, 53], ["human", "ANATOMY_MODIFIER", 118, 123], ["lung", "ANATOMY", 124, 128]]], ["They are ideal for studying developmental biology and tissue engineering.", [["tissue", "ANATOMY", 54, 60], ["tissue", "TISSUE", 54, 60]]], ["Considering that the cells are specific to the patient's genetics, the organoids that mimic lung disease may be critical for designing personalized medicine and screening for therapeutic responsiveness [107] .ConclusionWith the COVID-19 boom, many headStartclinical trialsheadEnd are being carried out using different sources with an emphasis on MSCs.", [["cells", "ANATOMY", 21, 26], ["organoids", "ANATOMY", 71, 80], ["lung", "ANATOMY", 92, 96], ["head", "ANATOMY", 248, 252], ["MSCs", "ANATOMY", 346, 350], ["lung disease", "DISEASE", 92, 104], ["cells", "CELL", 21, 26], ["patient", "ORGANISM", 47, 54], ["organoids", "CELL", 71, 80], ["lung", "ORGAN", 92, 96], ["head", "ORGANISM_SUBDIVISION", 248, 252], ["MSCs", "CELL", 346, 350], ["MSCs", "CELL_TYPE", 346, 350], ["patient", "SPECIES", 47, 54], ["lung disease", "PROBLEM", 92, 104], ["personalized medicine", "TREATMENT", 135, 156], ["screening", "TEST", 161, 170], ["therapeutic responsiveness", "PROBLEM", 175, 201], ["the COVID", "TEST", 224, 233], ["lung", "ANATOMY", 92, 96], ["head", "ANATOMY", 248, 252]]], ["We look forward to the results of the ongoing headStartclinical trialsheadEnd to find a treatment for the disease.", [["head", "ANATOMY", 46, 50], ["head", "ORGANISM_SUBDIVISION", 46, 50], ["a treatment", "TREATMENT", 86, 97], ["the disease", "PROBLEM", 102, 113], ["disease", "OBSERVATION", 106, 113]]], ["Researchers around the world are joining forces to help fight COVID-19.", [["COVID", "TEST", 62, 67]]], ["Stem cells used in the current clinical studies are a new therapeutic promise for COVID-19 where pharmacological treatments seem insufficient.ConclusionAcknowledgements The authors thank Kristine Schmidt for proof reading (language) of the manuscript.ConclusionAuthor Contributions FM, GLS and LV drafted the manuscript and wrote the article.", [["Stem cells", "ANATOMY", 0, 10], ["Stem cells", "CELL", 0, 10], ["Stem cells", "CELL_TYPE", 0, 10], ["Stem cells", "PROBLEM", 0, 10], ["COVID", "TEST", 82, 87], ["pharmacological treatments", "TREATMENT", 97, 123], ["GLS", "TEST", 286, 289], ["LV", "ANATOMY", 294, 296]]], ["SL and MIG participated in its design and coordination and helped to draft the manuscript.", [["MIG", "PROTEIN", 7, 10]]], ["All authors read and approved the final manuscript.ConclusionFunding Information This study was financed in part by the Coordena\u00e7\u00e3o de Aperfei\u00e7oamente de Pessoal de N\u00edvel Superior -Brasil (CAPES) -Finance Code 001.Compliance with Ethical StandardsConflicts of Interest The authors declare that they have no conflict of interest.Compliance with Ethical StandardsResearch Involving Human Participants and/or Animals Not applicable.Compliance with Ethical StandardsInformed Consent Not applicable.Compliance with Ethical StandardsAbbreviations", [["Human", "ORGANISM", 380, 385], ["Human", "SPECIES", 380, 385], ["Participants", "SPECIES", 386, 398], ["This study", "TEST", 81, 91], ["Ethical Standards", "TREATMENT", 230, 247], ["Ethical Standards", "TREATMENT", 344, 361], ["Ethical Standards", "TREATMENT", 510, 527]]]], "ee6474ec27fd935fdd66b88bfc84baf55874a926": [["El objetivo de este documento es recoger esas Page 3 of 22 J o u r n a l P r e -p r o o f experiencias y en base a las recomendaciones de los organismos oficiales ofrecer un documento de ayuda para la pr\u00e1ctica cl\u00ednica diaria.", [["experiencias", "PROBLEM", 90, 102]]], ["Dada la evoluci\u00f3n de la enfermedad es posible que haya cambios respecto a las recomendaciones en corto plazo de tiempo, por lo que se actualizar\u00e1 siempre que sea preciso.INTRODUCCI\u00d3NEl coronavirus SARS-CoV-2 se transmite de persona a persona por v\u00eda respiratoria a trav\u00e9s de las gotas respiratorias de m\u00e1s de 5 micras, cuando el enfermo presenta sintomatolog\u00eda respiratoria (tos y estornudos) y contacto con f\u00f3mites.", [["coronavirus SARS-CoV-2", "ORGANISM", 185, 207], ["coronavirus", "SPECIES", 185, 196], ["INTRODUCCI\u00d3NEl coronavirus SARS", "PROBLEM", 170, 201]]], ["La transmisi\u00f3n a\u00e9rea por n\u00facleo de gotitas o aerosoles (capaz de transmitirse a una distancia de m\u00e1s de 2 metros) no ha sido demostrada para el SARS-CoV-2.", [["ha", "PROBLEM", 117, 119]]], ["Se debe se\u00f1alar que la broncoscopia no debe usarse como un medio de rutina para el diagn\u00f3stico de la infecci\u00f3n COVID-19.INTRODUCCI\u00d3NEste documento tiene como objeto conocer los riesgos y beneficios de la realizaci\u00f3n de broncoscopias en este tipo de pacientes, as\u00ed como evitar las infecciones cruzadas pacientepaciente y garantizar la seguridad del personal sanitario implicado en la realizaci\u00f3n de estas 5 3.", [["pacientepaciente y garantizar la seguridad del personal sanitario implicado", "TREATMENT", 301, 376]]], ["Es importante que dos muestras de PCR sean negativas dado que la sensibilidad de la misma es de aproximadamente del 70%, incluso menor que la de la tomograf\u00eda computarizada del t\u00f3rax 7 .4.Si finalmente se precisa broncoscopia para toma de muestras de COVID-19, se tomar\u00e1n al menos 2-3 ml en recipiente est\u00e9ril de BAS o cat\u00e9ter telescopado, mejor que BAL por riesgo del personal sanitario 8 .5.No se recomienda el esputo inducido por el mayor riesgo de transmisi\u00f3n de aerosoles.5.6.", [["Si", "CHEMICAL", 188, 190], ["del personal sanitario", "TREATMENT", 365, 387]]], ["Las muestras ser\u00e1n recogidas en un reciente est\u00e9ril e introducidas en una bolsa con autocierre.", [["est\u00e9ril e introducidas en una bolsa con autocierre", "TREATMENT", 44, 94]]], ["Puede almacenarse a 2-8\u00baC las primeras 72 horas de su recolecci\u00f3n, y si se demora m\u00e1s el an\u00e1lisis precisa -70\u00b0 C 10,11 .INDICACIONES DE REALIZACI\u00d3N DE BRONCOSCOPIALa indicaci\u00f3n de una broncoscopia -flexible o r\u00edgida-para la toma de muestras respiratorias en un paciente con sospecha cl\u00ednico-epidemiol\u00f3gica de infecci\u00f3n por COVID-19 no es de primera elecci\u00f3n.", [["precisa", "TEST", 98, 105], ["broncoscopia", "TEST", 184, 196], ["r\u00edgida", "TEST", 209, 215]]], ["Sin embargo, en pacientes con diagn\u00f3stico confirmado de COVID-19 puede ser una herramienta muy valiosa en determinadas circunstancias.INDICACIONES DE REALIZACI\u00d3N DE BRONCOSCOPIAAs\u00ed, la indicaci\u00f3n de una t\u00e9cnica endosc\u00f3pica o pleural se debe valorar de forma individualizada en cada paciente seg\u00fan dos posibles escenarios (figura 1):INDICACIONES DE REALIZACI\u00d3N DE BRONCOSCOPIA1) Pacientes con diagn\u00f3stico de infecci\u00f3n por COVID-19.", [["pleural", "ANATOMY", 225, 232]]], ["El esputo puede ser una muestra adecuada para el diagn\u00f3stico, pero supone una t\u00e9cnica con alto riesgo de diseminaci\u00f3n y contagio del virus por lo que no se debe utilizar.", [["alto riesgo de diseminaci\u00f3n y contagio del virus", "TREATMENT", 90, 138]]], ["Esta circunstancia puede ocurrir especialmente en pacientes inmunocomprometidos.INDICACIONES DE REALIZACI\u00d3N DE BRONCOSCOPIA2) Si se presenta una atelectasia lobar o de un hemit\u00f3rax completo.INDICACIONES DE REALIZACI\u00d3N DE BRONCOSCOPIA3) Ante una hemoptisis cr\u00edtica con inestabilidad hemodin\u00e1mica que precise maniobras endosc\u00f3picas para controlar la hemorragia 14 . -En broncoscopia b\u00e1sica: endoscopista, enfermero y t\u00e9cnico auxiliar de enfermer\u00eda (TCAE).", [["hemoptisis", "PROBLEM", 245, 255], ["lobar", "OBSERVATION", 157, 162]]], ["Si es posible podr\u00eda realizarse s\u00f3lo con endoscopista y enfermero, y el TCAE responsabilizarse de las muestras en otra sala.INDICACIONES DE REALIZACI\u00d3N DE BRONCOSCOPIA-En broncoscopia avanzada: adem\u00e1s de lo anterior un anestesista.INDICACIONES DE REALIZACI\u00d3N DE BRONCOSCOPIA-En broncoscopia en UCI: adem\u00e1s de lo anterior un intensivista.INDICACIONES DE REALIZACI\u00d3N DE BRONCOSCOPIAEl equipo debe ser el m\u00e1s experimentado en la realizaci\u00f3n de procedimientos para reducir el tiempo de exploraci\u00f3n.EQUIPAMIENTO1-De elecci\u00f3n: broncoscopios desechables de un solo uso con pantalla electr\u00f3nica para la visualizaci\u00f3n de la broncoscopia.", [["Si", "CHEMICAL", 0, 2]]], ["Inmediatamente despu\u00e9s de la broncoscopia, inserte una botella de alcohol al 75% para succi\u00f3n de presi\u00f3n negativa para limpiar y desinfectar el canal de trabajo y de aspiraci\u00f3n del broncoscopio y limpie la superficie de este.EQUIPAMIENTOPosteriormente deber\u00e1 seguir las recomendaciones de limpieza descritas en el ep\u00edgrafe 5 de desinfecci\u00f3n de alto nivel.EQUIPAMIENTO3-Realizar lavado con cat\u00e9ter protegido mejor que BAL reglado, ya que minimiza el riesgo de contagio del personal que realiza la endoscopia.", [["alcohol", "CHEMICAL", 66, 73], ["EQUIPAMIENTO3", "TREATMENT", 355, 368], ["lavado con cat\u00e9ter protegido", "TREATMENT", 378, 406]]], ["Es recomendable recoger 2-3 mL en un contenedor est\u00e9ril, sellado y seco 10,11 .EQUIPAMIENTO4-Colocar una mascarilla quir\u00fargica la paciente y realizar la broncoscopia v\u00eda nasal.EQUIPAMIENTO5-En caso de pacientes de UCI se utilizar\u00e1 mascarillas orofaciales con entrada espec\u00edfica para el broncoscopio y en pacientes con tubo orotraqueal se utilizar\u00e1 una conexi\u00f3n en T.EQUIPAMIENTO6-Para minimizar las gotas de tos del paciente se puede colocar una sonda de aspiraci\u00f3n de presi\u00f3n negativa en la boca del paciente 16 .EQUIPAMIENTO7-Se desechar\u00e1n todas las tubuladuras de ox\u00edgeno, aire comprimido, recept\u00e1culos de aspiraci\u00f3n, etc, que hayan sido utilizadas con el paciente infectado.", [["est\u00e9ril", "TREATMENT", 48, 55], ["nasal", "ANATOMY", 170, 175]]], ["3.Cuando de la evaluaci\u00f3n de riesgos se derive que en el desarrollo de la actividad se realizan procedimientos asistenciales en los que se puedan generar bioaerosoles en concentraciones elevadas, se recomienda el uso por el personal sanitario de mascarillas autofiltrantes contra part\u00edculas FFP3 o media m\u00e1scara provista con filtro contra part\u00edculas P3.", [["Cuando de la evaluaci\u00f3n", "TREATMENT", 2, 25], ["que en el desarrollo de la actividad", "TREATMENT", 47, 83]]], ["J o u r n a l P r e -p r o o f seg\u00fan UNE EN 166 ser\u00edan: protecci\u00f3n frente a impactos (todo tipo de montura), l\u00edquidos (montura integral/pantalla facial), polvo grueso > 5 \u03bcm (montura integral), gas y polvo fino < 5 \u03bcm (montura integral).EQUIPAMIENTO3.", [["EQUIPAMIENTO3", "PROTEIN", 237, 250], ["UNE EN", "TEST", 37, 43], ["protecci\u00f3n", "TEST", 56, 66], ["l\u00edquidos (montura integral/pantalla facial", "TREATMENT", 109, 151], ["polvo grueso", "TREATMENT", 154, 166], ["gas y polvo fino", "TREATMENT", 194, 210]]], ["No obstante, si por el tipo de exposici\u00f3n se precisa garantizar cierta hermeticidad de las cuencas orbitales deberemos recurrir a gafas integrales (campos de uso 3, 4 o 5 seg\u00fan UNE-EN 166:2002, en funci\u00f3n de la hermeticidad requerida) y, para la protecci\u00f3n conjunta de ojos y cara, a pantallas faciales.", [["pantallas faciales", "DISEASE", 284, 302], ["obstante", "PROBLEM", 3, 11], ["UNE", "TEST", 177, 180], ["a pantallas faciales", "PROBLEM", 282, 302]]], ["Los campos de uso se definen: 3 (gotas de l\u00edquidos, admite ventilaci\u00f3n directa), 4 (polvo grueso, admite ventilaci\u00f3n indirecta), 5 (gas y polvo fino, no admite ventilaci\u00f3n).EQUIPAMIENTO4.", [["EQUIPAMIENTO4", "PROTEIN", 173, 186], ["gas y polvo fino", "TREATMENT", 132, 148]]], ["Se recomienda siempre protecci\u00f3n ocular durante los procedimientos de generaci\u00f3n de aerosoles.", [["Se recomienda siempre protecci\u00f3n", "TREATMENT", 0, 32]]], ["Cuando sea necesario el uso conjunto de m\u00e1s de un equipo de protecci\u00f3n individual, debe asegurarse la compatibilidad entre ellos, lo cual es particularmente importante en el caso de la protecci\u00f3n respiratoria y ocular simult\u00e1nea, para que la hermeticidad de estos y por tanto su capacidad de proteger no se vea mermada.EQUIPAMIENTOEn la tabla 1 se resumen los requisitos necesarios para la realizaci\u00f3n de broncoscopias en pacientes COVID-19.COLOCACI\u00d3N Y RETIRADA DE LOS EPITal y como se ha indicado, los EPI deben seleccionarse para garantizar la protecci\u00f3n adecuada en funci\u00f3n de la forma y nivel de exposici\u00f3n y que \u00e9sta se mantenga durante la realizaci\u00f3n de la actividad laboral.", [["ocular simult\u00e1nea", "DISEASE", 211, 228], ["EPI", "TEST", 504, 507]]], ["A su vez, la limpieza comprende varias fases:COLOCACI\u00d3N Y RETIRADA DE LOS EPI\uf0b7 Test de fugas: se realiza previamente a la inmersi\u00f3n del broncoscopio.COLOCACI\u00d3N Y RETIRADA DE LOS EPI\uf0b7 Inmersi\u00f3n completa del broncoscopio en desinfectante enzim\u00e1tico diluido seg\u00fan las instrucciones del fabricante.COLOCACI\u00d3N Y RETIRADA DE LOS EPI\uf0b7 Limpieza de la superficie externa: Lavado con esponja o compresa el exterior del broncoscopio de la parte m\u00e1s proximal a la m\u00e1s distal.COLOCACI\u00d3N Y RETIRADA DE LOS EPI\uf0b7 Aspirado: Accionar varias veces la v\u00e1lvula de succi\u00f3n para que la soluci\u00f3n enzim\u00e1tica fluya a trav\u00e9s del canal de trabajo.COLOCACI\u00d3N Y RETIRADA DE LOS EPI\uf0b7 Cepillado: Proceso de arrastre de los canales internos mediante cepillos de distinto calibre adaptados al canal de trabajo y al cub\u00edculo de la v\u00e1lvula, Los cepillos deben ser desechados.", [["Inmersi\u00f3n completa del broncoscopio en desinfectante enzim\u00e1tico diluido", "TREATMENT", 183, 254], ["EPI", "TEST", 492, 495], ["Aspirado", "TEST", 497, 505], ["Accionar", "TEST", 507, 515], ["proximal", "ANATOMY_MODIFIER", 438, 446], ["la m\u00e1s", "ANATOMY", 449, 455], ["distal", "ANATOMY_MODIFIER", 456, 462]]]], "88841c84315c914de952b2b85fda99e84760ef70": [["Dear Editor,Coronavirus disease 2019 (COVID-19) is associated with a high fatality rate in patients requiring invasive mechanical ventilation (IMV) [1] .", [["Coronavirus disease", "DISEASE", 12, 31], ["COVID-19", "CHEMICAL", 38, 46], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["Coronavirus disease", "PROBLEM", 12, 31], ["COVID", "TEST", 38, 43], ["a high fatality rate", "PROBLEM", 67, 87], ["invasive mechanical ventilation", "TREATMENT", 110, 141], ["Coronavirus disease", "OBSERVATION", 12, 31]]], ["COVID-19-related acute respiratory distress syndrome (COVID-ARDS) might exhibit vascular insults, resulting in loss of hypoxic pulmonary vasoconstriction, and subsequent dissociation between profound hypoxemia and preserved static compliance of the respiratory system (Cst-rs) [2] .", [["respiratory", "ANATOMY", 23, 34], ["vascular", "ANATOMY", 80, 88], ["pulmonary", "ANATOMY", 127, 136], ["respiratory system", "ANATOMY", 249, 267], ["COVID-19", "CHEMICAL", 0, 8], ["acute respiratory distress syndrome", "DISEASE", 17, 52], ["COVID", "DISEASE", 54, 59], ["ARDS", "DISEASE", 60, 64], ["vascular insults", "DISEASE", 80, 96], ["hypoxemia", "DISEASE", 200, 209], ["COVID-19", "GENE_OR_GENE_PRODUCT", 0, 8], ["vascular", "MULTI-TISSUE_STRUCTURE", 80, 88], ["pulmonary", "ORGAN", 127, 136], ["COVID", "TEST", 0, 5], ["acute respiratory distress syndrome", "PROBLEM", 17, 52], ["ARDS", "PROBLEM", 60, 64], ["vascular insults", "PROBLEM", 80, 96], ["hypoxic pulmonary vasoconstriction", "PROBLEM", 119, 153], ["subsequent dissociation", "PROBLEM", 159, 182], ["profound hypoxemia", "PROBLEM", 191, 209], ["acute", "OBSERVATION_MODIFIER", 17, 22], ["respiratory distress", "OBSERVATION", 23, 43], ["syndrome", "OBSERVATION", 44, 52], ["ARDS", "OBSERVATION", 60, 64], ["vascular", "ANATOMY", 80, 88], ["insults", "OBSERVATION", 89, 96], ["hypoxic", "OBSERVATION_MODIFIER", 119, 126], ["pulmonary", "ANATOMY", 127, 136], ["vasoconstriction", "OBSERVATION", 137, 153], ["profound", "OBSERVATION_MODIFIER", 191, 199], ["hypoxemia", "OBSERVATION", 200, 209], ["preserved", "OBSERVATION_MODIFIER", 214, 223], ["static compliance", "OBSERVATION", 224, 241], ["respiratory system", "ANATOMY", 249, 267]]], ["Experts recently distinguished two phenotypes of COVID-ARDS according to their Cst-rs [2] : patients were classified as groups L (low elastance (or high Cst-rs) and low recruitability) and H (high elastance and high recruitability).", [["ARDS", "DISEASE", 55, 59], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["ARDS", "PROBLEM", 55, 59], ["low elastance", "PROBLEM", 130, 143], ["low recruitability)", "PROBLEM", 165, 184], ["high recruitability)", "PROBLEM", 211, 231], ["ARDS", "OBSERVATION", 55, 59], ["low elastance", "OBSERVATION_MODIFIER", 130, 143], ["low recruitability", "OBSERVATION_MODIFIER", 165, 183], ["high recruitability", "OBSERVATION_MODIFIER", 211, 230]]], ["They recommended different ventilatory approaches [3] , contrary to Sepsis Surviving Campaign guidelines [4] .", [["Sepsis", "DISEASE", 68, 74], ["different ventilatory approaches", "TREATMENT", 17, 49], ["Sepsis", "PROBLEM", 68, 74]]], ["We describe characteristics and outcomes in patients with different initial Cst-rs, but all receiving IMV following ARDS guidelines.Dear Editor,We report the courses of respiratory parameters and outcomes in an observational cohort of 36 patients who developed COVID-ARDS requiring IMV from March 17 to April 18, 2020.", [["respiratory", "ANATOMY", 169, 180], ["ARDS", "DISEASE", 116, 120], ["ARDS", "DISEASE", 267, 271], ["patients", "ORGANISM", 44, 52], ["patients", "ORGANISM", 238, 246], ["patients", "SPECIES", 44, 52], ["patients", "SPECIES", 238, 246], ["IMV", "SPECIES", 102, 105], ["IMV", "TREATMENT", 102, 105], ["ARDS guidelines", "TREATMENT", 116, 131], ["respiratory parameters", "TEST", 169, 191], ["ARDS", "PROBLEM", 267, 271], ["IMV", "TREATMENT", 282, 285], ["ARDS", "OBSERVATION", 267, 271]]], ["Patients were divided into two groups (low and high Cst-rs) according to their initial Cst-rs was above or below the median value.", [["Patients", "ORGANISM", 0, 8], ["Cst", "GENE_OR_GENE_PRODUCT", 87, 90], ["Cst", "PROTEIN", 52, 55], ["Cst", "PROTEIN", 87, 90], ["Patients", "SPECIES", 0, 8]]], ["We applied institutional ARDS procedures to all patients.", [["ARDS", "DISEASE", 25, 29], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["institutional ARDS procedures", "TREATMENT", 11, 40]]], ["Our management was based on the systematic use of neuromuscular blockers for at least 48 h, positive end-expiratory pressures (PEEP) titrated on oxygenation, and prone positioning sessions if PaO 2 /FiO 2 ratio dropped below 150.", [["neuromuscular", "ANATOMY", 50, 63], ["PaO 2", "CHEMICAL", 192, 197], ["FiO 2", "CHEMICAL", 199, 204], ["FiO 2", "GENE_OR_GENE_PRODUCT", 199, 204], ["Our management", "TREATMENT", 0, 14], ["neuromuscular blockers", "TREATMENT", 50, 72], ["expiratory pressures", "TEST", 105, 125], ["PEEP", "TREATMENT", 127, 131], ["oxygenation", "TREATMENT", 145, 156], ["prone positioning sessions", "TREATMENT", 162, 188], ["PaO", "TEST", 192, 195], ["FiO 2 ratio", "TEST", 199, 210], ["expiratory pressures", "OBSERVATION", 105, 125]]], ["Patients' data were analyzed until patients were discharged from the intensive care unit or died.", [["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 35, 43], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 35, 43], ["Patients' data", "TEST", 0, 14]]], ["Courses of Cst-rs, PEEP, and tidal volumes were analyzed using a linear mixed model.Dear Editor,The median baseline Cst-rs was 36 mL/cmH 2 O [interquartile range (IQR) 29-44].", [["Cst-rs", "TEST", 11, 17], ["PEEP", "TREATMENT", 19, 23], ["tidal volumes", "TEST", 29, 42], ["a linear mixed model", "TREATMENT", 63, 83]]], ["Characteristics of the patients at baseline, therapeutic interventions, and outcome measures are provided in Table 1 .", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["therapeutic interventions", "TREATMENT", 45, 70], ["outcome measures", "TREATMENT", 76, 92]]], ["Twenty-nine patients (80.6%) in whom PaO 2 /FiO 2 ratio dropped below 150 were placed in prone position.", [["patients", "ORGANISM", 12, 20], ["FiO 2", "GENE_OR_GENE_PRODUCT", 44, 49], ["patients", "SPECIES", 12, 20], ["PaO", "TEST", 37, 40], ["FiO 2 ratio", "TEST", 44, 55]]], ["Courses of Cst-rs, PEEP levels, and tidal volumes are provided in Fig. 1 .", [["Cst-rs", "TEST", 11, 17], ["PEEP levels", "TEST", 19, 30], ["tidal volumes", "TEST", 36, 49], ["tidal volumes", "OBSERVATION", 36, 49]]], ["Cst-rs did not vary over time in both groups and remained higher in the high Cst-rs group (mean difference 17.7 mL/ cmH 2 O [95% CI 11.3-24.0] compared to the low Cst-rs group, P < 0.001).", [["Cst", "CHEMICAL", 77, 80], ["Cst", "GENE_OR_GENE_PRODUCT", 0, 3], ["Cst", "PROTEIN", 0, 3], ["CI", "TEST", 129, 131], ["higher", "OBSERVATION_MODIFIER", 58, 64]]], ["Tidal volumes were higher in the high Cst-rs group (mean difference 0.90 mL/ kg [95% CI 0.31-1.50] compared to the low Cst-rs group, P = 0.005).", [["Cst", "CHEMICAL", 38, 41], ["Tidal volumes", "TEST", 0, 13], ["CI", "TEST", 85, 87], ["P", "TEST", 133, 134], ["higher", "OBSERVATION_MODIFIER", 19, 25]]], ["PEEP levels were not different between groups and decreased over time.Dear Editor,On day 28, 32 patients (88.9%) survived and 25 (69.4%) were discharged from the intensive care unit.", [["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["PEEP levels", "TEST", 0, 11], ["different", "OBSERVATION_MODIFIER", 21, 30], ["decreased", "OBSERVATION_MODIFIER", 50, 59]]], ["As of May 30, 2020, weaning from mechanical ventilation was effective in 16 high Cst-rs patients (94.1%) and 13 low Cst-rs patients (68.4%) (P = 0.09).Dear Editor,As previously suggested [3] , some COVID-ARDS patients exhibit high initial Cst-rs.", [["ARDS", "DISEASE", 204, 208], ["patients", "ORGANISM", 88, 96], ["patients", "ORGANISM", 123, 131], ["patients", "ORGANISM", 209, 217], ["patients", "SPECIES", 88, 96], ["patients", "SPECIES", 123, 131], ["patients", "SPECIES", 209, 217], ["mechanical ventilation", "TREATMENT", 33, 55], ["P", "TEST", 141, 142], ["ARDS", "PROBLEM", 204, 208], ["high initial Cst-rs", "PROBLEM", 226, 245], ["ARDS", "OBSERVATION", 204, 208]]], ["However, the median baseline Cst-rs was not different from Cstrs observed in \"typical\" non-COVID-ARDS, as demonstrated in another study [5] .", [["ARDS", "DISEASE", 97, 101], ["Cst", "GENE_OR_GENE_PRODUCT", 29, 32], ["Cst", "PROTEIN", 29, 32], ["the median baseline Cst-rs", "TEST", 9, 35], ["ARDS", "PROBLEM", 97, 101], ["another study", "TEST", 122, 135], ["ARDS", "OBSERVATION", 97, 101]]], ["The high Cst-rs did not drop and remained different from the initial low Cst-rs during the first 28 days, suggesting a lack of transition from a high to a low Cst-rs phenotype in patients receiving neuromuscular blockers.", [["neuromuscular", "ANATOMY", 198, 211], ["Cst", "GENE_OR_GENE_PRODUCT", 9, 12], ["Cst", "GENE_OR_GENE_PRODUCT", 159, 162], ["patients", "ORGANISM", 179, 187], ["neuromuscular blockers", "SIMPLE_CHEMICAL", 198, 220], ["Cst", "PROTEIN", 9, 12], ["Cst", "PROTEIN", 73, 76], ["Cst", "PROTEIN", 159, 162], ["patients", "SPECIES", 179, 187], ["The high Cst-rs", "TEST", 0, 15], ["neuromuscular blockers", "TREATMENT", 198, 220], ["high", "OBSERVATION_MODIFIER", 4, 8]]], ["We therefore hypothesize that if this transition exists, self-inflicted lung injury during spontaneous ventilation or asynchronies is one of its main determinants.Dear Editor,Although therapeutic management of low Cst-rs patients is not disputed [2, 6] , a low-PEEP, high-FiO 2 , liberal tidal volume approach has been suggested for high Cst-rs patients.", [["lung", "ANATOMY", 72, 76], ["lung injury", "DISEASE", 72, 83], ["lung", "ORGAN", 72, 76], ["patients", "ORGANISM", 221, 229], ["patients", "ORGANISM", 345, 353], ["patients", "SPECIES", 221, 229], ["patients", "SPECIES", 345, 353], ["self-inflicted lung injury", "PROBLEM", 57, 83], ["spontaneous ventilation", "TREATMENT", 91, 114], ["asynchronies", "PROBLEM", 118, 130], ["therapeutic management", "TREATMENT", 184, 206], ["a low-PEEP", "TREATMENT", 255, 265], ["high-FiO 2", "TREATMENT", 267, 277], ["liberal tidal volume approach", "TREATMENT", 280, 309], ["lung", "ANATOMY", 72, 76], ["injury", "OBSERVATION", 77, 83], ["main", "OBSERVATION_MODIFIER", 145, 149]]], ["Using established ARDS therapies [3] with either low or high Cst-rs, the survival rate is better Obesity is defined by a body mass index above 30 kg/m 2 .", [["body", "ANATOMY", 121, 125], ["ARDS", "DISEASE", 18, 22], ["Obesity", "DISEASE", 97, 104], ["body", "ORGANISM_SUBDIVISION", 121, 125], ["established ARDS therapies", "TREATMENT", 6, 32], ["Obesity", "PROBLEM", 97, 104], ["a body mass index", "TEST", 119, 136], ["ARDS", "OBSERVATION", 18, 22]]], ["The formula for body mass index is weight in kilograms divided by height in meters squared c No statistical comparison performed than initially reported [1] , following a recent publication using the same strategy [5] .", [["body", "ANATOMY", 16, 20], ["body", "ORGANISM_SUBDIVISION", 16, 20], ["The formula", "TREATMENT", 0, 11], ["body mass index", "TEST", 16, 31], ["statistical comparison", "TEST", 96, 118]]], ["A low initial Cst-rs could be a marker of severity, as suggested by more extracorporeal membrane oxygenation requirement and less ventilator-free days at day 28.Dear Editor,Limitations include the small number of patients and the retrospective design.", [["extracorporeal membrane", "ANATOMY", 73, 96], ["Cst", "GENE_OR_GENE_PRODUCT", 14, 17], ["patients", "ORGANISM", 213, 221], ["Cst", "PROTEIN", 14, 17], ["patients", "SPECIES", 213, 221], ["A low initial Cst-rs", "PROBLEM", 0, 20], ["extracorporeal membrane oxygenation requirement", "TREATMENT", 73, 120], ["low", "OBSERVATION_MODIFIER", 2, 5], ["extracorporeal", "OBSERVATION_MODIFIER", 73, 87], ["membrane oxygenation", "OBSERVATION", 88, 108], ["small", "OBSERVATION_MODIFIER", 197, 202]]], ["While further study is needed, our findings provide arguments to treat all COVID-ARDS with established ARDS therapies, whatever the initial value of Cst-rs.", [["COVID", "DISEASE", 75, 80], ["ARDS", "DISEASE", 81, 85], ["ARDS", "DISEASE", 103, 107], ["further study", "TEST", 6, 19], ["all COVID", "PROBLEM", 71, 80], ["ARDS", "PROBLEM", 81, 85], ["established ARDS therapies", "TREATMENT", 91, 117], ["ARDS", "OBSERVATION", 81, 85], ["ARDS", "OBSERVATION", 103, 107]]]]}